1	Some	O
2	of	O
3	these	O
4	targets	O
5	were	O
6	reported	O
7	to	O
8	code	O
9	for	O
10	molecules	O
11	involved	O
12	in	O
13	cell	O
14	-	O
15	cell	O
16	interactions	O
17	,	O
18	whereas	O
19	no	O
20	relationship	O
21	has	O
22	yet	O
23	been	O
24	demonstrated	O
25	between	O
26	Hox	B
27	genes	I
28	and	O
29	other	O
30	transcription	O
31	factors	O
32	involved	O
33	in	O
34	determining	O
35	and	O
36	/	O
37	or	O
38	maintaining	O
39	tissue	O
40	specificity	O
41	.	O

1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	O
7	-	O
8	length	O
9	promoter	O
10	(-	O
11	295	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	197	O
23	,	O
24	-	O
25	154	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	O
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O

1	During	O
2	chronic	O
3	treatment	O
4	,	O
5	when	O
6	plasma	O
7	concentrations	O
8	fluctuated	O
9	between	O
10	23	O
11	.	O
12	5	O
13	ng	O
14	.	O
15	ml	O
16	-	O
17	1	O
18	at	O
19	8	O
20	h	O
21	and	O
22	14	O
23	ng	O
24	.	O
25	ml	O
26	-	O
27	1	O
28	at	O
29	24	O
30	h	O
31	post	O
32	-	O
33	dosing	O
34	,	O
35	ST	O
36	segment	O
37	depression	O
38	at	O
39	an	O
40	individually	O
41	comparable	O
42	workload	O
43	was	O
44	significantly	O
45	decreased	O
46	by	O
47	28	O
48	%	O
49	compared	O
50	with	O
51	placebo	O
52	(	O
53	P	O
54	<	O
55	0	O
56	.	O
57	005	O
58	)	O
59	at	O
60	both	O
61	points	O
62	in	O
63	time	O
64	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	introduce	O
5	an	O
6	image	O
7	analysis	O
8	of	O
9	the	O
10	cornea	O
11	in	O
12	photorefractive	O
13	keratectomy	O
14	(	O
15	PRK	O
16	)	O
17	for	O
18	preoperative	O
19	and	O
20	early	O
21	postoperative	O
22	determination	O
23	of	O
24	changes	O
25	in	O
26	the	O
27	condition	O
28	of	O
29	the	O
30	cornea	O
31	.	O

1	This	O
2	interaction	O
3	occurs	O
4	over	O
5	a	O
6	wide	O
7	range	O
8	of	O
9	both	O
10	parameters	O
11	;	O
12	for	O
13	charge	O
14	density	O
15	from	O
16	at	O
17	least	O
18	10	O
19	to	O
20	800	O
21	microC	O
22	/	O
23	cm2	O
24	and	O
25	,	O
26	for	O
27	charge	O
28	per	O
29	phase	O
30	,	O
31	from	O
32	at	O
33	least	O
34	0	O
35	.	O
36	05	O
37	to	O
38	5	O
39	.	O
40	0	O
41	microC	O
42	per	O
43	phase	O
44	.	O

1	The	O
2	novel	O
3	protein	O
4	kinases	O
5	,	O
6	c	B
7	-	I
8	Jun	I
9	NH2	I
10	-	I
11	terminal	I
12	kinases	I
13	(	O
14	JNKs	B
15	)/	O
16	stress	B
17	-	I
18	activated	I
19	protein	I
20	kinases	I
21	,	O
22	are	O
23	also	O
24	activated	O
25	by	O
26	TNF	B
27	-	I
28	alpha	I
29	,	O
30	IL	B
31	-	I
32	1	I
33	,	O
34	and	O
35	CD28	B
36	costimulation	O
37	.	O

1	Acute	O
2	feasibility	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	smoking	O
8	reduction	O
9	strategy	O
10	for	O
11	smokers	O
12	with	O
13	schizophrenia	O
14	.	O

1	Treatment	O
2	was	O
3	well	O
4	-	O
5	tolerated	O
6	.	O

1	Significance	O
2	of	O
3	cytokine	O
4	production	O
5	and	O
6	adhesion	O
7	molecules	O
8	in	O
9	malarial	O
10	immunopathology	O
11	.	O

1	The	O
2	kinase	O
3	inhibitor	O
4	staurosporine	O
5	(	O
6	1	O
7	microM	O
8	)	O
9	blocks	O
10	LPA	O
11	-	O
12	induced	O
13	,	O
14	but	O
15	not	O
16	epidermal	O
17	growth	O
18	factor	O
19	-	O
20	induced	O
21	,	O
22	activation	O
23	of	O
24	p21ras	B
25	and	O
26	MAP	B
27	kinase	I
28	,	O
29	consistent	O
30	with	O
31	an	O
32	intermediate	O
33	protein	O
34	kinase	O
35	linking	O
36	the	O
37	LPA	B
38	receptor	I
39	to	O
40	p21ras	B
41	activation	O
42	.	O

1	Although	O
2	most	O
3	SH2	B
4	-	O
5	pTyr	B
6	interactions	O
7	occur	O
8	between	O
9	two	O
10	different	O
11	types	O
12	of	O
13	molecules	O
14	,	O
15	some	O
16	appear	O
17	to	O
18	involve	O
19	only	O
20	a	O
21	single	O
22	molecular	O
23	type	O
24	.	O

1	Expression	O
2	of	O
3	the	O
4	second	O
5	gene	O
6	(	O
7	XT3	B
8	)	O
9	was	O
10	found	O
11	to	O
12	be	O
13	conserved	O
14	in	O
15	human	O
16	kidney	O
17	,	O
18	and	O
19	partial	O
20	sequence	O
21	was	O
22	obtained	O
23	from	O
24	a	O
25	human	O
26	cDNA	O
27	library	O
28	.	O

1	Six	O
2	of	O
3	them	O
4	,	O
5	NUC1	B
6	,	O
7	PRP21	B
8	(	O
9	also	O
10	called	O
11	SPP91	B
12	),	O
13	CDC6	B
14	,	O
15	CRY2	B
16	,	O
17	the	O
18	gene	O
19	encoding	O
20	the	O
21	ribosomal	B
22	protein	I
23	S24	I
24	and	O
25	the	O
26	gene	O
27	coding	O
28	for	O
29	a	O
30	hypothetical	O
31	protein	O
32	of	O
33	599	O
34	amino	O
35	acids	O
36	,	O
37	have	O
38	been	O
39	sequenced	O
40	previously	O
41	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	both	O
6	the	O
7	amino	O
8	and	O
9	carboxy	O
10	termini	O
11	of	O
12	the	O
13	NS1	B
14	protein	I
15	molecule	I
16	and	O
17	the	O
18	cysteines	O
19	at	O
20	residues	O
21	337	O
22	and	O
23	340	O
24	are	O
25	essential	O
26	for	O
27	tubule	O
28	formation	O
29	.	O

1	No	O
2	direct	O
3	repeats	O
4	flank	O
5	the	O
6	pseudogene	O
7	in	O
8	the	O
9	U2	B
10	/	I
11	4	I
12	locus	I
13	.	O

1	The	O
2	1	O
3	.	O
4	7	O
5	kb	O
6	cloned	O
7	fragment	O
8	was	O
9	sequenced	O
10	and	O
11	shown	O
12	to	O
13	contain	O
14	the	O
15	entire	O
16	fliA	B
17	gene	I
18	.	O

1	The	O
2	eukaryotic	O
3	cell	O
4	cycle	O
5	is	O
6	governed	O
7	in	O
8	part	O
9	by	O
10	the	O
11	periodic	O
12	transcription	O
13	of	O
14	cyclin	B
15	genes	I
16	,	O
17	whose	O
18	protein	O
19	products	O
20	associate	O
21	with	O
22	and	O
23	positively	O
24	regulate	O
25	the	O
26	cyclin	B
27	-	I
28	dependent	I
29	kinases	I
30	.	O

1	Clear	O
2	and	O
3	evidenced	O
4	-	O
5	based	O
6	information	O
7	should	O
8	be	O
9	provided	O
10	to	O
11	patients	O
12	as	O
13	to	O
14	the	O
15	means	O
16	of	O
17	prevention	O
18	with	O
19	special	O
20	attention	O
21	to	O
22	individual	O
23	risk	O
24	groups	O
25	such	O
26	as	O
27	IV	O
28	drug	O
29	abusers	O
30	.	O

1	We	O
2	concluded	O
3	that	O
4	Ga	O
5	-	O
6	fbg	O
7	scintigraphy	O
8	is	O
9	a	O
10	very	O
11	simple	O
12	method	O
13	and	O
14	sufficiently	O
15	useful	O
16	for	O
17	detecting	O
18	active	O
19	left	O
20	ventricular	O
21	thrombi	O
22	and	O
23	for	O
24	monitoring	O
25	the	O
26	effect	O
27	of	O
28	anticoagulant	O
29	therapy	O
30	.	O

1	There	O
2	has	O
3	been	O
4	similar	O
5	improvement	O
6	in	O
7	treating	O
8	ampullary	O
9	and	O
10	periampullary	O
11	cancer	O
12	,	O
13	gallbladder	O
14	cancer	O
15	,	O
16	or	O
17	extrahepatic	O
18	bile	O
19	duct	O
20	cancer	O
21	.	O

1	Responsibility	O
2	matters	O
3	--	O
4	this	O
5	is	O
6	a	O
7	scientific	O
8	council	O

1	Regulated	O
2	activity	O
3	of	O
4	the	O
5	distal	O
6	promoter	O
7	-	O
8	like	O
9	element	O
10	of	O
11	the	O
12	human	B
13	corticotropin	I
14	-	I
15	releasing	I
16	hormone	I
17	gene	I
18	and	O
19	secondary	O
20	structural	O
21	features	O
22	of	O
23	its	O
24	corresponding	O
25	transcripts	O
26	.	O

1	100	O
2	more	O
3	than	O
4	in	O
5	the	O
6	summer	O
7	coat	O
8	).	O

1	A	O
2	major	O
3	pool	O
4	of	O
5	Dsg	B
6	-	O
7	plakoglobin	B
8	complexes	O
9	sedimented	O
10	at	O
11	8S	O
12	and	O
13	exhibited	O
14	a	O
15	1	O
16	:	O
17	1	O
18	stoichiometry	O
19	.	O

1	Comparison	O
2	of	O
3	the	O
4	proportion	O
5	of	O
6	nonsynonymous	O
7	(	O
8	pN	O
9	)	O
10	and	O
11	synonymous	O
12	(	O
13	pS	O
14	)	O
15	substitutions	O
16	occurring	O
17	per	O
18	site	O
19	within	O
20	tamarin	B
21	variable	I
22	region	I
23	genes	I
24	demonstrated	O
25	a	O
26	reduction	O
27	in	O
28	pN	O
29	in	O
30	the	O
31	framework	O
32	regions	O
33	compared	O
34	with	O
35	pN	O
36	in	O
37	the	O
38	presumed	O
39	MHC	B
40	contact	I
41	regions	I
42	(	O
43	CDR1	B
44	and	O
45	CDR2	B
46	).	O

1	Manifest	O
2	anxiety	O
3	of	O
4	Vietnam	O
5	returnees	O
6	and	O
7	undergraduates	O
8	.	O

1	In	O
2	the	O
3	group	O
4	of	O
5	asthmatics	O
6	statistically	O
7	significant	O
8	correlation	O
9	was	O
10	found	O
11	between	O
12	PC20	O
13	PGF2	O
14	alpha	O
15	and	O
16	histamine	O
17	values	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	538	O
24	,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	05	O
31	).	O

1	IdB	O
2	1031	O
3	was	O
4	first	O
5	extracted	O
6	by	O
7	liquid	O
8	-	O
9	solid	O
10	partition	O
11	and	O
12	the	O
13	extracts	O
14	were	O
15	evaporated	O
16	and	O
17	analysed	O
18	on	O
19	a	O
20	reversed	O
21	-	O
22	phase	O
23	column	O
24	under	O
25	isocratic	O
26	conditions	O
27	,	O
28	using	O
29	either	O
30	an	O
31	electrochemical	O
32	or	O
33	a	O
34	UV	O
35	detector	O
36	.	O

1	The	O
2	different	O
3	holoenzyme	B
4	RNA	I
5	polymerases	I
6	generated	O
7	upon	O
8	reconstituting	O
9	these	O
10	mutants	O
11	independently	O
12	with	O
13	core	B
14	RNA	I
15	polymerase	I
16	(	O
17	alpha2beta	O
18	beta	O
19	')	O
20	have	O
21	shown	O
22	reduced	O
23	transcriptional	O
24	activity	O
25	in	O
26	comparison	O
27	to	O
28	the	O
29	enzyme	O
30	containing	O
31	wild	B
32	-	I
33	type	I
34	sigma	I
35	factor	I
36	.	O

1	The	O
2	muscles	O
3	from	O
4	the	O
5	ischemic	O
6	group	O
7	had	O
8	significantly	O
9	lower	O
10	(	O
11	P	O
12	less	O
13	than	O
14	.	O
15	05	O
16	)	O
17	values	O
18	for	O
19	capillary	O
20	density	O
21	and	O
22	capillary	O
23	to	O
24	fiber	O
25	ratio	O
26	and	O
27	significantly	O
28	higher	O
29	intercapillary	O
30	distance	O
31	than	O
32	those	O
33	from	O
34	the	O
35	normal	O
36	group	O
37	.	O

1	Furthermore	O
2	,	O
3	the	O
4	amount	O
5	of	O
6	tRNA	B
7	(	I
8	3Lys	I
9	)	I
10	that	O
11	was	O
12	placed	O
13	onto	O
14	viral	O
15	RNA	O
16	in	O
17	mutated	O
18	viruses	O
19	was	O
20	significantly	O
21	less	O
22	than	O
23	that	O
24	placed	O
25	in	O
26	the	O
27	wild	O
28	-	O
29	type	O
30	virus	O
31	.	O

1	Irradiation	O
2	of	O
3	human	O
4	blood	O
5	platelets	O
6	with	O
7	UV	O
8	-	O
9	A	O
10	in	O
11	vitro	O
12	impairs	O
13	their	O
14	ability	O
15	to	O
16	aggregate	O
17	after	O
18	challenge	O
19	with	O
20	collagen	B
21	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'-	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	human	B
11	multidrug	I
12	resistance	I
13	protein	I
14	2	I
15	(	O
16	MRP2	B
17	)	O
18	gene	O
19	and	O
20	its	O
21	regulation	O
22	in	O
23	comparison	O
24	withthe	O
25	multidrug	B
26	resistance	I
27	protein	I
28	3	I
29	(	O
30	MRP3	B
31	)	O
32	gene	O
33	.	O

1	The	O
2	signalling	O
3	molecules	O
4	Wnt1	B
5	and	O
6	Sonic	B
7	hedgehog	I
8	,	O
9	implicated	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	Myf5	B
15	in	O
16	myogenic	O
17	progenitor	O
18	cells	O
19	in	O
20	the	O
21	somite	O
22	,	O
23	are	O
24	also	O
25	produced	O
26	in	O
27	the	O
28	viscinity	O
29	of	O
30	the	O
31	Myf5	B
32	expression	I
33	domain	I
34	in	O
35	the	O
36	mesencephalon	O
37	.	O

1	Five	O
2	out	O
3	of	O
4	eight	O
5	consecutive	O
6	cases	O
7	with	O
8	initial	O
9	symptoms	O
10	of	O
11	a	O
12	'	O
13	midline	O
14	granuloma	O
15	'	O
16	were	O
17	identified	O
18	as	O
19	malignant	O
20	histiocytosis	O
21	(	O
22	histiocytic	O
23	sarcoma	O
24	)	O
25	which	O
26	within	O
27	5	O
28	months	O
29	to	O
30	4	O
31	years	O
32	led	O
33	to	O
34	generalization	O
35	and	O
36	death	O
37	.	O

1	Tensile	O
2	bond	O
3	strengths	O
4	between	O
5	resin	O
6	composite	O
7	and	O
8	bovine	O
9	dentin	O
10	using	O
11	dentin	O
12	adhesive	O
13	systems	O
14	(	O
15	Clearfil	O
16	Liner	O
17	Bond	O
18	II	O
19	:	O
20	LB	O
21	II	O
22	;	O
23	Scotchbond	O
24	Multi	O
25	-	O
26	Purpose	O
27	:	O
28	MP	O
29	)	O
30	bonding	O
31	systems	O
32	showed	O
33	a	O
34	large	O
35	scatter	O
36	among	O
37	students	O
38	and	O
39	dentists	O
40	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	DNA	O
6	methylation	O
7	,	O
8	chromatin	O
9	structure	O
10	,	O
11	and	O
12	transactivation	O
13	at	O
14	an	O
15	Sp1	B
16	site	I
17	contribute	O
18	to	O
19	the	O
20	highly	O
21	restricted	O
22	expression	O
23	of	O
24	this	O
25	myelomonocytic	O
26	lineage	O
27	specific	O
28	gene	O
29	.	O

1	Using	O
2	these	O
3	antibodies	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	define	O
10	the	O
11	conditions	O
12	to	O
13	completely	O
14	solubilize	O
15	the	O
16	Cdc25	B
17	protein	I
18	.	O

1	Plasma	B
2	lactoferrin	I
3	and	O
4	the	O
5	blood	O
6	count	O
7	of	O
8	polynuclear	O
9	neutrophils	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	the	O
6	GAL7	B
7	5	I
8	'	I
9	flanking	I
10	region	I
11	has	O
12	many	O
13	features	O
14	common	O
15	to	O
16	those	O
17	of	O
18	multicellular	O
19	eukaryotic	O
20	genes	O
21	.	O

1	Transcription	O
2	initiation	O
3	occurred	O
4	predominantly	O
5	at	O
6	the	O
7	putative	O
8	sigmaA	B
9	-	I
10	dependent	I
11	promoter	I
12	in	O
13	exponentially	O
14	growing	O
15	cells	O
16	and	O
17	was	O
18	induced	O
19	under	O
20	stress	O
21	conditions	O
22	.	O

1	The	O
2	cloning	O
3	of	O
4	PTR2	B
5	represents	O
6	the	O
7	first	O
8	example	O
9	of	O
10	the	O
11	molecular	O
12	genetic	O
13	characterization	O
14	of	O
15	a	O
16	eucaryotic	O
17	peptide	O
18	transport	O
19	gene	O
20	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	zygotically	O
6	activated	O
7	Xretpos	O
8	transcripts	O
9	are	O
10	restricted	O
11	to	O
12	ventro	O
13	-	O
14	posterior	O
15	specific	O
16	regions	O
17	and	O
18	induced	O
19	by	O
20	UV	O
21	-	O
22	irradiation	O
23	and	O
24	BMP	B
25	-	I
26	4	I
27	overexpression	O
28	in	O
29	cycloheximide	O
30	-	O
31	dependent	O
32	way	O
33	.	O
34	genesis	O
35	26	O
36	:	O
37	198	O
38	-	O
39	207	O
40	,	O
41	2000	O
42	.	O

1	MR	O
2	imaging	O
3	of	O
4	traumatic	O
5	head	O
6	injuries	O
7	using	O
8	FLAIR	O
9	technique	O

1	Most	O
2	kinases	O
3	are	O
4	not	O
5	significantly	O
6	inhibited	O
7	by	O
8	roscovitine	O
9	.	O
10	cdc2	B
11	/	O
12	cyclin	B
13	B	I
14	,	O
15	cdk2	B
16	/	O
17	cyclin	B
18	A	I
19	,	O
20	cdk2	B
21	/	O
22	cyclin	B
23	E	I
24	and	O
25	cdk5	B
26	/	O
27	p35	B
28	only	O
29	are	O
30	substantially	O
31	inhibited	O
32	(	O
33	IC50	O
34	values	O
35	of	O
36	0	O
37	.	O
38	65	O
39	,	O
40	0	O
41	.	O
42	7	O
43	,	O
44	0	O
45	.	O
46	7	O
47	and	O
48	0	O
49	.	O
50	2	O
51	microM	O
52	,	O
53	respectively	O
54	).	O
55	cdk4	B
56	/	O
57	cyclin	B
58	D1	I
59	and	O
60	cdk6	B
61	/	O
62	cyclin	B
63	D2	I
64	are	O
65	very	O
66	poorly	O
67	inhibited	O
68	by	O
69	roscovitine	O
70	(	O
71	IC50	O
72	>	O
73	100	O
74	microM	O
75	).	O

1	This	O
2	report	O
3	presents	O
4	an	O
5	analysis	O
6	of	O
7	the	O
8	vocal	O
9	repertoire	O
10	of	O
11	howler	O
12	monkeys	O
13	(	O
14	Alouatta	O
15	palliata	O
16	)	O
17	observed	O
18	during	O
19	a	O
20	field	O
21	study	O
22	in	O
23	southwestern	O
24	Panama	O
25	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	We	O
6	prospectively	O
7	compared	O
8	the	O
9	automated	O
10	measurements	O
11	of	O
12	left	O
13	ventricular	O
14	ejection	O
15	fraction	O
16	(	O
17	LVEF	O
18	)	O
19	and	O
20	volumes	O
21	from	O
22	rest	O
23	-	O
24	injected	O
25	gated	O
26	Technetium	O
27	99m	O
28	(	O
29	Tc99m	O
30	)	O
31	perfusion	O
32	SPECT	O
33	with	O
34	equilibrium	O
35	radionuclide	O
36	angiocardiography	O
37	(	O
38	ERNA	O
39	)	O
40	in	O
41	62	O
42	patients	O
43	and	O
44	the	O
45	assessment	O
46	of	O
47	regional	O
48	function	O
49	with	O
50	echocardiography	O
51	in	O
52	22	O
53	patients	O
54	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	P2	B
6	-	I
7	proximal	I
8	CTCF	I
9	binding	I
10	site	I
11	and	O
12	transient	O
13	-	O
14	cotransfection	O
15	experiments	O
16	demonstrate	O
17	that	O
18	CTCF	B
19	is	O
20	a	O
21	transcriptional	O
22	repressor	O
23	of	O
24	the	O
25	human	B
26	c	I
27	-	I
28	myc	I
29	gene	I
30	.	O

1	Aspirin	O
2	intolerance	O
3	:	O
4	unaltered	O
5	susceptibility	O
6	of	O
7	platelet	B
8	cyclo	I
9	-	I
10	oxygenase	I
11	to	O
12	inhibition	O
13	by	O
14	aspirin	O
15	in	O
16	vitro	O
17	.	O

1	Yeast	B
2	Gal11	I
3	protein	I
4	mediates	O
5	the	O
6	transcriptional	O
7	activation	O
8	signal	O
9	of	O
10	two	O
11	different	O
12	transacting	O
13	factors	O
14	,	O
15	Gal4	B
16	and	O
17	general	B
18	regulatory	I
19	factor	I
20	I	I
21	/	O
22	repressor	B
23	/	I
24	activator	I
25	site	I
26	binding	I
27	protein	I
28	1	I
29	/	I
30	translation	I
31	upstream	I
32	factor	I
33	.	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	demonstrate	O
7	that	O
8	strongyloidiasis	O
9	was	O
10	the	O
11	cause	O
12	of	O
13	sudden	O
14	death	O
15	.	O

1	These	O
2	findings	O
3	suggest	O
4	one	O
5	potential	O
6	mechanism	O
7	for	O
8	direct	O
9	recruitment	O
10	of	O
11	distal	O
12	regulatory	O
13	regions	O
14	of	O
15	the	O
16	globin	B
17	loci	I
18	to	O
19	the	O
20	individual	O
21	promoters	O
22	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	region	O
6	revealed	O
7	three	O
8	eight	O
9	-	O
10	bp	O
11	repetitive	O
12	elements	O
13	,	O
14	the	O
15	deletion	O
16	of	O
17	which	O
18	restored	O
19	wild	O
20	-	O
21	type	O
22	levels	O
23	of	O
24	luciferase	B
25	activity	O
26	to	O
27	the	O
28	-	O
29	916	O
30	-	O
31	bp	O
32	reporter	O
33	plasmid	O
34	.	O

1	Bioplastique	O
2	granuloma	O
3	presents	O
4	with	O
5	irregularly	O
6	shaped	O
7	cystic	O
8	spaces	O
9	of	O
10	varying	O
11	size	O
12	containing	O
13	jagged	O
14	,	O
15	translucent	O
16	,	O
17	nonbirefringent	O
18	foreign	O
19	bodies	O
20	whereas	O
21	Artecoll	O
22	granuloma	O
23	shows	O
24	numerous	O
25	round	O
26	vacuoles	O
27	nearly	O
28	identical	O
29	in	O
30	size	O
31	and	O
32	shape	O
33	enclosing	O
34	round	O
35	and	O
36	sharply	O
37	circumscribed	O
38	,	O
39	translucent	O
40	,	O
41	nonbirefringent	O
42	foreign	O
43	bodies	O
44	.	O

1	Optimal	O
2	monitoring	O
3	of	O
4	ODA	O
5	remains	O
6	undefined	O
7	.	O

1	The	O
2	fracture	O
3	groups	O
4	were	O
5	significantly	O
6	older	O
7	and	O
8	had	O
9	more	O
10	years	O
11	since	O
12	menopause	O
13	than	O
14	the	O
15	control	O
16	groups	O
17	.	O

1	MCh	O
2	infusion	O
3	caused	O
4	a	O
5	concentration	O
6	-	O
7	dependent	O
8	increase	O
9	in	O
10	airway	O
11	resistance	O
12	at	O
13	constant	O
14	QBA	O
15	.	O

1	A	O
2	second	O
3	study	O
4	group	O
5	,	O
6	with	O
7	intact	O
8	cardiac	O
9	innervation	O
10	,	O
11	consisted	O
12	of	O
13	19	O
14	patients	O
15	with	O
16	stable	O
17	angina	O
18	pectoris	O
19	class	O
20	I	O
21	to	O
22	III	O
23	.	O

1	The	O
2	method	O
3	was	O
4	adapted	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	nadolol	O
10	racemate	O
11	A	O
12	by	O
13	a	O
14	change	O
15	in	O
16	mobile	O
17	phase	O
18	composition	O
19	.	O

1	Experimentally	O
2	in	O
3	green	O
4	monkeys	O
5	,	O
6	Syrian	O
7	hamsters	O
8	and	O
9	white	O
10	mice	O
11	the	O
12	authors	O
13	studied	O
14	the	O
15	pathogenic	O
16	properties	O
17	of	O
18	a	O
19	new	O
20	virus	O
21	Issyk	O
22	-	O
23	Kul	O
24	.	O

1	Monitoring	O
2	changes	O
3	in	O
4	the	O
5	heart	O
6	rate	O
7	of	O
8	the	O
9	premature	O
10	fetus	O
11	during	O
12	tocolysis	O
13	with	O
14	the	O
15	beta	O
16	-	O
17	adrenomimetics	O
18	partusisten	O
19	and	O
20	Pre	O
21	-	O
22	par	O

1	There	O
2	were	O
3	35	O
4	boys	O
5	and	O
6	15	O
7	girls	O
8	,	O
9	with	O
10	a	O
11	mean	O
12	age	O
13	of	O
14	five	O
15	and	O
16	a	O
17	half	O
18	years	O
19	.	O

1	The	O
2	report	O
3	highlights	O
4	the	O
5	possible	O
6	contribution	O
7	of	O
8	stress	O
9	factors	O
10	in	O
11	the	O
12	context	O
13	of	O
14	therapy	O
15	resistant	O
16	periodontal	O
17	disease	O
18	,	O
19	and	O
20	the	O
21	results	O
22	seem	O
23	to	O
24	be	O
25	understandable	O
26	within	O
27	the	O
28	context	O
29	of	O
30	a	O
31	stress	O
32	system	O
33	disorder	O
34	perspective	O
35	.	O

1	The	O
2	12	B
3	,	I
4	000	I
5	MW	I
6	(	I
7	12K	I
8	)	I
9	IE	I
10	polypeptide	I
11	encoded	O
12	by	O
13	IEmRNA	B
14	-	I
15	5	I
16	is	O
17	translated	O
18	from	O
19	an	O
20	88	O
21	codon	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	leaving	O
27	a	O
28	1200	O
29	base	O
30	3	O
31	'	O
32	non	O
33	-	O
34	translated	O
35	region	O
36	.	O

1	The	O
2	effects	O
3	of	O
4	taloximine	O
5	and	O
6	aminophylline	O
7	on	O
8	isolated	O
9	human	O
10	smooth	O
11	muscle	O
12	.	O

1	Compared	O
2	to	O
3	controls	O
4	,	O
5	both	O
6	UB	O
7	and	O
8	OCS	O
9	rats	O
10	showed	O
11	a	O
12	small	O
13	but	O
14	significant	O
15	post	O
16	-	O
17	operative	O
18	reduction	O
19	in	O
20	the	O
21	nocturnality	O
22	of	O
23	drinking	O
24	.	O

1	Using	O
2	fluorescence	O
3	in	O
4	situ	O
5	hybridization	O
6	,	O
7	we	O
8	mapped	O
9	the	O
10	chromosome	O
11	-	O
12	17	O
13	breakpoint	O
14	in	O
15	a	O
16	patient	O
17	with	O
18	acampomelic	O
19	CMPD	O
20	and	O
21	sex	O
22	reversal	O
23	,	O
24	who	O
25	carries	O
26	a	O
27	de	O
28	novo	O
29	constitutional	O
30	t	O
31	(	O
32	12	O
33	;	O
34	17	O
35	)	O
36	translocation	O
37	,	O
38	between	O
39	two	O
40	known	O
41	cosmid	O
42	markers	O
43	in	O
44	the	O
45	17q24	O
46	-	O
47	q25	O
48	region	O
49	.	O

1	In	O
2	these	O
3	cells	O
4	,	O
5	E2	B
6	proteins	I
7	had	O
8	little	O
9	or	O
10	no	O
11	stimulatory	O
12	effect	O
13	on	O
14	the	O
15	transcriptional	O
16	activity	O
17	of	O
18	the	O
19	HPV	B
20	-	I
21	11	I
22	enhancer	I
23	-	O
24	SV40	B
25	promoter	I
26	.	O

1	However	O
2	,	O
3	in	O
4	contrast	O
5	with	O
6	previous	O
7	in	O
8	vitro	O
9	cell	O
10	-	O
11	free	O
12	integration	O
13	studies	O
14	,	O
15	alteration	O
16	of	O
17	the	O
18	highly	O
19	conserved	O
20	CA	O
21	dinucleotide	O
22	resulted	O
23	in	O
24	a	O
25	mutant	O
26	which	O
27	still	O
28	retained	O
29	40	O
30	%	O
31	of	O
32	wild	O
33	-	O
34	type	O
35	integration	O
36	activity	O
37	.	O

1	Genetic	O
2	abnormalities	O
3	that	O
4	could	O
5	lead	O
6	to	O
7	mutagenesis	O
8	include	O
9	chromosomal	O
10	abnormalities	O
11	and	O
12	single	O
13	-	O
14	gene	O
15	mutations	O
16	.	O

1	A	O
2	study	O
3	of	O
4	the	O
5	E	O
6	.	O
7	O	O
8	.	O
9	R	O
10	.	O
11	T	O
12	.	O
13	C	O
14	.	O

1	This	O
2	phosphorylation	O
3	can	O
4	be	O
5	catalyzed	O
6	by	O
7	a	O
8	break	O
9	-	O
10	ended	O
11	double	O
12	-	O
13	stranded	O
14	DNA	O
15	-	O
16	activated	O
17	protein	O
18	kinase	O
19	activity	O
20	from	O
21	the	O
22	sea	O
23	urchin	O
24	nucleus	O
25	in	O
26	vitro	O
27	.	O

1	18F	O
2	and	O
3	85Sr	O
4	scintimetry	O
5	in	O
6	the	O
7	study	O
8	of	O
9	primary	O
10	arthropathies	O
11	.	O

1	Restoration	O
2	of	O
3	impaired	O
4	immune	O
5	functions	O
6	in	O
7	aging	O
8	animals	O
9	.	O

1	Total	O
2	serum	O
3	calcium	O
4	was	O
5	7	O
6	.	O
7	8	O
8	+/-	O
9	0	O
10	.	O
11	8	O
12	mg	O
13	/	O
14	dl	O
15	,	O
16	whereas	O
17	ionized	O
18	calcium	O
19	was	O
20	5	O
21	.	O
22	7	O
23	+/-	O
24	0	O
25	.	O
26	7	O
27	mg	O
28	/	O
29	dl	O
30	,	O
31	phosphorus	O
32	3	O
33	.	O
34	2	O
35	+/-	O
36	1	O
37	.	O
38	2	O
39	mg	O
40	/	O
41	dl	O
42	,	O
43	and	O
44	alkaline	B
45	phosphatase	I
46	149	O
47	+/-	O
48	48	O
49	.	O
50	6	O
51	U	O
52	/	O
53	liter	O
54	.	O

1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	HBV	O
6	markers	O
7	was	O
8	higher	O
9	among	O
10	staff	O
11	members	O
12	than	O
13	in	O
14	the	O
15	blood	O
16	donors	O
17	of	O
18	our	O
19	area	O
20	.	O

1	Efficacy	O
2	of	O
3	a	O
4	three	O
5	-	O
6	versus	O
7	a	O
8	five	O
9	-	O
10	week	O
11	alcohol	O
12	treatment	O
13	program	O
14	.	O

1	Isomers	O
2	were	O
3	differentiated	O
4	based	O
5	on	O
6	the	O
7	MS	O
8	-	O
9	MS	O
10	data	O
11	of	O
12	the	O
13	trofluoroacetyl	O
14	-	O
15	biphenylol	O
16	derivatives	O
17	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	Swi4	B
6	and	O
7	Swi6	B
8	cell	O
9	viability	O
10	is	O
11	lost	O
12	,	O
13	but	O
14	can	O
15	be	O
16	regained	O
17	by	O
18	ectopic	O
19	expression	O
20	of	O
21	the	O
22	G1	B
23	cyclin	I
24	encoding	I
25	genes	I
26	,	O
27	CLN1	B
28	or	O
29	CLN2	B
30	.	O

1	Recording	O
2	of	O
3	the	O
4	digital	O
5	sphygmic	O
6	activity	O
7	in	O
8	the	O
9	lower	O
10	extremities	O
11	with	O
12	the	O
13	photoplethysmographic	O
14	and	O
15	strain	O
16	-	O
17	gauge	O
18	methods	O
19	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	effectiveness	O
5	of	O
6	monoamine	B
7	oxidase	I
8	inhibitors	O
9	(	O
10	MAOIs	O
11	)	O
12	in	O
13	tricyclic	O
14	resistant	O
15	depression	O
16	has	O
17	received	O
18	surprisingly	O
19	little	O
20	systematic	O
21	study	O
22	.	O

1	Implication	O
2	of	O
3	PAF	B
4	and	O
5	acetylhydrolase	B
6	(	O
7	PAF	B
8	-	I
9	AH	I
10	)	O
11	activity	O
12	in	O
13	periodontal	O
14	disease	O
15	.	O

1	The	O
2	ZNF274	B
3	gene	I
4	is	O
5	mapped	O
6	distal	O
7	to	O
8	marker	O
9	RP	O
10	S28	O
11	1	O
12	in	O
13	the	O
14	human	O
15	chromosome	O
16	19qter	O
17	region	O
18	,	O
19	by	O
20	RH	O
21	mapping	O
22	.	O

1	Two	O
2	potential	O
3	regulatory	O
4	sequences	O
5	for	O
6	DNA	O
7	binding	O
8	proteins	O
9	were	O
10	found	O
11	in	O
12	the	O
13	non	O
14	-	O
15	coding	O
16	5	O
17	'	O
18	region	O
19	:	O
20	a	O
21	HAP2	B
22	/	O
23	HAP3	B
24	consensus	O
25	recognition	O
26	sequence	O
27	at	O
28	nucleotide	O
29	-	O
30	154	O
31	and	O
32	a	O
33	BAF1	B
34	consensus	I
35	recognition	I
36	sequence	I
37	at	O
38	nucleotide	O
39	-	O
40	136	O
41	.	O

1	DNase	B
2	I	I
3	and	O
4	1	O
5	,	O
6	10	O
7	-	O
8	phenanthroline	O
9	-	O
10	copper	O
11	footprinting	O
12	of	O
13	MURA	B
14	-	O
15	Mu1	B
16	TIR	O
17	complexes	O
18	indicate	O
19	that	O
20	MURA	B
21	binds	O
22	to	O
23	a	O
24	conserved	O
25	approximately	O
26	32	O
27	-	O
28	bp	O
29	region	O
30	in	O
31	the	O
32	TIR	O
33	of	O
34	Mu1	B
35	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	how	O
6	these	O
7	expression	O
8	patterns	O
9	are	O
10	established	O
11	,	O
12	we	O
13	fused	O
14	promoter	O
15	regions	O
16	of	O
17	an	O
18	acidic	O
19	and	O
20	a	O
21	basic	O
22	glucanase	B
23	gene	I
24	to	O
25	the	O
26	beta	B
27	-	I
28	glucuronidase	I
29	(	O
30	GUS	B
31	)	O
32	reporter	O
33	gene	O
34	and	O
35	examined	O
36	expression	O
37	of	O
38	these	O
39	constructs	O
40	in	O
41	transgenic	O
42	tobacco	O
43	plants	O
44	.	O

1	Widening	O
2	of	O
3	the	O
4	abdominal	O
5	aortic	O
6	wall	O
7	on	O
8	an	O
9	ultrasound	O
10	examination	O
11	was	O
12	the	O
13	key	O
14	to	O
15	the	O
16	incidental	O
17	diagnosis	O
18	of	O
19	a	O
20	clinically	O
21	unsuspected	O
22	type	O
23	B	O
24	dissection	O
25	.	O

1	Two	O
2	distinct	O
3	recessive	O
4	susceptibility	O
5	loci	O
6	for	O
7	vasculitis	O
8	were	O
9	mapped	O
10	on	O
11	chromosome	O
12	(	O
13	Chr	O
14	)	O
15	4	O
16	at	O
17	D4Mit89	B
18	and	O
19	D4Mit147	B
20	in	O
21	both	O
22	progenies	O
23	.	O

1	METHODS	O
2	--	O
3	16	O
4	volunteered	O
5	for	O
6	spirometry	O
7	with	O
8	methacholine	O
9	provocation	O
10	test	O
11	including	O
12	a	O
13	test	O
14	for	O
15	small	O
16	airways	O
17	function	O
18	by	O
19	volume	O
20	of	O
21	trapped	O
22	gas	O
23	(	O
24	VTG	O
25	).	O

1	We	O
2	conclude	O
3	that	O
4	transcription	O
5	activation	O
6	by	O
7	LEF	B
8	-	I
9	1	I
10	in	O
11	vitro	O
12	is	O
13	a	O
14	chromatin	O
15	-	O
16	dependent	O
17	process	O
18	that	O
19	requires	O
20	a	O
21	functional	O
22	trans	O
23	-	O
24	activation	O
25	domain	O
26	in	O
27	addition	O
28	to	O
29	the	O
30	HMG	B
31	domain	I
32	.	O

1	Model	O
2	predictions	O
3	were	O
4	in	O
5	accord	O
6	with	O
7	the	O
8	nine	O
9	-	O
10	year	O
11	survival	O
12	experience	O
13	of	O
14	women	O
15	in	O
16	the	O
17	HIP	O
18	trial	O
19	,	O
20	and	O
21	,	O
22	with	O
23	the	O
24	exception	O
25	of	O
26	women	O
27	40	O
28	-	O
29	44	O
30	years	O
31	old	O
32	,	O
33	with	O
34	HIP	O
35	data	O
36	on	O
37	18	O
38	-	O
39	year	O
40	survival	O
41	.	O

1	Independent	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	cassette	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O

1	Dopamine	B
2	beta	I
3	-	I
4	hydroxylase	I
5	(	O
6	DBH	B
7	)	O
8	catalyzes	O
9	the	O
10	conversion	O
11	of	O
12	dopamine	O
13	to	O
14	noradrenaline	O
15	and	O
16	is	O
17	selectively	O
18	expressed	O
19	in	O
20	noradrenergic	O
21	and	O
22	adrenergic	O
23	neurons	O
24	and	O
25	neuroendocrine	O
26	cells	O
27	.	O

1	Practical	O
2	interest	O
3	of	O
4	such	O
5	studies	O
6	is	O
7	limited	O
8	since	O
9	the	O
10	pharmacokinetic	O
11	parameters	O
12	are	O
13	systematically	O
14	evaluated	O
15	in	O
16	man	O
17	during	O
18	phase	O
19	I	O
20	trials	O
21	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	direct	O
6	cDNA	O
7	mapping	O
8	using	O
9	fluorescence	O
10	in	O
11	situ	O
12	hybridization	O
13	provides	O
14	an	O
15	accurate	O
16	and	O
17	rapid	O
18	approach	O
19	to	O
20	the	O
21	definition	O
22	of	O
23	a	O
24	transcribed	O
25	map	O
26	of	O
27	the	O
28	human	O
29	genome	O
30	.	O

1	The	O
2	hematopoietic	B
3	colony	I
4	-	I
5	stimulating	I
6	factors	I
7	(	O
8	CSF	B
9	)	O
10	have	O
11	been	O
12	introduced	O
13	into	O
14	clinical	O
15	practice	O
16	as	O
17	additional	O
18	supportive	O
19	measures	O
20	that	O
21	can	O
22	reduce	O
23	the	O
24	incidence	O
25	of	O
26	infectious	O
27	complications	O
28	in	O
29	patients	O
30	with	O
31	cancer	O
32	and	O
33	neutropenia	O
34	.	O

1	Oncogenic	O
2	signalling	O
3	by	O
4	E2F1	B
5	has	O
6	recently	O
7	been	O
8	linked	O
9	to	O
10	stabilization	O
11	and	O
12	activation	O
13	of	O
14	the	O
15	tumour	O
16	suppressor	O
17	p53	B
18	(	O
19	refs	O
20	1	O
21	,	O
22	3	O
23	,	O
24	4	O
25	).	O

1	In	O
2	particular	O
3	,	O
4	Western	O
5	,	O
6	supershift	O
7	,	O
8	and	O
9	promoter	O
10	deletion	O
11	analyses	O
12	suggested	O
13	a	O
14	role	O
15	for	O
16	CCAAT	B
17	/	I
18	enhancer	I
19	-	I
20	binding	I
21	protein	I
22	-	I
23	beta	I
24	(	O
25	C	B
26	/	I
27	EBP	I
28	-	I
29	beta	I
30	)	O
31	binding	O
32	site	O
33	between	O
34	-	O
35	2010	O
36	and	O
37	-	O
38	1954	O
39	in	O
40	regulating	O
41	transcription	O
42	of	O
43	collagenase	B
44	-	I
45	1	I
46	in	O
47	monocytic	O
48	cells	O
49	.	O

1	A	O
2	poor	O
3	correlation	O
4	was	O
5	also	O
6	observed	O
7	between	O
8	PbB	O
9	and	O
10	ALAD	B
11	activity	O
12	of	O
13	the	O
14	stearate	O
15	workers	O
16	.	O

1	Cloning	O
2	and	O
3	sequence	O
4	analyses	O
5	revealed	O
6	a	O
7	second	O
8	cDNA	O
9	with	O
10	a	O
11	95	O
12	-	O
13	nt	O
14	deletion	O
15	in	O
16	the	O
17	region	O
18	coding	O
19	for	O
20	the	O
21	putative	O
22	second	O
23	intracellular	O
24	loop	O
25	and	O
26	the	O
27	fourth	O
28	transmembrane	O
29	domain	O
30	of	O
31	the	O
32	5	B
33	-	I
34	HT2C	I
35	-	I
36	R	I
37	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	rapidly	O
5	induces	O
6	a	O
7	reversible	O
8	change	O
9	in	O
10	the	O
11	electrophoretic	O
12	mobility	O
13	of	O
14	the	O
15	ternary	O
16	complex	O
17	,	O
18	accompanied	O
19	by	O
20	increased	O
21	phosphorylation	O
22	of	O
23	the	O
24	Elk	B
25	-	I
26	1	I
27	C	I
28	-	I
29	terminal	I
30	region	I
31	and	O
32	by	O
33	the	O
34	activation	O
35	of	O
36	a	O
37	42	B
38	kd	I
39	cellular	I
40	Elk	I
41	-	I
42	1	I
43	kinase	I
44	.	O

1	Six	O
2	hours	O
3	after	O
4	the	O
5	last	O
6	administration	O
7	,	O
8	uterus	O
9	of	O
10	Gf	O
11	and	O
12	Cv	O
13	mice	O
14	were	O
15	weight	O
16	337	O
17	.	O
18	6	O
19	mg	O
20	%	O
21	and	O
22	423	O
23	.	O
24	5	O
25	mg	O
26	%	O
27	respectively	O
28	,	O
29	the	O
30	difference	O
31	was	O
32	statistically	O
33	significant	O
34	(	O
35	p	O
36	less	O
37	than	O
38	0	O
39	.	O
40	01	O
41	).	O

1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	O
16	and	O
17	a	O
18	17	O
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	O
25	R7G	B
26	family	I
27	of	O
28	G	B
29	-	I
30	protein	I
31	coupled	I
32	membrane	I
33	-	I
34	bound	I
35	receptors	I
36	.	O

1	Further	O
2	studies	O
3	of	O
4	mandibular	O
5	movement	O
6	at	O
7	initial	O
8	tooth	O
9	contact	O
10	.	O

1	Simian	O
2	parainfluenza	O
3	virus	O
4	5	O
5	(	O
6	SV5	O
7	)	O
8	is	O
9	a	O
10	prototype	O
11	of	O
12	the	O
13	Paramyxoviridae	O
14	family	O
15	of	O
16	nonsegmented	O
17	negative	O
18	-	O
19	sense	O
20	RNA	O
21	viruses	O
22	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	pMxL1	O
6	plasmid	O
7	containing	O
8	the	O
9	invertible	O
10	region	O
11	contains	O
12	a	O
13	perfect	O
14	tandem	O
15	repeat	O
16	of	O
17	19	O
18	bp	O
19	in	O
20	the	O
21	orientation	O
22	1	O
23	nonexpressed	O
24	pilin	B
25	gene	I
26	at	O
27	the	O
28	middle	O
29	of	O
30	the	O
31	recombination	O
32	junction	O
33	site	O
34	.	O

1	To	O
2	the	O
3	problem	O
4	of	O
5	the	O
6	stimulation	O
7	of	O
8	the	O
9	growth	O
10	of	O
11	transplantable	O
12	tumors	O
13	of	O
14	animals	O
15	previously	O
16	treated	O
17	with	O
18	antineoplastic	O
19	antibiotics	O

1	The	O
2	inhibition	O
3	by	O
4	the	O
5	RIalpha	B
6	subunit	I
7	is	O
8	reversed	O
9	by	O
10	addition	O
11	of	O
12	nanomolar	O
13	concentrations	O
14	of	O
15	cAMP	O
16	(	O
17	Ka	O
18	=	O
19	40	O
20	nM	O
21	),	O
22	thus	O
23	demonstrating	O
24	that	O
25	PrKX	B
26	is	O
27	a	O
28	novel	O
29	,	O
30	type	B
31	I	I
32	cAMP	I
33	-	I
34	dependent	I
35	protein	I
36	kinase	I
37	that	O
38	is	O
39	activated	O
40	at	O
41	lower	O
42	cAMP	O
43	concentrations	O
44	than	O
45	the	O
46	holoenzyme	O
47	with	O
48	the	O
49	Calpha	B
50	subunit	I
51	of	O
52	cAMP	B
53	-	I
54	dependent	I
55	protein	I
56	kinase	I
57	.	O

1	Factor	O
2	V	O
3	Leiden	O
4	is	O
5	a	O
6	genetic	O
7	disorder	O
8	associated	O
9	with	O
10	an	O
11	increased	O
12	risk	O
13	of	O
14	venous	O
15	thrombosis	O
16	.	O

1	Topical	O
2	L	O
3	-	O
4	NNA	O
5	attenuated	O
6	the	O
7	hypercapnic	O
8	increase	O
9	of	O
10	CoBF	O
11	by	O
12	52	O
13	+/-	O
14	6	O
15	%	O
16	and	O
17	CeBF	O
18	by	O
19	29	O
20	+/-	O
21	5	O
22	%	O
23	after	O
24	45	O
25	-	O
26	min	O
27	exposure	O
28	.	O

1	Reconstitution	O
2	of	O
3	complexes	O
4	containing	O
5	p62	B
6	and	O
7	the	O
8	src	B
9	family	I
10	kinase	I
11	p59fyn	I
12	in	O
13	HeLa	O
14	cells	O
15	demonstrated	O
16	that	O
17	complex	O
18	formation	O
19	resulted	O
20	in	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	p62	B
25	and	O
26	was	O
27	mediated	O
28	by	O
29	both	O
30	the	O
31	SH3	B
32	and	O
33	SH2	B
34	domains	I
35	of	O
36	p59fyn	B
37	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	positions	O
6	of	O
7	the	O
8	VV	O
9	genes	O
10	(	O
11	genus	O
12	Orthopoxvirus	O
13	)	O
14	are	O
15	different	O
16	than	O
17	those	O
18	of	O
19	the	O
20	corresponding	O
21	ORFs	O
22	in	O
23	SFV	O
24	(	O
25	genus	O
26	Leporipoxvirus	O
27	),	O
28	indicating	O
29	complex	O
30	rearrangements	O
31	of	O
32	DNA	O
33	in	O
34	the	O
35	genome	O
36	of	O
37	one	O
38	or	O
39	both	O
40	of	O
41	these	O
42	viruses	O
43	subsequent	O
44	to	O
45	their	O
46	divergence	O
47	from	O
48	a	O
49	common	O
50	ancestor	O
51	.	O

1	However	O
2	,	O
3	further	O
4	analyses	O
5	of	O
6	the	O
7	data	O
8	indicate	O
9	that	O
10	increasing	O
11	VO2	O
12	AT	O
13	(	O
14	r	O
15	=	O
16	-	O
17	0	O
18	.	O
19	63	O
20	,	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	05	O
27	)	O
28	rather	O
29	than	O
30	VO2max	O
31	(	O
32	r	O
33	=	O
34	-	O
35	0	O
36	.	O
37	15	O
38	)	O
39	could	O
40	result	O
41	in	O
42	improving	O
43	the	O
44	10	O
45	,	O
46	000	O
47	m	O
48	race	O
49	performance	O
50	to	O
51	a	O
52	larger	O
53	extent	O
54	,	O
55	and	O
56	that	O
57	the	O
58	absolute	O
59	amount	O
60	of	O
61	change	O
62	(	O
63	delta	O
64	)	O
65	in	O
66	the	O
67	10	O
68	,	O
69	000	O
70	m	O
71	run	O
72	time	O
73	is	O
74	best	O
75	accounted	O
76	for	O
77	by	O
78	a	O
79	combination	O
80	of	O
81	delta	O
82	VO2	O
83	AT	O
84	and	O
85	delta	O
86	5	O
87	,	O
88	000	O
89	m	O
90	run	O
91	time	O
92	.	O

1	Selenium	O
2	(.	O
3	1	O
4	ppm	O
5	)	O
6	and	O
7	E	O
8	(	O
9	50	O
10	IU	O
11	/	O
12	kg	O
13	)	O
14	supplementation	O
15	of	O
16	the	O
17	diet	O
18	of	O
19	the	O
20	sow	O
21	increased	O
22	plasma	O
23	tocopherol	O
24	and	O
25	Se	O
26	concentrations	O
27	,	O
28	but	O
29	did	O
30	not	O
31	increase	O
32	plasma	B
33	glutathione	I
34	peroxidase	I
35	(	O
36	GSH	B
37	-	I
38	Px	I
39	)	O
40	activity	O
41	.	O

1	Three	O
2	experiments	O
3	contrasted	O
4	the	O
5	effects	O
6	of	O
7	6	O
8	-	O
9	hydroxydopamine	O
10	-	O
11	induced	O
12	lesions	O
13	of	O
14	the	O
15	ventral	O
16	noradrenergic	O
17	and	O
18	dorsal	O
19	noradrenergic	O
20	projections	O
21	,	O
22	predominantly	O
23	to	O
24	hypothalamus	O
25	and	O
26	cortex	O
27	,	O
28	respectively	O
29	,	O
30	upon	O
31	body	O
32	weight	O
33	changes	O
34	and	O
35	food	O
36	-	O
37	related	O
38	behaviour	O
39	in	O
40	the	O
41	rat	O
42	.	O

1	Sequence	O
2	comparisons	O
3	strongly	O
4	suggest	O
5	that	O
6	the	O
7	S27a	B
8	and	O
9	the	O
10	ubiquitin	B
11	coding	O
12	sequences	O
13	found	O
14	in	O
15	the	O
16	genome	O
17	of	O
18	CP	O
19	Rit	O
20	were	O
21	both	O
22	derived	O
23	from	O
24	a	O
25	bovine	O
26	mRNA	O
27	encoding	O
28	a	O
29	hybrid	O
30	protein	O
31	with	O
32	the	O
33	structure	O
34	NH2	O
35	-	O
36	ubiquitin	B
37	-	O
38	S27a	B
39	-	O
40	COOH	O
41	.	O

1	Members	O
2	of	O
3	SVA	B
4	are	O
5	also	O
6	present	O
7	in	O
8	the	O
9	complement	B
10	C2	I
11	gene	I
12	located	O
13	about	O
14	20	O
15	kilobases	O
16	upstream	O
17	of	O
18	RP1	B
19	in	O
20	the	O
21	HLA	B
22	and	O
23	in	O
24	the	O
25	cytochrome	B
26	CYP1A1	I
27	gene	I
28	.	O

1	A	O
2	comparison	O
3	among	O
4	the	O
5	5	O
6	'	O
7	flanking	O
8	regions	O
9	encompassing	O
10	the	O
11	presumptive	O
12	HS	B
13	promoter	I
14	of	O
15	the	O
16	soybean	B
17	HS	I
18	-	I
19	protein	I
20	genes	I
21	demonstrated	O
22	this	O
23	region	O
24	to	O
25	be	O
26	extremely	O
27	homologous	O
28	.	O

1	Vitamin	O
2	D3	O
3	and	O
4	calcium	O
5	absorption	O
6	in	O
7	the	O
8	chick	O
9	.	O

1	Both	O
2	quantitative	O
3	and	O
4	qualitative	O
5	analysis	O
6	of	O
7	individual	O
8	cytoarchitectonic	O
9	peculiarities	O
10	of	O
11	Meynart	O
12	'	O
13	s	O
14	nucleus	O
15	as	O
16	well	O
17	as	O
18	of	O
19	external	O
20	part	O
21	of	O
22	dorsomedial	O
23	nucleus	O
24	of	O
25	thalamus	O
26	was	O
27	performed	O
28	in	O
29	mentally	O
30	normal	O
31	individuals	O
32	.	O

1	Neural	O
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O

1	Ten	O
2	patients	O
3	with	O
4	advanced	O
5	,	O
6	diffuse	O
7	Hodgkin	O
8	'	O
9	s	O
10	and	O
11	non	O
12	-	O
13	Hodgkin	O
14	'	O
15	s	O
16	lymphomas	O
17	responding	O
18	poorly	O
19	to	O
20	the	O
21	most	O
22	widely	O
23	employed	O
24	primary	O
25	chemotherapy	O
26	regimens	O
27	were	O
28	treated	O
29	with	O
30	a	O
31	high	O
32	-	O
33	dose	O
34	chemotherapy	O
35	(	O
36	HDC	O
37	)	O
38	followed	O
39	by	O
40	rescue	O
41	with	O
42	non	O
43	-	O
44	frozen	O
45	autologous	O
46	bone	O
47	marrow	O
48	infusion	O
49	(	O
50	ABMT	O
51	).	O

1	Mean	O
2	weighted	O
3	skin	O
4	temperature	O
5	(	O
6	Tsk	O
7	)	O
8	was	O
9	lower	O
10	(	O
11	P	O
12	less	O
13	than	O
14	0	O
15	.	O
16	01	O
17	)	O
18	following	O
19	acclimation	O
20	than	O
21	before	O
22	,	O
23	and	O
24	acclimation	O
25	resulted	O
26	in	O
27	a	O
28	larger	O
29	(	O
30	P	O
31	less	O
32	than	O
33	0	O
34	.	O
35	02	O
36	)	O
37	Tre	O
38	-	O
39	to	O
40	-	O
41	Tsk	O
42	gradient	O
43	.	O

1	Control	O
2	of	O
3	transcription	O
4	of	O
5	the	O
6	erbB	B
7	-	I
8	2	I
9	gene	I
10	is	O
11	an	O
12	important	O
13	determinant	O
14	of	O
15	receptor	O
16	expression	O
17	.	O

1	The	O
2	debate	O
3	over	O
4	electives	O
5	--	O
6	1899	O
7	.	O

1	The	O
2	Lm	O
3	increased	O
4	and	O
5	the	O
6	alveoli	O
7	/	O
8	mm2	O
9	and	O
10	elastic	O
11	recoil	O
12	pressure	O
13	decreased	O
14	.	O

1	In	O
2	conclusion	O
3	,	O
4	we	O
5	observed	O
6	a	O
7	great	O
8	regeneration	O
9	ability	O
10	following	O
11	mechanical	O
12	injury	O
13	in	O
14	the	O
15	nasal	O
16	mucosa	O
17	.	O

1	Studies	O
2	on	O
3	alcoholic	O
4	liver	O
5	injury	O
6	.	O

1	No	O
2	serious	O
3	side	O
4	effects	O
5	were	O
6	observed	O
7	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	thrombin	B
9	-	O
10	stimulated	O
11	vascular	O
12	smooth	O
13	muscle	O
14	proliferation	O
15	is	O
16	delayed	O
17	and	O
18	requires	O
19	the	O
20	de	O
21	novo	O
22	expression	O
23	of	O
24	one	O
25	or	O
26	more	O
27	autocrine	O
28	mitogens	O
29	.	O

1	NuA4	B
2	has	O
3	an	O
4	apparent	O
5	molecular	O
6	mass	O
7	of	O
8	1	O
9	.	O
10	3	O
11	MDa	O
12	.	O

1	The	O
2	characteristic	O
3	feature	O
4	of	O
5	liver	O
6	and	O
7	spleen	O
8	MP	O
9	function	O
10	in	O
11	patients	O
12	with	O
13	VHA	O
14	associated	O
15	with	O
16	HBsAg	B
17	carriership	O
18	consisted	O
19	in	O
20	the	O
21	lack	O
22	of	O
23	the	O
24	compensatory	O
25	reaction	O
26	on	O
27	the	O
28	part	O
29	of	O
30	spleen	O
31	MP	O
32	,	O
33	which	O
34	was	O
35	likely	O
36	to	O
37	be	O
38	connected	O
39	with	O
40	overstrain	O
41	of	O
42	long	O
43	standing	O
44	and	O
45	depletion	O
46	of	O
47	the	O
48	MP	O
49	system	O
50	due	O
51	to	O
52	permanent	O
53	antigenic	O
54	stimulation	O
55	of	O
56	HBsAg	B
57	.	O

1	Purified	B
2	Pra	I
3	was	O
4	also	O
5	shown	O
6	to	O
7	physically	O
8	interact	O
9	with	O
10	pyruvate	B
11	kinase	I
12	(	O
13	Pk	B
14	);	O
15	Pk	B
16	and	O
17	Pra	B
18	can	O
19	form	O
20	a	O
21	complex	O
22	,	O
23	but	O
24	when	O
25	the	O
26	12	B
27	-	I
28	kDa	I
29	Ndk	I
30	,	O
31	Pk	B
32	,	O
33	and	O
34	Pra	B
35	are	O
36	all	O
37	present	O
38	,	O
39	Pk	B
40	has	O
41	a	O
42	higher	O
43	affinity	O
44	than	O
45	Pra	B
46	for	O
47	forming	O
48	a	O
49	complex	O
50	with	O
51	the	O
52	12	B
53	-	I
54	kDa	I
55	Ndk	I
56	.	O

1	L3	O
2	-	O
3	L4	O
4	compressive	O
5	load	O
6	was	O
7	calculated	O
8	using	O
9	a	O
10	model	O
11	of	O
12	the	O
13	anatomy	O
14	of	O
15	the	O
16	trunk	O
17	musculoskeletal	O
18	system	O
19	.	O

1	The	O
2	scr	B
3	regulon	I
4	of	O
5	pUR400	O
6	and	O
7	the	O
8	chromosomally	B
9	encoded	I
10	scr	I
11	regulon	I
12	of	I
13	Klebsiella	I
14	pneumoniae	I
15	KAY2026	I
16	are	O
17	both	O
18	negatively	O
19	controlled	O
20	by	O
21	a	O
22	specific	O
23	repressor	O
24	(	O
25	ScrR	B
26	).	O

1	Auto	O
2	-	O
3	and	O
4	isotopy	O
5	of	O
6	the	O
7	conjunctiva	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	transactivation	O
6	domain	O
7	of	O
8	heat	B
9	shock	I
10	factor	I
11	1	I
12	is	O
13	negatively	O
14	regulated	O
15	and	O
16	stress	O
17	responsive	O
18	.	O

1	The	O
2	rate	O
3	of	O
4	resectability	O
5	is	O
6	low	O
7	and	O
8	5	O
9	-	O
10	year	O
11	survival	O
12	is	O
13	very	O
14	poor	O
15	.	O

1	The	O
2	Abbreviated	O
3	Injury	O
4	Scale	O
5	(	O
6	AIS	O
7	),	O
8	Injury	O
9	Severity	O
10	Scale	O
11	and	O
12	TRISS	O
13	methodology	O
14	comprise	O
15	a	O
16	mathematically	O
17	sound	O
18	system	O
19	for	O
20	the	O
21	analysis	O
22	of	O
23	injuries	O
24	and	O
25	injured	O
26	patients	O
27	.	O

1	Three	O
2	group	O
3	1	O
4	patients	O
5	developed	O
6	CMV	O
7	disease	O
8	;	O
9	1	O
10	group	O
11	2	O
12	patient	O
13	developed	O
14	CMV	O
15	hepatitis	O
16	.	O

1	15	O
2	,	O
3	2500	O
4	-	O
5	2508	O
6	;	O
7	O	O
8	'	O
9	Neill	O
10	,	O
11	T	O
12	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	regions	O
6	of	O
7	both	O
8	pelA	B
9	and	O
10	pelB	B
11	were	O
12	translationally	O
13	fused	O
14	to	O
15	the	O
16	beta	B
17	-	I
18	glucuronidase	I
19	gene	I
20	and	O
21	introduced	O
22	into	O
23	F	O
24	.	O
25	solani	O
26	f	O
27	.	O
28	sp	O
29	.	O
30	pisi	O
31	,	O
32	and	O
33	beta	B
34	-	I
35	glucuronidase	I
36	activities	O
37	of	O
38	the	O
39	transformants	O
40	were	O
41	measured	O
42	.	O

1	Fifty	O
2	-	O
3	one	O
4	patients	O
5	with	O
6	primary	O
7	refractory	O
8	or	O
9	relapsed	O
10	malignant	O
11	lymphoma	O
12	(	O
13	47	O
14	non	O
15	-	O
16	Hodgkin	O
17	'	O
18	s	O
19	lymphoma	O
20	and	O
21	four	O
22	Hodgkin	O
23	'	O
24	s	O
25	disease	O
26	)	O
27	were	O
28	treated	O
29	with	O
30	a	O
31	new	O
32	chemotherapeutic	O
33	regimen	O
34	(	O
35	cisplatinum	O
36	,	O
37	methyl	O
38	GAG	O
39	,	O
40	bleomocyin	O
41	,	O
42	methyl	O
43	prednisolon	O
44	).	O

1	An	O
2	aromatic	O
3	stacking	O
4	interaction	O
5	between	O
6	subunits	O
7	helps	O
8	mediate	O
9	DNA	O
10	sequence	O
11	specificity	O
12	:	O
13	operator	O
14	site	O
15	discrimination	O
16	by	O
17	phage	B
18	lambda	I
19	cI	I
20	repressor	I
21	.	O

1	Signaling	O
2	from	O
3	the	O
4	small	B
5	GTP	I
6	-	I
7	binding	I
8	proteins	I
9	Rac1	I
10	and	O
11	Cdc42	B
12	to	O
13	the	O
14	c	B
15	-	I
16	Jun	I
17	N	I
18	-	I
19	terminal	I
20	kinase	I
21	/	O
22	stress	B
23	-	I
24	activated	I
25	protein	I
26	kinase	I
27	pathway	O
28	.	O

1	Interferon	B
2	Regulatory	I
3	Factor	I
4	(	I
5	IRF	I
6	)-	I
7	1	I
8	has	O
9	been	O
10	characterized	O
11	as	O
12	an	O
13	important	O
14	growth	O
15	regulatory	O
16	and	O
17	immunomodulatory	O
18	transcription	O
19	factor	O
20	.	O

1	Thus	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	the	O
7	Cln2	B
8	PEST	I
9	domain	I
10	was	O
11	sufficient	O
12	to	O
13	destabilize	O
14	a	O
15	heterologous	O
16	protein	O
17	.	O

1	One	O
2	such	O
3	element	O
4	,	O
5	1P	O
6	,	O
7	was	O
8	employed	O
9	to	O
10	clone	O
11	from	O
12	a	O
13	rat	O
14	pituitary	O
15	cDNA	O
16	expression	O
17	library	O
18	a	O
19	novel	O
20	417	B
21	-	I
22	amino	I
23	acid	I
24	WD	I
25	protein	I
26	,	O
27	designated	O
28	PREB	B
29	(	I
30	PRL	I
31	regulatory	I
32	element	I
33	binding	I
34	)	I
35	protein	I
36	.	O

1	Partial	O
2	sequencing	O
3	of	O
4	the	O
5	region	O
6	downstream	O
7	of	O
8	ORF	B
9	-	I
10	Pto	I
11	revealed	O
12	homology	O
13	to	O
14	the	O
15	ru	B
16	/	I
17	AB	I
18	genes	I
19	,	O
20	involved	O
21	in	O
22	UV	O
23	resistance	O
24	,	O
25	from	O
26	plasmid	O
27	pPSR1	O
28	.	O

1	In	O
2	contrast	O
3	with	O
4	previous	O
5	two	O
6	-	O
7	pool	O
8	models	O
9	,	O
10	provisions	O
11	were	O
12	made	O
13	for	O
14	folate	O
15	turnover	O
16	by	O
17	urinary	O
18	folate	O
19	excretion	O
20	(	O
21	as	O
22	measured	O
23	here	O
24	)	O
25	and	O
26	by	O
27	fecal	O
28	excretion	O
29	and	O
30	catabolic	O
31	processes	O
32	.	O

1	Mutations	O
2	in	O
3	the	O
4	RP2	B
5	locus	I
6	at	I
7	Xp11	I
8	.	I
9	3	I
10	were	O
11	found	O
12	in	O
13	a	O
14	further	O
15	10	O
16	-	O
17	20	O
18	%	O
19	of	O
20	XLRP	O
21	patients	O
22	,	O
23	as	O
24	predicted	O
25	from	O
26	linkage	O
27	studies	O
28	.	O

1	(	O
2	5	O
3	)	O
4	No	O
5	changes	O
6	were	O
7	observed	O
8	in	O
9	the	O
10	gastric	O
11	venous	O
12	blood	O
13	flow	O
14	by	O
15	continuous	O
16	intravenous	O
17	injection	O
18	of	O
19	cimetidine	O
20	,	O
21	but	O
22	by	O
23	rapid	O
24	injection	O
25	both	O
26	the	O
27	flow	O
28	was	O
29	augmented	O
30	and	O
31	the	O
32	systemic	O
33	blood	O
34	pressure	O
35	decreased	O
36	transiently	O
37	.	O

1	Interestingly	O
2	,	O
3	Csx	B
4	/	O
5	Nkx2	B
6	.	O

1	The	O
2	protein	O
3	encoded	O
4	is	O
5	114	O
6	kDa	O
7	and	O
8	contains	O
9	eight	O
10	zinc	O
11	finger	O
12	motifs	O
13	,	O
14	seven	O
15	of	O
16	which	O
17	are	O
18	present	O
19	in	O
20	two	O
21	clusters	O
22	at	O
23	opposite	O
24	ends	O
25	of	O
26	the	O
27	molecule	O
28	.	O

1	N	O
2	-	O
3	Substituted	O
4	trimethylsilylcarbamates	O
5	were	O
6	tested	O
7	as	O
8	derivatizing	O
9	reagents	O
10	for	O
11	gas	O
12	chromatographic	O
13	analysis	O
14	.	O

1	When	O
2	the	O
3	l	O
4	-	O
5	methadone	O
6	-	O
7	sensitive	O
8	,	O
9	opioid	B
10	receptor	I
11	is	O
12	blocked	O
13	by	O
14	naloxone	O
15	or	O
16	tolerance	O
17	has	O
18	developed	O
19	,	O
20	than	O
21	l	O
22	-	O
23	methadone	O
24	can	O
25	produce	O
26	behavioral	O
27	effects	O
28	by	O
29	a	O
30	nonopioid	O
31	mechanism	O
32	.	O

1	It	O
2	could	O
3	also	O
4	inhibit	O
5	C1q	B
6	-	O
7	dependent	O
8	haemolysis	O
9	of	O
10	both	O
11	IgG	B
12	-	O
13	and	O
14	IgM	B
15	-	O
16	sensitized	O
17	erythrocytes	O
18	.	O

1	Drosophila	O
2	230	O
3	-	O
4	kD	O
5	TFIID	B
6	subunit	O
7	,	O
8	a	O
9	functional	O
10	homolog	O
11	of	O
12	the	O
13	human	O
14	cell	O
15	cycle	O
16	gene	O
17	product	O
18	,	O
19	negatively	O
20	regulates	O
21	DNA	O
22	binding	O
23	of	O
24	the	O
25	TATA	B
26	box	I
27	-	I
28	binding	I
29	subunit	I
30	of	I
31	TFIID	I
32	.	O

1	The	O
2	thrombolytic	O
3	effects	O
4	of	O
5	native	O
6	tissue	B
7	-	I
8	type	I
9	plasminogen	I
10	activator	I
11	(	O
12	AK	B
13	-	I
14	124	I
15	)	O
16	on	O
17	experimental	O
18	canine	O
19	coronary	O
20	thrombosis	O
21	.	O

1	Serum	O
2	induction	O
3	of	O
4	a	O
5	MEF2	B
6	reporter	I
7	gene	I
8	was	O
9	not	O
10	observed	O
11	in	O
12	a	O
13	line	O
14	of	O
15	NIH	O
16	3T3	O
17	cells	O
18	which	O
19	contain	O
20	low	O
21	MEF2	B
22	site	I
23	binding	O
24	activity	O
25	.	O

1	In	O
2	overdoses	O
3	up	O
4	to	O
5	2	O
6	g	O
7	fluvoxamine	O
8	no	O
9	lasting	O
10	toxic	O
11	effects	O
12	were	O
13	observed	O
14	.	O

1	Typical	O
2	and	O
3	atypical	O
4	clinical	O
5	features	O
6	of	O
7	this	O
8	lacrimal	O
9	sac	O
10	cyst	O
11	are	O
12	emphasized	O
13	.	O

1	W	O
2	.	O

1	Clinically	O
2	meaningful	O
3	decreases	O
4	due	O
5	to	O
6	alkalinization	O
7	alone	O
8	within	O
9	30	O
10	minutes	O
11	are	O
12	unlikely	O
13	.	O

1	Based	O
2	on	O
3	peptide	O
4	map	O
5	similarities	O
6	,	O
7	partial	O
8	amino	O
9	-	O
10	terminal	O
11	sequence	O
12	data	O
13	,	O
14	and	O
15	common	O
16	genetic	O
17	origin	O
18	,	O
19	it	O
20	is	O
21	suggested	O
22	that	O
23	p60	B
24	and	O
25	p62	B
26	have	O
27	identical	O
28	amino	O
29	acid	O
30	sequences	O
31	carboxy	O
32	-	O
33	terminal	O
34	to	O
35	the	O
36	p60	B
37	initiator	O
38	methionine	O
39	(	O
40	residue	O
41	21	O
42	of	O
43	p62	B
44	).	O

1	It	O
2	was	O
3	possible	O
4	to	O
5	classify	O
6	the	O
7	animals	O
8	into	O
9	high	O
10	and	O
11	low	O
12	responders	O
13	according	O
14	to	O
15	the	O
16	pattern	O
17	of	O
18	humoral	O
19	immune	O
20	response	O
21	.	O

1	The	O
2	amplitude	O
3	of	O
4	detrusor	O
5	contractions	O
6	at	O
7	6	O
8	,	O
9	12	O
10	,	O
11	and	O
12	24	O
13	hours	O
14	showed	O
15	no	O
16	significant	O
17	difference	O
18	from	O
19	that	O
20	in	O
21	the	O
22	controls	O
23	.	O

1	Acute	O
2	pancreatitis	O
3	is	O
4	a	O
5	rather	O
6	common	O
7	abdominal	O
8	disorder	O
9	.	O

1	Mutations	O
2	in	O
3	the	O
4	alpha	B
5	and	I
6	sigma	I
7	-	I
8	70	I
9	subunits	I
10	of	I
11	RNA	I
12	polymerase	I
13	affect	O
14	expression	O
15	of	O
16	the	O
17	mer	B
18	operon	I
19	.	O

1	X	O
2	-	O
3	linked	O
4	liver	O
5	glycogenosis	O
6	:	O
7	localization	O
8	and	O
9	isolation	O
10	of	O
11	a	O
12	candidate	O
13	gene	O
14	.	O

1	Monospecific	O
2	antibodies	O
3	raised	O
4	against	O
5	rat	B
6	cytochrome	I
7	P	I
8	-	I
9	450	I
10	1A1	I
11	recognized	O
12	a	O
13	protein	O
14	in	O
15	the	O
16	hepatic	O
17	microsomes	O
18	of	O
19	the	O
20	double	O
21	-	O
22	crested	O
23	cormorant	O
24	,	O
25	and	O
26	also	O
27	in	O
28	those	O
29	of	O
30	the	O
31	great	O
32	blue	O
33	heron	O
34	(	O
35	Ardea	O
36	herodias	O
37	),	O
38	using	O
39	immunoblotting	O
40	.	O

1	EIAV	B
2	LTR	I
3	sequence	I
4	variability	O
5	is	O
6	confined	O
7	mostly	O
8	to	O
9	a	O
10	small	O
11	portion	O
12	of	O
13	the	O
14	enhancer	O
15	within	O
16	the	O
17	U3	O
18	segment	O
19	of	O
20	the	O
21	LTR	O
22	.	O

1	TG	O
2	-	O
3	day	O
4	and	O
5	TG	O
6	-	O
7	night	O
8	were	O
9	19	O
10	.	O
11	4	O
12	+/-	O
13	6	O
14	.	O
15	1	O
16	%,	O
17	26	O
18	.	O
19	6	O
20	+/-	O
21	5	O
22	.	O
23	3	O
24	%,	O
25	(	O
26	750	O
27	mm3	O
28	<	O
29	T	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	5	O
5	'	O
6	deletions	O
7	removing	O
8	all	O
9	but	O
10	34	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	transcription	O
16	start	O
17	point	O
18	retained	O
19	greater	O
20	than	O
21	90	O
22	%	O
23	promoter	O
24	activity	O
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	-	O
30	35	O
31	hexamer	O
32	was	O
33	not	O
34	essential	O
35	for	O
36	promoter	O
37	activity	O
38	.	O

1	The	O
2	genes	O
3	encoding	O
4	the	O
5	transcription	B
6	factor	I
7	yTAFII60	I
8	,	O
9	the	O
10	G4p1	B
11	protein	I
12	and	O
13	a	O
14	putative	O
15	glucose	O
16	transporter	O
17	are	O
18	contained	O
19	in	O
20	a	O
21	12	O
22	.	O
23	3	O
24	kb	O
25	DNA	O
26	fragment	O
27	on	O
28	the	O
29	left	O
30	arm	O
31	of	O
32	Saccharomyces	O
33	cerevisiae	O
34	chromosome	O
35	VII	O
36	.	O

1	Identification	O
2	of	O
3	an	O
4	AfsA	B
5	homologue	I
6	(	O
7	BarX	B
8	)	O
9	from	O
10	Streptomyces	O
11	virginiae	O
12	as	O
13	a	O
14	pleiotropic	O
15	regulator	O
16	controlling	O
17	autoregulator	O
18	biosynthesis	O
19	,	O
20	virginiamycin	O
21	biosynthesis	O
22	and	O
23	virginiamycin	O
24	M1	O
25	resistance	O
26	.	O

1	This	O
2	core	O
3	sequence	O
4	,	O
5	along	O
6	with	O
7	additional	O
8	nonspecific	O
9	downstream	O
10	nucleotides	O
11	,	O
12	is	O
13	sufficient	O
14	for	O
15	partial	O
16	suppression	O
17	of	O
18	spliceosome	O
19	assembly	O
20	and	O
21	splicing	O
22	of	O
23	BPV	O
24	-	O
25	1	O
26	pre	O
27	-	O
28	mRNAs	O
29	.	O

1	When	O
2	a	O
3	tumour	O
4	is	O
5	present	O
6	nipple	O
7	discharge	O
8	is	O
9	of	O
10	little	O
11	importance	O
12	for	O
13	the	O
14	diagnosis	O
15	and	O
16	treatment	O
17	.	O

1	Exposure	O
2	of	O
3	peripheral	O
4	blood	O
5	T	O
6	cells	O
7	from	O
8	young	O
9	subjects	O
10	to	O
11	PHA	B
12	or	O
13	cross	O
14	-	O
15	linked	O
16	anti	B
17	-	I
18	CD3	I
19	monoclonal	I
20	antibodies	I
21	stimulated	O
22	rapid	O
23	increases	O
24	in	O
25	MAPK	B
26	and	O
27	MEK	B
28	enzymatic	O
29	activity	O
30	.	O

1	Both	O
2	groups	O
3	rejected	O
4	pops	O
5	with	O
6	added	O
7	SOA	O
8	,	O
9	decreasing	O
10	mouthing	O
11	times	O
12	as	O
13	SOA	O
14	concentration	O
15	increased	O
16	.	O

1	This	O
2	slope	O
3	tended	O
4	to	O
5	be	O
6	higher	O
7	(	O
8	approximately	O
9	1	O
10	.	O
11	6	O
12	dB	O
13	/	O
14	dB	O
15	)	O
16	for	O
17	L1	O
18	=	O
19	L2	O
20	greater	O
21	than	O
22	80	O
23	dB	O
24	.	O

1	We	O
2	also	O
3	demonstrate	O
4	that	O
5	preformed	O
6	triplexes	O
7	are	O
8	quite	O
9	stable	O
10	when	O
11	precipitated	O
12	with	O
13	ethanol	O
14	and	O
15	resuspended	O
16	in	O
17	water	O
18	.	O

1	The	O
2	sub	O
3	-	O
4	acute	O
5	inhalation	O
6	toxicity	O
7	of	O
8	furfural	O
9	was	O
10	studied	O
11	in	O
12	Syrian	O
13	golden	O
14	hamsters	O
15	.	O

1	AB004534	B
2	.	O

1	A	O
2	5	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	DNA	O
8	fragment	O
9	,	O
10	which	O
11	included	O
12	the	O
13	entire	O
14	structural	O
15	porin	B
16	gene	I
17	(	O
18	named	O
19	porCa	B
20	)	O
21	and	O
22	its	O
23	flanking	O
24	regions	O
25	,	O
26	was	O
27	identified	O
28	.	O

1	The	O
2	git1	B
3	,	O
4	git3	B
5	,	O
6	git5	B
7	,	O
8	git7	B
9	,	O
10	git8	B
11	and	O
12	git10	B
13	genes	I
14	act	O
15	upstream	O
16	of	O
17	adenylate	B
18	cyclase	I
19	,	O
20	presumably	O
21	encoding	O
22	an	O
23	adenylate	B
24	cyclase	I
25	activation	O
26	pathway	O
27	.	O

1	The	O
2	rate	O
3	-	O
4	decreasing	O
5	effects	O
6	of	O
7	morphine	O
8	and	O
9	U50488	O
10	were	O
11	reversed	O
12	completely	O
13	by	O
14	a	O
15	0	O
16	.	O
17	01	O
18	and	O
19	1	O
20	.	O
21	0	O
22	mg	O
23	/	O
24	kg	O
25	dose	O
26	of	O
27	naloxone	O
28	,	O
29	respectively	O
30	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	relationship	O
7	between	O
8	comprehension	O
9	and	O
10	production	O
11	is	O
12	different	O
13	at	O
14	different	O
15	stages	O
16	in	O
17	development	O
18	.	O

1	This	O
2	agent	O
3	,	O
4	isolated	O
5	from	O
6	the	O
7	fungus	O
8	Streptomyces	O
9	tsukubaensis	O
10	,	O
11	has	O
12	a	O
13	mechanism	O
14	of	O
15	action	O
16	similar	O
17	to	O
18	that	O
19	of	O
20	cyclosporine	O
21	.	O

1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	B
13	TATA	I
14	motif	I
15	.	O

1	The	O
2	247	O
3	-	O
4	kDa	O
5	complex	O
6	appears	O
7	to	O
8	contain	O
9	two	O
10	distinct	O
11	protein	O
12	-	O
13	DNA	O
14	complexes	O
15	of	O
16	approximately	O
17	232	O
18	and	O
19	256	O
20	kDa	O
21	and	O
22	represents	O
23	two	O
24	proteins	O
25	covalently	O
26	cross	O
27	-	O
28	linked	O
29	to	O
30	a	O
31	single	O
32	DRE	O
33	oligonucleotide	O
34	,	O
35	while	O
36	the	O
37	97	O
38	,	O
39	105	O
40	,	O
41	and	O
42	115	O
43	-	O
44	kDa	O
45	complexes	O
46	represent	O
47	single	O
48	protein	O
49	-	O
50	DRE	O
51	cross	O
52	-	O
53	links	O
54	.	O

1	Computer	O
2	analysis	O
3	included	O
4	digital	O
5	averaging	O
6	,	O
7	followed	O
8	by	O
9	digital	O
10	filtering	O
11	in	O
12	different	O
13	frequency	O
14	bands	O
15	in	O
16	order	O
17	to	O
18	determine	O
19	the	O
20	frequency	O
21	range	O
22	corresponding	O
23	to	O
24	notches	O
25	and	O
26	slurs	O
27	.	O

1	A	O
2	DNA	O
3	fragment	O
4	carrying	O
5	1	O
6	,	O
7	100	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	UGT1A1	B
19	gene	I
20	was	O
21	enough	O
22	for	O
23	MC	O
24	induction	O
25	.	O

1	As	O
2	in	O
3	the	O
4	other	O
5	three	O
6	members	O
7	whose	O
8	gene	O
9	expression	O
10	is	O
11	altered	O
12	during	O
13	tumorigenesis	O
14	,	O
15	PI12	B
16	expression	O
17	was	O
18	found	O
19	to	O
20	be	O
21	down	O
22	-	O
23	regulated	O
24	in	O
25	tumor	O
26	brain	O
27	tissues	O
28	and	O
29	in	O
30	two	O
31	brain	O
32	cancer	O
33	cell	O
34	lines	O
35	:	O
36	U	O
37	-	O
38	87	O
39	MG	O
40	and	O
41	H4	O
42	.	O

1	Under	O
2	halothane	O
3	anesthesia	O
4	,	O
5	the	O
6	flow	O
7	pneumocardiogram	O
8	(	O
9	PnCG	O
10	)	O
11	and	O
12	its	O
13	time	O
14	derivative	O
15	(	O
16	acceleration	O
17	pneumocardiogram	O
18	or	O
19	dPn	O
20	/	O
21	dt	O
22	)	O
23	were	O
24	transduced	O
25	during	O
26	apnea	O
27	by	O
28	a	O
29	small	O
30	high	O
31	-	O
32	gain	O
33	pneumotachograph	O
34	.	O

1	Examination	O
2	of	O
3	neurohumoral	O
4	factors	O
5	revealed	O
6	a	O
7	hyperactive	O
8	sympathetic	O
9	nervous	O
10	system	O
11	and	O
12	an	O
13	increase	O
14	in	O
15	plasma	O
16	renin	B
17	activity	O
18	.	O

1	Solution	O
2	structure	O
3	of	O
4	the	O
5	IRF	B
6	-	I
7	2	I
8	DNA	I
9	-	I
10	binding	I
11	domain	I
12	:	O
13	a	O
14	novel	O
15	subgroup	O
16	of	O
17	the	O
18	winged	B
19	helix	I
20	-	I
21	turn	I
22	-	I
23	helix	I
24	family	I
25	.	O

1	The	O
2	intensity	O
3	of	O
4	myocardial	O
5	uptake	O
6	of	O
7	Tc	O
8	-	O
9	99m	O
10	-	O
11	PYP	O
12	in	O
13	patients	O
14	with	O
15	echocardiographic	O
16	left	O
17	ventricular	O
18	hypertrophy	O
19	and	O
20	/	O
21	or	O
22	highly	O
23	refractile	O
24	myocardial	O
25	echoes	O
26	,	O
27	so	O
28	-	O
29	called	O
30	granular	O
31	sparkling	O
32	appearance	O
33	(	O
34	GS	O
35	)	O
36	was	O
37	slightly	O
38	greater	O
39	than	O
40	that	O
41	in	O
42	patients	O
43	with	O
44	neither	O
45	myocardial	O
46	hypertrophy	O
47	nor	O
48	GS	O
49	.	O

1	Identification	O
2	of	O
3	eotaxin	B
4	-	I
5	3	I
6	will	O
7	further	O
8	promote	O
9	our	O
10	understanding	O
11	of	O
12	the	O
13	control	O
14	of	O
15	eosinophil	O
16	trafficking	O
17	and	O
18	other	O
19	CCR3	B
20	-	O
21	mediated	O
22	biological	O
23	phenomena	O
24	.	O

1	Thus	O
2	,	O
3	phosphodiesterase	O
4	inhibitors	O
5	that	O
6	produce	O
7	an	O
8	opiate	O
9	quasi	O
10	-	O
11	withdrawal	O
12	syndrome	O
13	potentiate	O
14	interoceptive	O
15	stimuli	O
16	and	O
17	weight	O
18	loss	O
19	associated	O
20	with	O
21	the	O
22	withdrawal	O
23	syndrome	O
24	precipitated	O
25	by	O
26	naltrexone	O
27	in	O
28	morphine	O
29	-	O
30	dependent	O
31	rats	O
32	.	O

1	Van	O
2	der	O
3	Ende	O
4	,	O
5	R	O
6	.	O

1	Together	O
2	,	O
3	the	O
4	data	O
5	suggest	O
6	that	O
7	cAMP	O
8	-	O
9	dependent	O
10	control	O
11	of	O
12	the	O
13	amounts	O
14	of	O
15	the	O
16	activator	O
17	SF	B
18	-	I
19	1	I
20	vs	O
21	.	O
22	the	O
23	repressor	O
24	COUP	B
25	-	I
26	TF	I
27	could	O
28	influence	O
29	CRS2	O
30	-	O
31	dependent	O
32	transcription	O
33	.	O

1	Several	O
2	PTPases	B
3	were	O
4	expressed	O
5	abundantly	O
6	in	O
7	the	O
8	5	O
9	-	O
10	FU	O
11	-	O
12	treated	O
13	bone	O
14	marrow	O
15	stem	O
16	cells	O
17	.	O

1	The	O
2	detectability	O
3	of	O
4	the	O
5	defects	O
6	in	O
7	RCA	O
8	or	O
9	LAD	O
10	region	O
11	was	O
12	80	O
13	%	O
14	in	O
15	single	O
16	-	O
17	position	O
18	scans	O
19	in	O
20	stress	O
21	studies	O
22	.	O

1	This	O
2	open	O
3	reading	O
4	frame	O
5	was	O
6	confirmed	O
7	the	O
8	correct	O
9	one	O
10	by	O
11	direct	O
12	amino	O
13	-	O
14	terminal	O
15	sequence	O
16	analysis	O
17	of	O
18	the	O
19	overproduced	O
20	msgB	B
21	gene	I
22	product	I
23	.	O

1	Inhibition	O
2	of	O
3	phosphatidylinositol	B
4	-	I
5	3	I
6	kinase	I
7	did	O
8	not	O
9	have	O
10	a	O
11	significant	O
12	effect	O
13	on	O
14	p53	B
15	conformation	O
16	but	O
17	did	O
18	have	O
19	a	O
20	weak	O
21	but	O
22	significant	O
23	effect	O
24	on	O
25	Tpo	B
26	-	O
27	enhanced	O
28	viability	O
29	.	O

1	The	O
2	prescription	O
3	for	O
4	apoplexy	O
5	includes	O
6	C1	O
7	-	O
8	7	O
9	,	O
10	T1	O
11	-	O
12	9	O
13	and	O
14	L2	O
15	-	O
16	4	O
17	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	largest	O
7	subunit	O
8	of	O
9	RNA	B
10	polymerase	I
11	II	I
12	and	O
13	TFIIB	B
14	are	O
15	important	O
16	determinants	O
17	of	O
18	transcription	O
19	start	O
20	site	O
21	selection	O
22	in	O
23	S	O
24	.	O
25	cerevisiae	O
26	and	O
27	suggest	O
28	that	O
29	this	O
30	function	O
31	might	O
32	be	O
33	conferred	O
34	by	O
35	interaction	O
36	between	O
37	these	O
38	two	O
39	proteins	O
40	.	O

1	Induction	O
2	requires	O
3	the	O
4	ACE1	B
5	gene	I
6	product	I
7	,	O
8	which	O
9	binds	O
10	to	O
11	specific	O
12	sites	O
13	in	O
14	the	O
15	promoter	O
16	region	O
17	of	O
18	the	O
19	CUP1	B
20	gene	I
21	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	cis	O
8	-	O
9	acting	O
10	element	O
11	,	O
12	the	O
13	E1	O
14	E	O
15	-	O
16	box	O
17	,	O
18	located	O
19	in	O
20	the	O
21	GAP	B
22	-	I
23	43	I
24	promoter	O
25	region	O
26	that	O
27	modulates	O
28	either	O
29	positively	O
30	or	O
31	negatively	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	GAP	B
37	-	I
38	43	I
39	gene	I
40	depending	O
41	on	O
42	which	O
43	E	B
44	-	I
45	box	I
46	-	I
47	binding	I
48	proteins	I
49	occupy	O
50	this	O
51	site	O
52	.	O

1	Improvement	O
2	of	O
3	the	O
4	polypyrimidine	O
5	tract	O
6	also	O
7	increased	O
8	the	O
9	splicing	O
10	efficiency	O
11	,	O
12	but	O
13	to	O
14	a	O
15	degree	O
16	slightly	O
17	less	O
18	than	O
19	that	O
20	obtained	O
21	with	O
22	the	O
23	branchpoint	O
24	mutation	O
25	.	O

1	An	O
2	NF1	B
3	-	I
4	related	I
5	vitellogenin	I
6	activator	I
7	element	I
8	mediates	O
9	transcription	O
10	from	O
11	the	O
12	estrogen	O
13	-	O
14	regulated	O
15	Xenopus	B
16	laevis	I
17	vitellogenin	I
18	promoter	I
19	.	O

1	In	O
2	the	O
3	premating	O
4	period	O
5	male	O
6	rate	O
7	of	O
8	aggression	O
9	was	O
10	not	O
11	significantly	O
12	correlated	O
13	with	O
14	testosterone	O
15	level	O
16	.	O

1	Codon	O
2	usage	O
3	in	O
4	C	O
5	.	O
6	reinhardtii	O
7	mitochondria	O
8	is	O
9	highly	O
10	biased	O
11	,	O
12	with	O
13	eight	O
14	codons	O
15	entirely	O
16	absent	O
17	from	O
18	all	O
19	protein	O
20	-	O
21	coding	O
22	genes	O
23	;	O
24	however	O
25	,	O
26	even	O
27	though	O
28	codon	O
29	usage	O
30	is	O
31	restricted	O
32	,	O
33	it	O
34	appears	O
35	that	O
36	C	O
37	.	O
38	reinhardtii	O
39	mtDNA	O
40	cannot	O
41	encode	O
42	the	O
43	minimum	O
44	number	O
45	of	O
46	tRNAs	O
47	needed	O
48	to	O
49	support	O
50	mitochondrial	O
51	protein	O
52	synthesis	O
53	.	O

1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	pro	O
8	-	O
9	inflammatory	O
10	cytokines	O
11	tumor	B
12	necrosis	I
13	factor	I
14	alpha	I
15	and	O
16	interferon	B
17	gamma	I
18	reduce	O
19	the	O
20	expression	O
21	of	O
22	the	O
23	cystic	B
24	fibrosis	I
25	transmembrane	I
26	conductance	I
27	regulator	I
28	(	O
29	CFTR	B
30	)	O
31	gene	O
32	(	O
33	CFTR	B
34	)	O
35	in	O
36	HT	O
37	-	O
38	29	O
39	and	O
40	T84	O
41	cells	O
42	by	O
43	acting	O
44	post	O
45	-	O
46	transcriptionally	O
47	.	O

1	These	O
2	introns	O
3	belong	O
4	to	O
5	the	O
6	class	O
7	of	O
8	nuclear	O
9	pre	O
10	-	O
11	mRNA	O
12	introns	O
13	and	O
14	contain	O
15	typical	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	consensus	O
22	sequences	O
23	,	O
24	as	O
25	well	O
26	as	O
27	unique	O
28	features	O
29	.	O

1	RESULTS	O
2	:	O
3	Prevalence	O
4	of	O
5	obesity	O
6	(	O
7	BMI	O
8	SDS	O
9	>	O
10	2	O
11	.	O
12	0	O
13	)	O
14	was	O
15	<	O
16	2	O
17	%	O
18	at	O
19	diagnosis	O
20	,	O
21	but	O
22	increased	O
23	to	O
24	16	O
25	%	O
26	at	O
27	3y	O
28	.	O

1	The	O
2	results	O
3	of	O
4	replicase	B
5	assays	O
6	performed	O
7	with	O
8	mutant	B
9	VP2	I
10	containing	O
11	a	O
12	deletion	O
13	in	O
14	its	O
15	RNA	O
16	-	O
17	binding	O
18	domain	O
19	suggests	O
20	that	O
21	the	O
22	essential	O
23	role	O
24	for	O
25	VP2	B
26	in	O
27	replication	O
28	is	O
29	linked	O
30	to	O
31	the	O
32	protein	O
33	'	O
34	s	O
35	ability	O
36	to	O
37	bind	O
38	the	O
39	mRNA	O
40	template	O
41	for	O
42	minus	O
43	-	O
44	strand	O
45	synthesis	O
46	.	O

1	Two	O
2	phosphopeptides	O
3	,	O
4	identified	O
5	as	O
6	RS	O
7	-[	O
8	32P	O
9	]	O
10	SGASGLLTSEHHSR	O
11	and	O
12	S	O
13	-[	O
14	32P	O
15	]	O
16	SGASGLLTSEHHSR	O
17	,	O
18	were	O
19	obtained	O
20	after	O
21	stoichiometric	O
22	phosphorylation	O
23	and	O
24	trypsinization	O
25	of	O
26	the	O
27	peptide	O
28	.	O

1	To	O
2	characterize	O
3	this	O
4	effect	O
5	,	O
6	we	O
7	looked	O
8	for	O
9	targets	O
10	of	O
11	NS1	B
12	influenza	I
13	virus	I
14	protein	I
15	among	O
16	cellular	O
17	translation	O
18	factors	O
19	.	O

1	Cardiac	B
2	myosin	I
3	-	I
4	binding	I
5	protein	I
6	C	I
7	(	O
8	MyBP	B
9	-	I
10	C	I
11	):	O
12	identification	O
13	of	O
14	protein	B
15	kinase	I
16	A	I
17	and	O
18	protein	B
19	kinase	I
20	C	I
21	phosphorylation	O
22	sites	O
23	.	O

1	The	O
2	control	O
3	group	O
4	revealed	O
5	significantly	O
6	higher	O
7	levels	O
8	of	O
9	coagulation	B
10	factors	I
11	II	I
12	,	I
13	V	I
14	and	I
15	VIII	I
16	,	O
17	compared	O
18	to	O
19	the	O
20	index	O
21	group	O
22	.	O

1	The	O
2	Babcock	O
3	Surgical	O
4	Clinic	O
5	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	etr	B
6	-	I
7	1	I
8	is	O
9	essential	O
10	for	O
11	muscle	O
12	development	O
13	in	O
14	C	O
15	.	O
16	elegans	O
17	,	O
18	perhaps	O
19	by	O
20	playing	O
21	a	O
22	role	O
23	in	O
24	post	O
25	-	O
26	transcriptional	O
27	processing	O
28	of	O
29	some	O
30	muscle	O
31	component	O
32	,	O
33	and	O
34	thus	O
35	suggesting	O
36	a	O
37	possible	O
38	conservation	O
39	of	O
40	gene	O
41	function	O
42	with	O
43	human	B
44	CUG	I
45	-	I
46	bp	I
47	.	O

1	The	O
2	CANNTG	O
3	motifs	O
4	were	O
5	found	O
6	to	O
7	bind	O
8	MyoD	B
9	and	O
10	myogenin	B
11	fusion	I
12	proteins	I
13	and	O
14	to	O
15	interact	O
16	with	O
17	proteins	O
18	in	O
19	nuclear	O
20	extracts	O
21	from	O
22	cultured	O
23	myotubes	O
24	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	R	O
6	has	O
7	revealed	O
8	similarities	O
9	to	O
10	the	O
11	R1	O
12	plasmid	O
13	found	O
14	in	O
15	some	O
16	South	O
17	American	O
18	maize	O
19	races	O
20	with	O
21	RU	O
22	cytoplasm	O
23	,	O
24	to	O
25	the	O
26	M1	O
27	plasmid	O
28	found	O
29	in	O
30	one	O
31	source	O
32	of	O
33	Zea	O
34	luxurians	O
35	teosinte	O
36	,	O
37	to	O
38	the	O
39	atp9	B
40	mitochondrial	I
41	gene	I
42	and	O
43	its	O
44	3	O
45	'	O
46	flanking	O
47	sequence	O
48	,	O
49	and	O
50	also	O
51	to	O
52	a	O
53	region	O
54	3	O
55	'	O
56	to	O
57	the	O
58	orf221	B
59	gene	I
60	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	RNU2	B
6	fragility	O
7	can	O
8	be	O
9	induced	O
10	by	O
11	transfection	O
12	with	O
13	an	O
14	expression	O
15	vector	O
16	encoding	O
17	Ad12	B
18	E1B	I
19	55	O
20	kDa	O
21	alone	O
22	but	O
23	not	O
24	by	O
25	an	O
26	E1	B
27	vector	O
28	encoding	O
29	all	O
30	E1	B
31	products	I
32	(	O
33	3	O
34	E1A	B
35	proteins	I
36	,	O
37	as	O
38	well	O
39	as	O
40	the	O
41	E1B	B
42	19	O
43	kDa	O
44	and	O
45	55	O
46	kDa	O
47	proteins	O
48	).	O

1	Marked	O
2	elevation	O
3	of	O
4	creatine	B
5	kinase	I
6	was	O
7	observed	O
8	while	O
9	serum	O
10	albumin	B
11	,	O
12	immunoglobulin	B
13	,	O
14	and	O
15	complement	O
16	were	O
17	decreased	O
18	.	O

1	During	O
2	exercise	O
3	K	O
4	+	O
5	is	O
6	released	O
7	from	O
8	contracting	O
9	muscle	O
10	and	O
11	plasma	O
12	K	O
13	+	O
14	concentration	O
15	rises	O
16	.	O

1	Plasma	O
2	and	O
3	erthrocyte	O
4	lipid	O
5	profile	O
6	and	O
7	lipoprotein	B
8	lipase	I
9	activity	O
10	in	O
11	postheparin	O
12	plasma	O
13	on	O
14	vasectomized	O
15	rabbits	O
16	were	O
17	studied	O
18	and	O
19	also	O
20	the	O
21	incidence	O
22	of	O
23	atherosclerosis	O
24	in	O
25	different	O
26	arterial	O
27	beds	O
28	.	O

1	Patient	O
2	characteristics	O
3	associated	O
4	with	O
5	deep	O
6	wounds	O
7	as	O
8	well	O
9	as	O
10	patient	O
11	and	O
12	wound	O
13	characteristics	O
14	predictive	O
15	of	O
16	the	O
17	extent	O
18	of	O
19	healing	O
20	and	O
21	time	O
22	required	O
23	for	O
24	healing	O
25	were	O
26	identified	O
27	.	O

1	The	O
2	results	O
3	confirm	O
4	and	O
5	extend	O
6	previous	O
7	work	O
8	by	O
9	other	O
10	researchers	O
11	.	O

1	The	O
2	cDNA	O
3	clone	O
4	was	O
5	used	O
6	as	O
7	a	O
8	homologous	O
9	probe	O
10	to	O
11	isolate	O
12	a	O
13	truncated	O
14	genomic	O
15	clone	O
16	encoding	O
17	H2A1	B
18	.	O

1	In	O
2	early	O
3	Xenopus	O
4	embryos	O
5	,	O
6	the	O
7	transforming	B
8	growth	I
9	factor	I
10	-	I
11	beta	I
12	member	O
13	activin	B
14	induces	O
15	the	O
16	gene	B
17	Mix	I
18	.	I
19	2	I
20	by	O
21	stimulating	O
22	the	O
23	formation	O
24	of	O
25	a	O
26	multiprotein	O
27	complex	O
28	,	O
29	activin	B
30	-	I
31	responsive	I
32	factor	I
33	(	O
34	ARF	B
35	).	O

1	The	O
2	recombinant	B
3	vaccinia	I
4	virus	I
5	-	I
6	expressed	I
7	mutant	I
8	P1	I
9	polyproteins	I
10	were	O
11	analyzed	O
12	for	O
13	proteolytic	O
14	processing	O
15	defects	O
16	in	O
17	cells	O
18	coinfected	O
19	with	O
20	a	O
21	recombinant	O
22	vaccinia	O
23	virus	O
24	(	O
25	VVP3	O
26	)	O
27	that	O
28	expresses	O
29	the	O
30	poliovirus	B
31	3CD	I
32	protease	I
33	and	O
34	for	O
35	processing	O
36	and	O
37	assembly	O
38	defects	O
39	by	O
40	using	O
41	a	O
42	trans	O
43	complementation	O
44	system	O
45	in	O
46	which	O
47	P1	B
48	-	O
49	expressing	O
50	recombinant	O
51	vaccinia	O
52	viruses	O
53	provide	O
54	capsid	B
55	precursor	I
56	to	O
57	a	O
58	defective	O
59	poliovirus	O
60	genome	O
61	that	O
62	does	O
63	not	O
64	express	O
65	functional	O
66	capsid	B
67	proteins	I
68	(	O
69	D	O
70	.	O

1	Previously	O
2	,	O
3	we	O
4	reported	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	gene	B
10	encoding	I
11	human	I
12	K14	I
13	(	O
14	D	O
15	.	O

1	Through	O
2	a	O
3	stretch	O
4	of	O
5	56	O
6	amino	O
7	acids	O
8	,	O
9	constituting	O
10	the	O
11	MADS	B
12	domain	I
13	,	O
14	the	O
15	two	O
16	proteins	O
17	are	O
18	identical	O
19	except	O
20	for	O
21	two	O
22	conservative	O
23	amino	O
24	acid	O
25	substitutions	O
26	.	O

1	Neither	O
2	the	O
3	p42	B
4	/	I
5	44	I
6	nor	O
7	the	O
8	JNK	B
9	pathway	O
10	was	O
11	involved	O
12	in	O
13	the	O
14	action	O
15	of	O
16	IL	B
17	-	I
18	1beta	I
19	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	these	O
6	sequences	O
7	located	O
8	immediately	O
9	3	O
10	'	O
11	to	O
12	the	O
13	breakpoint	O
14	of	O
15	the	O
16	HPFH	B
17	-	I
18	3	I
19	deletion	I
20	,	O
21	exhibit	O
22	both	O
23	the	O
24	structure	O
25	and	O
26	the	O
27	function	O
28	of	O
29	an	O
30	enhancer	O
31	,	O
32	and	O
33	can	O
34	modify	O
35	the	O
36	developmental	O
37	specificity	O
38	of	O
39	the	O
40	fetal	B
41	gamma	I
42	-	I
43	globin	I
44	genes	I
45	,	O
46	resulting	O
47	in	O
48	their	O
49	continued	O
50	expression	O
51	during	O
52	adult	O
53	life	O
54	.	O

1	The	O
2	effect	O
3	of	O
4	these	O
5	cell	O
6	cycle	O
7	regulators	O
8	is	O
9	not	O
10	specific	O
11	to	O
12	the	O
13	rap1s	B
14	or	O
15	hmr	B
16	delta	I
17	A	I
18	mutation	I
19	,	O
20	since	O
21	swi6	B
22	,	O
23	swi4	B
24	,	O
25	and	O
26	clb5	B
27	mutations	I
28	also	O
29	suppress	O
30	mutations	O
31	in	O
32	SIR1	B
33	,	O
34	another	O
35	gene	O
36	implicated	O
37	in	O
38	the	O
39	establishment	O
40	of	O
41	silencing	O
42	.	O

1	Consistent	O
2	with	O
3	the	O
4	protein	O
5	expression	O
6	data	O
7	,	O
8	V	B
9	beta	I
10	8	I
11	.	I
12	3	I
13	gene	I
14	transcripts	I
15	were	O
16	found	O
17	only	O
18	in	O
19	the	O
20	transgenic	O
21	lines	O
22	with	O
23	the	O
24	wild	O
25	-	O
26	type	O
27	promoter	O
28	.	O

1	An	O
2	exaggerated	O
3	tissue	O
4	response	O
5	adjacent	O
6	to	O
7	the	O
8	cyanoacrylate	O
9	site	O
10	suggested	O
11	a	O
12	potential	O
13	toxic	O
14	chemical	O
15	or	O
16	thermal	O
17	reaction	O
18	,	O
19	or	O
20	both	O
21	,	O
22	to	O
23	the	O
24	tissue	O
25	adhesive	O
26	,	O
27	but	O
28	there	O
29	was	O
30	no	O
31	evidence	O
32	of	O
33	any	O
34	distant	O
35	ocular	O
36	effects	O
37	.	O

1	This	O
2	analysis	O
3	revealed	O
4	that	O
5	SAP	B
6	145	I
7	,	O
8	together	O
9	with	O
10	four	O
11	other	O
12	SF3a	B
13	/	O
14	SF3b	B
15	subunits	O
16	,	O
17	UV	O
18	cross	O
19	-	O
20	links	O
21	to	O
22	pre	O
23	-	O
24	mRNA	O
25	in	O
26	a	O
27	20	O
28	-	O
29	nucleotide	O
30	region	O
31	upstream	O
32	of	O
33	the	O
34	BPS	O
35	.	O

1	The	O
2	high	O
3	sequence	O
4	homology	O
5	,	O
6	similar	O
7	genomic	O
8	structure	O
9	,	O
10	and	O
11	identical	O
12	chromosomal	O
13	loci	O
14	of	O
15	hKID	B
16	,	O
17	MIP	B
18	,	O
19	and	O
20	AQP	B
21	-	I
22	2	I
23	suggest	O
24	a	O
25	MIP	B
26	family	I
27	gene	I
28	cluster	I
29	at	O
30	chromosome	O
31	locus	O
32	12q13	O
33	.	O

1	These	O
2	observations	O
3	indicate	O
4	that	O
5	there	O
6	are	O
7	multiple	O
8	mechanisms	O
9	by	O
10	which	O
11	an	O
12	individual	O
13	transcript	O
14	can	O
15	be	O
16	degraded	O
17	following	O
18	deadenylation	O
19	.	O

1	Primary	O
2	and	O
3	secondary	O
4	structural	O
5	elements	O
6	required	O
7	for	O
8	synthesis	O
9	of	O
10	barley	O
11	yellow	O
12	dwarf	O
13	virus	O
14	subgenomic	O
15	RNA1	O
16	.	O

1	Also	O
2	,	O
3	the	O
4	anti	O
5	-	O
6	inflammatory	O
7	activities	O
8	of	O
9	an	O
10	aqueous	O
11	extract	O
12	of	O
13	Buddleia	O
14	cordata	O
15	and	O
16	its	O
17	principal	O
18	glycoside	O
19	linarin	O
20	were	O
21	evaluated	O
22	.	O

1	Induction	O
2	of	O
3	the	O
4	urokinase	B
5	promoter	I
6	by	O
7	HGF	B
8	/	O
9	SF	B
10	via	O
11	the	O
12	Met	B
13	receptor	I
14	was	O
15	blocked	O
16	by	O
17	co	O
18	-	O
19	expression	O
20	of	O
21	a	O
22	dominant	O
23	-	O
24	negative	O
25	Grb2	B
26	and	O
27	Sos1	B
28	expression	O
29	construct	O
30	.	O

1	He	O
2	is	O
3	well	O
4	,	O
5	five	O
6	years	O
7	after	O
8	relapse	O
9	.	O

1	Diethylene	O
2	benzene	O

1	Type	O
2	I	O
3	position	O
4	-	O
5	vestibular	O
6	-	O
7	pause	O
8	(	O
9	PVP	O
10	I	O
11	)	O
12	and	O
13	vestibular	O
14	-	O
15	only	O
16	(	O
17	V	O
18	I	O
19	)	O
20	neurons	O
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	smaller	O
27	number	O
28	of	O
29	other	O
30	type	O
31	I	O
32	and	O
33	type	O
34	II	O
35	eye	O
36	-	O
37	plus	O
38	-	O
39	vestibular	O
40	neurons	O
41	were	O
42	studied	O
43	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	minimal	O
6	promoter	O
7	was	O
8	found	O
9	to	O
10	be	O
11	controlled	O
12	by	O
13	a	O
14	combination	O
15	of	O
16	the	O
17	activities	O
18	of	O
19	the	O
20	transcription	O
21	factors	O
22	Sp1	B
23	,	O
24	Sp3	B
25	,	O
26	and	O
27	NF	B
28	-	I
29	Y	I
30	.	O

1	An	O
2	interatrial	O
3	communication	O
4	mitigates	O
5	the	O
6	impairment	O
7	of	O
8	LV	O
9	function	O
10	after	O
11	an	O
12	acute	O
13	and	O
14	sustained	O
15	drop	O
16	of	O
17	intrathoracic	O
18	pressure	O
19	.	O

1	Pharmacodynamic	O
2	studies	O
3	on	O
4	the	O
5	cardiovascular	O
6	system	O
7	of	O
8	spontaneously	O
9	hypertensive	O
10	rats	O
11	.	O

1	The	O
2	range	O
3	of	O
4	eosinophils	O
5	was	O
6	22	O
7	-	O
8	56	O
9	%	O
10	of	O
11	the	O
12	number	O
13	of	O
14	peripheral	O
15	white	O
16	blood	O
17	cells	O
18	(	O
19	mean	O
20	nadir	O
21	33	O
22	%).	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	and	O
7	characterization	O
8	of	O
9	Xenopus	B
10	Pax	I
11	-	I
12	5	I
13	and	O
14	Pax	B
15	-	I
16	8	I
17	,	O
18	two	O
19	orthologues	O
20	of	O
21	the	O
22	Pax	B
23	-	I
24	2	I
25	/	I
26	5	I
27	/	I
28	8	I
29	gene	I
30	family	I
31	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	ketamine	O
6	-	O
7	treated	O
8	rats	O
9	had	O
10	more	O
11	neurons	O
12	and	O
13	glial	O
14	cells	O
15	surrounding	O
16	the	O
17	ventricles	O
18	.	O

1	The	O
2	homeobox	B
3	gene	I
4	ATK1	I
5	of	O
6	Arabidopsis	O
7	thaliana	O
8	is	O
9	expressed	O
10	in	O
11	the	O
12	shoot	O
13	apex	O
14	of	O
15	the	O
16	seedling	O
17	and	O
18	in	O
19	flowers	O
20	and	O
21	inflorescence	O
22	stems	O
23	of	O
24	mature	O
25	plants	O
26	.	O

1	Eastern	O
2	Cooperative	O
3	Oncology	O
4	Group	O
5	trial	O
6	E3186	O
7	was	O
8	initiated	O
9	to	O
10	explore	O
11	this	O
12	question	O
13	.	O

1	Ectopic	O
2	expression	O
3	of	O
4	d	B
5	-	I
6	axin	I
7	inhibited	O
8	Wingless	B
9	signaling	O
10	.	O

1	Hair	O
2	and	O
3	blood	O
4	samples	O
5	were	O
6	taken	O
7	before	O
8	vitamin	O
9	C	O
10	or	O
11	placebo	O
12	supplementation	O
13	was	O
14	started	O
15	and	O
16	at	O
17	monthly	O
18	intervals	O
19	thereafter	O
20	for	O
21	three	O
22	months	O
23	.	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	(	O
10	E2	O
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O

1	A	O
2	chicken	B
3	paxillin	I
4	cDNA	I
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	B
21	paxil	I
22	-	I
23	lin	I
24	.	O

1	Retrogradely	O
2	labelled	O
3	neurons	O
4	significantly	O
5	prevailed	O
6	in	O
7	the	O
8	ipsilateral	O
9	substantia	O
10	nigra	O
11	pars	O
12	compacta	O
13	.	O

1	Epithelial	O
2	nerve	O
3	fiber	O
4	defects	O
5	included	O
6	absence	O
7	or	O
8	distorted	O
9	architecture	O
10	of	O
11	the	O
12	basal	O
13	epithelial	O
14	plexus	O
15	and	O
16	intra	O
17	-	O
18	epithelial	O
19	terminals	O
20	.	O

1	Regarding	O
2	"	O
3	the	O
4	relation	O
5	between	O
6	sexual	O
7	orientation	O
8	and	O
9	penile	O
10	size	O
11	,"	O
12	by	O
13	A	O
14	.	O

1	The	O
2	promoter	O
3	for	O
4	HMG	B
5	-	I
6	CoA	I
7	synthase	I
8	contains	O
9	two	O
10	binding	O
11	sites	O
12	for	O
13	the	O
14	sterol	B
15	regulatory	I
16	element	I
17	-	I
18	binding	I
19	proteins	I
20	(	O
21	SREBPs	B
22	).	O

1	Diagnosis	O
2	:	O
3	progressive	O
4	multifocal	O
5	leukoencephalopathy	O
6	.	O

1	This	O
2	repression	O
3	was	O
4	reversed	O
5	agonists	O
6	of	O
7	either	O
8	receptor	O
9	demonstrating	O
10	a	O
11	functional	O
12	interaction	O
13	between	O
14	NCoR	B
15	and	O
16	PPARalpha	B
17	.	O
18	RXRalpha	B
19	heterodimeric	O
20	complexes	O
21	in	O
22	mammalian	O
23	cells	O
24	.	O

1	Therefore	O
2	,	O
3	it	O
4	was	O
5	concluded	O
6	that	O
7	thrombotic	O
8	tendency	O
9	certainly	O
10	existed	O
11	in	O
12	patients	O
13	with	O
14	MS	O
15	compared	O
16	to	O
17	those	O
18	with	O
19	non	O
20	RHD	O
21	and	O
22	that	O
23	it	O
24	was	O
25	one	O
26	of	O
27	the	O
28	causes	O
29	of	O
30	the	O
31	significantly	O
32	high	O
33	incidence	O
34	of	O
35	thromboembolism	O
36	in	O
37	comparison	O
38	with	O
39	non	O
40	RHD	O
41	.	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	the	O
6	ORF	O
7	of	O
8	hAMPK	B
9	encodes	O
10	552	O
11	amino	O
12	acids	O
13	(	O
14	aa	O
15	)	O
16	(	O
17	62	O
18	.	O
19	250	O
20	kDa	O
21	)	O
22	and	O
23	is	O
24	highly	O
25	conserved	O
26	with	O
27	rAMPK	B
28	with	O
29	identities	O
30	of	O
31	97	O
32	.	O
33	3	O
34	and	O
35	90	O
36	%	O
37	at	O
38	the	O
39	aa	O
40	and	O
41	nt	O
42	levels	O
43	,	O
44	respectively	O
45	.	O

1	In	O
2	the	O
3	matched	O
4	control	O
5	group	O
6	the	O
7	acquisition	O
8	-	O
9	rate	O
10	of	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	0acteriuria	O
16	was	O
17	over	O
18	12	O
19	%,	O
20	a	O
21	figure	O
22	similar	O
23	to	O
24	the	O
25	percentage	O
26	of	O
27	women	O
28	present	O
29	in	O
30	the	O
31	practice	O
32	population	O
33	during	O
34	one	O
35	year	O
36	with	O
37	transient	O
38	,	O
39	symptomatic	O
40	,	O
41	and	O
42	persistent	O
43	A	O
44	.	O
45	B	O
46	.	O

1	The	O
2	in	O
3	vitro	O
4	activity	O
5	of	O
6	mecillinam	O
7	and	O
8	amoxicillin	O
9	/	O
10	clavulanic	O
11	acid	O
12	against	O
13	Escherichia	O
14	coli	O
15	strains	O
16	producing	O
17	beta	B
18	-	I
19	lactamases	I
20	of	O
21	the	O
22	TEM	B
23	-	I
24	1	I
25	,	O
26	Oxa	B
27	-	I
28	1	I
29	and	O
30	chromosomal	O
31	type	O
32	were	O
33	studied	O
34	using	O
35	the	O
36	broth	O
37	and	O
38	agar	O
39	dilution	O
40	technique	O
41	.	O

1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	the	O
10	neuron	B
11	-	I
12	specific	I
13	SCG10	I
14	gene	I
15	evolved	O
16	by	O
17	duplication	O
18	and	O
19	modification	O
20	of	O
21	the	O
22	more	O
23	broadly	O
24	expressed	O
25	stathmin	B
26	/	O
27	Lap18	B
28	gene	O
29	.	O

1	The	O
2	promoter	O
3	region	O
4	showed	O
5	no	O
6	consensus	O
7	TATA	O
8	box	O
9	but	O
10	it	O
11	contains	O
12	CCAAT	O
13	and	O
14	CreA	B
15	boxes	O
16	known	O
17	to	O
18	be	O
19	involved	O
20	in	O
21	both	O
22	stress	O
23	and	O
24	carbon	O
25	-	O
26	catabolite	O
27	regulation	O
28	of	O
29	fungal	O
30	promoters	O
31	.	O

1	The	O
2	ARG	B
3	SH2	I
4	domain	I
5	exhibited	O
6	relatively	O
7	weak	O
8	affinity	O
9	for	O
10	BCR	B
11	and	O
12	was	O
13	determined	O
14	to	O
15	bind	O
16	about	O
17	10	O
18	-	O
19	fold	O
20	less	O
21	strongly	O
22	than	O
23	the	O
24	ABL	B
25	SH2	I
26	domain	I
27	.	O

1	Synergistic	O
2	transactivation	O
3	of	O
4	the	O
5	BMRF1	B
6	promoter	I
7	by	O
8	the	O
9	Z	B
10	/	O
11	c	B
12	-	I
13	myb	I
14	combination	O
15	appears	O
16	to	O
17	involve	O
18	direct	O
19	binding	O
20	by	O
21	the	O
22	Z	B
23	protein	I
24	but	O
25	not	O
26	the	O
27	c	B
28	-	I
29	myb	I
30	protein	I
31	.	O

1	The	O
2	site	O
3	-	O
4	specific	O
5	DNA	O
6	inversion	O
7	system	O
8	Cin	B
9	encoded	O
10	by	O
11	the	O
12	bacteriophage	O
13	P1	O
14	consists	O
15	of	O
16	a	O
17	recombinase	B
18	,	O
19	two	O
20	inverted	O
21	crossing	O
22	-	O
23	over	O
24	sites	O
25	and	O
26	a	O
27	recombinational	O
28	enhancer	O
29	.	O

1	By	O
2	site	O
3	-	O
4	specific	O
5	mutagenesis	O
6	,	O
7	we	O
8	also	O
9	show	O
10	that	O
11	individual	O
12	ICP27	B
13	C	I
14	-	I
15	terminal	I
16	amino	I
17	acid	I
18	residues	I
19	that	O
20	are	O
21	positionally	O
22	conserved	O
23	in	O
24	ICP27	B
25	homologs	I
26	in	O
27	other	O
28	herpesviruses	O
29	(	O
30	D	O
31	-	O
32	357	O
33	,	O
34	E	O
35	-	O
36	358	O
37	,	O
38	H	O
39	-	O
40	479	O
41	,	O
42	C	O
43	-	O
44	400	O
45	,	O
46	C	O
47	-	O
48	483	O
49	,	O
50	and	O
51	C	O
52	-	O
53	488	O
54	)	O
55	are	O
56	critical	O
57	for	O
58	trans	O
59	-	O
60	regulatory	O
61	activity	O
62	.	O

1	Up	O
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O

1	Contraction	O
2	of	O
3	the	O
4	tracheal	O
5	muscle	O
6	and	O
7	the	O
8	activity	O
9	of	O
10	stretch	O
11	receptors	O
12	in	O
13	the	O
14	trachea	O

1	Concussion	O
2	of	O
3	the	O
4	spinal	O
5	cord	O

1	Indirect	O
2	plasma	O
3	parameters	O
4	such	O
5	as	O
6	vitamin	O
7	E	O
8	,	O
9	thiol	O
10	and	O
11	uric	O
12	acid	O
13	levels	O
14	were	O
15	also	O
16	quantified	O
17	.	O

1	Can	O
2	thyroglobulin	B
3	assay	O
4	really	O
5	supplant	O
6	radioiodine	O
7	scans	O
8	in	O
9	patients	O
10	with	O
11	differentiated	O
12	thyroid	O
13	cancer	O
14	?	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	bZIP	O
7	structural	O
8	homology	O
9	,	O
10	meq	B
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	B
19	-	O
20	fos	B
21	gene	O
22	family	O
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O

1	Removal	O
2	of	O
3	beta	B
4	2	I
5	-	I
6	microglobulin	I
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	Nephrectomy	O
2	applied	O
3	to	O
4	cattle	O

1	The	O
2	skin	O
3	site	O
4	,	O
5	6	O
6	-	O
7	cm	O
8	-	O
9	distal	O
10	and	O
11	-	O
12	proximal	O
13	subcutaneous	O
14	segments	O
15	of	O
16	the	O
17	catheter	O
18	,	O
19	exudates	O
20	,	O
21	and	O
22	blood	O
23	were	O
24	cultured	O
25	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	requirements	O
8	for	O
9	induction	O
10	of	O
11	PEPCK	B
12	by	O
13	PKA	B
14	and	O
15	inhibition	O
16	by	O
17	insulin	B
18	include	O
19	:	O
20	1	O
21	)	O
22	the	O
23	CREB	B
24	activation	I
25	domain	I
26	,	O
27	2	O
28	)	O
29	the	O
30	PEPCK	B
31	TATA	I
32	sequence	I
33	,	O
34	and	O
35	3	O
36	)	O
37	insulin	B
38	-	O
39	responsive	O
40	hepatoma	O
41	cells	O
42	.	O

1	Additionally	O
2	,	O
3	I	B
4	kappa	I
5	B	I
6	beta	I
7	,	O
8	but	O
9	not	O
10	I	B
11	kappa	I
12	B	I
13	alpha	I
14	,	O
15	also	O
16	prevented	O
17	the	O
18	binding	O
19	of	O
20	Rel	B
21	to	O
22	the	O
23	kappa	B
24	B	I
25	site	I
26	.	O

1	Effects	O
2	of	O
3	Trypanosoma	O
4	vivax	O
5	on	O
6	pregnancy	O
7	of	O
8	Yankasa	O
9	sheep	O
10	and	O
11	the	O
12	results	O
13	of	O
14	homidum	O
15	chloride	O
16	chemotherapy	O
17	.	O

1	This	O
2	-	O
3	2485	O
4	/-	O
5	2458	O
6	element	O
7	bound	O
8	PPARalpha	B
9	and	O
10	PPARgamma	B
11	from	O
12	brown	O
13	fat	O
14	nuclei	O
15	.	O

1	But	O
2	the	O
3	application	O
4	solutions	O
5	of	O
6	instrument	O
7	disinfectants	O
8	should	O
9	not	O
10	be	O
11	used	O
12	longer	O
13	than	O
14	one	O
15	day	O
16	.	O

1	Expression	O
2	and	O
3	regulation	O
4	by	O
5	interferon	B
6	of	O
7	a	O
8	double	B
9	-	I
10	stranded	I
11	-	I
12	RNA	I
13	-	I
14	specific	I
15	adenosine	I
16	deaminase	I
17	from	O
18	human	O
19	cells	O
20	:	O
21	evidence	O
22	for	O
23	two	O
24	forms	O
25	of	O
26	the	O
27	deaminase	O
28	.	O

1	Treatment	O
2	of	O
3	keratinocytes	O
4	expressing	O
5	a	O
6	normal	O
7	epidermal	B
8	growth	I
9	factor	I
10	receptor	I
11	(	O
12	EGFR	B
13	)	O
14	with	O
15	TGFalpha	B
16	or	O
17	epidermal	B
18	growth	I
19	factor	I
20	for	O
21	5	O
22	min	O
23	induced	O
24	PKCdelta	B
25	tyrosine	O
26	phosphorylation	O
27	.	O

1	V	O
2	.	O

1	High	O
2	-	O
3	frequency	O
4	electrical	O
5	stimulation	O
6	in	O
7	the	O
8	hippocampus	O
9	leads	O
10	to	O
11	an	O
12	increase	O
13	in	O
14	synaptic	O
15	efficacy	O
16	that	O
17	lasts	O
18	for	O
19	many	O
20	hours	O
21	.	O

1	The	O
2	Aa	B
3	-	I
4	Pri2	I
5	gene	I
6	,	O
7	specifically	O
8	expressed	O
9	during	O
10	basidiocarp	O
11	differentiation	O
12	of	O
13	the	O
14	mushroom	O
15	Agrocybe	O
16	aegerita	O
17	,	O
18	was	O
19	cloned	O
20	.	O

1	Examination	O
2	of	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	Punta	B
8	Toro	I
9	M	I
10	gene	I
11	product	I
12	reveals	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	hydrophobic	O
18	sequences	O
19	including	O
20	a	O
21	19	O
22	-	O
23	amino	O
24	acid	O
25	,	O
26	carboxy	O
27	-	O
28	proximal	O
29	,	O
30	hydrophobic	O
31	region	O
32	(	O
33	G2	O
34	).	O

1	Like	O
2	the	O
3	p190	B
4	-	I
5	B	I
6	exon	O
7	,	O
8	the	O
9	first	O
10	exon	O
11	of	O
12	p190	B
13	-	I
14	A	I
15	is	O
16	extremely	O
17	large	O
18	(	O
19	3	O
20	.	O
21	7	O
22	kb	O
23	in	O
24	length	O
25	),	O
26	encoding	O
27	both	O
28	the	O
29	GTPase	B
30	and	O
31	middle	O
32	domains	O
33	(	O
34	residues	O
35	1	O
36	-	O
37	1228	O
38	),	O
39	but	O
40	not	O
41	the	O
42	remaining	O
43	GAP	B
44	domain	I
45	,	O
46	suggesting	O
47	a	O
48	high	O
49	conservation	O
50	of	O
51	genomic	O
52	structure	O
53	between	O
54	two	O
55	p190	B
56	genes	I
57	.	O

1	ANIMALS	O
2	:	O
3	Fifty	O
4	dogs	O
5	with	O
6	naturally	O
7	developing	O
8	DM	O
9	.	O

1	The	O
2	Southern	O
3	technique	O
4	allowed	O
5	a	O
6	further	O
7	localization	O
8	of	O
9	the	O
10	region	O
11	of	O
12	most	O
13	extensive	O
14	transcription	O
15	to	O
16	a	O
17	1	O
18	.	O
19	8	O
20	kb	O
21	HindIII	B
22	-	O
23	EcoRI	B
24	fragment	O
25	.	O

1	In	O
2	all	O
3	cells	O
4	,	O
5	the	O
6	accumulation	O
7	of	O
8	high	O
9	Dsg	B
10	protein	I
11	levels	O
12	required	O
13	calcium	O
14	and	O
15	was	O
16	not	O
17	observed	O
18	in	O
19	low	O
20	calcium	O
21	(	O
22	0	O
23	.	O
24	05	O
25	-	O
26	0	O
27	.	O
28	07	O
29	mM	O
30	)	O
31	media	O
32	.	O

1	Transcriptional	O
2	activity	O
3	was	O
4	measured	O
5	by	O
6	slot	O
7	-	O
8	blot	O
9	hybridization	O
10	with	O
11	steady	O
12	-	O
13	state	O
14	RNA	O
15	isolated	O
16	from	O
17	lacZ	B
18	+	I
19	M	I
20	.	I
21	smegmatis	I
22	clones	O
23	.	O

1	SGPT	B
2	,	O
3	SGOT	B
4	,	O
5	and	O
6	alkaline	B
7	phosphatase	I
8	concentrations	O
9	were	O
10	essentially	O
11	normal	O
12	in	O
13	all	O
14	subjects	O
15	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	multiple	O
6	oIGF	B
7	-	I
8	I	I
9	transcripts	I
10	in	O
11	a	O
12	broad	O
13	band	O
14	at	O
15	800	O
16	-	O
17	1	O
18	,	O
19	100	O
20	nucleotides	O
21	and	O
22	other	O
23	transcripts	O
24	of	O
25	higher	O
26	molecular	O
27	weight	O
28	in	O
29	liver	O
30	.	O

1	Importantly	O
2	,	O
3	concomitant	O
4	expression	O
5	of	O
6	constitutive	O
7	activated	O
8	Raf	B
9	and	O
10	V12N38	B
11	Ras	I
12	results	O
13	in	O
14	almost	O
15	complete	O
16	loss	O
17	of	O
18	TTF	B
19	-	I
20	1	I
21	activity	O
22	.	O

1	In	O
2	adulthood	O
3	these	O
4	rats	O
5	were	O
6	hyperactive	O
7	and	O
8	learned	O
9	the	O
10	active	O
11	avoidance	O
12	response	O
13	later	O
14	than	O
15	the	O
16	controls	O
17	.	O

1	We	O
2	further	O
3	show	O
4	that	O
5	proteolytic	O
6	targeting	O
7	by	O
8	calpain	B
9	II	I
10	and	O
11	the	O
12	proteasome	O
13	involves	O
14	different	O
15	structural	O
16	elements	O
17	of	O
18	YY1	B
19	.	O

1	The	O
2	DAP5	B
3	/	O
4	p86	B
5	apoptotic	O
6	form	O
7	was	O
8	more	O
9	potent	O
10	than	O
11	DAP5	B
12	/	O
13	p97	B
14	in	O
15	these	O
16	functional	O
17	assays	O
18	.	O

1	RNAs	O
2	are	O
3	not	O
4	only	O
5	essential	O
6	components	O
7	of	O
8	both	O
9	ribosomal	O
10	subunits	O
11	but	O
12	also	O
13	transiently	O
14	interacting	O
15	factors	O
16	during	O
17	particle	O
18	formation	O
19	.	O

1	Subhuman	O
2	primates	O
3	appear	O
4	to	O
5	be	O
6	more	O
7	sensitive	O
8	to	O
9	reproductive	O
10	and	O
11	other	O
12	adverse	O
13	effects	O
14	of	O
15	PCBs	O
16	than	O
17	humans	O
18	.	O

1	Change	O
2	in	O
3	the	O
4	makeup	O
5	of	O
6	the	O
7	blood	O
8	following	O
9	a	O
10	short	O
11	-	O
12	term	O
13	local	O
14	action	O
15	of	O
16	a	O
17	permanent	O
18	magnetic	O
19	field	O
20	on	O
21	the	O
22	human	O
23	body	O

1	Peripheral	O
2	polyneuropathy	O
3	associated	O
4	with	O
5	multiple	O
6	myeloma	O
7	.	O

1	For	O
2	wild	O
3	type	O
4	MutT	B
5	and	O
6	its	O
7	E53D	B
8	and	O
9	E44D	B
10	mutants	I
11	,	O
12	plots	O
13	of	O
14	log	O
15	(	O
16	k	O
17	(	O
18	cat	O
19	))	O
20	versus	O
21	pH	O
22	exhibited	O
23	a	O
24	limiting	O
25	slope	O
26	of	O
27	1	O
28	on	O
29	the	O
30	ascending	O
31	limb	O
32	and	O
33	then	O
34	a	O
35	hump	O
36	,	O
37	i	O
38	.	O
39	e	O
40	.,	O
41	a	O
42	sharply	O
43	defined	O
44	maximum	O
45	near	O
46	pH	O
47	8	O
48	followed	O
49	by	O
50	a	O
51	plateau	O
52	,	O
53	yielding	O
54	apparent	O
55	pK	O
56	(	O
57	a	O
58	)	O
59	values	O
60	of	O
61	7	O
62	.	O
63	6	O
64	+/-	O
65	0	O
66	.	O
67	3	O
68	and	O
69	8	O
70	.	O
71	4	O
72	+/-	O
73	0	O
74	.	O
75	4	O
76	for	O
77	an	O
78	essential	O
79	base	O
80	and	O
81	a	O
82	nonessential	O
83	acid	O
84	catalyst	O
85	,	O
86	respectively	O
87	,	O
88	in	O
89	the	O
90	active	O
91	quaternary	O
92	MutT	B
93	-	O
94	Mg	O
95	(	O
96	2	O
97	+)-	O
98	dGTP	O
99	-	O
100	Mg	O
101	(	O
102	2	O
103	+)	O
104	complex	O
105	.	O

1	Increase	O
2	in	O
3	urinary	O
4	calcium	O
5	and	O
6	oxalate	O
7	after	O
8	fructose	O
9	infusion	O
10	.	O

1	Prostaglandin	O
2	synthesis	O
3	inhibitors	O
4	have	O
5	been	O
6	shown	O
7	to	O
8	delay	O
9	healing	O
10	of	O
11	bone	O
12	and	O
13	this	O
14	has	O
15	led	O
16	to	O
17	limitations	O
18	on	O
19	their	O
20	use	O
21	clinically	O
22	in	O
23	some	O
24	situations	O
25	.	O

1	Thirty	O
2	-	O
3	five	O
4	strains	O
5	of	O
6	Legionnaires	O
7	'	O
8	disease	O
9	bacteria	O
10	were	O
11	shown	O
12	to	O
13	belong	O
14	in	O
15	four	O
16	distinct	O
17	serologic	O
18	groups	O
19	on	O
20	the	O
21	basis	O
22	of	O
23	findings	O
24	obtained	O
25	with	O
26	direct	O
27	fluorescent	O
28	antibody	O
29	testing	O
30	.	O

1	Wrist	O
2	measurement	O
3	of	O
4	blood	O
5	pressure	O
6	:	O
7	some	O
8	critical	O
9	remarks	O
10	to	O
11	oscillometry	O
12	.	O

1	CONCLUSION	O
2	:	O
3	TNF	B
4	alpha	I
5	,	O
6	TGF	B
7	beta	I
8	,	O
9	PDGF	B
10	and	O
11	IL	B
12	-	I
13	1beta	I
14	increased	O
15	LDLr	B
16	gene	I
17	expression	O
18	by	O
19	increasing	O
20	sterol	O
21	-	O
22	independent	O
23	and	O
24	mitogenesis	O
25	-	O
26	independent	O
27	gene	O
28	transcription	O
29	.	O

1	The	O
2	study	O
3	disclosed	O
4	generalized	O
5	atrophy	O
6	and	O
7	diffuse	O
8	symmetric	O
9	white	O
10	matter	O
11	hypodensities	O
12	.	O

1	188	O
2	patients	O
3	received	O
4	cimetidine	O
5	400	O
6	mg	O
7	q	O
8	.	O
9	i	O
10	.	O
11	d	O
12	.	O
13	intravenously	O
14	and	O
15	1	O
16	,	O
17	000	O
18	mg	O
19	daily	O
20	orally	O
21	in	O
22	divided	O
23	doses	O
24	.	O

1	Effect	O
2	of	O
3	biliary	O
4	obstruction	O
5	and	O
6	cholangitis	O
7	on	O
8	serum	B
9	SPan	I
10	-	I
11	1	I
12	level	O

1	Dsh	B
2	is	O
3	required	O
4	for	O
5	two	O
6	different	O
7	pathways	O
8	,	O
9	the	O
10	Wnt	B
11	pathway	O
12	and	O
13	planar	O
14	polarity	O
15	pathway	O
16	in	O
17	Drosophila	O
18	.	O

1	A	O
2	Golgi	O
3	study	O
4	of	O
5	the	O
6	sixth	O
7	layer	O
8	of	O
9	the	O
10	cerebral	O
11	cortex	O
12	.	O

1	Insulin	B
2	receptor	I
3	substrate	I
4	-	I
5	1	I
6	-	O
7	mediated	O
8	enhancement	O
9	of	O
10	growth	B
11	hormone	I
12	-	O
13	induced	O
14	mitogen	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	activation	O
20	.	O

1	The	O
2	sympathetic	O
3	neuroeffector	O
4	influence	O
5	on	O
6	the	O
7	myocardium	O
8	with	O
9	ATCI	O
10	depends	O
11	to	O
12	a	O
13	large	O
14	measure	O
15	on	O
16	the	O
17	intensity	O
18	of	O
19	the	O
20	neurotransmitter	O
21	biosynthesis	O
22	and	O
23	function	O
24	of	O
25	cardiomyocyte	O
26	adrenoreceptors	O
27	.	O

1	We	O
2	exploit	O
3	the	O
4	properties	O
5	of	O
6	LexA	B
7	fusion	I
8	proteins	I
9	to	O
10	study	O
11	the	O
12	dimerization	O
13	and	O
14	DNA	O
15	-	O
16	contacting	O
17	domains	O
18	of	O
19	cRel	B
20	.	O

1	Furthermore	O
2	,	O
3	experiments	O
4	with	O
5	32D	O
6	temperature	O
7	-	O
8	sensitive	O
9	p53	B
10	cells	O
11	indicate	O
12	that	O
13	aberrant	O
14	tal	B
15	-	I
16	1	I
17	expression	O
18	at	O
19	the	O
20	permissive	O
21	temperature	O
22	does	O
23	not	O
24	exert	O
25	a	O
26	proliferative	O
27	effect	O
28	but	O
29	causes	O
30	p53	B
31	-	O
32	mediated	O
33	apoptosis	O
34	,	O
35	i	O
36	.	O
37	e	O
38	.,	O
39	the	O
40	tal	B
41	-	I
42	1	I
43	proliferative	O
44	effect	O
45	depends	O
46	on	O
47	the	O
48	integrity	O
49	of	O
50	the	O
51	cell	O
52	cycle	O
53	checkpoints	O
54	of	O
55	the	O
56	host	O
57	cell	O
58	,	O
59	as	O
60	observed	O
61	for	O
62	c	B
63	-	I
64	myc	I
65	and	O
66	other	O
67	oncogenes	O
68	.	O
69	tal	B
70	-	I
71	1	I
72	mutant	I
73	experiments	O
74	indicate	O
75	that	O
76	ectopic	O
77	tal	B
78	-	I
79	1	I
80	effects	O
81	are	O
82	mediated	O
83	by	O
84	both	O
85	the	O
86	DNA	O
87	-	O
88	binding	O
89	and	O
90	the	O
91	heterodimerization	O
92	domains	O
93	,	O
94	while	O
95	the	O
96	N	B
97	-	I
98	terminally	I
99	truncated	I
100	tal	I
101	-	I
102	1	I
103	variant	I
104	(	O
105	M3	B
106	)	O
107	expressed	O
108	in	O
109	T	O
110	-	O
111	ALL	O
112	malignant	O
113	cells	O
114	mimics	O
115	the	O
116	effects	O
117	of	O
118	the	O
119	wild	O
120	-	O
121	type	O
122	protein	O
123	.	O

1	Pups	O
2	placed	O
3	into	O
4	the	O
5	novel	O
6	environment	O
7	with	O
8	their	O
9	mothers	O
10	exhibited	O
11	an	O
12	intermediate	O
13	level	O
14	of	O
15	DA	O
16	turnover	O
17	.	O

1	Tec	B
2	kinase	I
3	signaling	O
4	in	O
5	T	O
6	cells	O
7	is	O
8	regulated	O
9	by	O
10	phosphatidylinositol	B
11	3	I
12	-	I
13	kinase	I
14	and	O
15	the	O
16	Tec	B
17	pleckstrin	I
18	homology	I
19	domain	I
20	.	O

1	The	O
2	mean	O
3	minimum	O
4	steady	O
5	-	O
6	state	O
7	concentration	O
8	after	O
9	the	O
10	oral	O
11	regimen	O
12	(	O
13	23	O
14	micrograms	O
15	.	O
16	l	O
17	-	O
18	1	O
19	)	O
20	was	O
21	78	O
22	%	O
23	of	O
24	that	O
25	after	O
26	the	O
27	intramuscular	O
28	regime	O
29	(	O
30	29	O
31	micrograms	O
32	.	O
33	l	O
34	-	O
35	1	O
36	).	O

1	In	O
2	addition	O
3	,	O
4	npm3	B
5	,	O
6	which	O
7	is	O
8	usually	O
9	coactivated	O
10	with	O
11	fgf8	B
12	by	O
13	MMTV	O
14	insertion	O
15	,	O
16	was	O
17	not	O
18	up	O
19	-	O
20	regulated	O
21	by	O
22	androgens	O
23	in	O
24	SC	O
25	-	O
26	3	O
27	cells	O
28	.	O

1	The	O
2	study	O
3	goals	O
4	were	O
5	to	O
6	isolate	O
7	a	O
8	full	O
9	-	O
10	length	O
11	clone	O
12	encoding	O
13	CO	B
14	-	I
15	Ag	I
16	from	O
17	a	O
18	bovine	O
19	corneal	O
20	cDNA	O
21	library	O
22	and	O
23	to	O
24	express	O
25	this	O
26	clone	O
27	in	O
28	Escherichia	O
29	coli	O
30	(	O
31	E	O
32	.	O
33	coli	O
34	).	O

1	Incorporation	O
2	of	O
3	the	O
4	polyene	O
5	antibiotic	O
6	amphotericin	O
7	B	O
8	(	O
9	AMB	O
10	)	O
11	in	O
12	liposomes	O
13	results	O
14	in	O
15	a	O
16	marked	O
17	reduction	O
18	in	O
19	drug	O
20	toxicity	O
21	with	O
22	no	O
23	loss	O
24	of	O
25	antifungal	O
26	potency	O
27	.	O

1	Cluster	O
2	formation	O
3	of	O
4	E	B
5	-	I
6	cadherin	I
7	on	O
8	the	O
9	cell	O
10	surface	O
11	is	O
12	believed	O
13	to	O
14	be	O
15	of	O
16	major	O
17	importance	O
18	for	O
19	cell	O
20	-	O
21	cell	O
22	adhesion	O
23	.	O

1	A	O
2	cAMP	O
3	response	O
4	element	O
5	(	O
6	CRE	O
7	)	O
8	consensus	O
9	signal	O
10	was	O
11	identified	O
12	in	O
13	the	O
14	5	O
15	'-	O
16	noncoding	O
17	region	O
18	.	O
19	cAMP	O
20	regulates	O
21	the	O
22	expression	O
23	of	O
24	Kv1	B
25	.	I
26	5	I
27	gene	I
28	in	O
29	a	O
30	cell	O
31	-	O
32	specific	O
33	manner	O
34	.	O

1	Its	O
2	potential	O
3	as	O
4	a	O
5	diagnostic	O
6	tool	O
7	for	O
8	epidemiological	O
9	surveillance	O
10	was	O
11	assessed	O
12	in	O
13	comparison	O
14	with	O
15	three	O
16	other	O
17	diagnostic	O
18	tests	O
19	:	O
20	stool	O
21	examination	O
22	,	O
23	ELISA	O
24	with	O
25	soluble	B
26	egg	I
27	antigen	I
28	(	O
29	SEA	B
30	)	O
31	and	O
32	the	O
33	circumoval	O
34	precipitin	B
35	test	O
36	(	O
37	COPT	O
38	).	O

1	Furthermore	O
2	,	O
3	the	O
4	validity	O
5	of	O
6	this	O
7	new	O
8	subset	O
9	of	O
10	questions	O
11	was	O
12	shown	O
13	to	O
14	be	O
15	significant	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	037	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	)	O
29	for	O
30	the	O
31	correlation	O
32	between	O
33	a	O
34	measure	O
35	of	O
36	the	O
37	severity	O
38	of	O
39	binocular	O
40	visual	O
41	field	O
42	loss	O
43	and	O
44	the	O
45	mean	O
46	score	O
47	of	O
48	the	O
49	variables	O
50	used	O
51	in	O
52	the	O
53	glaucoma	O
54	specific	O
55	subgroup	O
56	of	O
57	questions	O
58	.	O

1	Ras	B
2	p21Val	I
3	inhibits	O
4	myogenesis	O
5	without	O
6	altering	O
7	the	O
8	DNA	O
9	binding	O
10	or	O
11	transcriptional	O
12	activities	O
13	of	O
14	the	O
15	myogenic	B
16	basic	I
17	helix	I
18	-	I
19	loop	I
20	-	I
21	helix	I
22	factors	I
23	.	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	that	O
6	the	O
7	P68	B
8	amino	O
9	terminus	O
10	was	O
11	both	O
12	necessary	O
13	and	O
14	sufficient	O
15	for	O
16	binding	O
17	dsRNA	O
18	as	O
19	we	O
20	were	O
21	able	O
22	to	O
23	transfer	O
24	dsRNA	O
25	-	O
26	binding	O
27	properties	O
28	to	O
29	a	O
30	reporter	O
31	gene	O
32	product	O
33	previously	O
34	unable	O
35	to	O
36	bind	O
37	RNA	O
38	.	O

1	Plasma	O
2	ion	O
3	changes	O
4	in	O
5	venous	O
6	blood	O
7	incubated	O
8	with	O
9	beta	B
10	receptor	I
11	blockers	O
12	and	O
13	subjected	O
14	to	O
15	tonometry	O
16	in	O
17	vitro	O
18	.	O

1	Furthermore	O
2	,	O
3	synergistic	O
4	activation	O
5	of	O
6	ERK2	B
7	occurred	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	changes	O
13	in	O
14	intracellular	O
15	Ca2	O
16	+,	O
17	and	O
18	was	O
19	not	O
20	blocked	O
21	by	O
22	inhibition	O
23	of	O
24	protein	B
25	kinase	I
26	C	I
27	activity	O
28	and	O
29	represents	O
30	a	O
31	separate	O
32	pathway	O
33	by	O
34	which	O
35	CD19	B
36	regulates	O
37	B	O
38	cell	O
39	function	O
40	.	O

1	Thus	O
2	,	O
3	in	O
4	normal	O
5	intestinal	O
6	epithelial	O
7	goblet	O
8	cells	O
9	,	O
10	TbetaRI	B
11	and	O
12	TbetaRII	B
13	can	O
14	respond	O
15	to	O
16	autocrine	O
17	but	O
18	not	O
19	exogenous	O
20	TGF	B
21	-	I
22	beta	I
23	without	O
24	the	O
25	participation	O
26	of	O
27	TbetaRIII	B
28	.	O

1	Nerve	O
2	stimulation	O
3	(	O
4	1	O
5	.	O
6	5	O
7	-	O
8	12	O
9	cycles	O
10	/	O
11	s	O
12	)	O
13	produced	O
14	frequency	O
15	-	O
16	dependent	O
17	reductions	O
18	in	O
19	CBF	O
20	,	O
21	a	O
22	decrease	O
23	of	O
24	50	O
25	percent	O
26	occurring	O
27	with	O
28	the	O
29	highest	O
30	frequency	O
31	.	O

1	Oestrogen	O
2	implant	O
3	overdose	O
4	.	O

1	desmethyltrimebutine	O
2	was	O
3	inactive	O
4	.	O

1	A	O
2	pharmacokinetic	O
3	study	O
4	of	O
5	apalcillin	O
6	was	O
7	performed	O
8	in	O
9	12	O
10	patients	O
11	in	O
12	an	O
13	intensive	O
14	-	O
15	care	O
16	unit	O
17	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	1	I
7	(	I
8	HIV	I
9	-	I
10	1	I
11	)	I
12	Rev	I
13	protein	I
14	is	O
15	a	O
16	positive	O
17	posttranscriptional	O
18	regulator	O
19	of	O
20	viral	O
21	structural	O
22	gene	O
23	expression	O
24	and	O
25	essential	O
26	for	O
27	virus	O
28	replication	O
29	.	O

1	What	O
2	young	O
3	people	O
4	think	O
5	and	O
6	do	O
7	when	O
8	the	O
9	option	O
10	for	O
11	cystic	O
12	fibrosis	O
13	carrier	O
14	testing	O
15	is	O
16	available	O
17	.	O

1	Animal	O
2	age	O
3	and	O
4	sex	O
5	had	O
6	no	O
7	significant	O
8	effects	O
9	on	O
10	CSF	O
11	composition	O
12	,	O
13	but	O
14	serum	O
15	IgG	B
16	concentration	O
17	increased	O
18	with	O
19	age	O
20	.	O

1	A	O
2	third	O
3	prominent	O
4	component	O
5	of	O
6	apparent	O
7	molecular	O
8	mass	O
9	16	O
10	kDa	O
11	displayed	O
12	several	O
13	properties	O
14	,	O
15	including	O
16	ability	O
17	to	O
18	bind	O
19	45Ca2	O
20	+,	O
21	that	O
22	are	O
23	characteristic	O
24	of	O
25	the	O
26	regulatory	O
27	(	O
28	B	O
29	)	O
30	subunit	O
31	of	O
32	mammalian	B
33	calcineurin	I
34	and	O
35	was	O
36	recognized	O
37	by	O
38	an	O
39	antiserum	O
40	raised	O
41	against	O
42	bovine	B
43	calcineurin	I
44	.	O

1	Methods	O
2	used	O
3	include	O
4	Cobb	O
5	angle	O
6	and	O
7	a	O
8	segmental	O
9	evaluation	O
10	(	O
11	T7	O
12	-	O
13	T12	O
14	)	O
15	of	O
16	each	O
17	of	O
18	convex	O
19	and	O
20	concave	O
21	rib	O
22	-	O
23	vertebra	O
24	angles	O
25	(	O
26	RVAs	O
27	),	O
28	rib	O
29	-	O
30	vertebra	O
31	angle	O
32	differences	O
33	(	O
34	RVADs	O
35	),	O
36	vertebral	O
37	rotation	O
38	,	O
39	tilt	O
40	and	O
41	displacement	O
42	.	O

1	We	O
2	have	O
3	reviewed	O
4	the	O
5	experience	O
6	of	O
7	a	O
8	major	O
9	MMT	O
10	general	O
11	practice	O
12	with	O
13	hepatitis	O
14	C	O
15	virus	O
16	(	O
17	HCV	O
18	)	O
19	infection	O
20	from	O
21	1991	O
22	to	O
23	1995	O
24	.	O

1	We	O
2	did	O
3	not	O
4	observe	O
5	any	O
6	changes	O
7	in	O
8	Bcl	B
9	-	I
10	2	I
11	or	O
12	Bcl	B
13	-	I
14	2	I
15	-	I
16	related	I
17	proteins	I
18	(	O
19	Bcl	B
20	-	I
21	x	I
22	,	O
23	Bax	B
24	,	O
25	and	O
26	Bad	B
27	)	O
28	in	O
29	control	O
30	or	O
31	KCREB	B
32	-	O
33	transfected	O
34	cells	O
35	before	O
36	or	O
37	after	O
38	treatment	O
39	with	O
40	Tg	O
41	.	O

1	Among	O
2	genes	O
3	induced	O
4	by	O
5	added	O
6	pMesogenin1	B
7	is	O
8	Xwnt	B
9	-	I
10	8	I
11	,	O
12	a	O
13	signaling	O
14	factor	O
15	that	O
16	induces	O
17	a	O
18	similar	O
19	repertoire	O
20	of	O
21	marker	O
22	genes	O
23	and	O
24	a	O
25	similar	O
26	cellular	O
27	phenotype	O
28	.	O

1	Perturbation	O
2	of	O
3	dNTP	O
4	pools	O
5	also	O
6	affected	O
7	the	O
8	frameshift	O
9	fidelity	O
10	of	O
11	the	O
12	replicative	O
13	yeast	B
14	DNA	I
15	polymerase	I
16	alpha	I
17	.	O

1	Coronary	O
2	flow	O
3	was	O
4	reduced	O
5	by	O
6	10	O
7	%	O
8	in	O
9	the	O
10	phosphocreatine	O
11	and	O
12	by	O
13	18	O
14	%	O
15	in	O
16	the	O
17	control	O
18	group	O
19	.	O

1	In	O
2	the	O
3	ISO	O
4	group	O
5	,	O
6	at	O
7	pre	O
8	-	O
9	DEX	O
10	,	O
11	CBF	O
12	increased	O
13	from	O
14	86	O
15	+/-	O
16	8	O
17	to	O
18	166	O
19	+/-	O
20	19	O
21	mL	O
22	.	O
23	min	O
24	-	O
25	1	O
26	.	O
27	100	O
28	g	O
29	-	O
30	1	O
31	in	O
32	response	O
33	to	O
34	hypercapnia	O
35	(	O
36	PCO2	O
37	approximately	O
38	90	O
39	mmHg	O
40	).(	O
41	ABSTRACT	O
42	TRUNCATED	O
43	AT	O
44	250	O
45	WORDS	O
46	)	O

1	Both	O
2	BG	O
3	and	O
4	IRI	B
5	concentrations	O
6	during	O
7	the	O
8	OGTT	O
9	were	O
10	the	O
11	lowest	O
12	in	O
13	body	O
14	builders	O
15	,	O
16	medium	O
17	in	O
18	controls	O
19	,	O
20	and	O
21	the	O
22	highest	O
23	in	O
24	obese	O
25	men	O
26	.	O

1	C	B
2	/	I
3	EBP	I
4	alpha	I
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	B
12	class	I
13	-	I
14	I	I
15	ADH	I
16	gene	I
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	Potter	O
25	et	O
26	al	O
27	.,	O
28	Arch	O
29	.	O

1	Its	O
2	transcription	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	be	O
8	induced	O
9	40	O
10	-	O
11	50	O
12	-	O
13	fold	O
14	in	O
15	response	O
16	to	O
17	oxygen	O
18	or	O
19	heme	O
20	deficiency	O
21	,	O
22	in	O
23	part	O
24	through	O
25	relief	O
26	of	O
27	repression	O
28	exerted	O
29	by	O
30	Rox1p	B
31	and	O
32	in	O
33	part	O
34	by	O
35	activation	O
36	mediated	O
37	by	O
38	an	O
39	upstream	O
40	activation	O
41	sequence	O
42	(	O
43	UAS	O
44	).	O

1	MpB	B
2	GroEL	I
3	has	O
4	extensive	O
5	sequence	O
6	similarity	O
7	(	O
8	92	O
9	%)	O
10	with	O
11	Escherichia	B
12	coli	I
13	GroEL	I
14	and	O
15	other	O
16	members	O
17	of	O
18	the	O
19	chaperonin	B
20	-	I
21	60	I
22	family	I
23	.	O

1	In	O
2	vitro	O
3	DNase	B
4	I	I
5	footprinting	O
6	of	O
7	the	O
8	200	O
9	-	O
10	bp	O
11	proximal	O
12	region	O
13	of	O
14	the	O
15	promoter	O
16	with	O
17	a	O
18	murine	O
19	Hepa	O
20	1	O
21	-	O
22	6	O
23	cell	O
24	nuclear	O
25	extract	O
26	revealed	O
27	a	O
28	clear	O
29	footprint	O
30	of	O
31	a	O
32	region	O
33	corresponding	O
34	to	O
35	-	O
36	80	O
37	to	O
38	-	O
39	28	O
40	bp	O
41	of	O
42	the	O
43	murine	B
44	fVII	I
45	gene	I
46	,	O
47	suggesting	O
48	that	O
49	liver	O
50	factors	O
51	interact	O
52	with	O
53	this	O
54	region	O
55	of	O
56	the	O
57	DNA	O
58	.	O

1	This	O
2	gene	O
3	encodes	O
4	a	O
5	putative	O
6	transcription	O
7	factor	O
8	with	O
9	regions	O
10	of	O
11	homology	O
12	to	O
13	several	O
14	other	O
15	proteins	O
16	including	O
17	the	O
18	zinc	O
19	fingers	O
20	and	O
21	other	O
22	domains	O
23	of	O
24	the	O
25	Drosophila	B
26	trithorax	I
27	gene	I
28	product	I
29	,	O
30	and	O
31	the	O
32	"	O
33	AT	O
34	-	O
35	hook	O
36	"	O
37	DNA	O
38	-	O
39	binding	O
40	motif	O
41	of	O
42	high	B
43	mobility	I
44	group	I
45	proteins	I
46	.	O

1	The	O
2	full	O
3	protocol	O
4	was	O
5	completed	O
6	by	O
7	33	O
8	patients	O
9	(	O
10	45	O
11	%	O
12	of	O
13	original	O
14	cohort	O
15	).	O

1	We	O
2	have	O
3	subcloned	O
4	into	O
5	pBR322	O
6	deoxyribonucleic	O
7	acid	O
8	(	O
9	DNA	O
10	)	O
11	sequences	O
12	mapping	O
13	either	O
14	in	O
15	the	O
16	coding	O
17	region	O
18	,	O
19	the	O
20	5	O
21	'	O
22	spacer	O
23	,	O
24	or	O
25	the	O
26	3	O
27	'	O
28	spacer	O
29	of	O
30	the	O
31	H2B	B
32	histone	I
33	gene	I
34	.	O

1	Once	O
2	the	O
3	proliferation	O
4	of	O
5	fibroblasts	O
6	and	O
7	collagen	B
8	synthesis	O
9	had	O
10	led	O
11	to	O
12	an	O
13	increase	O
14	of	O
15	mechanical	O
16	strength	O
17	,	O
18	no	O
19	negative	O
20	effect	O
21	on	O
22	wound	O
23	healing	O
24	could	O
25	be	O
26	detected	O
27	applying	O
28	the	O
29	same	O
30	chemotherapeutic	O
31	agents	O
32	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	Bazett	O
5	-	O
6	corrected	O
7	QT	O
8	(	O
9	QTc	O
10	)	O
11	interval	O
12	during	O
13	exercise	O
14	has	O
15	been	O
16	used	O
17	as	O
18	a	O
19	marker	O
20	for	O
21	ischemic	O
22	disease	O
23	,	O
24	arrhythmogenic	O
25	substrate	O
26	and	O
27	the	O
28	long	O
29	QT	O
30	syndrome	O
31	.	O

1	Interlimb	O
2	coordination	O
3	during	O
4	fictive	O
5	locomotion	O
6	in	O
7	the	O
8	thalamic	O
9	cat	O
10	.	O

1	The	O
2	two	O
3	ParA	B
4	proteins	I
5	that	O
6	are	O
7	produced	O
8	as	O
9	a	O
10	result	O
11	of	O
12	independent	O
13	translation	O
14	initiation	O
15	at	O
16	two	O
17	different	O
18	start	O
19	codons	O
20	within	O
21	the	O
22	same	O
23	open	O
24	reading	O
25	frame	O
26	were	O
27	overexpressed	O
28	in	O
29	Escherichia	O
30	coli	O
31	and	O
32	partially	O
33	purified	O
34	.	O

1	KRN2391	O
2	and	O
3	cromakalim	O
4	produced	O
5	a	O
6	dose	O
7	-	O
8	dependent	O
9	increase	O
10	in	O
11	aortic	O
12	and	O
13	coronary	O
14	blood	O
15	flow	O
16	.	O

1	Despite	O
2	this	O
3	DNA	O
4	binding	O
5	activity	O
6	,	O
7	AP	B
8	-	I
9	1	I
10	reporter	I
11	activity	O
12	was	O
13	suppressed	O
14	in	O
15	these	O
16	cells	O
17	.	O

1	In	O
2	a	O
3	highly	O
4	select	O
5	group	O
6	of	O
7	stable	O
8	hypertensive	O
9	patients	O
10	,	O
11	we	O
12	have	O
13	assessed	O
14	the	O
15	strength	O
16	of	O
17	association	O
18	between	O
19	various	O
20	blood	O
21	pressure	O
22	measurements	O
23	(	O
24	24	O
25	h	O
26	average	O
27	automated	O
28	ambulatory	O
29	blood	O
30	pressure	O
31	,	O
32	4	O
33	h	O
34	automated	O
35	ambulatory	O
36	morning	O
37	average	O
38	blood	O
39	pressure	O
40	,	O
41	multiple	O
42	office	O
43	visit	O
44	average	O
45	blood	O
46	pressure	O
47	,	O
48	and	O
49	a	O
50	single	O
51	office	O
52	visit	O
53	average	O
54	blood	O
55	pressure	O
56	)	O
57	and	O
58	various	O
59	echocardiographic	O
60	indices	O
61	of	O
62	hypertensive	O
63	cardiac	O
64	target	O
65	organ	O
66	damage	O
67	(	O
68	left	O
69	atrial	O
70	diameter	O
71	,	O
72	left	O
73	ventricular	O
74	end	O
75	diastolic	O
76	diameter	O
77	,	O
78	posterior	O
79	wall	O
80	thickness	O
81	,	O
82	combined	O
83	wall	O
84	thickness	O
85	,	O
86	relative	O
87	wall	O
88	thickness	O
89	,	O
90	left	O
91	ventricular	O
92	mass	O
93	and	O
94	mass	O
95	index	O
96	,	O
97	and	O
98	combined	O
99	wall	O
100	thickness	O
101	/	O
102	left	O
103	ventricular	O
104	diastolic	O
105	diameter	O
106	ratio	O
107	).	O

1	The	O
2	authors	O
3	proposed	O
4	that	O
5	the	O
6	highly	O
7	convergent	O
8	inputs	O
9	to	O
10	the	O
11	entorhinal	O
12	cortex	O
13	indicate	O
14	this	O
15	region	O
16	may	O
17	be	O
18	particularly	O
19	important	O
20	for	O
21	selecting	O
22	or	O
23	compressing	O
24	information	O
25	.	O

1	Although	O
2	within	O
3	normal	O
4	limits	O
5	,	O
6	latency	O
7	was	O
8	high	O
9	.	O

1	In	O
2	summary	O
3	,	O
4	Ca	O
5	(	O
6	2	O
7	+)-	O
8	dependent	O
9	activation	O
10	of	O
11	NO	O
12	production	O
13	mediates	O
14	apoptosis	O
15	after	O
16	TG	B
17	exposure	O
18	in	O
19	JT	O
20	/	O
21	Neo	O
22	cells	O
23	.	O

1	It	O
2	has	O
3	been	O
4	proposed	O
5	that	O
6	the	O
7	parCBA	B
8	operon	I
9	encodes	O
10	a	O
11	plasmid	O
12	partitioning	O
13	system	O
14	(	O
15	M	O
16	.	O

1	In	O
2	the	O
3	region	O
4	Walgau	O
5	with	O
6	mixed	O
7	industrial	O
8	-	O
9	rural	O
10	population	O
11	an	O
12	iodine	O
13	deficiency	O
14	I	O
15	was	O
16	found	O
17	in	O
18	81	O
19	%	O
20	and	O
21	an	O
22	iodine	O
23	deficiency	O
24	II	O
25	in	O
26	45	O
27	%.	O

1	Although	O
2	elevated	O
3	serum	O
4	levels	O
5	of	O
6	antibodies	O
7	to	O
8	the	O
9	nicotinic	B
10	acetylcholine	I
11	receptor	I
12	(	O
13	nAChR	B
14	)	O
15	have	O
16	been	O
17	reported	O
18	in	O
19	neuroleptic	O
20	treated	O
21	patients	O
22	with	O
23	tardive	O
24	dyskinesia	O
25	,	O
26	such	O
27	antibodies	O
28	have	O
29	not	O
30	been	O
31	determined	O
32	in	O
33	comparable	O
34	nondyskinetic	O
35	patients	O
36	.	O

1	An	O
2	approximately	O
3	37	O
4	-	O
5	kDa	O
6	cytoplasmic	O
7	protein	O
8	is	O
9	rapidly	O
10	tyrosine	O
11	-	O
12	phosphorylated	O
13	in	O
14	the	O
15	response	O
16	of	O
17	mouse	O
18	BAC1	O
19	.	O
20	2F5	O
21	macrophages	O
22	to	O
23	colony	B
24	stimulating	I
25	factor	I
26	-	I
27	1	I
28	(	O
29	CSF	B
30	-	I
31	1	I
32	).	O
33	pp37	B
34	was	O
35	purified	O
36	from	O
37	the	O
38	cytosolic	O
39	fraction	O
40	by	O
41	anti	B
42	-	I
43	Tyr	I
44	(	I
45	P	I
46	)	I
47	affinity	O
48	chromatography	O
49	,	O
50	size	O
51	exclusion	O
52	chromatography	O
53	,	O
54	and	O
55	C4	O
56	reverse	O
57	phase	O
58	high	O
59	pressure	O
60	liquid	O
61	chromatography	O
62	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	the	O
9	cooperation	O
10	of	O
11	transcription	B
12	factors	I
13	NF	I
14	-	I
15	kappaB	I
16	and	O
17	AP	B
18	-	I
19	1	I
20	is	O
21	essential	O
22	for	O
23	transactivation	O
24	of	O
25	IL	B
26	-	I
27	8	I
28	gene	I
29	by	O
30	HTLV	B
31	-	I
32	I	I
33	Tax	I
34	.	O

1	The	O
2	risk	O
3	for	O
4	these	O
5	complications	O
6	is	O
7	increased	O
8	by	O
9	the	O
10	following	O
11	factors	O
12	:	O
13	multiple	O
14	gestation	O
15	,	O
16	the	O
17	combination	O
18	of	O
19	magnesium	O
20	sulfate	O
21	and	O
22	beta	O
23	-	O
24	adrenergic	O
25	agonist	O
26	,	O
27	and	O
28	the	O
29	use	O
30	of	O
31	adrenocortico	O
32	-	O
33	steroids	O
34	to	O
35	hasten	O
36	fetal	O
37	pulmonary	O
38	maturity	O
39	.	O

1	The	O
2	role	O
3	of	O
4	HIV	B
5	tat	I
6	,	O
7	which	O
8	is	O
9	the	O
10	main	O
11	enhancing	O
12	factor	O
13	for	O
14	viral	B
15	LTR	I
16	,	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	IL	B
22	-	I
23	2	I
24	gene	I
25	transcription	O
26	has	O
27	been	O
28	studied	O
29	following	O
30	transient	O
31	expression	O
32	of	O
33	the	O
34	tat	B
35	gene	I
36	in	O
37	phorbol	O
38	ester	O
39	and	O
40	calcium	O
41	ionophore	O
42	-	O
43	activated	O
44	Jurkat	O
45	cells	O
46	transfected	O
47	with	O
48	IL	B
49	-	I
50	2	I
51	promoter	O
52	-	O
53	chloramphenicol	B
54	acetyltransferase	I
55	reporter	O
56	constructs	O
57	.	O

1	Thus	O
2	,	O
3	the	O
4	PCE	B
5	binds	O
6	a	O
7	Pbx	B
8	dimer	I
9	partner	I
10	that	O
11	behaves	O
12	unlike	O
13	Class	B
14	I	I
15	Hox	I
16	proteins	I
17	.	O

1	Students	O
2	,	O
3	parents	O
4	,	O
5	teachers	O
6	and	O
7	hearing	O
8	disorders	O

1	The	O
2	lytic	O
3	cycle	O
4	of	O
5	KSHV	O
6	,	O
7	probably	O
8	under	O
9	the	O
10	initial	O
11	control	O
12	of	O
13	the	O
14	KSHV	B
15	/	I
16	Rta	I
17	gene	I
18	,	O
19	may	O
20	directly	O
21	contribute	O
22	to	O
23	tumor	O
24	pathogenesis	O
25	.	O

1	J	O
2	.	O

1	The	O
2	risk	O
3	factors	O
4	studied	O
5	were	O
6	male	O
7	sex	O
8	,	O
9	hypertension	O
10	,	O
11	diabetes	O
12	mellitus	O
13	,	O
14	hypercholesterolemia	O
15	,	O
16	cigarette	O
17	smoking	O
18	,	O
19	sedentary	O
20	life	O
21	-	O
22	style	O
23	,	O
24	and	O
25	family	O
26	history	O
27	.	O

1	Is	O
2	nisoldipine	O
3	capable	O
4	of	O
5	reducing	O
6	left	O
7	ventricular	O
8	preload	O
9	?	O
10	In	O
11	ten	O
12	anesthetized	O
13	pigs	O
14	,	O
15	nisoldipine	O
16	(	O
17	2	O
18	-	O
19	4	O
20	micrograms	O
21	X	O
22	kg	O
23	-	O
24	1	O
25	X	O
26	min	O
27	-	O
28	1	O
29	),	O
30	a	O
31	calcium	O
32	channel	O
33	blocker	O
34	structurally	O
35	related	O
36	to	O
37	nifedipine	O
38	,	O
39	reduced	O
40	left	O
41	ventricular	O
42	systolic	O
43	pressure	O
44	(	O
45	40	O
46	%)	O
47	and	O
48	systemic	O
49	vascular	O
50	resistance	O
51	(	O
52	35	O
53	%),	O
54	whereas	O
55	maxLVdP	O
56	/	O
57	dt	O
58	decreased	O
59	by	O
60	20	O
61	%	O
62	and	O
63	cardiac	O
64	output	O
65	was	O
66	unchanged	O
67	.	O

1	Time	O
2	shifts	O
3	increase	O
4	growth	B
5	hormone	I
6	release	O
7	.	O

1	In	O
2	3	O
3	treatments	O
4	the	O
5	diet	O
6	was	O
7	supplemented	O
8	with	O
9	0	O
10	,	O
11	100	O
12	and	O
13	150	O
14	mg	O
15	probiotic	O
16	/	O
17	kg	O
18	food	O
19	.	O

1	The	O
2	outcome	O
3	of	O
4	the	O
5	optimization	O
6	of	O
7	the	O
8	seven	O
9	-	O
10	field	O
11	plan	O
12	prompted	O
13	an	O
14	investigation	O
15	into	O
16	the	O
17	best	O
18	results	O
19	that	O
20	could	O
21	be	O
22	achieved	O
23	by	O
24	an	O
25	"	O
26	ideal	O
27	"	O
28	conformal	O
29	radiotherapy	O
30	technique	O
31	.	O

1	This	O
2	last	O
3	includes	O
4	tissue	O
5	O2	O
6	transfer	O
7	(	O
8	Ft	O
9	')	O
10	and	O
11	mitochondrial	O
12	O2	O
13	utilization	O
14	(	O
15	Fm	O
16	').	O

1	We	O
2	tried	O
3	amphotericin	O
4	B	O
5	(	O
6	AmB	O
7	),	O
8	and	O
9	remission	O
10	of	O
11	the	O
12	tumor	O
13	was	O
14	obtained	O
15	.	O

1	To	O
2	study	O
3	a	O
4	possible	O
5	functional	O
6	role	O
7	of	O
8	this	O
9	putative	O
10	chicken	O
11	ICS	B
12	,	O
13	an	O
14	oligonucleotide	O
15	spanning	O
16	the	O
17	upstream	O
18	sequences	O
19	of	O
20	the	O
21	BF	B
22	-	I
23	IV	I
24	gene	I
25	(-	O
26	174	O
27	/-	O
28	194	O
29	)	O
30	was	O
31	cloned	O
32	singly	O
33	or	O
34	in	O
35	multiple	O
36	copies	O
37	before	O
38	the	O
39	herpes	O
40	TK	B
41	promoter	I
42	controlling	O
43	the	O
44	chloramphenicol	B
45	acetyl	I
46	transferase	I
47	(	O
48	CAT	B
49	)	O
50	gene	O
51	(	O
52	pBLCAT2	B
53	).	O

1	The	O
2	DRF	B
3	-	I
4	2	I
5	nuclear	I
6	protein	I
7	has	O
8	characteristics	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	muscle	O
15	-	O
16	specific	O
17	regulatory	O
18	factor	O
19	,	O
20	MEF	B
21	-	I
22	2	I
23	(	O
24	Buskin	O
25	and	O
26	Hauschka	O
27	1989	O
28	;	O
29	Gossett	O
30	et	O
31	al	O
32	.,	O
33	1989	O
34	).	O

1	Computer	O
2	assisted	O
3	mapping	O
4	in	O
5	quantitative	O
6	analysis	O
7	of	O
8	cerebral	O
9	positron	O
10	emission	O
11	tomograms	O
12	.	O

1	Effects	O
2	of	O
3	estrogen	O
4	and	O
5	glucocorticoids	O
6	on	O
7	the	O
8	adrenal	O
9	development	O
10	of	O
11	the	O
12	fetus	O
13	.	O

1	The	O
2	survival	O
3	in	O
4	the	O
5	case	O
6	of	O
7	these	O
8	patients	O
9	was	O
10	studied	O
11	five	O
12	years	O
13	later	O
14	.	O

1	The	O
2	early	O
3	lethality	O
4	of	O
5	the	O
6	left	O
7	-	O
8	sided	O
9	resectio	O
10	was	O
11	0	O
12	%	O
13	and	O
14	the	O
15	postoperative	O
16	survival	O
17	--	O
18	5	O
19	-	O
20	10	O
21	months	O
22	.	O

1	In	O
2	about	O
3	one	O
4	third	O
5	of	O
6	the	O
7	cases	O
8	this	O
9	operation	O
10	results	O
11	in	O
12	tonal	O
13	and	O
14	vocal	O
15	improvement	O
16	for	O
17	patients	O
18	suffering	O
19	from	O
20	progressive	O
21	perceptive	O
22	deafness	O
23	.	O

1	The	O
2	eluting	O
3	solvent	O
4	was	O
5	methanol	O
6	-	O
7	chloroform	O
8	(	O
9	10	O
10	+	O
11	90	O
12	)	O
13	at	O
14	a	O
15	flow	O
16	rate	O
17	of	O
18	2	O
19	.	O
20	0	O
21	ml	O
22	/	O
23	min	O
24	.	O

1	Of	O
2	115	O
3	hepatitis	O
4	B	O
5	patients	O
6	seen	O
7	at	O
8	12	O
9	months	O
10	,	O
11	6	O
12	%	O
13	had	O
14	chronic	O
15	hepatitis	O
16	Bs	O
17	antigenaemia	O
18	,	O
19	60	O
20	%	O
21	had	O
22	developed	O
23	anti	B
24	-	I
25	HBs	I
26	antibodies	I
27	,	O
28	and	O
29	7	O
30	.	O
31	3	O
32	%	O
33	still	O
34	had	O
35	abnormal	O
36	liver	O
37	function	O
38	.	O

1	Comparison	O
2	of	O
3	human	B
4	and	I
5	murine	I
6	blk	I
7	sequences	I
8	indicated	O
9	that	O
10	they	O
11	share	O
12	86	O
13	%	O
14	amino	O
15	acid	O
16	identity	O
17	,	O
18	the	O
19	most	O
20	conserved	O
21	region	O
22	being	O
23	the	O
24	catalytic	O
25	domain	O
26	(	O
27	93	O
28	%	O
29	identity	O
30	).	O

1	Histamine	O
2	-	O
3	2	O
4	blockade	O
5	in	O
6	psoriasis	O

1	The	O
2	human	O
3	gene	O
4	fragment	O
5	ligated	O
6	to	O
7	the	O
8	minimal	O
9	rat	O
10	liver	O
11	glucokinase	B
12	promoter	O
13	was	O
14	shown	O
15	to	O
16	work	O
17	as	O
18	an	O
19	enhancer	O
20	in	O
21	the	O
22	hepatocyte	O
23	transfection	O
24	system	O
25	.	O

1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	paxillin	B
6	localizes	O
7	to	O
8	focal	O
9	adhesions	O
10	independent	O
11	of	O
12	interactions	O
13	with	O
14	vinculin	B
15	and	O
16	/	O
17	or	O
18	FAK	B
19	,	O
20	and	O
21	represents	O
22	the	O
23	first	O
24	definitive	O
25	demonstration	O
26	of	O
27	LIM	B
28	domains	I
29	functioning	O
30	as	O
31	a	O
32	primary	O
33	determinant	O
34	of	O
35	protein	O
36	subcellular	O
37	localization	O
38	to	O
39	focal	O
40	adhesions	O
41	.	O

1	The	O
2	limits	O
3	of	O
4	agreement	O
5	between	O
6	DBS	O
7	and	O
8	TOF	O
9	responses	O
10	were	O
11	so	O
12	wide	O
13	that	O
14	they	O
15	cannot	O
16	be	O
17	used	O
18	interchangeably	O
19	.	O

1	Peptide	O
2	sequences	O
3	of	O
4	the	O
5	zinc	B
6	finger	I
7	protein	I
8	Ttk	I
9	and	O
10	the	O
11	transcription	B
12	factor	I
13	Adf	I
14	-	I
15	1	I
16	were	O
17	obtained	O
18	.	O

1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	sectional	O
7	study	O
8	.	O

1	The	O
2	PDGFR	B
3	mutants	I
4	that	O
5	failed	O
6	to	O
7	associate	O
8	with	O
9	PLC	B
10	gamma	I
11	were	O
12	not	O
13	able	O
14	to	O
15	mediate	O
16	the	O
17	PDGF	B
18	-	O
19	dependent	O
20	production	O
21	of	O
22	inositol	O
23	phosphates	O
24	.	O

1	We	O
2	then	O
3	studied	O
4	four	O
5	unrelated	O
6	Japanese	O
7	families	O
8	with	O
9	GSD	O
10	-	O
11	Ib	O
12	,	O
13	and	O
14	found	O
15	three	O
16	novel	O
17	mutations	O
18	:	O
19	a	O
20	four	O
21	-	O
22	base	O
23	deletion	O
24	/	O
25	two	O
26	-	O
27	base	O
28	insertion	O
29	,	O
30	a	O
31	point	O
32	mutation	O
33	within	O
34	a	O
35	consensus	O
36	splicing	O
37	donor	O
38	site	O
39	,	O
40	and	O
41	a	O
42	missense	O
43	mutation	O
44	(	O
45	W118R	O
46	).	O

1	The	O
2	results	O
3	from	O
4	the	O
5	first	O
6	five	O
7	years	O
8	of	O
9	follow	O
10	up	O
11	in	O
12	1972	O
13	showed	O
14	a	O
15	4	O
16	.	O
17	7	O
18	-	O
19	fold	O
20	excess	O
21	mortality	O
22	for	O
23	ischaemic	O
24	and	O
25	other	O
26	heart	O
27	diseases	O
28	(	O
29	ICD	O
30	A83	O
31	-	O
32	A84	O
33	)	O
34	compared	O
35	with	O
36	a	O
37	comparable	O
38	reference	O
39	cohort	O
40	of	O
41	paper	O
42	mill	O
43	workers	O
44	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	P	B
6	-	I
7	type	I
8	ATPase	I
9	gene	I
10	from	O
11	the	O
12	cyanobacterium	O
13	Synechocystis	O
14	sp	O
15	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	gene	O
9	has	O
10	significant	O
11	homology	O
12	to	O
13	the	O
14	interferon	B
15	regulatory	I
16	factors	I
17	(	O
18	IRFs	B
19	).	O

1	Nuclease	O
2	footprinting	O
3	revealed	O
4	that	O
5	purified	O
6	glucocorticoid	B
7	receptor	I
8	bound	O
9	at	O
10	multiple	O
11	discrete	O
12	sites	O
13	within	O
14	and	O
15	at	O
16	the	O
17	borders	O
18	of	O
19	the	O
20	tandemly	O
21	repeated	O
22	sequence	O
23	motif	O
24	that	O
25	defines	O
26	Sa	B
27	.	O

1	In	O
2	contrast	O
3	,	O
4	a	O
5	similar	O
6	fragment	O
7	lacking	O
8	the	O
9	38	O
10	-	O
11	base	O
12	-	O
13	pair	O
14	region	O
15	had	O
16	no	O
17	such	O
18	stabilizing	O
19	effect	O
20	.	O

1	RNA	O
2	gel	O
3	retardation	O
4	and	O
5	competition	O
6	analyses	O
7	indicate	O
8	that	O
9	TRP	B
10	-	I
11	185	I
12	binding	O
13	is	O
14	strongly	O
15	dependent	O
16	on	O
17	the	O
18	TAR	O
19	RNA	O
20	loop	O
21	sequences	O
22	.	O

1	The	O
2	incidence	O
3	of	O
4	cryptosporidiosis	O
5	in	O
6	young	O
7	children	O
8	was	O
9	determined	O
10	by	O
11	staining	O
12	of	O
13	faecal	O
14	specimens	O
15	with	O
16	a	O
17	modified	O
18	Kinyoun	O
19	stain	O
20	.	O

1	Results	O
2	confirmed	O
3	that	O
4	stress	O
5	produced	O
6	CA3	O
7	dendritic	O
8	atrophy	O
9	and	O
10	tianeptine	O
11	prevented	O
12	it	O
13	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	clinical	O
6	profile	O
7	of	O
8	cavernous	O
9	malformations	O
10	with	O
11	and	O
12	without	O
13	associated	O
14	venous	O
15	malformations	O
16	.	O

1	Eleven	O
2	strains	O
3	of	O
4	Fusarium	O
5	poae	O
6	and	O
7	F	O
8	.	O
9	sporotrichioides	O
10	from	O
11	the	O
12	U	O
13	.	O
14	S	O
15	.	O
16	S	O
17	.	O
18	R	O
19	.	O
20	and	O
21	7	O
22	strains	O
23	of	O
24	these	O
25	species	O
26	and	O
27	one	O
28	of	O
29	F	O
30	.	O
31	sporotrichioides	O
32	var	O
33	.	O
34	tricinctum	O
35	from	O
36	U	O
37	.	O
38	S	O
39	.	O
40	A	O
41	.	O
42	and	O
43	France	O
44	have	O
45	been	O
46	compared	O
47	as	O
48	to	O
49	their	O
50	capacity	O
51	to	O
52	yield	O
53	T	B
54	-	I
55	2	I
56	toxin	I
57	.	O

1	It	O
2	contains	O
3	a	O
4	5	O
5	'-	O
6	noncoding	O
7	region	O
8	(	O
9	NCR	O
10	)	O
11	of	O
12	73	O
13	nucleotides	O
14	,	O
15	five	O
16	open	O
17	reading	O
18	frames	O
19	(	O
20	ORFs	O
21	1	O
22	to	O
23	5	O
24	)	O
25	which	O
26	encode	O
27	proteins	O
28	with	O
29	M	O
30	(	O
31	r	O
32	)	O
33	160	O
34	kDa	O
35	RNA	O
36	-	O
37	dependent	O
38	RNA	O
39	polymerase	O
40	(	O
41	ORF1	O
42	),	O
43	26	O
44	kDa	O
45	movement	O
46	protein	O
47	1	O
48	(	O
49	ORF2	O
50	),	O
51	13	O
52	kDa	O
53	movement	O
54	protein	O
55	2	O
56	(	O
57	ORF3	O
58	),	O
59	10	O
60	kDa	O
61	movement	O
62	protein	O
63	3	O
64	(	O
65	ORF4	O
66	),	O
67	24	O
68	kDa	O
69	coat	O
70	protein	O
71	(	O
72	OFR5	O
73	),	O
74	and	O
75	a	O
76	3	O
77	'	O
78	NCR	O
79	of	O
80	76	O
81	nucleotides	O
82	.	O

1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	The	O
2	human	O
3	coreceptor	O
4	was	O
5	as	O
6	active	O
7	as	O
8	the	O
9	simian	O
10	for	O
11	SIV	O
12	entry	O
13	.	O

1	In	O
2	addition	O
3	,	O
4	mutation	O
5	of	O
6	the	O
7	Sp1	B
8	site	I
9	also	O
10	significantly	O
11	reduced	O
12	promoter	O
13	activity	O
14	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	O
7	1a	B
8	is	O
9	a	O
10	distant	O
11	homolog	B
12	of	I
13	alphavirus	I
14	nonstructural	I
15	protein	I
16	nsP1	I
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	O
23	capping	O
24	viral	O
25	RNAs	O
26	.	O

1	No	O
2	reflow	O
3	occurred	O
4	in	O
5	approximately	O
6	30	O
7	percent	O
8	of	O
9	the	O
10	muscle	O
11	microvasculature	O
12	upon	O
13	reperfusion	O
14	.	O

1	The	O
2	average	O
3	coefficients	O
4	of	O
5	correlation	O
6	were	O
7	0	O
8	.	O
9	9998	O
10	and	O
11	0	O
12	.	O
13	9993	O
14	for	O
15	the	O
16	QMF	O
17	and	O
18	the	O
19	QIT	O
20	system	O
21	,	O
22	respectively	O
23	.	O

1	It	O
2	appears	O
3	that	O
4	the	O
5	pulmonary	O
6	gas	O
7	exchange	O
8	parenchyma	O
9	of	O
10	these	O
11	smallest	O
12	mammals	O
13	is	O
14	well	O
15	suited	O
16	to	O
17	supply	O
18	the	O
19	organism	O
20	with	O
21	the	O
22	comparatively	O
23	high	O
24	levels	O
25	of	O
26	O2	O
27	required	O
28	by	O
29	the	O
30	high	O
31	metabolic	O
32	rates	O
33	,	O
34	exhibiting	O
35	a	O
36	structural	O
37	adaptation	O
38	of	O
39	the	O
40	lung	O
41	to	O
42	higher	O
43	VO2	O
44	.	O

1	We	O
2	isolated	O
3	several	O
4	overlapping	O
5	A	O
6	-	O
7	phage	O
8	and	O
9	cosmid	O
10	clones	O
11	that	O
12	cover	O
13	more	O
14	than	O
15	100	O
16	kb	O
17	of	O
18	human	O
19	DNA	O
20	and	O
21	contained	O
22	the	O
23	entire	O
24	VDR	B
25	gene	I
26	.	O

1	Functional	O
2	domains	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	promoter	I
8	binding	I
9	protein	I
10	1	I
11	involved	O
12	in	O
13	transcriptional	O
14	repression	O
15	and	O
16	cell	O
17	growth	O
18	regulation	O
19	.	O

1	Retinal	O
2	changes	O
3	in	O
4	pigmentary	O
5	retinopathy	O
6	in	O
7	children	O

1	To	O
2	evaluate	O
3	the	O
4	hepatic	O
5	regenerative	O
6	response	O
7	in	O
8	patients	O
9	with	O
10	alcoholic	O
11	liver	O
12	disease	O
13	,	O
14	sera	O
15	from	O
16	263	O
17	patients	O
18	with	O
19	severe	O
20	alcoholic	O
21	hepatitis	O
22	and	O
23	/	O
24	or	O
25	cirrhosis	O
26	were	O
27	analyzed	O
28	for	O
29	hepatocyte	B
30	growth	I
31	factor	I
32	(	O
33	HGF	B
34	)	O
35	and	O
36	alpha	B
37	-	I
38	fetoprotein	I
39	(	O
40	AFP	B
41	).	O

1	Tissue	O
2	pressure	O
3	,	O
4	rCBF	O
5	,	O
6	and	O
7	water	O
8	content	O
9	were	O
10	measured	O
11	from	O
12	gray	O
13	matter	O
14	in	O
15	the	O
16	central	O
17	core	O
18	and	O
19	the	O
20	peripheral	O
21	margin	O
22	of	O
23	the	O
24	MCA	O
25	territory	O
26	over	O
27	6	O
28	h	O
29	after	O
30	MCAO	O
31	.	O

1	However	O
2	,	O
3	parallax	O
4	measurements	O
5	showed	O
6	that	O
7	at	O
8	150K	O
9	,	O
10	collapse	O
11	of	O
12	Epon	O
13	sections	O
14	does	O
15	not	O
16	take	O
17	place	O
18	.	O

1	Plasma	O
2	,	O
3	LDL	B
4	and	O
5	liver	O
6	cholesterol	O
7	concentrations	O
8	were	O
9	higher	O
10	in	O
11	the	O
12	hyperlipidemic	O
13	control	O
14	than	O
15	the	O
16	nonhyperlipidemic	O
17	control	O
18	and	O
19	lower	O
20	in	O
21	the	O
22	groups	O
23	fed	O
24	diets	O
25	containing	O
26	pectin	B
27	or	O
28	prune	O
29	fiber	O
30	than	O
31	in	O
32	the	O
33	hyperlipidemic	O
34	control	O
35	group	O
36	.	O

1	Our	O
2	data	O
3	show	O
4	that	O
5	multiple	O
6	MLSN1	B
7	transcripts	I
8	,	O
9	both	O
10	constitutively	O
11	expressed	O
12	and	O
13	inducible	O
14	,	O
15	are	O
16	present	O
17	in	O
18	cultured	O
19	pigmented	O
20	melanoma	O
21	cells	O
22	,	O
23	and	O
24	suggest	O
25	that	O
26	MLSN1	B
27	expression	O
28	can	O
29	be	O
30	regulated	O
31	at	O
32	the	O
33	level	O
34	of	O
35	both	O
36	transcription	O
37	and	O
38	mRNA	O
39	processing	O
40	.	O

1	Our	O
2	results	O
3	implicate	O
4	TGF	B
5	-	I
6	beta	I
7	RII	I
8	as	O
9	a	O
10	direct	O
11	target	O
12	of	O
13	EWS	B
14	-	O
15	FLI1	B
16	.	O

1	The	O
2	Sarns	O
3	51F	O
4	cavoatrial	O
5	cannula	O
6	decompressed	O
7	the	O
8	venous	O
9	system	O
10	as	O
11	efficiently	O
12	as	O
13	the	O
14	double	O
15	caval	O
16	cannulas	O
17	.	O

1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	proteins	O
6	showed	O
7	that	O
8	24	O
9	h	O
10	of	O
11	lovastatin	O
12	treatment	O
13	in	O
14	the	O
15	control	O
16	cells	O
17	caused	O
18	an	O
19	elevation	O
20	in	O
21	the	O
22	levels	O
23	of	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinase	I
29	inhibitor	O
30	p27	B
31	(	O
32	kip1	B
33	),	O
34	inhibition	O
35	of	O
36	both	O
37	cyclin	B
38	E	I
39	-	I
40	and	I
41	cyclin	I
42	A	I
43	-	I
44	dependent	I
45	kinase	I
46	activity	O
47	,	O
48	and	O
49	decreased	O
50	levels	O
51	of	O
52	hyperphosphorylated	O
53	retinoblastoma	B
54	protein	I
55	(	O
56	pRb	B
57	).	O

1	ORF	O
2	M1	O
3	has	O
4	striking	O
5	homology	O
6	to	O
7	poxvirus	O
8	serpins	B
9	,	O
10	while	O
11	ORF	O
12	M11	O
13	encodes	O
14	a	O
15	potential	O
16	homolog	O
17	of	O
18	Bcl	B
19	-	I
20	2	I
21	-	I
22	like	I
23	molecules	I
24	encoded	O
25	by	O
26	other	O
27	gammaherpesviruses	O
28	(	O
29	gene	B
30	16	I
31	of	O
32	HVS	O
33	and	O
34	KSHV	O
35	and	O
36	the	O
37	BHRF1	B
38	gene	I
39	of	O
40	EBV	O
41	).	O

1	The	O
2	7	O
3	-	O
4	day	O
5	treatment	O
6	resulted	O
7	in	O
8	a	O
9	decrease	O
10	in	O
11	mitochondrial	O
12	uptake	O
13	of	O
14	Rh123	O
15	and	O
16	an	O
17	increase	O
18	in	O
19	NAO	O
20	uptake	O
21	.	O

1	Stability	O
2	of	O
3	pyrimethamine	O
4	in	O
5	a	O
6	liquid	O
7	dosage	O
8	formulation	O
9	stored	O
10	for	O
11	three	O
12	months	O
13	.	O

1	The	O
2	method	O
3	has	O
4	been	O
5	routinely	O
6	used	O
7	in	O
8	our	O
9	laboratory	O
10	for	O
11	1	O
12	year	O
13	and	O
14	has	O
15	proven	O
16	to	O
17	be	O
18	a	O
19	reliable	O
20	procedure	O
21	for	O
22	the	O
23	biological	O
24	control	O
25	of	O
26	occupational	O
27	exposure	O
28	to	O
29	toluene	O
30	and	O
31	/	O
32	or	O
33	xylene	O
34	.	O

1	Changes	O
2	in	O
3	prognosis	O
4	of	O
5	twin	O
6	births	O
7	over	O
8	20	O
9	years	O
10	.	O

1	We	O
2	find	O
3	that	O
4	BCL	B
5	-	I
6	6	I
7	POZ	O
8	domain	O
9	mutations	O
10	that	O
11	disrupt	O
12	the	O
13	interaction	O
14	with	O
15	N	B
16	-	I
17	CoR	I
18	and	O
19	SMRT	B
20	no	O
21	longer	O
22	repress	O
23	transcription	O
24	.	O

1	Dual	O
2	roles	O
3	of	O
4	p82	B
5	,	O
6	the	O
7	clam	O
8	CPEB	B
9	homolog	I
10	,	O
11	in	O
12	cytoplasmic	O
13	polyadenylation	O
14	and	O
15	translational	O
16	masking	O
17	.	O

1	Electrical	O
2	activity	O
3	was	O
4	evaluated	O
5	by	O
6	monitoring	O
7	the	O
8	general	O
9	electrocorticogram	O
10	(	O
11	ECoG	O
12	)	O
13	as	O
14	well	O
15	as	O
16	local	O
17	DC	O
18	steady	O
19	potential	O
20	(	O
21	two	O
22	sites	O
23	).	O

1	Sequence	O
2	requirements	O
3	for	O
4	premature	O
5	transcription	O
6	arrest	O
7	within	O
8	the	O
9	first	O
10	intron	O
11	of	O
12	the	O
13	mouse	B
14	c	I
15	-	I
16	fos	I
17	gene	I
18	.	O

1	These	O
2	alternative	O
3	splice	O
4	variants	O
5	were	O
6	detected	O
7	in	O
8	RNA	O
9	isolated	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	primary	O
16	leptomeningeal	O
17	tissue	O
18	and	O
19	an	O
20	established	O
21	line	O
22	of	O
23	leptomeningeal	O
24	cells	O
25	(	O
26	LMC	O
27	).	O

1	Grossly	O
2	,	O
3	the	O
4	experimental	O
5	vulvitis	O
6	was	O
7	identical	O
8	to	O
9	the	O
10	field	O
11	condition	O
12	,	O
13	and	O
14	bacteria	O
15	indistinguishable	O
16	from	O
17	the	O
18	inoculated	O
19	strains	O
20	were	O
21	reisolated	O
22	.	O

1	The	O
2	role	O
3	of	O
4	intraoperative	O
5	echocardiography	O
6	in	O
7	surgery	O
8	of	O
9	the	O
10	heart	O
11	and	O
12	large	O
13	vessels	O

1	Expression	O
2	of	O
3	this	O
4	cDNA	O
5	in	O
6	vitro	O
7	yields	O
8	a	O
9	peptide	O
10	which	O
11	comigrates	O
12	with	O
13	natural	B
14	eIF	I
15	-	I
16	2B	I
17	alpha	I
18	in	O
19	SDS	O
20	/	O
21	polyacrylamide	O
22	gels	O
23	.	O

1	Expression	O
2	in	O
3	early	O
4	postnatal	O
5	pituitary	O
6	and	O
7	in	O
8	pre	O
9	-	O
10	somatotrophic	O
11	cells	O
12	suggests	O
13	that	O
14	Zn	B
15	-	I
16	16	I
17	could	O
18	play	O
19	a	O
20	role	O
21	in	O
22	pituitary	O
23	development	O
24	prior	O
25	to	O
26	somatotroph	O
27	differentiation	O
28	.	O

1	A	O
2	reduction	O
3	of	O
4	the	O
5	aspartate	B
6	aminotransferase	I
7	activity	O
8	was	O
9	observed	O
10	from	O
11	800	O
12	mg	O
13	/	O
14	kg	O
15	b	O
16	.	O
17	w	O
18	./	O
19	d	O
20	onwards	O
21	.	O

1	Heme	B
2	oxygenase	I
3	1	I
4	is	O
5	an	O
6	essential	O
7	enzyme	O
8	in	O
9	heme	O
10	catabolism	O
11	that	O
12	cleaves	O
13	heme	O
14	to	O
15	form	O
16	biliverdin	O
17	,	O
18	iron	O
19	,	O
20	and	O
21	carbon	O
22	monoxide	O
23	.	O

1	It	O
2	has	O
3	come	O
4	out	O
5	that	O
6	CAEC	O
7	is	O
8	between	O
9	CC	O
10	and	O
11	CIEC	O
12	and	O
13	that	O
14	attacks	O
15	of	O
16	biliary	O
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	O
22	alkaline	B
23	phosphatase	I
24	and	O
25	transaminases	O
26	in	O
27	the	O
28	serum	O
29	are	O
30	the	O
31	helpful	O
32	findings	O
33	for	O
34	preoperative	O
35	diagnosis	O
36	.	O

1	OUTCOME	O
2	:	O
3	Acetylcholine	B
4	receptor	I
5	antibodies	I
6	and	O
7	single	O
8	-	O
9	fibre	O
10	electromyogram	O
11	were	O
12	useful	O
13	in	O
14	the	O
15	diagnosis	O
16	of	O
17	myasthenia	O
18	gravis	O
19	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	transiently	O
8	expressed	O
9	in	O
10	primary	O
11	cultures	O
12	of	O
13	rat	O
14	hepatocytes	O
15	plasmids	O
16	consisting	O
17	of	O
18	CYP3A1	B
19	5	I
20	'-	I
21	flanking	I
22	sequences	I
23	fused	O
24	to	O
25	a	O
26	chloramphenicol	B
27	acetyltransferase	I
28	reporter	I
29	plasmid	O
30	.	O

1	A	O
2	variety	O
3	of	O
4	nuclear	O
5	ribonucleoproteins	O
6	are	O
7	believed	O
8	to	O
9	associate	O
10	directly	O
11	with	O
12	nascent	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcripts	I
17	and	O
18	remain	O
19	associated	O
20	during	O
21	subsequent	O
22	nuclear	O
23	RNA	O
24	processing	O
25	reactions	O
26	,	O
27	including	O
28	pre	O
29	-	O
30	mRNA	O
31	polyadenylation	O
32	and	O
33	splicing	O
34	as	O
35	well	O
36	as	O
37	nucleocytoplasmic	O
38	mRNA	O
39	transport	O
40	.	O

1	A	O
2	recent	O
3	index	O
4	(	O
5	Fluorosis	O
6	Risk	O
7	Index	O
8	)	O
9	developed	O
10	by	O
11	Pendrys	O
12	(	O
13	1990	O
14	)	O
15	is	O
16	also	O
17	included	O
18	in	O
19	this	O
20	review	O
21	.	O

1	Analysis	O
2	of	O
3	the	O
4	gag	B
5	and	O
6	rev	B
7	proteins	I
8	in	O
9	the	O
10	transfected	O
11	cells	O
12	demonstrated	O
13	that	O
14	these	O
15	proteins	O
16	were	O
17	not	O
18	detectable	O
19	in	O
20	cells	O
21	transfected	O
22	with	O
23	the	O
24	tat	B
25	mutants	I
26	but	O
27	could	O
28	be	O
29	readily	O
30	detected	O
31	when	O
32	the	O
33	mutations	O
34	were	O
35	complemented	O
36	in	O
37	trans	O
38	with	O
39	a	O
40	tat	B
41	expression	O
42	vector	O
43	.	O

1	Mean	O
2	growth	O
3	changes	O
4	in	O
5	this	O
6	Class	O
7	II	O
8	sample	O
9	were	O
10	comparable	O
11	to	O
12	those	O
13	previously	O
14	reported	O
15	for	O
16	male	O
17	subjects	O
18	with	O
19	Class	O
20	I	O
21	malocclusions	O
22	over	O
23	the	O
24	same	O
25	age	O
26	period	O
27	,	O
28	suggesting	O
29	a	O
30	similarity	O
31	in	O
32	postpubertal	O
33	development	O
34	between	O
35	these	O
36	two	O
37	groups	O
38	.	O

1	Purified	O
2	Hsk1	B
3	phosphorylates	O
4	the	O
5	Cdc19	B
6	(	O
7	Mcm2	B
8	)	O
9	subunit	O
10	of	O
11	the	O
12	six	B
13	-	I
14	member	I
15	minichromosome	I
16	maintenance	I
17	protein	I
18	complex	I
19	purified	O
20	from	O
21	fission	O
22	yeast	O
23	.	O

1	Testing	O
2	for	O
3	serum	B
4	IgM	I
5	binding	O
6	to	O
7	GM1	O
8	ganglioside	O
9	in	O
10	clinical	O
11	practice	O
12	.	O

1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	O
8	Uzbekistan	O

1	In	O
2	some	O
3	instances	O
4	,	O
5	this	O
6	is	O
7	partly	O
8	mediated	O
9	by	O
10	the	O
11	expression	O
12	of	O
13	virally	O
14	encoded	O
15	proteases	O
16	which	O
17	lead	O
18	to	O
19	the	O
20	cleavage	O
21	of	O
22	initiation	B
23	factor	I
24	eIF4G	I
25	.	O

1	A	O
2	method	O
3	for	O
4	establishing	O
5	stimulus	O
6	control	O
7	of	O
8	ethanol	O
9	responding	O
10	was	O
11	developed	O
12	.	O

1	Immunofluorescence	O
2	microscopy	O
3	and	O
4	cell	O
5	fractionation	O
6	analyses	O
7	showed	O
8	that	O
9	the	O
10	110	O
11	-	O
12	kDa	O
13	protein	O
14	was	O
15	exclusively	O
16	nuclear	O
17	,	O
18	whereas	O
19	the	O
20	150	O
21	-	O
22	kDa	O
23	protein	O
24	was	O
25	present	O
26	in	O
27	both	O
28	the	O
29	cytoplasm	O
30	and	O
31	nucleus	O
32	of	O
33	human	O
34	cells	O
35	.	O

1	No	O
2	differences	O
3	in	O
4	total	O
5	cholesterol	O
6	levels	O
7	were	O
8	observed	O
9	between	O
10	mapuches	O
11	and	O
12	aymaras	O
13	.	O

1	Absence	O
2	of	O
3	action	O
4	potentials	O
5	in	O
6	frog	O
7	slow	O
8	muscle	O
9	fibres	O
10	paralysed	O
11	by	O
12	botulinum	B
13	toxin	I
14	.	O

1	Specifically	O
2	,	O
3	this	O
4	study	O
5	determined	O
6	the	O
7	influence	O
8	of	O
9	:	O
10	(	O
11	1	O
12	)	O
13	an	O
14	awareness	O
15	strategy	O
16	,	O
17	(	O
18	2	O
19	)	O
20	a	O
21	non	O
22	-	O
23	awareness	O
24	strategy	O
25	,	O
26	(	O
27	3	O
28	)	O
29	a	O
30	Five	O
31	-	O
32	Step	O
33	Approach	O
34	strategy	O
35	and	O
36	(	O
37	4	O
38	)	O
39	a	O
40	control	O
41	condition	O
42	.	O

1	To	O
2	understand	O
3	whether	O
4	Shc	B
5	localization	O
6	in	O
7	membrane	O
8	rafts	O
9	is	O
10	sufficient	O
11	to	O
12	regulate	O
13	Shc	B
14	function	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	Shc	B
20	chimera	I
21	containing	O
22	the	O
23	Ras	B
24	membrane	I
25	localization	I
26	motif	I
27	at	O
28	the	O
29	C	O
30	-	O
31	terminus	O
32	.	O

1	J	O
2	.	O

1	Previously	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	51	O
7	-	O
8	bp	O
9	promoter	O
10	fragment	O
11	,	O
12	oligo31	O
13	/	O
14	32	O
15	,	O
16	which	O
17	conferred	O
18	heat	O
19	shock	O
20	inducibility	O
21	on	O
22	the	O
23	heterologous	O
24	CYC1	B
25	-	O
26	lacZ	B
27	reporter	O
28	gene	O
29	in	O
30	S	O
31	.	O
32	cerevisiae	O
33	(	O
34	N	O
35	.	O

1	Because	O
2	of	O
3	a	O
4	rapid	O
5	development	O
6	of	O
7	the	O
8	connective	O
9	tissue	O
10	scars	O
11	,	O
12	however	O
13	,	O
14	at	O
15	the	O
16	place	O
17	of	O
18	the	O
19	destroyed	O
20	glandular	O
21	parenchyma	O
22	areas	O
23	,	O
24	there	O
25	is	O
26	no	O
27	normalization	O
28	of	O
29	the	O
30	organ	O
31	'	O
32	s	O
33	structure	O
34	and	O
35	function	O
36	by	O
37	the	O
38	42d	O
39	day	O
40	.	O

1	Moreover	O
2	,	O
3	by	O
4	complementation	O
5	of	O
6	the	O
7	WA	B
8	fyuA	I
9	mutant	I
10	by	O
11	the	O
12	cloned	O
13	fyuA	B
14	gene	I
15	,	O
16	yersiniabactin	O
17	uptake	O
18	and	O
19	mouse	O
20	virulence	O
21	were	O
22	restored	O
23	.	O

1	Analysis	O
2	of	O
3	the	O
4	rate	O
5	constants	O
6	indicated	O
7	that	O
8	the	O
9	isomerization	O
10	rate	O
11	k12	O
12	was	O
13	approximately	O
14	equal	O
15	to	O
16	the	O
17	apparent	O
18	degradation	O
19	rate	O
20	of	O
21	the	O
22	delta	O
23	3	O
24	ester	O
25	kdeg	O
26	,	O
27	and	O
28	slower	O
29	than	O
30	the	O
31	hydrolysis	O
32	rate	O
33	of	O
34	the	O
35	delta	O
36	2	O
37	ester	O
38	k24	O
39	.	O

1	Dopamine	O
2	SERS	O
3	spectra	O
4	from	O
5	these	O
6	electrodes	O
7	are	O
8	similar	O
9	to	O
10	those	O
11	obtained	O
12	at	O
13	uncoated	O
14	electrodes	O
15	.	O

1	FK506	O
2	is	O
3	10	O
4	-	O
5	to	O
6	100	O
7	-	O
8	fold	O
9	more	O
10	potent	O
11	than	O
12	cyclosporin	O
13	A	O
14	in	O
15	preventing	O
16	organ	O
17	rejection	O
18	and	O
19	in	O
20	toxicity	O
21	.	O

1	High	O
2	expression	O
3	of	O
4	the	O
5	peroxisome	B
6	proliferator	I
7	-	I
8	activated	I
9	receptor	I
10	alpha	I
11	(	O
12	PPARalpha	B
13	)	O
14	differentiates	O
15	brown	O
16	fat	O
17	from	O
18	white	O
19	,	O
20	and	O
21	is	O
22	related	O
23	to	O
24	its	O
25	high	O
26	capacity	O
27	of	O
28	lipid	O
29	oxidation	O
30	.	O

1	We	O
2	demonstrate	O
3	that	O
4	a	O
5	VT	O
6	+	O
7	peptide	O
8	was	O
9	specifically	O
10	phosphorylated	O
11	by	O
12	protein	B
13	kinase	I
14	C	I
15	(	O
16	PKC	B
17	)	O
18	in	O
19	vitro	O
20	,	O
21	but	O
22	not	O
23	by	O
24	protein	B
25	kinase	I
26	A	I
27	(	O
28	PKA	B
29	).	O

1	Evidence	O
2	is	O
3	presented	O
4	that	O
5	Leber	O
6	'	O
7	s	O
8	military	O
9	aneurysm	O
10	retinitis	O
11	is	O
12	not	O
13	a	O
14	separate	O
15	entity	O
16	but	O
17	a	O
18	special	O
19	form	O
20	of	O
21	Coats	O
22	'	O
23	disease	O
24	.	O

1	Alkoxymetgyl	O
2	-	O
3	3	O
4	,	O
5	4	O
6	-	O
7	dimethylpyridinium	O
8	chlorides	O
9	were	O
10	synthetized	O
11	by	O
12	reacting	O
13	3	O
14	,	O
15	4	O
16	-	O
17	dimethylpyridine	O
18	with	O
19	chloromethyl	O
20	alkyl	O
21	ethers	O
22	,	O
23	while	O
24	1	O
25	-	O
26	ethyloxymethyl	O
27	-	O
28	3	O
29	-	O
30	alkylthiomethylimidazolium	O
31	chlorides	O
32	were	O
33	obtained	O
34	in	O
35	reactions	O
36	of	O
37	1	O
38	-	O
39	ethyloxymethylimidazol	O
40	with	O
41	chloromethyl	O
42	alkyl	O
43	sulfides	O
44	.	O

1	During	O
2	the	O
3	years	O
4	1980	O
5	-	O
6	87	O
7	a	O
8	total	O
9	of	O
10	287	O
11	persons	O
12	received	O
13	disability	O
14	pensions	O
15	in	O
16	the	O
17	municipality	O
18	of	O
19	Nordreisa	O
20	in	O
21	northern	O
22	Norway	O
23	.	O

1	An	O
2	AP	B
3	-	I
4	1	I
5	binding	I
6	sequence	I
7	is	O
8	essential	O
9	for	O
10	regulation	O
11	of	O
12	the	O
13	human	B
14	alpha2	I
15	(	I
16	I	I
17	)	I
18	collagen	I
19	(	O
20	COL1A2	B
21	)	O
22	promoter	O
23	activity	O
24	by	O
25	transforming	B
26	growth	I
27	factor	I
28	-	I
29	beta	I
30	.	O

1	The	O
2	used	O
3	expression	O
4	system	O
5	could	O
6	allow	O
7	to	O
8	produce	O
9	mutated	O
10	forms	O
11	of	O
12	SsEF	B
13	-	I
14	2	I
15	obtained	O
16	by	O
17	mutagenesis	O
18	of	O
19	the	O
20	corresponding	O
21	gene	O
22	.	O

1	If	O
2	this	O
3	is	O
4	the	O
5	case	O
6	,	O
7	identification	O
8	and	O
9	characterization	O
10	of	O
11	transcripts	O
12	from	O
13	the	O
14	Ig	B
15	loci	I
16	should	O
17	permit	O
18	a	O
19	better	O
20	understanding	O
21	of	O
22	the	O
23	gene	O
24	rearrangement	O
25	process	O
26	.	O

1	It	O
2	acts	O
3	on	O
4	Cdks	B
5	in	O
6	the	O
7	G1	O
8	and	O
9	S	O
10	phases	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	,	O
16	and	O
17	also	O
18	binds	O
19	to	O
20	proliferating	B
21	cell	I
22	nuclear	I
23	antigen	I
24	(	O
25	PCNA	B
26	),	O
27	blocking	O
28	DNA	O
29	replication	O
30	in	O
31	vitro	O
32	.	O

1	Consistent	O
2	with	O
3	this	O
4	prediction	O
5	,	O
6	transfections	O
7	into	O
8	the	O
9	hematopoietic	O
10	cell	O
11	line	O
12	Jurkat	O
13	showed	O
14	a	O
15	9	O
16	.	O
17	0	O
18	-	O
19	and	O
20	2	O
21	.	O
22	5	O
23	-	O
24	fold	O
25	activation	O
26	of	O
27	the	O
28	mim	B
29	-	I
30	1	I
31	promoter	I
32	by	O
33	the	O
34	p32	B
35	and	O
36	p30	B
37	isoforms	I
38	,	O
39	respectively	O
40	.	O

1	Chem	O
2	.	O

1	Pacing	O
2	the	O
3	Roux	O
4	limb	O
5	abolished	O
6	the	O
7	ectopic	O
8	pacemakers	O
9	,	O
10	restored	O
11	the	O
12	slow	O
13	emptying	O
14	of	O
15	liquids	O
16	to	O
17	the	O
18	more	O
19	rapid	O
20	rate	O
21	found	O
22	in	O
23	the	O
24	Billroth	O
25	dogs	O
26	(	O
27	t1	O
28	/	O
29	2	O
30	:	O
31	paced	O
32	Roux	O
33	,	O
34	72	O
35	+/-	O
36	15	O
37	minutes	O
38	;	O
39	Billroth	O
40	,	O
41	43	O
42	+/-	O
43	9	O
44	minutes	O
45	;	O
46	p	O
47	greater	O
48	than	O
49	0	O
50	.	O
51	05	O
52	)	O
53	and	O
54	did	O
55	not	O
56	change	O
57	emptying	O
58	of	O
59	solids	O
60	.	O

1	Thin	O
2	melanomas	O
3	can	O
4	metastasize	O
5	and	O
6	be	O
7	lethal	O
8	.	O

1	Collectively	O
2	,	O
3	these	O
4	experiments	O
5	demonstrate	O
6	that	O
7	CFTR	B
8	'	I
9	s	I
10	NBF1	I
11	+	I
12	R	I
13	region	I
14	and	O
15	its	O
16	NBF2	B
17	domain	I
18	,	O
19	after	O
20	folding	O
21	separately	O
22	as	O
23	distinct	O
24	units	O
25	,	O
26	have	O
27	a	O
28	strong	O
29	propensity	O
30	to	O
31	interact	O
32	and	O
33	that	O
34	this	O
35	interaction	O
36	is	O
37	stable	O
38	in	O
39	the	O
40	absence	O
41	of	O
42	added	O
43	nucleotides	O
44	or	O
45	exogenously	O
46	induced	O
47	phosphorylation	O
48	.	O

1	Among	O
2	mucus	O
3	-	O
4	secreting	O
5	cells	O
6	,	O
7	the	O
8	gastric	O
9	gland	O
10	mucous	O
11	cells	O
12	,	O
13	Brunner	O
14	'	O
15	s	O
16	glands	O
17	,	O
18	accessory	O
19	glands	O
20	of	O
21	pancreaticobiliary	O
22	tract	O
23	,	O
24	and	O
25	pancreatic	O
26	ducts	O
27	exhibiting	O
28	gastric	O
29	metaplasia	O
30	are	O
31	unique	O
32	in	O
33	that	O
34	they	O
35	express	O
36	class	B
37	III	I
38	mucin	I
39	identified	O
40	by	O
41	paradoxical	O
42	Con	B
43	A	I
44	staining	O
45	composed	O
46	of	O
47	periodate	O
48	oxidation	O
49	,	O
50	sodium	O
51	borohydride	O
52	reduction	O
53	,	O
54	Con	B
55	A	I
56	,	O
57	and	O
58	horseradish	B
59	peroxidase	I
60	reaction	O
61	.	O

1	An	O
2	int6	B
3	deletion	I
4	(	O
5	int6Delta	B
6	)	O
7	mutant	O
8	was	O
9	viable	O
10	but	O
11	grew	O
12	slowly	O
13	in	O
14	minimal	O
15	medium	O
16	.	O

1	The	O
2	promoter	O
3	and	O
4	upstream	O
5	region	O
6	of	O
7	the	O
8	Brassica	B
9	napus	I
10	2S	I
11	storage	I
12	protein	I
13	napA	I
14	gene	I
15	were	O
16	studied	O
17	to	O
18	identify	O
19	cis	O
20	-	O
21	acting	O
22	sequences	O
23	involved	O
24	in	O
25	developmental	O
26	seed	O
27	-	O
28	specific	O
29	expression	O
30	.	O

1	Furthermore	O
2	,	O
3	the	O
4	PH	B
5	and	O
6	PTB	O
7	domains	O
8	are	O
9	highly	O
10	homologous	O
11	(	O
12	at	O
13	least	O
14	40	O
15	%	O
16	identical	O
17	)	O
18	to	O
19	those	O
20	found	O
21	in	O
22	insulin	B
23	receptor	I
24	substrates	I
25	1	I
26	,	I
27	2	I
28	,	I
29	and	I
30	3	I
31	(	O
32	IRS	B
33	-	I
34	1	I
35	,	O
36	IRS	B
37	-	I
38	2	I
39	,	O
40	and	O
41	IRS	B
42	-	I
43	3	I
44	).	O

1	One	O
2	of	O
3	these	O
4	fragments	O
5	shows	O
6	the	O
7	highest	O
8	amino	O
9	acid	O
10	sequence	O
11	homology	O
12	to	O
13	the	O
14	insect	O
15	ecdysone	O
16	inducible	O
17	gene	B
18	E75	I
19	.	O

1	In	O
2	broken	O
3	L	O
4	-	O
5	cell	O
6	membranes	O
7	expressing	O
8	wild	O
9	type	O
10	or	O
11	mutant	B
12	M6P	I
13	/	I
14	IGF	I
15	II	I
16	receptors	I
17	,	O
18	30	O
19	nM	O
20	IGF	B
21	II	I
22	also	O
23	failed	O
24	to	O
25	affect	O
26	the	O
27	pertussis	B
28	toxin	I
29	substrate	O
30	activity	O
31	.	O

1	The	O
2	diabetic	O
3	state	O
4	was	O
5	characterized	O
6	by	O
7	mild	O
8	insulin	B
9	deficiency	O
10	,	O
11	plasma	O
12	levels	O
13	being	O
14	73	O
15	%	O
16	of	O
17	controls	O
18	,	O
19	and	O
20	mild	O
21	hyperglycemia	O
22	,	O
23	with	O
24	nonfasting	O
25	plasma	O
26	glucose	O
27	levels	O
28	of	O
29	1	O
30	.	O
31	5	O
32	times	O
33	normal	O
34	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	description	O
6	,	O
7	to	O
8	our	O
9	knowledge	O
10	,	O
11	of	O
12	regulatory	O
13	elements	O
14	that	O
15	control	O
16	expression	O
17	of	O
18	a	O
19	gene	O
20	encoding	O
21	a	O
22	B7	B
23	costimulatory	I
24	molecule	I
25	.	O

1	In	O
2	electromobility	O
3	shift	O
4	assays	O
5	,	O
6	EWS	B
7	-	O
8	FLI	B
9	-	I
10	1	I
11	binding	O
12	to	O
13	the	O
14	SRE	O
15	is	O
16	detectable	O
17	in	O
18	the	O
19	absence	O
20	of	O
21	SRF	B
22	whereas	O
23	the	O
24	binding	O
25	of	O
26	FLI	B
27	-	I
28	1	I
29	is	O
30	not	O
31	,	O
32	suggesting	O
33	that	O
34	the	O
35	interaction	O
36	with	O
37	DNA	O
38	is	O
39	the	O
40	step	O
41	which	O
42	limits	O
43	ternary	O
44	complex	O
45	formation	O
46	by	O
47	FLI	B
48	-	I
49	1	I
50	.	O

1	Partial	O
2	engorgement	O
3	was	O
4	higher	O
5	in	O
6	the	O
7	treatments	O
8	.	O

1	The	O
2	hormonal	O
3	response	O
4	to	O
5	a	O
6	standardized	O
7	bicycle	O
8	exercise	O
9	test	O
10	was	O
11	studied	O
12	in	O
13	11	O
14	male	O
15	cadets	O
16	exposed	O
17	to	O
18	a	O
19	course	O
20	of	O
21	107	O
22	h	O
23	of	O
24	continuous	O
25	activity	O
26	with	O
27	less	O
28	than	O
29	2	O
30	h	O
31	sleep	O
32	.	O

1	Moreover	O
2	,	O
3	this	O
4	enhancement	O
5	of	O
6	transcriptional	O
7	activation	O
8	by	O
9	COUP	B
10	-	I
11	TFI	I
12	requires	O
13	specifically	O
14	the	O
15	AF	O
16	-	O
17	1	O
18	transactivation	O
19	function	O
20	of	O
21	ER	B
22	and	O
23	can	O
24	be	O
25	observed	O
26	in	O
27	the	O
28	presence	O
29	of	O
30	E2	O
31	or	O
32	4	O
33	-	O
34	hydroxytamoxifen	O
35	but	O
36	not	O
37	ICI	O
38	164384	O
39	.	O

1	The	O
2	determination	O
3	of	O
4	the	O
5	double	O
6	bounds	O
7	in	O
8	blood	O
9	serum	O
10	lipids	O
11	by	O
12	titration	O
13	with	O
14	ozone	O
15	:	O
16	the	O
17	pathophysiology	O
18	and	O
19	diagnostic	O
20	significance	O
21	]	O
22	In	O
23	this	O
24	article	O
25	the	O
26	method	O
27	of	O
28	definition	O
29	of	O
30	double	O
31	binders	O
32	in	O
33	lipids	O
34	of	O
35	blood	O
36	serum	O
37	in	O
38	patients	O
39	with	O
40	different	O
41	diseases	O
42	basically	O
43	atherosclerosis	O
44	and	O
45	ischemic	O
46	heart	O
47	disease	O
48	,	O
49	with	O
50	use	O
51	titration	O
52	by	O
53	ozone	O
54	is	O
55	given	O
56	.	O

1	Expression	O
2	of	O
3	constitutively	O
4	active	O
5	MEK1	B
6	,	O
7	the	O
8	kinase	O
9	that	O
10	activates	O
11	ERKs	B
12	,	O
13	or	O
14	overexpression	O
15	of	O
16	ERK2	B
17	,	O
18	but	O
19	not	O
20	JNK1	B
21	,	O
22	inhibited	O
23	Stat3	B
24	activation	O
25	.	O

1	Transient	O
2	cotransfection	O
3	of	O
4	tat	B
5	cDNA	I
6	in	O
7	sense	O
8	orientation	O
9	(	O
10	tat	B
11	/	I
12	S	I
13	),	O
14	together	O
15	with	O
16	a	O
17	plasmid	O
18	containing	O
19	the	O
20	c	B
21	-	I
22	fos	I
23	promoter	I
24	(	O
25	FC3	B
26	,	O
27	from	O
28	-	O
29	711	O
30	to	O
31	+	O
32	42	O
33	)	O
34	in	O
35	front	O
36	of	O
37	the	O
38	bacterial	B
39	chloramphenicol	I
40	acetyltransferase	I
41	(	O
42	CAT	B
43	)	O
44	gene	O
45	significantly	O
46	enhanced	O
47	CAT	B
48	activity	O
49	in	O
50	Jurkat	O
51	cells	O
52	activated	O
53	by	O
54	the	O
55	addition	O
56	of	O
57	15	O
58	%	O
59	fetal	O
60	calf	O
61	serum	O
62	(	O
63	FCS	O
64	)	O
65	or	O
66	5	O
67	micrograms	O
68	/	O
69	mL	O
70	phytohemagglutinin	B
71	plus	O
72	10	O
73	(-	O
74	7	O
75	)	O
76	mol	O
77	/	O
78	L	O
79	phorbol	O
80	myristate	O
81	acetate	O
82	(	O
83	PMA	O
84	)	O
85	and	O
86	U937	O
87	cells	O
88	activated	O
89	by	O
90	15	O
91	%	O
92	FCS	O
93	or	O
94	10	O
95	(-	O
96	7	O
97	)	O
98	mol	O
99	/	O
100	L	O
101	PMA	O
102	.	O

1	Serological	O
2	studies	O
3	at	O
4	the	O
5	early	O
6	relapse	O
7	stage	O
8	of	O
9	this	O
10	disease	O
11	showed	O
12	increased	O
13	serum	B
14	ANA	I
15	,	O
16	IgA	B
17	and	O
18	IgM	B
19	level	O
20	with	O
21	normal	O
22	IgG	B
23	and	O
24	decrease	O
25	of	O
26	C3	B
27	and	O
28	C4	B
29	.	O

1	To	O
2	determine	O
3	which	O
4	region	O
5	of	O
6	SulA	B
7	is	O
8	essential	O
9	for	O
10	the	O
11	inhibition	O
12	of	O
13	cell	O
14	division	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	series	O
20	of	O
21	N	O
22	-	O
23	terminal	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	deletions	O
29	of	O
30	SulA	B
31	and	O
32	a	O
33	series	O
34	of	O
35	alanine	O
36	substitution	O
37	mutants	O
38	.	O

1	Although	O
2	eight	O
3	contiguous	O
4	genes	O
5	necessary	O
6	for	O
7	urease	B
8	activity	O
9	have	O
10	been	O
11	cloned	O
12	and	O
13	sequenced	O
14	,	O
15	the	O
16	transcriptional	O
17	organization	O
18	and	O
19	regulation	O
20	of	O
21	specific	O
22	genes	O
23	within	O
24	the	O
25	Proteus	B
26	gene	I
27	cluster	I
28	has	O
29	not	O
30	been	O
31	investigated	O
32	in	O
33	detail	O
34	.	O

1	The	O
2	neglect	O
3	of	O
4	Richards	O
5	'	O
6	s	O
7	theory	O
8	demonstrates	O
9	the	O
10	range	O
11	of	O
12	factors	O
13	,	O
14	other	O
15	than	O
16	the	O
17	strictly	O
18	scientific	O
19	,	O
20	which	O
21	can	O
22	be	O
23	important	O
24	in	O
25	determining	O
26	the	O
27	influence	O
28	or	O
29	otherwise	O
30	of	O
31	a	O
32	psychological	O
33	theory	O
34	.	O

1	Cloning	O
2	,	O
3	expression	O
4	,	O
5	and	O
6	nucleotide	O
7	sequence	O
8	of	O
9	rat	B
10	liver	I
11	sterol	I
12	carrier	I
13	protein	I
14	2	I
15	cDNAs	I
16	.	O

1	These	O
2	studies	O
3	suggest	O
4	an	O
5	additional	O
6	component	O
7	or	O
8	cellular	O
9	environment	O
10	is	O
11	required	O
12	for	O
13	SPRK	B
14	activation	O
15	by	O
16	Cdc42	B
17	.	O

1	In	O
2	one	O
3	of	O
4	these	O
5	tumors	O
6	the	O
7	observed	O
8	rearrangement	O
9	was	O
10	not	O
11	due	O
12	to	O
13	the	O
14	insertion	O
15	of	O
16	an	O
17	intact	O
18	MoMuLV	O
19	provirus	O
20	.	O

1	Splice	O
2	variations	O
3	in	O
4	genes	O
5	coding	O
6	for	O
7	the	O
8	transmembrane	B
9	FGF	I
10	receptor	I
11	(	O
12	FGFR	B
13	)	O
14	result	O
15	in	O
16	isoforms	O
17	that	O
18	vary	O
19	in	O
20	the	O
21	ectodomain	O
22	,	O
23	intracellular	O
24	juxtamembrane	O
25	domain	O
26	,	O
27	and	O
28	the	O
29	intracellular	O
30	kinase	O
31	domain	O
32	.	O

1	New	O
2	Langevin	O
3	equations	O
4	for	O
5	a	O
6	translating	O
7	and	O
8	simultaneously	O
9	rotating	O
10	asymmetric	O
11	top	O
12	.	O

1	Thus	O
2	,	O
3	Esigma54	B
4	promoters	I
5	are	O
6	responsive	O
7	to	O
8	CRP	B
9	,	O
10	a	O
11	protein	O
12	unrelated	O
13	to	O
14	sigma54	B
15	activators	I
16	,	O
17	and	O
18	the	O
19	repression	O
20	exerted	O
21	is	O
22	the	O
23	direct	O
24	result	O
25	of	O
26	an	O
27	interaction	O
28	between	O
29	Esigma54	B
30	and	O
31	the	O
32	CRP	B
33	-	I
34	cAMP	I
35	complex	I
36	.	O

1	The	O
2	more	O
3	traditional	O
4	SERMS	O
5	,	O
6	clomiphene	O
7	citrate	O
8	and	O
9	tamoxifen	O
10	,	O
11	will	O
12	be	O
13	reviewed	O
14	along	O
15	with	O
16	such	O
17	modern	O
18	drugs	O
19	as	O
20	raloxifene	O
21	and	O
22	faslodex	O
23	,	O
24	with	O
25	emphasis	O
26	upon	O
27	their	O
28	actions	O
29	on	O
30	breast	O
31	,	O
32	uterus	O
33	,	O
34	bone	O
35	and	O
36	lipids	O
37	.	O

1	They	O
2	contrast	O
3	trends	O
4	in	O
5	fertility	O
6	,	O
7	life	O
8	expectancy	O
9	ratios	O
10	,	O
11	and	O
12	gender	O
13	differences	O
14	in	O
15	these	O
16	countries	O
17	with	O
18	the	O
19	Hispanic	O
20	population	O
21	of	O
22	the	O
23	United	O
24	States	O
25	.	O

1	These	O
2	losses	O
3	account	O
4	for	O
5	the	O
6	resistance	O
7	of	O
8	EDS	O
9	-	O
10	IV	O
11	collagen	B
12	to	O
13	cyanogen	O
14	bromide	O
15	and	O
16	mammalian	B
17	collagenase	I
18	digestion	O
19	.	O

1	We	O
2	find	O
3	that	O
4	beta	B
5	II	I
6	PKC	I
7	phosphorylates	O
8	nuclear	B
9	envelope	I
10	lamin	I
11	B	I
12	at	O
13	10	O
14	-	O
15	20	O
16	times	O
17	the	O
18	rate	O
19	of	O
20	alpha	B
21	PKC	I
22	,	O
23	whereas	O
24	both	O
25	kinases	O
26	phosphorylate	O
27	soluble	B
28	lamin	I
29	B	I
30	at	O
31	similar	O
32	rates	O
33	.	O

1	CodY	B
2	does	O
3	not	O
4	have	O
5	any	O
6	homologues	O
7	in	O
8	the	O
9	data	O
10	-	O
11	bases	O
12	.	O

1	The	O
2	growth	O
3	defect	O
4	of	O
5	a	O
6	reg1	B
7	reg2	I
8	double	I
9	mutant	I
10	is	O
11	alleviated	O
12	by	O
13	a	O
14	loss	O
15	-	O
16	of	O
17	-	O
18	function	O
19	mutation	O
20	in	O
21	the	O
22	SNF1	B
23	-	I
24	encoded	I
25	protein	I
26	kinase	I
27	.	O

1	The	O
2	husband	O
3	in	O
4	one	O
5	of	O
6	the	O
7	married	O
8	couples	O
9	was	O
10	treated	O
11	for	O
12	hepatitis	O
13	of	O
14	unidentified	O
15	etiology	O
16	in	O
17	an	O
18	Infectology	O
19	Department	O
20	four	O
21	years	O
22	ago	O
23	.	O

1	A	O
2	combination	O
3	of	O
4	cisplatin	O
5	and	O
6	5	O
7	-	O
8	fluorouracil	O
9	,	O
10	both	O
11	administered	O
12	4	O
13	days	O
14	continuously	O
15	as	O
16	infusion	O
17	,	O
18	was	O
19	assessed	O
20	in	O
21	advanced	O
22	head	O
23	and	O
24	neck	O
25	cancer	O
26	.	O

1	Sak	B
2	kinase	I
3	gene	O
4	structure	O
5	and	O
6	transcriptional	O
7	regulation	O
8	.	O

1	The	O
2	single	O
3	most	O
4	important	O
5	element	O
6	,	O
7	by	O
8	linker	O
9	-	O
10	scanning	O
11	analysis	O
12	,	O
13	is	O
14	a	O
15	10	O
16	-	O
17	bp	O
18	region	O
19	that	O
20	contains	O
21	a	O
22	CCAAT	O
23	motif	O
24	.	O

1	This	O
2	,	O
3	together	O
4	with	O
5	the	O
6	data	O
7	obtained	O
8	with	O
9	haloperidol	O
10	,	O
11	suggests	O
12	that	O
13	a	O
14	minimal	O
15	increase	O
16	in	O
17	the	O
18	firing	O
19	rate	O
20	of	O
21	LC	O
22	cells	O
23	(+	O
24	140	O
25	%)	O
26	is	O
27	required	O
28	before	O
29	it	O
30	could	O
31	influence	O
32	the	O
33	turnover	O
34	of	O
35	NA	O
36	,	O
37	as	O
38	measured	O
39	by	O
40	DOPAC	O
41	changes	O
42	.	O

1	Collaborative	O
2	study	O
3	of	O
4	Japanese	O
5	Pharmacopoeia	O
6	Heparin	O
7	Sodium	O
8	Reference	O
9	Standard	O

1	The	O
2	mapping	O
3	was	O
4	completed	O
5	with	O
6	Southern	O
7	blotting	O
8	and	O
9	restriction	O
10	analysis	O
11	.	O

1	However	O
2	,	O
3	the	O
4	requirement	O
5	of	O
6	rev3	B
7	for	O
8	the	O
9	production	O
10	of	O
11	G	O
12	.	O
13	C	O
14	-->	O
15	T	O
16	.	O
17	A	O
18	transversions	O
19	by	O
20	the	O
21	rad18	B
22	mutator	I
23	,	O
24	which	O
25	induces	O
26	only	O
27	these	O
28	substitutions	O
29	,	O
30	was	O
31	similar	O
32	to	O
33	that	O
34	for	O
35	rad6	B
36	-	O
37	mediated	O
38	G	O
39	.	O
40	C	O
41	-->	O
42	T	O
43	.	O
44	A	O
45	transversion	O
46	.	O

1	Because	O
2	endogenous	O
3	HSF	B
4	DNA	O
5	-	O
6	binding	O
7	activity	O
8	is	O
9	low	O
10	and	O
11	anti	B
12	-	I
13	hHSF1	I
14	antibody	I
15	does	O
16	not	O
17	recognize	O
18	Xenopus	B
19	HSF	I
20	,	O
21	we	O
22	employed	O
23	this	O
24	system	O
25	for	O
26	mapping	O
27	regions	O
28	in	O
29	hHSF1	B
30	that	O
31	are	O
32	required	O
33	for	O
34	the	O
35	maintenance	O
36	of	O
37	the	O
38	monomeric	O
39	state	O
40	.	O

1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	graft	O
8	survival	O
9	between	O
10	groups	O
11	with	O
12	early	O
13	graft	O
14	function	O
15	(	O
16	EGF	O
17	)	O
18	and	O
19	DGF	O
20	,	O
21	either	O
22	in	O
23	first	O
24	transplantations	O
25	or	O
26	retransplantations	O
27	.	O

1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	a	O
7	Chessmaster	O
8	gradually	O
9	increases	O
10	the	O
11	number	O
12	of	O
13	boards	O
14	he	O
15	can	O
16	reproduce	O
17	with	O
18	higher	O
19	than	O
20	70	O
21	%	O
22	average	O
23	accuracy	O
24	to	O
25	nine	O
26	,	O
27	replacing	O
28	as	O
29	many	O
30	as	O
31	160	O
32	pieces	O
33	correctly	O
34	.	O

1	NF	B
2	-	I
3	kappa	I
4	B	I
5	/	O
6	Rel	B
7	transcription	O
8	factors	O
9	participate	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	numerous	O
15	genes	O
16	involved	O
17	in	O
18	immune	O
19	regulation	O
20	/	O
21	inflammation	O
22	including	O
23	cytokines	O
24	,	O
25	cell	O
26	surface	O
27	receptors	O
28	,	O
29	adhesion	O
30	molecules	O
31	,	O
32	and	O
33	acute	O
34	phase	O
35	proteins	O
36	.	O

1	Three	O
2	new	O
3	aromatase	B
4	inhibitors	O
5	have	O
6	recently	O
7	completed	O
8	phase	O
9	III	O
10	evaluation	O
11	as	O
12	treatment	O
13	of	O
14	metastatic	O
15	breast	O
16	cancer	O
17	in	O
18	post	O
19	-	O
20	menopausal	O
21	women	O
22	whose	O
23	disease	O
24	has	O
25	progressed	O
26	despite	O
27	tamoxifen	O
28	therapy	O
29	:	O
30	anastrozole	O
31	(	O
32	ARIMIDEX	O
33	,	O
34	Zeneca	O
35	),	O
36	letrozole	O
37	(	O
38	FEMARA	O
39	,	O
40	Novartis	O
41	)	O
42	and	O
43	vorozole	O
44	(	O
45	RIVIZOR	O
46	,	O
47	Janssen	O
48	).	O

1	Spliced	O
2	exons	O
3	of	O
4	adenovirus	O
5	late	O
6	RNAs	O
7	colocalize	O
8	with	O
9	snRNP	O
10	in	O
11	a	O
12	specific	O
13	nuclear	O
14	domain	O
15	.	O

1	Of	O
2	those	O
3	injuries	O
4	,	O
5	143	O
6	cases	O
7	were	O
8	snowboard	O
9	related	O
10	and	O
11	158	O
12	cases	O
13	were	O
14	ski	O
15	related	O
16	.	O

1	The	O
2	pentafluorobenzyl	O
3	derivative	O
4	of	O
5	clonidine	O
6	yields	O
7	an	O
8	intense	O
9	ion	O
10	fragment	O
11	at	O
12	m	O
13	/	O
14	z	O
15	354	O
16	,	O
17	and	O
18	the	O
19	lower	O
20	limit	O
21	of	O
22	detection	O
23	is	O
24	0	O
25	.	O
26	025	O
27	ng	O
28	/	O
29	ml	O
30	for	O
31	a	O
32	1	O
33	-	O
34	ml	O
35	plasma	O
36	sample	O
37	.	O

1	Bailey	O
2	Instruments	O
3	and	O
4	Owen	O
5	Mumford	O
6	filaments	O
7	were	O
8	the	O
9	most	O
10	accurate	O
11	with	O
12	100	O
13	%	O
14	buckling	O
15	within	O
16	+/-	O
17	1	O
18	.	O
19	0	O
20	g	O
21	of	O
22	10	O
23	g	O
24	.	O

1	Re	O
2	-	O
3	examining	O
4	methylbenzene	O
5	(	O
6	toluene	O
7	)	O
8	as	O
9	a	O
10	treatment	O
11	for	O
12	Ancylostomum	O
13	caninum	O
14	.	O

1	Furthermore	O
2	,	O
3	we	O
4	demonstrated	O
5	that	O
6	Galpha11	B
7	Q209L	I
8	stimulated	O
9	Src	B
10	family	I
11	kinase	O
12	activity	O
13	and	O
14	induced	O
15	tyrosine	O
16	phosphorylation	O
17	of	O
18	several	O
19	proteins	O
20	in	O
21	HEK	O
22	-	O
23	293	O
24	cells	O
25	.	O

1	In	O
2	mammals	O
3	,	O
4	the	O
5	Rb	B
6	protein	I
7	interacts	O
8	specifically	O
9	with	O
10	D	B
11	-	I
12	type	I
13	cyclins	I
14	and	O
15	regulates	O
16	cell	O
17	proliferation	O
18	by	O
19	binding	O
20	and	O
21	inhibiting	O
22	E2F	B
23	transcription	I
24	factors	I
25	.	O

1	Two	O
2	studies	O
3	assessed	O
4	two	O
5	types	O
6	of	O
7	reliability	O
8	of	O
9	the	O
10	student	O
11	Jenkins	O
12	Activity	O
13	Survey	O
14	(	O
15	JAS	O
16	;	O
17	a	O
18	questionnaire	O
19	measure	O
20	of	O
21	Type	O
22	A	O
23	behavior	O
24	).	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	two	O
7	overlapping	O
8	cDNA	O
9	fragments	O
10	which	O
11	could	O
12	encode	O
13	the	O
14	complete	O
15	amino	O
16	acid	O
17	sequence	O
18	of	O
19	rat	B
20	testis	I
21	fructose	I
22	-	I
23	6	I
24	-	I
25	phosphate	I
26	,	I
27	2	I
28	-	I
29	kinase	I
30	:	O
31	fructose	B
32	-	I
33	2	I
34	,	I
35	6	I
36	-	I
37	bisphosphatase	I
38	.	O

1	Reconstitution	O
2	of	O
3	Raf	B
4	-	I
5	1	I
6	activity	O
7	was	O
8	observed	O
9	only	O
10	with	O
11	kinase	O
12	active	O
13	Jak1	B
14	in	O
15	both	O
16	cell	O
17	lines	O
18	.	O

1	Mutant	O
2	enzyme	O
3	forms	O
4	were	O
5	prepared	O
6	to	O
7	eliminate	O
8	the	O
9	initial	O
10	autoprocessing	O
11	site	O
12	and	O
13	thus	O
14	form	O
15	an	O
16	active	O
17	single	O
18	-	O
19	chain	O
20	protein	O
21	for	O
22	structure	O
23	-	O
24	function	O
25	studies	O
26	.	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	several	O
6	E1	B
7	mutants	I
8	mapping	O
9	in	O
10	both	O
11	the	O
12	M	O
13	and	O
14	R	O
15	regions	O
16	and	O
17	a	O
18	single	O
19	mutant	O
20	of	O
21	the	O
22	upstream	O
23	regulatory	O
24	region	O
25	have	O
26	a	O
27	higher	O
28	transforming	O
29	activity	O
30	on	O
31	mouse	O
32	C127	O
33	cells	O
34	than	O
35	the	O
36	wild	O
37	-	O
38	type	O
39	genome	O
40	does	O
41	.	O

1	No	O
2	TATA	O
3	box	O
4	was	O
5	found	O
6	in	O
7	the	O
8	putative	O
9	promoter	O
10	region	O
11	,	O
12	but	O
13	multiple	O
14	GC	O
15	boxes	O
16	were	O
17	found	O
18	around	O
19	the	O
20	cap	O
21	sites	O
22	,	O
23	supporting	O
24	the	O
25	previously	O
26	inferred	O
27	housekeeping	O
28	nature	O
29	of	O
30	CYP51	B
31	gene	I
32	and	O
33	the	O
34	existence	O
35	of	O
36	the	O
37	multiple	O
38	transcription	O
39	initiation	O
40	sites	O
41	.	O

1	Mus81p	B
2	also	O
3	shares	O
4	homology	O
5	with	O
6	motifs	O
7	found	O
8	in	O
9	the	O
10	XPF	B
11	endonuclease	I
12	superfamily	I
13	.	O

1	Heterogeneous	B
2	nuclear	I
3	ribonucleoprotein	I
4	A1	I
5	binds	O
6	to	O
7	the	O
8	transcription	O
9	-	O
10	regulatory	O
11	region	O
12	of	O
13	mouse	O
14	hepatitis	O
15	virus	O
16	RNA	O
17	.	O

1	These	O
2	cell	O
3	lines	O
4	displayed	O
5	methylation	O
6	of	O
7	the	O
8	CpG	O
9	island	O
10	surrounding	O
11	the	O
12	first	O
13	exon	O
14	of	O
15	p16INK4A	B
16	and	O
17	expressed	O
18	abundant	O
19	levels	O
20	of	O
21	a	O
22	nontranslated	O
23	mRNA	O
24	containing	O
25	an	O
26	alternative	O
27	first	O
28	exon	O
29	(	O
30	E1	O
31	beta	O
32	),	O
33	as	O
34	did	O
35	all	O
36	other	O
37	cell	O
38	lines	O
39	in	O
40	which	O
41	the	O
42	p16INK4A	B
43	locus	I
44	was	O
45	not	O
46	deleted	O
47	.	O

1	Retroviral	O
2	transduction	O
3	of	O
4	T	B
5	/	I
6	T	I
7	(	I
8	L	I
9	)	I
10	causes	O
11	a	O
12	rapidly	O
13	fatal	O
14	myeloproliferative	O
15	disease	O
16	in	O
17	a	O
18	murine	O
19	bone	O
20	marrow	O
21	transplant	O
22	(	O
23	BMT	O
24	)	O
25	model	O
26	,	O
27	whereas	O
28	T	B
29	/	I
30	T	I
31	(	I
32	F	I
33	)	I
34	causes	O
35	a	O
36	long	O
37	-	O
38	latency	O
39	,	O
40	pre	O
41	-	O
42	B	O
43	-	O
44	cell	O
45	lymphoblastic	O
46	lymphoma	O
47	.	O

1	They	O
2	self	O
3	-	O
4	completed	O
5	the	O
6	SF	O
7	-	O
8	36	O
9	questionnaire	O
10	and	O
11	their	O
12	QoL	O
13	was	O
14	described	O
15	and	O
16	retrospectively	O
17	compared	O
18	to	O
19	that	O
20	of	O
21	historical	O
22	controls	O
23	.	O

1	AF154055	B
2	.	O

1	DMCM	O
2	also	O
3	permits	O
4	extension	O
5	of	O
6	the	O
7	possibilities	O
8	of	O
9	obtaining	O
10	and	O
11	transplanting	O
12	donor	O
13	organs	O
14	.	O

1	Electromobility	O
2	shift	O
3	and	O
4	cotransfection	O
5	assays	O
6	demonstrated	O
7	that	O
8	HNF1alpha	B
9	,	O
10	but	O
11	not	O
12	HNF4	B
13	,	O
14	bound	O
15	to	O
16	its	O
17	cognate	O
18	site	O
19	and	O
20	transactivated	O
21	G6Pase	B
22	gene	I
23	expression	O
24	.	O

1	The	O
2	amount	O
3	of	O
4	these	O
5	factors	O
6	was	O
7	reduced	O
8	in	O
9	GEO	O
10	cells	O
11	in	O
12	which	O
13	the	O
14	u	B
15	-	I
16	PAR	I
17	gene	I
18	is	O
19	only	O
20	weakly	O
21	transcriptionally	O
22	activated	O
23	.	O

1	A	O
2	major	O
3	mechanism	O
4	whereby	O
5	steroid	B
6	hydroxylase	I
7	gene	I
8	transcription	O
9	is	O
10	regulated	O
11	in	O
12	the	O
13	adrenal	O
14	cortex	O
15	requires	O
16	the	O
17	pituitary	O
18	peptide	O
19	hormone	O
20	,	O
21	ACTH	B
22	,	O
23	which	O
24	acts	O
25	via	O
26	cAMP	O
27	.	O

1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	O
7	MHC	B
8	class	I
9	II	I
10	molecules	I
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O

1	Trial	O
2	3	O
3	broiler	O
4	chickens	O
5	were	O
6	maintained	O
7	on	O
8	control	O
9	feed	O
10	until	O
11	they	O
12	reached	O
13	3	O
14	weeks	O
15	of	O
16	age	O
17	at	O
18	which	O
19	time	O
20	they	O
21	were	O
22	taken	O
23	off	O
24	of	O
25	feed	O
26	for	O
27	2	O
28	.	O
29	5	O
30	hr	O
31	and	O
32	then	O
33	placed	O
34	on	O
35	either	O
36	control	O
37	feed	O
38	or	O
39	feed	O
40	containing	O
41	4	O
42	.	O
43	0	O
44	ppm	O
45	ochratoxin	O
46	A	O
47	,	O
48	and	O
49	heart	O
50	rate	O
51	and	O
52	blood	O
53	pressure	O
54	were	O
55	measured	O
56	every	O
57	half	O
58	hour	O
59	through	O
60	7	O
61	hr	O
62	.	O

1	These	O
2	results	O
3	provide	O
4	the	O
5	first	O
6	demonstration	O
7	that	O
8	an	O
9	SR	B
10	protein	I
11	can	O
12	influence	O
13	splicing	O
14	of	O
15	specific	O
16	pre	O
17	-	O
18	mRNAs	O
19	in	O
20	vivo	O
21	.	O

1	Abstracts	O
2	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	crude	O
7	extracts	O
8	from	O
9	FREJ4	O
10	cells	O
11	revealed	O
12	the	O
13	binding	O
14	of	O
15	a	O
16	member	O
17	(	O
18	s	O
19	)	O
20	of	O
21	the	O
22	Ets	B
23	family	I
24	of	I
25	transcription	I
26	factors	I
27	to	O
28	the	O
29	P4	B
30	EBS	I
31	,	O
32	as	O
33	well	O
34	as	O
35	the	O
36	interaction	O
37	of	O
38	two	O
39	members	O
40	of	O
41	the	O
42	Sp1	B
43	family	I
44	,	O
45	Sp1	B
46	and	O
47	Sp3	B
48	,	O
49	with	O
50	the	O
51	adjacent	O
52	GC	O
53	box	O
54	.	O

1	A	O
2	Bub2p	B
3	-	O
4	dependent	O
5	spindle	O
6	checkpoint	O
7	pathway	O
8	regulates	O
9	the	O
10	Dbf2p	B
11	kinase	I
12	in	I
13	budding	I
14	yeast	I
15	.	O

1	Recent	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	U1	B
8	snRNP	I
9	is	O
10	recruited	O
11	to	O
12	the	O
13	5	O
14	'	O
15	splice	O
16	site	O
17	by	O
18	protein	O
19	/	O
20	protein	O
21	interactions	O
22	involving	O
23	the	O
24	SR	B
25	domains	O
26	of	O
27	the	O
28	U1	B
29	-	I
30	70K	I
31	protein	I
32	and	O
33	SF2	B
34	/	O
35	ASF	B
36	.	O

1	The	O
2	maximum	O
3	period	O
4	of	O
5	treatment	O
6	was	O
7	73	O
8	(	O
9	oral	O
10	),	O
11	73	O
12	(	O
13	intraperitoneal	O
14	)	O
15	or	O
16	75	O
17	(	O
18	dermal	O
19	)	O
20	weeks	O
21	.	O

1	The	O
2	urinary	O
3	protein	O
4	,	O
5	serum	O
6	albumin	B
7	,	O
8	BUN	O
9	and	O
10	SCr	O
11	all	O
12	had	O
13	very	O
14	significant	O
15	improvement	O
16	.	O

1	Similar	O
2	to	O
3	Hp140	B
4	,	O
5	isolated	O
6	Hp55	B
7	binds	O
8	DNA	O
9	with	O
10	moderate	O
11	strength	O
12	and	O
13	was	O
14	a	O
15	specificity	O
16	for	O
17	double	O
18	-	O
19	stranded	O
20	primer	O
21	-	O
22	template	O
23	DNA	O
24	.	O

1	Diagnostic	O
2	value	O
3	of	O
4	adenosine	B
5	deaminase	I
6	activity	O
7	in	O
8	tuberculous	O
9	effusions	O
10	.	O

1	A	O
2	secondary	O
3	phosphorylation	O
4	of	O
5	CREB341	B
6	at	O
7	Ser129	O
8	is	O
9	required	O
10	for	O
11	the	O
12	cAMP	O
13	-	O
14	mediated	O
15	control	O
16	of	O
17	gene	O
18	expression	O
19	.	O

1	Hepatitis	O
2	B	O
3	vaccination	O
4	strategy	O
5	for	O
6	health	O
7	-	O
8	care	O
9	workers	O
10	in	O
11	a	O
12	country	O
13	of	O
14	intermediate	O
15	hepatitis	O
16	B	O
17	endemicity	O
18	.	O

1	The	O
2	effect	O
3	of	O
4	maternal	O
5	ingestion	O
6	of	O
7	the	O
8	reduced	O
9	energy	O
10	sweetener	O
11	erythritol	O
12	was	O
13	investigated	O
14	in	O
15	KBL	O
16	:	O
17	JW	O
18	strain	O
19	pregnant	O
20	rabbits	O
21	.	O

1	The	O
2	repetitive	O
3	ETn	B
4	(	O
5	early	B
6	transposon	I
7	)	O
8	family	O
9	of	O
10	sequences	O
11	represents	O
12	an	O
13	active	O
14	"	O
15	mobile	O
16	mutagen	O
17	"	O
18	in	O
19	the	O
20	mouse	O
21	genome	O
22	.	O

1	METHODS	O
2	:	O
3	A	O
4	population	O
5	survey	O
6	was	O
7	undertaken	O
8	in	O
9	10	O
10	,	O
11	148	O
12	individuals	O
13	to	O
14	measure	O
15	the	O
16	prevalence	O
17	and	O
18	identify	O
19	the	O
20	causes	O
21	of	O
22	blindness	O
23	in	O
24	Lebanon	O
25	.	O

1	After	O
2	28	O
3	days	O
4	of	O
5	haloperidol	O
6	treatment	O
7	,	O
8	similar	O
9	changes	O
10	were	O
11	observed	O
12	for	O
13	delta	O
14	,	O
15	together	O
16	with	O
17	an	O
18	increase	O
19	of	O
20	alpha	O
21	1	O
22	,	O
23	and	O
24	a	O
25	decrease	O
26	of	O
27	fast	O
28	beta	O
29	.	O

1	CONCLUSIONS	O
2	:	O
3	Serum	O
4	levels	O
5	of	O
6	S	B
7	-	I
8	100beta	I
9	are	O
10	reliable	O
11	markers	O
12	for	O
13	adverse	O
14	neurologic	O
15	outcomes	O
16	after	O
17	cardiac	O
18	surgery	O
19	.	O

1	Localized	O
2	fluorescence	O
3	was	O
4	detectable	O
5	only	O
6	in	O
7	cells	O
8	containing	O
9	a	O
10	visible	O
11	midcell	O
12	constriction	O
13	,	O
14	suggesting	O
15	that	O
16	FtsK	B
17	targeting	O
18	normally	O
19	occurs	O
20	only	O
21	at	O
22	a	O
23	late	O
24	stage	O
25	of	O
26	septation	O
27	.	O

1	Opposite	O
2	effects	O
3	of	O
4	CYP1	B
5	are	O
6	observed	O
7	in	O
8	aerobic	O
9	,	O
10	heme	O
11	-	O
12	sufficient	O
13	cells	O
14	.	O

1	One	O
2	enigmatic	O
3	aspect	O
4	of	O
5	GATA	B
6	factor	I
7	expression	O
8	is	O
9	that	O
10	several	O
11	GATA	B
12	proteins	I
13	,	O
14	which	O
15	ostensibly	O
16	share	O
17	the	O
18	same	O
19	DNA	O
20	-	O
21	binding	O
22	site	O
23	specificity	O
24	,	O
25	are	O
26	coexpressed	O
27	in	O
28	erythroid	O
29	cells	O
30	.	O

1	Selection	O
2	was	O
3	based	O
4	on	O
5	expression	O
6	of	O
7	an	O
8	integrated	O
9	DNA	O
10	fragment	O
11	containing	O
12	the	O
13	con	B
14	-	I
15	10	I
16	promoter	I
17	-	I
18	regulatory	I
19	region	I
20	followed	O
21	by	O
22	the	O
23	initial	O
24	segment	O
25	of	O
26	the	O
27	con	B
28	-	I
29	10	I
30	open	I
31	reading	I
32	frame	I
33	fused	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	bacterial	B
39	hygromycin	I
40	B	I
41	phosphotransferase	I
42	structural	I
43	gene	I
44	(	O
45	con10	B
46	'-'	I
47	hph	I
48	).	O

1	To	O
2	evaluate	O
3	the	O
4	gas	O
5	chromatographic	O
6	electron	O
7	capture	O
8	detection	O
9	method	O
10	described	O
11	earlier	O
12	,	O
13	23	O
14	plasma	O
15	samples	O
16	have	O
17	been	O
18	analysed	O
19	by	O
20	both	O
21	techniques	O
22	.	O

1	Transient	O
2	overexpression	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	induced	O
8	tenascin	B
9	-	I
10	C	I
11	expression	O
12	in	O
13	primary	O
14	REF	O
15	and	O
16	in	O
17	FR3T3	O
18	,	O
19	an	O
20	established	O
21	fibroblast	O
22	cell	O
23	line	O
24	.	O

1	Sequence	O
2	comparison	O
3	of	O
4	cytochromes	B
5	bd	I
6	and	O
7	their	O
8	homologs	O
9	from	O
10	various	O
11	organisms	O
12	demonstrates	O
13	that	O
14	the	O
15	proteins	O
16	can	O
17	be	O
18	classified	O
19	into	O
20	two	O
21	subfamilies	O
22	,	O
23	a	O
24	proteobacterial	O
25	type	O
26	including	O
27	E	B
28	.	I
29	coli	I
30	bd	I
31	and	O
32	a	O
33	more	O
34	widely	O
35	distributed	O
36	type	O
37	including	O
38	the	O
39	B	O
40	.	O
41	stearothermophilus	O
42	enzyme	O
43	,	O
44	suggesting	O
45	that	O
46	the	O
47	latter	O
48	type	O
49	is	O
50	evolutionarily	O
51	older	O
52	.	O

1	Marked	O
2	racial	O
3	variation	O
4	in	O
5	birthweight	O
6	percentiles	O
7	by	O
8	gestational	O
9	age	O
10	was	O
11	evident	O
12	.	O

1	An	O
2	open	O
3	reading	O
4	frame	O
5	encoding	O
6	a	O
7	protein	O
8	which	O
9	shows	O
10	significant	O
11	similarity	O
12	to	O
13	invertases	B
14	and	O
15	resolvases	B
16	was	O
17	located	O
18	immediately	O
19	upstream	O
20	of	O
21	the	O
22	Pac25I	B
23	R	I
24	-	I
25	M	I
26	operon	I
27	.	O

1	Merosin	B
2	positive	O
3	congenital	O
4	muscular	O
5	dystrophy	O
6	with	O
7	mental	O
8	deficiency	O
9	,	O
10	epilepsy	O
11	and	O
12	MRI	O
13	changes	O
14	in	O
15	the	O
16	cerebral	O
17	white	O
18	matter	O
19	.	O

1	Acute	O
2	experiments	O
3	on	O
4	nembutal	O
5	-	O
6	anesthetized	O
7	cats	O
8	(	O
9	50	O
10	mg	O
11	/	O
12	kg	O
13	)	O
14	were	O
15	employed	O
16	to	O
17	investigate	O
18	the	O
19	effect	O
20	of	O
21	1	O
22	T	O
23	pulsating	O
24	magnetic	O
25	field	O
26	(	O
27	PMF	O
28	)	O
29	on	O
30	neuromuscular	O
31	system	O
32	of	O
33	the	O
34	leg	O
35	.	O

1	The	O
2	potential	O
3	for	O
4	highly	O
5	reactive	O
6	nanoparticles	O
7	(	O
8	RNP	O
9	)	O
10	to	O
11	absorb	O
12	destructively	O
13	,	O
14	i	O
15	.	O
16	e	O
17	.	O
18	to	O
19	neutralize	O
20	highly	O
21	toxic	O
22	substances	O
23	such	O
24	as	O
25	the	O
26	warfare	O
27	agents	O
28	GA	O
29	,	O
30	GB	O
31	,	O
32	HD	O
33	and	O
34	VX	O
35	,	O
36	has	O
37	been	O
38	demonstrated	O
39	in	O
40	the	O
41	laboratory	O
42	.	O

1	The	O
2	11	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	specifically	O
8	linked	O
9	to	O
10	Ewing	O
11	sarcoma	O
12	and	O
13	primitive	O
14	neuroectodermal	O
15	tumor	O
16	results	O
17	in	O
18	a	O
19	chimeric	O
20	molecule	O
21	fusing	O
22	the	O
23	amino	O
24	-	O
25	terminal	O
26	-	O
27	encoding	O
28	portion	O
29	of	O
30	the	O
31	EWS	B
32	gene	I
33	to	O
34	the	O
35	carboxyl	O
36	-	O
37	terminal	O
38	DNA	O
39	-	O
40	binding	O
41	domain	O
42	encoded	O
43	by	O
44	the	O
45	FLI1	B
46	gene	I
47	.	O

1	Processing	O
2	of	O
3	the	O
4	NS3	O
5	'-	O
6	5B	B
7	polyprotein	O
8	was	O
9	complex	O
10	and	O
11	occurred	O
12	rapidly	O
13	.	O

1	Finally	O
2	,	O
3	the	O
4	mechanism	O
5	of	O
6	ASK1	B
7	activation	O
8	involves	O
9	,	O
10	in	O
11	part	O
12	,	O
13	homo	O
14	-	O
15	oligomerization	O
16	.	O

1	Some	O
2	of	O
3	the	O
4	peptide	B
5	:	I
6	MBP	I
7	fusions	I
8	were	O
9	also	O
10	analyzed	O
11	using	O
12	surface	O
13	plasmon	O
14	resonance	O
15	.	O

1	In	O
2	general	O
3	,	O
4	however	O
5	,	O
6	this	O
7	study	O
8	provided	O
9	little	O
10	evidence	O
11	of	O
12	any	O
13	effect	O
14	of	O
15	supplementation	O
16	to	O
17	athletic	O
18	performance	O
19	for	O
20	athletes	O
21	consuming	O
22	the	O
23	dietary	O
24	RDIs	O
25	.	O

1	As	O
2	the	O
3	half	O
4	-	O
5	life	O
6	of	O
7	the	O
8	compound	O
9	did	O
10	never	O
11	exceed	O
12	8	O
13	-	O
14	9	O
15	h	O
16	,	O
17	the	O
18	data	O
19	do	O
20	not	O
21	support	O
22	any	O
23	change	O
24	of	O
25	pidotimod	O
26	administration	O
27	schedule	O
28	(	O
29	every	O
30	24	O
31	-	O
32	12	O
33	h	O
34	).	O

1	Optimal	O
2	activation	O
3	of	O
4	T	O
5	cells	O
6	requires	O
7	at	O
8	least	O
9	two	O
10	signals	O
11	.	O

1	Serum	O
2	concentrations	O
3	of	O
4	E2	O
5	and	O
6	TBOH	O
7	were	O
8	measured	O
9	on	O
10	d	O
11	0	O
12	,	O
13	1	O
14	,	O
15	3	O
16	,	O
17	5	O
18	,	O
19	7	O
20	,	O
21	13	O
22	,	O
23	21	O
24	,	O
25	28	O
26	,	O
27	42	O
28	,	O
29	56	O
30	,	O
31	84	O
32	,	O
33	112	O
34	,	O
35	and	O
36	140	O
37	in	O
38	finishing	O
39	heifers	O
40	administered	O
41	the	O
42	following	O
43	treatments	O
44	:	O
45	1	O
46	)	O
47	control	O
48	;	O
49	2	O
50	)	O
51	MGA	O
52	,	O
53	.	O
54	5	O
55	mg	O
56	per	O
57	heifer	O
58	daily	O
59	;	O
60	3	O
61	)	O
62	Revalor	O
63	-	O
64	H	O
65	(	O
66	140	O
67	mg	O
68	TBA	O
69	+	O
70	14	O
71	mg	O
72	E2	O
73	);	O
74	4	O
75	)	O
76	Revalor	O
77	-	O
78	H	O
79	+	O
80	MGA	O
81	;	O
82	5	O
83	)	O
84	Finaplix	O
85	-	O
86	H	O
87	(	O
88	200	O
89	mg	O
90	TBA	O
91	);	O
92	and	O
93	6	O
94	)	O
95	Finaplix	O
96	-	O
97	H	O
98	+	O
99	MGA	O
100	.	O

1	Binding	O
2	to	O
3	sulphatides	O
4	and	O
5	the	O
6	alpha	B
7	-	I
8	dystroglycan	I
9	receptor	I
10	was	O
11	much	O
12	stronger	O
13	and	O
14	required	O
15	at	O
16	least	O
17	two	O
18	LG	B
19	modules	I
20	.	O

1	Considering	O
2	these	O
3	sources	O
4	of	O
5	error	O
6	some	O
7	of	O
8	the	O
9	variability	O
10	in	O
11	the	O
12	present	O
13	investigation	O
14	might	O
15	be	O
16	avoided	O
17	by	O
18	systematic	O
19	instructions	O
20	.	O

1	Man	O
2	and	O
3	insect	O
4	,	O
5	past	O
6	,	O
7	present	O
8	,	O
9	future	O

1	35	O
2	patients	O
3	with	O
4	acute	O
5	arterial	O
6	occlusions	O
7	[	O
8	27	O
9	]	O
10	and	O
11	graft	O
12	thromboses	O
13	[	O
14	8	O
15	],	O
16	responsible	O
17	for	O
18	severe	O
19	and	O
20	recent	O
21	ischemia	O
22	,	O
23	were	O
24	treated	O
25	by	O
26	fibrinolytic	O
27	therapy	O
28	(	O
29	Urokinase	B
30	:	O
31	1	O
32	000	O
33	units	O
34	/	O
35	kg	O
36	/	O
37	hour	O
38	,	O
39	and	O
40	Lys	O
41	Plasminogen	B
42	).	O

1	Coronary	O
2	T1	O
3	and	O
4	T2	O
5	weighted	O
6	images	O
7	were	O
8	obtained	O
9	.	O

1	The	O
2	galactose	B
3	transporter	I
4	shows	O
5	both	O
6	sequence	O
7	and	O
8	structural	O
9	homology	O
10	with	O
11	a	O
12	superfamily	O
13	of	O
14	sugar	B
15	transporters	I
16	which	O
17	includes	O
18	the	O
19	human	B
20	HepG2	I
21	-	I
22	erythrocyte	I
23	and	I
24	fetal	I
25	muscle	I
26	glucose	I
27	transporters	I
28	,	O
29	the	O
30	rat	B
31	brain	I
32	and	I
33	liver	I
34	glucose	I
35	transporters	I
36	,	O
37	the	O
38	Escherichia	B
39	coli	I
40	xylose	I
41	and	I
42	arabinose	I
43	permeases	I
44	,	O
45	and	O
46	the	O
47	S	B
48	.	I
49	cerevisiae	I
50	glucose	I
51	,	I
52	maltose	I
53	,	I
54	and	I
55	galactose	I
56	transporters	I
57	.	O

1	We	O
2	report	O
3	the	O
4	successful	O
5	use	O
6	of	O
7	electroconvulsive	O
8	therapy	O
9	for	O
10	treatment	O
11	of	O
12	severe	O
13	depression	O
14	in	O
15	a	O
16	young	O
17	man	O
18	with	O
19	adult	O
20	GM2	O
21	gangliosidosis	O
22	.	O

1	Mutations	O
2	at	O
3	three	O
4	sites	O
5	have	O
6	larger	O
7	effects	O
8	in	O
9	muscle	O
10	than	O
11	nonmuscle	O
12	cells	O
13	;	O
14	an	O
15	A	O
16	/	O
17	T	O
18	-	O
19	rich	O
20	site	O
21	mutation	O
22	has	O
23	a	O
24	pronounced	O
25	effect	O
26	in	O
27	both	O
28	striated	O
29	muscle	O
30	types	O
31	,	O
32	mutations	O
33	at	O
34	the	O
35	MEF1	B
36	(	I
37	Right	I
38	E	I
39	-	I
40	box	I
41	)	I
42	site	I
43	are	O
44	relatively	O
45	specific	O
46	to	O
47	expression	O
48	in	O
49	skeletal	O
50	muscle	O
51	,	O
52	and	O
53	mutations	O
54	at	O
55	the	O
56	CArG	O
57	site	O
58	are	O
59	relatively	O
60	specific	O
61	to	O
62	expression	O
63	in	O
64	cardiac	O
65	muscle	O
66	.	O

1	This	O
2	fragment	O
3	contained	O
4	the	O
5	C	O
6	-	O
7	terminal	O
8	47	O
9	nucleotides	O
10	of	O
11	leuB	B
12	,	O
13	encoding	O
14	3	B
15	-	I
16	isopropylmalate	I
17	dehydrogenase	I
18	;	O
19	asd	B
20	,	O
21	encoding	O
22	aspartate	B
23	-	I
24	beta	I
25	-	I
26	semialdehyde	I
27	dehydrogenase	I
28	(	O
29	Asd	B
30	);	O
31	and	O
32	orfA	O
33	,	O
34	whose	O
35	product	O
36	showed	O
37	similarity	O
38	to	O
39	the	O
40	Asd	B
41	proteins	I
42	from	I
43	Vibrio	I
44	spp	I
45	.	O

1	In	O
2	lean	O
3	mice	O
4	,	O
5	the	O
6	fat	O
7	/	O
8	water	O
9	intensity	O
10	ratio	O
11	was	O
12	about	O
13	1	O
14	:	O
15	4	O
16	,	O
17	about	O
18	half	O
19	that	O
20	in	O
21	normal	O
22	mice	O
23	.	O

1	Year	O
2	one	O
3	of	O
4	the	O
5	first	O
6	general	O
7	practitioner	O
8	medical	O
9	unit	O
10	in	O
11	the	O
12	greater	O
13	Glasgow	O
14	area	O
15	.	O

1	Upstream	O
2	from	O
3	the	O
4	transcription	O
5	start	O
6	point	O
7	(	O
8	tsp	O
9	),	O
10	a	O
11	nucleotide	O
12	sequence	O
13	highly	O
14	homologous	O
15	to	O
16	the	O
17	consensus	B
18	sequence	I
19	motif	I
20	for	I
21	the	I
22	sigma	I
23	35	I
24	-	I
25	recognized	I
26	promoters	I
27	was	O
28	found	O
29	.	O

1	In	O
2	a	O
3	randomized	O
4	double	O
5	-	O
6	blind	O
7	cross	O
8	-	O
9	over	O
10	study	O
11	,	O
12	the	O
13	subjects	O
14	received	O
15	theophylline	O
16	5	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	per	O
23	day	O
24	with	O
25	omeprazole	O
26	20	O
27	mg	O
28	per	O
29	day	O
30	or	O
31	identical	O
32	placebo	O
33	during	O
34	two	O
35	periods	O
36	,	O
37	each	O
38	of	O
39	7	O
40	days	O
41	,	O
42	separated	O
43	by	O
44	a	O
45	washout	O
46	period	O
47	of	O
48	7	O
49	days	O
50	.	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	,	O
6	by	O
7	screening	O
8	a	O
9	lambda	O
10	gt11	O
11	expression	O
12	library	O
13	,	O
14	murine	B
15	protein	I
16	mXBP	I
17	,	O
18	which	O
19	binds	O
20	to	O
21	a	O
22	sequence	O
23	which	O
24	overlaps	O
25	the	O
26	3	O
27	'	O
28	end	O
29	of	O
30	the	O
31	murine	B
32	class	I
33	II	I
34	major	I
35	histocompatibility	I
36	complex	I
37	A	I
38	alpha	I
39	gene	I
40	X	I
41	box	I
42	,	O
43	a	O
44	conserved	O
45	transcription	O
46	element	O
47	found	O
48	upstream	O
49	of	O
50	all	O
51	class	O
52	II	O
53	genes	O
54	.	O

1	Serum	B
2	relaxin	I
3	levels	O
4	in	O
5	prostaglandin	O
6	E2	O
7	induced	O
8	abortions	O
9	.	O

1	Failure	O
2	of	O
3	stapedius	O
4	reflexometry	O
5	in	O
6	the	O
7	diagnosis	O
8	of	O
9	myasthenia	O
10	gravis	O
11	.	O

1	For	O
2	colostral	O
3	milk	O
4	there	O
5	was	O
6	a	O
7	significant	O
8	correlation	O
9	of	O
10	vitamin	O
11	K1	O
12	to	O
13	cholesterol	O
14	(	O
15	r	O
16	=	O
17	0	O
18	.	O
19	62	O
20	)	O
21	but	O
22	not	O
23	to	O
24	total	O
25	lipid	O
26	or	O
27	phospholipid	O
28	suggesting	O
29	a	O
30	role	O
31	for	O
32	cholesterol	O
33	in	O
34	the	O
35	secretion	O
36	of	O
37	vitamin	O
38	K1	O
39	into	O
40	colostral	O
41	milk	O
42	.	O

1	RNP1	B
2	,	O
3	a	O
4	new	O
5	ribonucleoprotein	O
6	gene	O
7	of	O
8	the	O
9	yeast	O
10	Saccharomyces	O
11	cerevisiae	O
12	.	O

1	The	O
2	peak	O
3	velocities	O
4	of	O
5	the	O
6	atrial	O
7	systolic	O
8	waves	O
9	of	O
10	the	O
11	transmitral	O
12	and	O
13	pulmonary	O
14	venous	O
15	flow	O
16	velocities	O
17	(	O
18	A	O
19	and	O
20	PVA	O
21	,	O
22	respectively	O
23	)	O
24	and	O
25	first	O
26	systolic	O
27	wave	O
28	(	O
29	PVS1	O
30	)	O
31	of	O
32	pulmonary	O
33	venous	O
34	flow	O
35	,	O
36	durations	O
37	of	O
38	both	O
39	atrial	O
40	systolic	O
41	waves	O
42	,	O
43	and	O
44	amplitude	O
45	of	O
46	interatrial	O
47	septal	O
48	motion	O
49	during	O
50	atrial	O
51	systole	O
52	increased	O
53	significantly	O
54	ten	O
55	days	O
56	after	O
57	cardioversion	O
58	compared	O
59	with	O
60	those	O
61	measured	O
62	within	O
63	a	O
64	day	O
65	of	O
66	cardioversion	O
67	in	O
68	all	O
69	patients	O
70	except	O
71	the	O
72	5	O
73	patients	O
74	with	O
75	dilated	O
76	cardiomyopathy	O
77	.	O

1	The	O
2	qualitative	O
3	concentrations	O
4	of	O
5	HCG	B
6	had	O
7	a	O
8	sensitivity	O
9	of	O
10	37	O
11	.	O
12	5	O
13	%	O
14	and	O
15	a	O
16	specificity	O
17	of	O
18	100	O
19	%.	O

1	The	O
2	65	O
3	-	O
4	bp	O
5	sequence	O
6	contains	O
7	the	O
8	octameric	O
9	cAMP	O
10	-	O
11	responsive	O
12	enhancer	O
13	(	O
14	CRE	O
15	)	O
16	TGACGTCA	O
17	(	O
18	nucleotides	O
19	-	O
20	48	O
21	to	O
22	-	O
23	41	O
24	).	O

1	The	O
2	same	O
3	rhythmic	O
4	structure	O
5	enables	O
6	a	O
7	prediction	O
8	to	O
9	be	O
10	made	O
11	concerning	O
12	when	O
13	vowels	O
14	of	O
15	stressed	O
16	syllables	O
17	will	O
18	be	O
19	auditorily	O
20	perceived	O
21	.	O

1	Elimination	O
2	of	O
3	Haemophilus	O
4	influenzae	O
5	type	O
6	b	O
7	meningitis	O
8	after	O
9	introduction	O
10	of	O
11	vaccination	O

1	HL	O
2	02	O
3	type	O
4	oculomotor	O
5	stimulator	O
6	.	O

1	The	O
2	effect	O
3	of	O
4	diffusion	O
5	limitation	O
6	was	O
7	quantified	O
8	in	O
9	terms	O
10	of	O
11	the	O
12	ratio	O
13	O2	O
14	uptake	O
15	/	O
16	O2	O
17	requirement	O
18	(=	O
19	fraction	O
20	of	O
21	cross	O
22	-	O
23	sectional	O
24	area	O
25	supplied	O
26	with	O
27	O2	O
28	),	O
29	assuming	O
30	local	O
31	O2	O
32	requirement	O
33	per	O
34	unit	O
35	volume	O
36	to	O
37	be	O
38	constant	O
39	and	O
40	independent	O
41	of	O
42	PO2	O
43	at	O
44	PO2	O
45	greater	O
46	than	O
47	0	O
48	.	O

1	Studies	O
2	on	O
3	the	O
4	method	O
5	of	O
6	size	O
7	reduction	O
8	of	O
9	medicinal	O
10	compounds	O
11	.	O

1	Furthermore	O
2	,	O
3	the	O
4	striking	O
5	ability	O
6	of	O
7	polyoma	B
8	middle	I
9	T	I
10	antigens	I
11	to	O
12	promote	O
13	retinoic	O
14	acid	O
15	-	O
16	induced	O
17	differentiation	O
18	appears	O
19	to	O
20	utilize	O
21	ERK	B
22	,	O
23	but	O
24	not	O
25	JNK	B
26	/	O
27	SPK	B
28	or	O
29	p38	B
30	signaling	O
31	.	O

1	Distal	O
2	tubular	O
3	acidification	O
4	and	O
5	the	O
6	threshold	O
7	for	O
8	proximal	O
9	tubular	O
10	bicarbonate	O
11	reabsorption	O
12	were	O
13	normal	O
14	,	O
15	as	O
16	was	O
17	urine	O
18	concentrating	O
19	capacity	O
20	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	determine	O
9	the	O
10	risk	O
11	factors	O
12	for	O
13	background	O
14	diabetic	O
15	retinopathy	O
16	(	O
17	BDR	O
18	)	O
19	and	O
20	PDR	O
21	by	O
22	following	O
23	394	O
24	Japanese	O
25	patients	O
26	with	O
27	early	O
28	-	O
29	onset	O
30	type	O
31	2	O
32	diabetes	O
33	diagnosed	O
34	before	O
35	30	O
36	years	O
37	of	O
38	age	O
39	(	O
40	mean	O
41	age	O
42	27	O
43	,	O
44	mean	O
45	blood	O
46	pressure	O
47	at	O
48	entry	O
49	116	O
50	/	O
51	73	O
52	mm	O
53	Hg	O
54	).	O

1	Self	O
2	-	O
3	emasculation	O
4	is	O
5	the	O
6	end	O
7	result	O
8	of	O
9	an	O
10	unusual	O
11	psychiatric	O
12	disorder	O
13	,	O
14	which	O
15	initially	O
16	requires	O
17	surgical	O
18	treatment	O
19	.	O

1	RESULTS	O
2	:	O
3	Total	O
4	IgE	B
5	levels	O
6	showed	O
7	a	O
8	tendency	O
9	to	O
10	diminish	O
11	.	O

1	A	O
2	prospectively	O
3	gated	O
4	2D	O
5	axial	O
6	sequence	O
7	with	O
8	velocity	O
9	encoding	O
10	in	O
11	the	O
12	craniocaudal	O
13	direction	O
14	in	O
15	the	O
16	cervical	O
17	region	O
18	was	O
19	set	O
20	at	O
21	a	O
22	velocity	O
23	of	O
24	+/-	O
25	10	O
26	cm	O
27	/	O
28	s	O
29	.	O

1	These	O
2	include	O
3	the	O
4	CACCC	O
5	and	O
6	CAAT	O
7	motifs	O
8	.	O

1	The	O
2	variability	O
3	is	O
4	most	O
5	likely	O
6	a	O
7	result	O
8	of	O
9	alternative	O
10	splicing	O
11	of	O
12	exons	O
13	from	O
14	the	O
15	primary	O
16	elastin	B
17	transcripts	I
18	.	O

1	Both	O
2	mutations	O
3	confer	O
4	amino	O
5	acid	O
6	substitutions	O
7	in	O
8	the	O
9	viral	B
10	coat	I
11	protein	I
12	but	O
13	differ	O
14	in	O
15	their	O
16	relative	O
17	abilities	O
18	to	O
19	utilize	O
20	the	O
21	foreign	O
22	scaffolding	B
23	protein	I
24	.	O

1	In	O
2	this	O
3	study	O
4	26	O
5	patients	O
6	(	O
7	20	O
8	females	O
9	and	O
10	6	O
11	males	O
12	)	O
13	were	O
14	evaluated	O
15	.	O

1	The	O
2	role	O
3	of	O
4	daunorubicin	O
5	in	O
6	induction	O
7	therapy	O
8	for	O
9	adult	O
10	acute	O
11	myeloid	O
12	leukemia	O

1	Using	O
2	the	O
3	balloon	O
4	-	O
5	gas	O
6	procedure	O
7	with	O
8	a	O
9	single	O
10	gas	O
11	injection	O
12	,	O
13	a	O
14	bubble	O
15	was	O
16	obtained	O
17	that	O
18	was	O
19	large	O
20	enough	O
21	to	O
22	tamponade	O
23	a	O
24	giant	O
25	tear	O
26	without	O
27	prior	O
28	drainage	O
29	of	O
30	subretinal	O
31	fluid	O
32	or	O
33	vitrectomy	O
34	.	O

1	Effects	O
2	of	O
3	verapamil	O
4	and	O
5	propranolol	O
6	on	O
7	early	O
8	afterdepolarizations	O
9	and	O
10	ventricular	O
11	arrhythmias	O
12	induced	O
13	by	O
14	epinephrine	O
15	in	O
16	congenital	O
17	long	O
18	QT	O
19	syndrome	O
20	.	O

1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	NF	B
7	-	I
8	4FA	I
9	,	O
10	NF	B
11	-	I
12	4FB	I
13	,	O
14	and	O
15	AP	B
16	-	I
17	1	I
18	sequences	O
19	are	O
20	each	O
21	necessary	O
22	for	O
23	full	O
24	enhancer	O
25	activity	O
26	.	O

1	The	O
2	authors	O
3	found	O
4	that	O
5	except	O
6	for	O
7	fear	O
8	and	O
9	pugnacity	O
10	all	O
11	husband	O
12	-	O
13	wife	O
14	trait	O
15	correlations	O
16	were	O
17	positive	O
18	,	O
19	in	O
20	contrast	O
21	to	O
22	Winch	O
23	'	O
24	s	O
25	principle	O
26	of	O
27	type	O
28	I	O
29	complementarity	O
30	.	O

1	Twenty	O
2	-	O
3	two	O
4	consecutive	O
5	patients	O
6	with	O
7	ischaemic	O
8	ulcers	O
9	had	O
10	tcPO2	O
11	measured	O
12	and	O
13	the	O
14	ankle	O
15	/	O
16	brachial	O
17	(	O
18	ABI	O
19	)	O
20	and	O
21	toe	O
22	/	O
23	brachial	O
24	(	O
25	TBI	O
26	)	O
27	indices	O
28	calculated	O
29	.	O

1	The	O
2	authors	O
3	conclude	O
4	that	O
5	nonspecificity	O
6	of	O
7	low	O
8	platelet	B
9	MAO	I
10	as	O
11	a	O
12	possible	O
13	correlate	O
14	of	O
15	bipolar	O
16	affective	O
17	disorder	O
18	,	O
19	as	O
20	well	O
21	as	O
22	schizophrenia	O
23	,	O
24	increases	O
25	the	O
26	burden	O
27	of	O
28	proof	O
29	necessary	O
30	before	O
31	findings	O
32	of	O
33	low	O
34	platelet	B
35	MAO	I
36	can	O
37	be	O
38	accepted	O
39	as	O
40	primary	O
41	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	fludarabine	O
6	is	O
7	a	O
8	highly	O
9	useful	O
10	agent	O
11	in	O
12	CLL	O
13	.	O

1	We	O
2	cloned	O
3	and	O
4	sequenced	O
5	the	O
6	cDNAs	O
7	against	O
8	genomic	O
9	RNA	O
10	and	O
11	mRNA	O
12	for	O
13	phosphoprotein	B
14	(	I
15	P	I
16	)	I
17	of	O
18	human	O
19	parainfluenza	O
20	type	O
21	2	O
22	virus	O
23	(	O
24	PIV	O
25	-	O
26	2	O
27	).	O
28	cDNA	O
29	clone	O
30	from	O
31	genomic	O
32	RNA	O
33	was	O
34	1439	O
35	nucleotides	O
36	in	O
37	length	O
38	excluding	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	and	O
44	was	O
45	found	O
46	to	O
47	have	O
48	two	O
49	small	O
50	open	O
51	reading	O
52	frames	O
53	encoding	O
54	proteins	O
55	of	O
56	233	O
57	and	O
58	249	O
59	amino	O
60	acids	O
61	.	O

1	Histopathologic	O
2	response	O
3	of	O
4	gingival	O
5	tissues	O
6	to	O
7	hemodent	O
8	and	O
9	aluminum	O
10	chloride	O
11	solutions	O
12	as	O
13	tissue	O
14	displacement	O
15	materials	O
16	.	O

1	Thus	O
2	,	O
3	included	O
4	in	O
5	the	O
6	KG1a	O
7	EST	O
8	dataset	O
9	are	O
10	candidates	O
11	for	O
12	new	O
13	human	O
14	genes	O
15	that	O
16	may	O
17	play	O
18	roles	O
19	in	O
20	hematopoietic	O
21	differentiative	O
22	progression	O
23	and	O
24	lineage	O
25	commitment	O
26	.	O

1	Repression	O
2	is	O
3	alleviated	O
4	when	O
5	the	O
6	two	O
7	(	O
8	for	O
9	E2	B
10	)	O
11	or	O
12	three	O
13	(	O
14	for	O
15	E2	B
16	-	I
17	C	I
18	)	O
19	promoter	O
20	-	O
21	proximal	O
22	copies	O
23	of	O
24	E2	B
25	-	O
26	RS	O
27	are	O
28	mutated	O
29	.	O

1	The	O
2	10	O
3	kDa	O
4	polypeptide	O
5	was	O
6	phosphorylated	O
7	in	O
8	vitro	O
9	by	O
10	incubating	O
11	wheat	O
12	etioplast	O
13	membranes	O
14	with	O
15	[	O
16	gamma	O
17	32P	O
18	]	O
19	ATP	O
20	.	O

1	Relation	O
2	between	O
3	mixing	O
4	ratio	O
5	of	O
6	raw	O
7	materials	O
8	and	O
9	composition	O
10	of	O
11	products	O
12	in	O
13	the	O
14	synthesis	O
15	of	O
16	aluminosilicates	O

1	The	O
2	osmotic	O
3	diuretic	O
4	mannitol	O
5	was	O
6	administered	O
7	to	O
8	21	O
9	patients	O
10	.	O

1	Both	O
2	HEF1	B
3	and	O
4	Cas	B
5	were	O
6	found	O
7	to	O
8	complex	O
9	with	O
10	the	O
11	related	B
12	adhesion	I
13	focal	I
14	tyrosine	I
15	kinase	I
16	(	O
17	RAFTK	B
18	),	O
19	and	O
20	when	O
21	tyrosine	O
22	phosphorylated	O
23	,	O
24	with	O
25	the	O
26	adapter	O
27	molecule	O
28	CrkL	B
29	.	O

1	Thus	O
2	,	O
3	this	O
4	study	O
5	provides	O
6	evidence	O
7	that	O
8	a	O
9	novel	O
10	,	O
11	ubiquitous	O
12	factor	O
13	(	O
14	HF	B
15	-	I
16	1a	I
17	)	O
18	and	O
19	a	O
20	muscle	O
21	factor	O
22	(	O
23	HF	B
24	-	I
25	1b	I
26	/	O
27	MEF	B
28	-	I
29	2	I
30	)	O
31	can	O
32	form	O
33	a	O
34	novel	O
35	,	O
36	E	O
37	-	O
38	box	O
39	-	O
40	independent	O
41	pathway	O
42	for	O
43	muscle	O
44	-	O
45	specific	O
46	expression	O
47	in	O
48	ventricular	O
49	cardiac	O
50	muscle	O
51	cells	O
52	.	O

1	Comparison	O
2	of	O
3	elastase	B
4	-	I
5	1	I
6	with	O
7	amylase	B
8	,	O
9	lipase	B
10	,	O
11	and	O
12	trypsin	B
13	-	O
14	like	O
15	immunoreactivity	O
16	in	O
17	the	O
18	diagnosis	O
19	of	O
20	acute	O
21	pancreatitis	O
22	.	O

1	Multiple	O
2	regression	O
3	analyses	O
4	revealed	O
5	that	O
6	WAIS	O
7	-	O
8	R	O
9	factor	O
10	scores	O
11	Verbal	O
12	Comprehension	O
13	and	O
14	Freedom	O
15	from	O
16	Distractibility	O
17	accounted	O
18	for	O
19	up	O
20	to	O
21	42	O
22	%	O
23	of	O
24	the	O
25	variance	O
26	in	O
27	WMS	O
28	-	O
29	R	O
30	and	O
31	CVLT	O
32	indices	O
33	.	O

1	Temafloxacin	O
2	400	O
3	mg	O
4	b	O
5	.	O
6	i	O
7	.	O
8	d	O
9	.	O
10	administered	O
11	orally	O
12	for	O
13	28	O
14	days	O
15	represents	O
16	a	O
17	safe	O
18	and	O
19	effective	O
20	treatment	O
21	for	O
22	chronic	O
23	bacterial	O
24	prostatitis	O
25	.	O

1	These	O
2	and	O
3	other	O
4	data	O
5	presented	O
6	suggest	O
7	that	O
8	TAg	B
9	'	O
10	re	O
11	-	O
12	models	O
13	'	O
14	host	O
15	cell	O
16	transcription	O
17	factors	O
18	that	O
19	are	O
20	used	O
21	early	O
22	in	O
23	viral	O
24	infection	O
25	,	O
26	and	O
27	thereby	O
28	mimics	O
29	an	O
30	event	O
31	that	O
32	naturally	O
33	occurs	O
34	during	O
35	transformation	O
36	.	O

1	Thus	O
2	it	O
3	appears	O
4	that	O
5	insertion	O
6	of	O
7	a	O
8	transposable	O
9	element	O
10	near	O
11	the	O
12	5	O
13	'	O
14	terminus	O
15	of	O
16	the	O
17	structural	O
18	gene	O
19	can	O
20	produce	O
21	constitutive	O
22	expression	O
23	of	O
24	a	O
25	normally	O
26	glucose	O
27	-	O
28	repressed	O
29	enzyme	O
30	.	O

1	Range	O
2	behavior	O
3	of	O
4	Hereford	O
5	,	O
6	Hereford	O
7	x	O
8	Holstein	O
9	and	O
10	Holstein	O
11	non	O
12	-	O
13	lactating	O
14	heifers	O
15	.	O

1	Thirty	O
2	-	O
3	five	O
4	patients	O
5	were	O
6	included	O
7	.	O

1	Antimicrobial	O
2	Susceptibility	O
3	of	O
4	Klebsiella	O
5	pneumoniae	O
6	Producing	O
7	Extended	B
8	-	I
9	Spectrum	I
10	beta	I
11	-	I
12	lactamase	I
13	(	O
14	ESBL	B
15	)	O
16	Isolated	O
17	in	O
18	Hospitals	O
19	in	O
20	Brazil	O
21	.	O

1	Because	O
2	single	O
3	-	O
4	chamber	O
5	rate	O
6	-	O
7	adaptive	O
8	atrial	O
9	pacing	O
10	leaves	O
11	the	O
12	patient	O
13	exposed	O
14	to	O
15	the	O
16	risk	O
17	of	O
18	future	O
19	development	O
20	of	O
21	AV	O
22	block	O
23	and	O
24	DDD	O
25	pacing	O
26	does	O
27	not	O
28	provide	O
29	chronotropic	O
30	support	O
31	,	O
32	it	O
33	is	O
34	likely	O
35	that	O
36	the	O
37	new	O
38	rate	O
39	-	O
40	adaptive	O
41	dual	O
42	-	O
43	chamber	O
44	(	O
45	DDDR	O
46	)	O
47	devices	O
48	will	O
49	be	O
50	used	O
51	in	O
52	a	O
53	significant	O
54	number	O
55	of	O
56	these	O
57	patients	O
58	.(	O
59	ABSTRACT	O
60	TRUNCATED	O
61	AT	O
62	250	O
63	WORDS	O
64	)	O

1	Patients	O
2	received	O
3	either	O
4	diltiazem	O
5	CD	O
6	180	O
7	mg	O
8	or	O
9	placebo	O
10	once	O
11	/	O
12	day	O
13	in	O
14	combination	O
15	with	O
16	existing	O
17	antianginal	O
18	therapy	O
19	.	O

1	Distribution	O
2	and	O
3	changing	O
4	morphological	O
5	course	O

1	As	O
2	an	O
3	alternative	O
4	approach	O
5	to	O
6	this	O
7	question	O
8	,	O
9	we	O
10	have	O
11	studied	O
12	the	O
13	effects	O
14	of	O
15	ectopically	O
16	expressed	O
17	SHIP	B
18	,	O
19	SHP	B
20	-	I
21	1	I
22	,	O
23	or	O
24	SHP	B
25	-	I
26	2	I
27	SH2	O
28	-	O
29	containing	O
30	decoy	O
31	proteins	O
32	on	O
33	Fc	B
34	gamma	I
35	RIIB1	I
36	signaling	O
37	.	O

1	The	O
2	sequence	O
3	of	O
4	four	O
5	clones	O
6	was	O
7	sufficient	O
8	to	O
9	construct	O
10	a	O
11	3018	B
12	-	I
13	bp	I
14	BAL	I
15	cDNA	I
16	structure	O
17	.	O

1	OBJECTIVE	O
2	:	O
3	Although	O
4	the	O
5	preponderance	O
6	of	O
7	findings	O
8	offer	O
9	support	O
10	for	O
11	transient	O
12	(	O
13	where	O
14	is	O
15	it	O
16	?)	O
17	as	O
18	opposed	O
19	to	O
20	sustained	O
21	(	O
22	what	O
23	is	O
24	it	O
25	?)	O
26	deficit	O
27	,	O
28	a	O
29	need	O
30	remains	O
31	for	O
32	specific	O
33	depiction	O
34	of	O
35	the	O
36	deficit	O
37	.	O

1	Contrary	O
2	to	O
3	the	O
4	observation	O
5	made	O
6	with	O
7	other	O
8	S	O
9	.	O
10	pombe	O
11	genes	O
12	transcribed	O
13	in	O
14	the	O
15	budding	O
16	yeast	O
17	,	O
18	the	O
19	heterologous	O
20	actin	B
21	gene	I
22	transcript	I
23	is	O
24	initiated	O
25	39	O
26	nucleotides	O
27	upstream	O
28	of	O
29	the	O
30	initiation	O
31	start	O
32	site	O
33	used	O
34	in	O
35	the	O
36	homologous	O
37	yeast	O
38	.	O

1	Remarkably	O
2	,	O
3	U21	B
4	contains	O
5	a	O
6	long	O
7	stretch	O
8	(	O
9	13	O
10	nt	O
11	.)	O
12	of	O
13	complementarity	O
14	to	O
15	a	O
16	highly	O
17	conserved	O
18	sequence	O
19	in	O
20	28S	B
21	rRNA	I
22	.	O

1	Measurements	O
2	were	O
3	compared	O
4	with	O
5	two	O
6	computerised	O
7	treatment	O
8	planning	O
9	systems	O
10	--	O
11	Theraplan	O
12	VO5B	O
13	and	O
14	ADAC	O
15	Pinnacle3	O
16	V4	O
17	.	O
18	0b	O
19	.	O

1	The	O
2	Pro	O
3	-	O
4	258	O
5	-->	O
6	Leu	O
7	(	O
8	P258L	O
9	)	O
10	mutation	O
11	caused	O
12	constitutive	O
13	receptor	O
14	signaling	O
15	that	O
16	was	O
17	equivalent	O
18	to	O
19	about	O
20	45	O
21	%	O
22	of	O
23	the	O
24	maximum	O
25	level	O
26	observed	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	cells	O
32	stimulated	O
33	with	O
34	alpha	B
35	-	I
36	factor	I
37	.	O

1	IVOX	O
2	was	O
3	named	O
4	as	O
5	an	O
6	acronym	O
7	for	O
8	intravascular	O
9	oxygenator	O
10	.	O

1	The	O
2	network	O
3	evolution	O
4	was	O
5	interpreted	O
6	by	O
7	an	O
8	approach	O
9	based	O
10	on	O
11	the	O
12	Flory	O
13	model	O
14	.	O

1	Plectin	B
2	and	O
3	desmoplakin	B
4	have	O
5	GSR	O
6	-	O
7	containing	O
8	domains	O
9	at	O
10	their	O
11	C	O
12	-	O
13	termini	O
14	and	O
15	we	O
16	further	O
17	demonstrate	O
18	that	O
19	the	O
20	GSR	O
21	-	O
22	containing	O
23	domain	O
24	of	O
25	plectin	B
26	,	O
27	but	O
28	not	O
29	desmoplakin	B
30	,	O
31	can	O
32	bind	O
33	to	O
34	MTs	O
35	in	O
36	vivo	O
37	.	O

1	It	O
2	is	O
3	likely	O
4	that	O
5	the	O
6	sequence	O
7	similarities	O
8	reflect	O
9	a	O
10	common	O
11	molecular	O
12	architecture	O
13	of	O
14	the	O
15	two	O
16	heme	O
17	binding	O
18	sites	O
19	and	O
20	of	O
21	a	O
22	copper	O
23	binding	O
24	site	O
25	in	O
26	these	O
27	enzymes	O
28	.	O

1	The	O
2	Functional	O
3	Independence	O
4	Measure	O
5	:	O
6	a	O
7	comparative	O
8	study	O
9	of	O
10	clinician	O
11	and	O
12	self	O
13	ratings	O
14	.	O

1	Cut	O
2	-	O
3	off	O
4	levels	O
5	that	O
6	define	O
7	abnormality	O
8	are	O
9	rather	O
10	arbitrary	O
11	and	O
12	this	O
13	decreases	O
14	the	O
15	specificity	O
16	of	O
17	the	O
18	test	O
19	in	O
20	apparently	O
21	healthy	O
22	patients	O
23	.	O

1	The	O
2	Nur77	B
3	protein	I
4	can	O
5	act	O
6	as	O
7	a	O
8	potent	O
9	transcription	O
10	activator	O
11	and	O
12	may	O
13	function	O
14	to	O
15	regulate	O
16	the	O
17	expression	O
18	of	O
19	downstream	O
20	genes	O
21	in	O
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	.	O

1	Clinical	O
2	differentiation	O
3	of	O
4	patients	O
5	with	O
6	mild	O
7	diplegic	O
8	cerebral	O
9	palsy	O
10	(	O
11	CP	O
12	)	O
13	and	O
14	idiopathic	O
15	toe	O
16	walking	O
17	(	O
18	ITW	O
19	)	O
20	can	O
21	be	O
22	difficult	O
23	.	O

1	Two	O
2	Pax2	B
3	/	I
4	5	I
5	/	I
6	8	I
7	-	I
8	binding	I
9	sites	I
10	in	O
11	Engrailed2	B
12	are	O
13	required	O
14	for	O
15	proper	O
16	initiation	O
17	of	O
18	endogenous	O
19	mid	O
20	-	O
21	hindbrain	O
22	expression	O
23	.	O

1	Video	O
2	images	O
3	of	O
4	the	O
5	nostrils	O
6	were	O
7	captured	O
8	and	O
9	then	O
10	analyzed	O
11	for	O
12	area	O
13	,	O
14	perimeter	O
15	,	O
16	centroid	O
17	,	O
18	principal	O
19	axis	O
20	,	O
21	moments	O
22	about	O
23	the	O
24	major	O
25	and	O
26	minor	O
27	axes	O
28	(	O
29	I11	O
30	,	O
31	I22	O
32	),	O
33	anisometry	O
34	,	O
35	bulkiness	O
36	,	O
37	lateral	O
38	offset	O
39	,	O
40	internostril	O
41	angle	O
42	,	O
43	and	O
44	rotational	O
45	angle	O
46	.	O

1	B	O
2	cell	O
3	-	O
4	specific	O
5	mb	B
6	-	I
7	1	I
8	and	O
9	B29	B
10	genes	I
11	encode	O
12	the	O
13	alpha	O
14	/	O
15	beta	O
16	components	O
17	of	O
18	the	O
19	BCR	B
20	-	I
21	associated	I
22	complex	I
23	in	O
24	mature	O
25	sIgM	B
26	+	I
27	B	O
28	cells	O
29	.	O

1	Endoscopic	O
2	examinations	O
3	,	O
4	peripheral	O
5	white	O
6	blood	O
7	cell	O
8	(	O
9	WBC	O
10	)	O
11	counts	O
12	,	O
13	and	O
14	assays	O
15	of	O
16	myeloperoxidase	B
17	activity	O
18	(	O
19	MPO	B
20	)	O
21	in	O
22	homogenates	O
23	of	O
24	colon	O
25	mucosa	O
26	were	O
27	performed	O
28	after	O
29	one	O
30	week	O
31	(	O
32	4	O
33	%	O
34	DSS	O
35	model	O
36	)	O
37	and	O
38	eight	O
39	weeks	O
40	(	O
41	1	O
42	%	O
43	DSS	O
44	model	O
45	).	O

1	Concordance	O
2	of	O
3	IBDQ	O
4	scores	O
5	was	O
6	tested	O
7	in	O
8	280	O
9	stable	O
10	subjects	O
11	.	O

1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	O
8	extracellular	O
9	matrix	O
10	glycoprotein	O
11	undulin	B
12	.	O

1	GN101	O
2	,	O
3	YC819	O
4	-	O
5	9	O
6	,	O
7	and	O
8	SB3	O
9	.	O

1	Multiparity	O
2	had	O
3	a	O
4	protective	O
5	effect	O
6	with	O
7	0	O
8	.	O
9	66	O
10	less	O
11	risk	O
12	(	O
13	95	O
14	%	O
15	CI	O
16	0	O
17	.	O
18	44	O
19	-	O
20	0	O
21	.	O
22	99	O
23	).	O

1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	EF	O
8	between	O
9	the	O
10	two	O
11	studies	O
12	,	O
13	both	O
14	at	O
15	rest	O
16	(	O
17	56	O
18	.	O
19	0	O
20	+/-	O
21	13	O
22	.	O
23	8	O
24	%	O
25	vs	O
26	58	O
27	.	O
28	2	O
29	+/-	O
30	11	O
31	.	O
32	7	O
33	%,	O
34	p	O
35	=	O
36	NS	O
37	)	O
38	and	O
39	with	O
40	exercise	O
41	(	O
42	51	O
43	.	O
44	1	O
45	+/-	O
46	17	O
47	.	O
48	6	O
49	%	O
50	vs	O
51	54	O
52	.	O
53	3	O
54	+/-	O
55	17	O
56	.	O
57	6	O
58	%,	O
59	p	O
60	=	O
61	NS	O
62	)	O
63	and	O
64	a	O
65	highly	O
66	significant	O
67	correlation	O
68	was	O
69	shown	O
70	between	O
71	the	O
72	two	O
73	groups	O
74	of	O
75	values	O
76	(	O
77	rest	O
78	r	O
79	=	O
80	0	O
81	.	O
82	90	O
83	,	O
84	exercise	O
85	r	O
86	=	O
87	0	O
88	.	O
89	93	O
90	,	O
91	p	O
92	less	O
93	than	O
94	0	O
95	.	O
96	001	O
97	).	O

1	We	O
2	show	O
3	that	O
4	the	O
5	en	B
6	stripes	O
7	expand	O
8	anteriorly	O
9	in	O
10	slp	B
11	mutant	O
12	embryos	O
13	and	O
14	that	O
15	slp	B
16	activity	O
17	is	O
18	an	O
19	absolute	O
20	requirement	O
21	for	O
22	maintenance	O
23	of	O
24	wg	B
25	expression	O
26	at	O
27	the	O
28	same	O
29	time	O
30	that	O
31	wg	B
32	transcription	O
33	is	O
34	dependent	O
35	on	O
36	hh	B
37	.	O

1	Intestinal	O
2	adaptation	O
3	(	O
4	first	O
5	of	O
6	two	O
7	parts	O
8	).	O

1	Neonatal	O
2	Chagas	O
3	disease	O
4	:	O
5	laboratory	O
6	diagnosis	O
7	during	O
8	the	O
9	first	O
10	year	O
11	of	O
12	life	O

1	Is	O
2	criticism	O
3	of	O
4	patient	O
5	care	O
6	justified	O
7	and	O
8	does	O
9	it	O
10	have	O
11	educational	O
12	value	O
13	?	O
14	Patients	O
15	'	O
16	criticism	O
17	contributes	O
18	to	O
19	improved	O
20	patient	O
21	care	O

1	Promoter	O
2	region	O
3	of	O
4	the	O
5	transcriptional	O
6	unit	O
7	for	O
8	human	B
9	alpha	I
10	1	I
11	-	I
12	chimaerin	I
13	,	O
14	a	O
15	neuron	B
16	-	I
17	specific	I
18	GTPase	I
19	-	I
20	activating	I
21	protein	I
22	for	O
23	p21rac	B
24	.	O
25	alpha	B
26	1	I
27	-	I
28	chimaerin	I
29	is	O
30	a	O
31	neuron	B
32	-	I
33	specific	I
34	GTPase	I
35	-	I
36	activating	I
37	protein	I
38	for	O
39	p21rac	B
40	,	O
41	a	O
42	protein	O
43	involved	O
44	in	O
45	morphological	O
46	events	O
47	.	O

1	It	O
2	was	O
3	not	O
4	possible	O
5	to	O
6	study	O
7	the	O
8	basis	O
9	for	O
10	tissue	O
11	-	O
12	specific	O
13	expression	O
14	of	O
15	this	O
16	gene	O
17	,	O
18	because	O
19	the	O
20	beta	B
21	3	I
22	gene	I
23	promoter	I
24	had	O
25	not	O
26	been	O
27	isolated	O
28	previously	O
29	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	human	B
10	DSG3	I
11	gene	I
12	and	O
13	examined	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	its	O
19	expression	O
20	.	O

1	Disruption	O
2	of	O
3	ARF2	B
4	causes	O
5	no	O
6	detectable	O
7	phenotype	O
8	.	O

1	The	O
2	concentration	O
3	of	O
4	PGI2	O
5	on	O
6	the	O
7	newly	O
8	-	O
9	formed	O
10	luminal	O
11	surface	O
12	remained	O
13	low	O
14	.	O

1	We	O
2	have	O
3	separated	O
4	a	O
5	dermatan	O
6	sulfate	O
7	proteoglycan	O
8	,	O
9	epiphycan	O
10	,	O
11	from	O
12	decorin	B
13	and	O
14	biglycan	O
15	by	O
16	using	O
17	dissociative	O
18	extraction	O
19	of	O
20	bovine	O
21	fetal	O
22	epiphyseal	O
23	cartilage	O
24	,	O
25	followed	O
26	by	O
27	sequential	O
28	ion	O
29	-	O
30	exchange	O
31	,	O
32	gel	O
33	permeation	O
34	,	O
35	hydrophobic	O
36	,	O
37	and	O
38	Zn2	O
39	+	O
40	chelate	O
41	chromatographic	O
42	steps	O
43	.	O

1	We	O
2	previously	O
3	described	O
4	two	O
5	alanine	O
6	cluster	O
7	mutations	O
8	,	O
9	R77	O
10	to	O
11	A	O
12	(	O
13	R77A	O
14	)-	O
15	K79A	O
16	and	O
17	E192A	O
18	-	O
19	E194A	O
20	,	O
21	which	O
22	selectively	O
23	inactivated	O
24	the	O
25	triphosphatase	O
26	component	O
27	.	O

1	Myocardial	O
2	interstitial	O
3	edema	O
4	is	O
5	more	O
6	likely	O
7	a	O
8	potential	O
9	mechanism	O
10	of	O
11	diastolic	O
12	dysfunction	O
13	after	O
14	DC	O
15	shocks	O
16	.	O

1	The	O
2	motor	O
3	unit	O
4	viewed	O
5	from	O
6	above	O
7	.	O

1	Max	B
2	:	O
3	functional	O
4	domains	O
5	and	O
6	interaction	O
7	with	O
8	c	B
9	-	I
10	Myc	I
11	.	O

1	Wild	O
2	type	O
3	HA	B
4	-	O
5	p190	B
6	induced	O
7	a	O
8	phenotype	O
9	of	O
10	rounded	O
11	cells	O
12	with	O
13	long	O
14	,	O
15	beaded	O
16	extensions	O
17	similar	O
18	to	O
19	that	O
20	seen	O
21	when	O
22	Rho	B
23	function	O
24	is	O
25	disrupted	O
26	by	O
27	ADP	O
28	-	O
29	ribosylation	O
30	.	O

1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	tmy	B
8	-	I
9	1	I
10	gene	I
11	was	O
12	determined	O
13	by	O
14	microinjection	O
15	of	O
16	a	O
17	promoter	B
18	/	I
19	lacZ	I
20	fusion	I
21	gene	I
22	and	O
23	with	O
24	immunohistochemistry	O
25	by	O
26	using	O
27	affinity	O
28	-	O
29	purified	O
30	tissue	B
31	-	I
32	specific	I
33	anti	I
34	-	I
35	tropomyosins	I
36	.	O

1	Cell	O
2	factor	O
3	-	O
4	mediated	O
5	regulatory	O
6	interactions	O
7	are	O
8	involved	O
9	in	O
10	regulating	O
11	the	O
12	restricted	O
13	expression	O
14	of	O
15	the	O
16	HCMV	B
17	major	I
18	immediate	I
19	-	I
20	early	I
21	(	I
22	IE	I
23	)	I
24	gene	I
25	(	O
26	J	O
27	.	O

1	Presidential	O
2	address	O
3	1990	O
4	--	O
5	coming	O
6	in	O
7	from	O
8	the	O
9	cold	O
10	.	O

1	Sensitization	O
2	to	O
3	hyperlactatemia	O
4	induced	O
5	by	O
6	phenformin	O
7	after	O
8	subtotal	O
9	ablation	O
10	of	O
11	the	O
12	pancreas	O
13	.	O

1	T	B
2	-	I
3	cell	I
4	receptor	I
5	beta	I
6	(	O
7	TCR	B
8	beta	I
9	)	O
10	gene	O
11	rearrangements	O
12	occur	O
13	in	O
14	a	O
15	third	O
16	of	O
17	early	O
18	B	O
19	-	O
20	cell	O
21	acute	O
22	lymphoblastic	O
23	leukemias	O
24	(	O
25	ALLs	O
26	).	O

1	Polysome	O
2	analysis	O
3	further	O
4	indicated	O
5	that	O
6	these	O
7	germ	B
8	cell	I
9	-	I
10	specific	I
11	Sp1	I
12	mRNAs	I
13	are	O
14	translated	O
15	,	O
16	albeit	O
17	with	O
18	a	O
19	lower	O
20	efficiency	O
21	than	O
22	the	O
23	somatic	O
24	transcript	O
25	.	O

1	This	O
2	hypothesis	O
3	was	O
4	tested	O
5	by	O
6	introducing	O
7	mutations	O
8	at	O
9	each	O
10	of	O
11	the	O
12	three	O
13	histidine	O
14	pairs	O
15	,	O
16	the	O
17	H382	O
18	-	O
19	X2	O
20	-	O
21	H385	O
22	pair	O
23	,	O
24	the	O
25	H411	O
26	-	O
27	X2	O
28	-	O
29	H414	O
30	pair	O
31	and	O
32	the	O
33	H430	O
34	-	O
35	X5	O
36	-	O
37	H436	O
38	pair	O
39	,	O
40	which	O
41	constitute	O
42	the	O
43	histidine	O
44	-	O
45	rich	O
46	region	O
47	near	O
48	the	O
49	C	O
50	terminus	O
51	of	O
52	gp17	B
53	.	O

1	Polyprotein	O
2	processing	O
3	in	O
4	Southampton	O
5	virus	O
6	:	O
7	identification	O
8	of	O
9	3C	B
10	-	I
11	like	I
12	protease	I
13	cleavage	O
14	sites	O
15	by	O
16	in	O
17	vitro	O
18	mutagenesis	O
19	.	O

1	LHbeta	B
2	is	O
3	expressed	O
4	in	O
5	pituitary	O
6	gonadotrope	O
7	cells	O
8	and	O
9	CGbeta	B
10	is	O
11	expressed	O
12	in	O
13	placental	O
14	trophoblast	O
15	cells	O
16	.	O

1	The	O
2	model	O
3	also	O
4	predicts	O
5	that	O
6	blood	O
7	flow	O
8	shunt	O
9	fraction	O
10	(	O
11	Qs	O
12	/	O
13	QT	O
14	)	O
15	is	O
16	directly	O
17	related	O
18	to	O
19	the	O
20	oxygen	O
21	sine	O
22	-	O
23	wave	O
24	amplitude	O
25	perturbations	O
26	transmitted	O
27	to	O
28	end	O
29	-	O
30	expired	O
31	air	O
32	and	O
33	arterial	O
34	and	O
35	mixed	O
36	-	O
37	venous	O
38	blood	O
39	through	O
40	two	O
41	simple	O
42	equations	O
43	.	O

1	The	O
2	architecture	O
3	of	O
4	microvasculature	O
5	in	O
6	these	O
7	two	O
8	regions	O
9	was	O
10	also	O
11	examined	O
12	by	O
13	scanning	O
14	electron	O
15	microscopy	O
16	,	O
17	using	O
18	the	O
19	resin	O
20	casting	O
21	method	O
22	.	O

1	Soft	O
2	-	O
3	x	O
4	-	O
5	ray	O
6	lasing	O
7	at	O
8	32	O
9	.	O
10	6	O
11	nm	O
12	in	O
13	Ne	O
14	-	O
15	like	O
16	Ti	O
17	ions	O
18	driven	O
19	by	O
20	40	O
21	J	O
22	of	O
23	energy	O
24	from	O
25	two	O
26	650	O
27	-	O
28	ps	O
29	laser	O
30	pulses	O
31	.	O

1	Quantitative	O
2	evaluation	O
3	of	O
4	magneto	O
5	-	O
6	optical	O
7	parameters	O
8	is	O
9	necessary	O
10	in	O
11	order	O
12	to	O
13	apply	O
14	scanning	O
15	near	O
16	-	O
17	field	O
18	optical	O
19	microscope	O
20	(	O
21	SNOM	O
22	)	O
23	technology	O
24	to	O
25	the	O
26	study	O
27	of	O
28	magnetism	O
29	on	O
30	the	O
31	mesoscopic	O
32	scale	O
33	.	O

1	The	O
2	analysis	O
3	of	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	sleep	O
9	period	O
10	as	O
11	a	O
12	whole	O
13	reveals	O
14	that	O
15	with	O
16	increasing	O
17	of	O
18	the	O
19	age	O
20	the	O
21	delta	O
22	-	O
23	wave	O
24	stage	O
25	(	O
26	DS	O
27	)	O
28	of	O
29	the	O
30	QS	O
31	(	O
32	determined	O
33	by	O
34	defined	O
35	polygraphic	O
36	parameters	O
37	)	O
38	increases	O
39	,	O
40	while	O
41	the	O
42	paradoxical	O
43	phase	O
44	of	O
45	sleep	O
46	(	O
47	PS	O
48	)	O
49	decreases	O
50	,	O
51	this	O
52	change	O
53	being	O
54	more	O
55	pronounced	O
56	during	O
57	the	O
58	first	O
59	six	O
60	months	O
61	than	O
62	during	O
63	the	O
64	second	O
65	ones	O
66	of	O
67	the	O
68	first	O
69	year	O
70	of	O
71	the	O
72	life	O
73	.	O

1	The	O
2	pathogenicity	O
3	of	O
4	Achromobacter	O
5	puntatum	O
6	for	O
7	cold	O
8	blooded	O
9	and	O
10	warm	O
11	blooded	O
12	animals	O

1	The	O
2	specificity	O
3	of	O
4	action	O
5	of	O
6	C	B
7	/	I
8	EBP	I
9	family	I
10	members	I
11	may	O
12	be	O
13	derived	O
14	from	O
15	the	O
16	characteristics	O
17	of	O
18	each	O
19	factor	O
20	,	O
21	including	O
22	the	O
23	expression	O
24	profiles	O
25	,	O
26	the	O
27	DNA	O
28	binding	O
29	affinities	O
30	,	O
31	the	O
32	cofactors	O
33	,	O
34	and	O
35	so	O
36	on	O
37	,	O
38	in	O
39	addition	O
40	to	O
41	the	O
42	DNA	O
43	binding	O
44	specificities	O
45	.	O

1	Platelet	O
2	function	O
3	and	O
4	platelet	O
5	-	O
6	polymorphonuclear	O
7	-	O
8	neutrophil	O
9	interaction	O
10	in	O
11	patients	O
12	with	O
13	deficient	O
14	platelet	B
15	lipoxygenase	I
16	activity	O
17	.	O

1	Transfection	O
2	of	O
3	increasing	O
4	amounts	O
5	of	O
6	delta5ERalpha	B
7	expression	O
8	vector	O
9	into	O
10	[	O
11	ERalpha	B
12	+]	O
13	OS	O
14	cells	O
15	resulted	O
16	in	O
17	potentiation	O
18	of	O
19	E2	O
20	-	O
21	stimulated	O
22	ERELuc	B
23	activity	O
24	in	O
25	a	O
26	synergistic	O
27	,	O
28	dose	O
29	-	O
30	dependent	O
31	manner	O
32	.	O

1	The	O
2	low	O
3	number	O
4	of	O
5	false	O
6	positives	O
7	indicates	O
8	that	O
9	our	O
10	scheme	O
11	would	O
12	not	O
13	confuse	O
14	the	O
15	radiologist	O
16	by	O
17	suggesting	O
18	normal	O
19	regions	O
20	as	O
21	suspicious	O
22	.	O

1	Component	O
2	P100	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	frontal	O
8	negativity	O
9	of	O
10	similar	O
11	latency	O
12	favoring	O
13	the	O
14	hypothesis	O
15	of	O
16	a	O
17	dipolar	O
18	occipital	O
19	generator	O
20	.	O

1	SUMMARY	O
2	BACKGROUND	O
3	DATA	O
4	:	O
5	Melanoma	O
6	care	O
7	has	O
8	not	O
9	changed	O
10	significantly	O
11	in	O
12	the	O
13	last	O
14	20	O
15	years	O
16	,	O
17	and	O
18	the	O
19	controversy	O
20	of	O
21	elective	O
22	lymph	O
23	node	O
24	dissections	O
25	in	O
26	this	O
27	disease	O
28	continues	O
29	to	O
30	be	O
31	discussed	O
32	.	O

1	Marked	O
2	thrombocytopenia	O
3	,	O
4	depletion	O
5	of	O
6	serum	B
7	fibrinogen	I
8	and	O
9	prolonged	O
10	prothrombin	B
11	and	O
12	activated	O
13	partial	O
14	thromboplastin	B
15	time	O
16	,	O
17	were	O
18	recorded	O
19	at	O
20	5	O
21	to	O
22	10	O
23	and	O
24	30	O
25	to	O
26	40	O
27	minutes	O
28	after	O
29	intravenous	O
30	envenomation	O
31	.	O

1	The	O
2	preferential	O
3	serum	B
4	IgA	I
5	response	O
6	observed	O
7	in	O
8	the	O
9	patient	O
10	population	O
11	suggests	O
12	that	O
13	bronchial	O
14	associated	O
15	lymphoid	O
16	tissue	O
17	in	O
18	the	O
19	diseased	O
20	lung	O
21	is	O
22	an	O
23	important	O
24	source	O
25	of	O
26	circulating	O
27	IgA	B
28	.	O

1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	human	B
6	Lnk	I
7	,	O
8	an	O
9	adaptor	O
10	protein	O
11	with	O
12	pleckstrin	B
13	homology	O
14	and	O
15	Src	B
16	homology	I
17	2	I
18	domains	I
19	that	O
20	can	O
21	inhibit	O
22	T	O
23	cell	O
24	activation	O
25	.	O

1	Identification	O
2	and	O
3	structure	O
4	of	O
5	the	O
6	Marek	B
7	'	I
8	s	I
9	disease	I
10	virus	I
11	serotype	I
12	2	I
13	glycoprotein	I
14	M	I
15	gene	I
16	:	O
17	comparison	O
18	with	O
19	glycoprotein	B
20	M	I
21	genes	I
22	of	O
23	Herpesviridae	O
24	family	O
25	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	the	O
7	mouse	B
8	NMO1	I
9	cDNA	I
10	,	O
11	which	O
12	encodes	O
13	the	O
14	NAD	B
15	(	I
16	P	I
17	)	I
18	H	I
19	:	I
20	menadione	I
21	oxidoreductase	I
22	[	O
23	also	O
24	called	O
25	NAD	B
26	(	I
27	P	I
28	)	I
29	H	I
30	:(	I
31	quinone	I
32	acceptor	I
33	)	I
34	oxidoreductase	I
35	;	O
36	quinone	B
37	reductase	I
38	;	O
39	azo	B
40	dye	I
41	reductase	I
42	;	O
43	DT	B
44	diaphorase	I
45	;	O
46	EC	B
47	1	I
48	.	I
49	6	I
50	.	I
51	99	I
52	.	I
53	2	I
54	].	O

1	Uses	O
2	of	O
3	orthoclone	O
4	OKT3	B
5	for	O
6	prophylaxis	O
7	of	O
8	rejection	O
9	and	O
10	induction	O
11	in	O
12	initial	O
13	nonfunction	O
14	in	O
15	kidney	O
16	transplantation	O
17	.	O

1	Frog	O
2	type	O
3	I	O
4	(	O
5	Ft	O
6	I	O
7	)	O
8	and	O
9	frog	O
10	type	O
11	II	O
12	(	O
13	Ft	O
14	II	O
15	)	O
16	slowly	O
17	adapting	O
18	(	O
19	SA	O
20	)	O
21	units	O
22	produced	O
23	spikes	O
24	only	O
25	at	O
26	the	O
27	indentation	O
28	phase	O
29	,	O
30	and	O
31	the	O
32	threshold	O
33	response	O
34	phase	O
35	(	O
36	TRP	O
37	),	O
38	i	O
39	.	O
40	e	O
41	..	O
42	the	O
43	phase	O
44	of	O
45	the	O
46	first	O
47	spike	O
48	was	O
49	for	O
50	ca	O
51	.	O

1	A	O
2	limited	O
3	study	O
4	in	O
5	a	O
6	glassware	O
7	factory	O
8	(	O
9	As2O3	O
10	exposure	O
11	)	O
12	involving	O
13	the	O
14	measurement	O
15	of	O
16	total	O
17	airborne	O
18	arsenic	O
19	,	O
20	the	O
21	determination	O
22	of	O
23	urinary	O
24	arsenic	O
25	,	O
26	and	O
27	the	O
28	evaluation	O
29	of	O
30	hand	O
31	and	O
32	mouth	O
33	contamination	O
34	by	O
35	arsenic	O
36	before	O
37	and	O
38	after	O
39	the	O
40	workshift	O
41	suggests	O
42	that	O
43	the	O
44	high	O
45	urinary	O
46	arsenic	O
47	levels	O
48	(	O
49	300	O
50	microgram	O
51	/	O
52	g	O
53	creatinine	O
54	)	O
55	are	O
56	likely	O
57	to	O
58	be	O
59	more	O
60	related	O
61	to	O
62	an	O
63	increased	O
64	oral	O
65	intake	O
66	from	O
67	contaminated	O
68	hands	O
69	than	O
70	to	O
71	an	O
72	increased	O
73	absorption	O
74	from	O
75	the	O
76	lungs	O
77	.	O

1	67	O
2	393	O
3	bp	O
4	of	O
5	contiguous	O
6	DNA	O
7	located	O
8	between	O
9	markers	O
10	cdc18	B
11	and	O
12	cdc14	B
13	on	O
14	the	O
15	right	O
16	arm	O
17	of	O
18	fission	O
19	yeast	O
20	chromosome	O
21	II	O
22	has	O
23	been	O
24	sequenced	O
25	as	O
26	part	O
27	of	O
28	the	O
29	European	O
30	Union	O
31	Schizosaccharomyces	O
32	pombe	O
33	genome	O
34	sequencing	O
35	project	O
36	.	O

1	The	O
2	pheromone	O
3	response	O
4	pathway	O
5	activates	O
6	transcription	O
7	of	O
8	Ty5	B
9	retrotransposons	I
10	located	O
11	within	O
12	silent	O
13	chromatin	O
14	of	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	Consistent	O
2	with	O
3	ErbB	B
4	-	I
5	2	I
6	being	O
7	a	O
8	shared	O
9	receptor	O
10	subunit	O
11	,	O
12	its	O
13	tyrosine	O
14	phosphorylation	O
15	was	O
16	increased	O
17	by	O
18	both	O
19	heterologous	O
20	ligands	O
21	and	O
22	it	O
23	mediated	O
24	a	O
25	trans	O
26	-	O
27	inhibitory	O
28	effect	O
29	of	O
30	NDF	B
31	on	O
32	EGF	B
33	binding	O
34	.	O

1	R	O
2	.,	O
3	Fleischmann	O
4	,	O
5	R	O
6	.,	O
7	Venter	O
8	,	O
9	J	O
10	.	O

1	Management	O
2	of	O
3	hypertension	O
4	in	O
5	the	O
6	elderly	O
7	.	O

1	Mycobacterium	O
2	avium	O
3	-	O
4	intracellulare	O
5	complex	O
6	infections	O
7	in	O
8	the	O
9	acquired	O
10	immunodeficiency	O
11	syndrome	O
12	.	O

1	The	O
2	early	O
3	dg	O
4	.	O
5	of	O
6	rejection	O
7	and	O
8	especially	O
9	acute	O
10	rejection	O
11	,	O
12	it	O
13	'	O
14	s	O
15	adequate	O
16	management	O
17	,	O
18	decreased	O
19	risk	O
20	for	O
21	the	O
22	future	O
23	chronic	O
24	rejection	O
25	nephropathy	O
26	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	impact	O
7	of	O
8	the	O
9	introduction	O
10	of	O
11	clarithromycin	O
12	and	O
13	azithromycin	O
14	on	O
15	the	O
16	treatment	O
17	and	O
18	survival	O
19	of	O
20	patients	O
21	with	O
22	AIDS	O
23	and	O
24	disseminated	O
25	Mycobacterium	O
26	avium	O
27	complex	O
28	(	O
29	DMAC	O
30	).	O

1	Hydrophobicity	O
2	analysis	O
3	indicated	O
4	that	O
5	the	O
6	KlaA	B
7	and	O
8	KlaB	B
9	polypeptides	I
10	are	O
11	likely	O
12	to	O
13	be	O
14	soluble	O
15	,	O
16	whereas	O
17	the	O
18	KlaC	B
19	polypeptide	I
20	was	O
21	predicted	O
22	to	O
23	have	O
24	four	O
25	potential	O
26	membrane	O
27	-	O
28	spanning	O
29	domains	O
30	.	O

1	Sixty	O
2	days	O
3	after	O
4	the	O
5	intervention	O
6	,	O
7	twitch	O
8	and	O
9	tetanic	O
10	tensions	O
11	remained	O
12	dependent	O
13	upon	O
14	the	O
15	extracellular	O
16	Ca2	O
17	+	O
18	concentration	O
19	([	O
20	Ca	O
21	]	O
22	o	O
23	)	O
24	both	O
25	in	O
26	groups	O
27	A	O
28	and	O
29	B	O
30	.	O

1	We	O
2	isolated	O
3	a	O
4	ribosomal	B
5	protein	I
6	L18	I
7	by	O
8	interaction	O
9	with	O
10	PKR	B
11	.	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	study	O
6	was	O
7	to	O
8	correlate	O
9	the	O
10	responsiveness	O
11	to	O
12	bronchoprovocation	O
13	with	O
14	methacholine	O
15	in	O
16	subjects	O
17	a	O
18	with	O
19	allergic	O
20	rhinitis	O
21	during	O
22	and	O
23	out	O
24	of	O
25	the	O
26	pollen	O
27	season	O
28	with	O
29	total	O
30	serum	O
31	IgE	B
32	and	O
33	blood	O
34	eosinophils	O
35	.	O

1	Each	O
2	patient	O
3	had	O
4	measurable	O
5	LH	B
6	and	O
7	FSH	B
8	levels	O
9	,	O
10	with	O
11	pulsed	O
12	nocturnal	O
13	secretion	O
14	,	O
15	and	O
16	pubertal	O
17	LH	B
18	and	O
19	FSH	B
20	responses	O
21	to	O
22	LRH	B
23	.	O

1	Treatment	O
2	of	O
3	Graves	O
4	'	O
5	disease	O
6	.	O

1	Oligonucleotide	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	EpRE	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	super	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O

1	A	O
2	new	O
3	technique	O
4	to	O
5	create	O
6	an	O
7	artificial	O
8	stenosis	O
9	in	O
10	the	O
11	native	O
12	LAD	O
13	using	O
14	a	O
15	hemoclip	O
16	.	O

1	(	O
2	iv	O
3	)	O
4	Although	O
5	UCRBP	B
6	has	O
7	been	O
8	previously	O
9	shown	O
10	to	O
11	act	O
12	as	O
13	a	O
14	transcriptional	O
15	repressor	O
16	,	O
17	we	O
18	show	O
19	here	O
20	that	O
21	UCRBP	B
22	can	O
23	also	O
24	act	O
25	as	O
26	a	O
27	positive	O
28	transactivator	O
29	of	O
30	a	O
31	reporter	O
32	driven	O
33	by	O
34	UCR	O
35	elements	O
36	when	O
37	used	O
38	in	O
39	co	O
40	-	O
41	transfection	O
42	assays	O
43	.	O

1	We	O
2	conclude	O
3	that	O
4	cephalothin	O
5	clearance	O
6	of	O
7	S	O
8	.	O
9	aureus	O
10	from	O
11	a	O
12	site	O
13	accessible	O
14	to	O
15	phagocytes	O
16	was	O
17	delayed	O
18	when	O
19	compared	O
20	to	O
21	a	O
22	phagocyte	O
23	-	O
24	inaccessible	O
25	site	O
26	.	O

1	Aneurysmal	O
2	bone	O
3	cyst	O
4	of	O
5	the	O
6	jaws	O
7	:	O
8	analysis	O
9	of	O
10	11	O
11	cases	O
12	.	O

1	Genes	O
2	for	O
3	ocs	B
4	element	I
5	binding	I
6	factors	I
7	(	O
8	OBFs	B
9	),	O
10	belonging	O
11	to	O
12	a	O
13	specific	O
14	class	O
15	of	O
16	basic	B
17	-	I
18	region	I
19	leucine	I
20	zipper	I
21	(	I
22	bZIP	I
23	)	I
24	transcription	I
25	factors	I
26	,	O
27	have	O
28	been	O
29	isolated	O
30	in	O
31	a	O
32	number	O
33	of	O
34	plants	O
35	.	O

1	Using	O
2	a	O
3	high	O
4	-	O
5	copy	O
6	suppression	O
7	strategy	O
8	,	O
9	we	O
10	have	O
11	identified	O
12	a	O
13	yeast	O
14	gene	O
15	(	O
16	UBS1	B
17	)	O
18	whose	O
19	elevated	O
20	expression	O
21	suppresses	O
22	the	O
23	conditional	O
24	cell	O
25	cycle	O
26	defects	O
27	associated	O
28	with	O
29	cdc34	B
30	mutations	O
31	.	O

1	The	O
2	need	O
3	in	O
4	the	O
5	small	O
6	hospital	O
7	.	O

1	This	O
2	difference	O
3	may	O
4	result	O
5	from	O
6	the	O
7	lower	O
8	match	O
9	to	O
10	the	O
11	ARG	O
12	box	O
13	consensus	O
14	of	O
15	the	O
16	O	B
17	(	I
18	rocD	I
19	)	I
20	site	I
21	.	O

1	Five	O
2	of	O
3	the	O
4	PDP1	B
5	isoforms	I
6	differ	O
7	by	O
8	the	O
9	substitution	O
10	or	O
11	insertion	O
12	of	O
13	amino	O
14	acids	O
15	at	O
16	or	O
17	near	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	of	O
23	the	O
24	protein	O
25	.	O

1	Furthermore	O
2	,	O
3	analysis	O
4	of	O
5	the	O
6	E2	B
7	proteins	I
8	present	O
9	in	O
10	various	O
11	cell	O
12	lines	O
13	harboring	O
14	specific	O
15	BPV	O
16	-	O
17	1	O
18	mutants	O
19	,	O
20	including	O
21	the	O
22	2558	O
23	acceptor	O
24	mutant	O
25	,	O
26	proves	O
27	that	O
28	alternate	O
29	modes	O
30	of	O
31	E2	B
32	expression	O
33	exist	O
34	.	O

1	Polyvinyl	O
2	alcohol	O
3	as	O
4	a	O
5	solution	O
6	mediator	O

1	Little	O
2	is	O
3	known	O
4	about	O
5	the	O
6	mechanism	O
7	,	O
8	but	O
9	the	O
10	availability	O
11	of	O
12	rapid	O
13	facile	O
14	assays	O
15	for	O
16	monitoring	O
17	immunoglobulin	B
18	hypermutation	O
19	would	O
20	greatly	O
21	aid	O
22	the	O
23	development	O
24	of	O
25	culture	O
26	systems	O
27	for	O
28	hypermutating	O
29	B	O
30	cells	O
31	as	O
32	well	O
33	as	O
34	the	O
35	screening	O
36	for	O
37	individuals	O
38	deficient	O
39	in	O
40	the	O
41	process	O
42	.	O

1	This	O
2	means	O
3	that	O
4	the	O
5	loss	O
6	of	O
7	recessives	O
8	must	O
9	be	O
10	calculated	O
11	by	O
12	using	O
13	a	O
14	hypergeometric	O
15	and	O
16	not	O
17	a	O
18	binomial	O
19	model	O
20	as	O
21	Fisher	O
22	did	O
23	.	O

1	Genesis	O
2	of	O
3	foam	O
4	cells	O
5	:	O
6	study	O
7	in	O
8	rats	O
9	after	O
10	administration	O
11	of	O
12	Cloforex	O
13	.	O

1	With	O
2	the	O
3	exception	O
4	of	O
5	virus	O
6	assay	O
7	and	O
8	quantitation	O
9	,	O
10	these	O
11	methods	O
12	are	O
13	simple	O
14	and	O
15	inexpensive	O
16	enough	O
17	to	O
18	be	O
19	done	O
20	in	O
21	typical	O
22	shellfish	O
23	microbiology	O
24	laboratories	O
25	.	O

1	Furthermore	O
2	,	O
3	the	O
4	NH2	O
5	-	O
6	terminal	O
7	portion	O
8	of	O
9	the	O
10	homologue	O
11	was	O
12	not	O
13	translocated	O
14	into	O
15	the	O
16	outer	O
17	membrane	O
18	without	O
19	its	O
20	COOH	O
21	-	O
22	terminal	O
23	part	O
24	.	O

1	This	O
2	is	O
3	particularly	O
4	intriguing	O
5	because	O
6	SKUT	O
7	-	O
8	1B	O
9	-	O
10	20	O
11	cells	O
12	lack	O
13	the	O
14	transcription	O
15	factor	O
16	Pit	B
17	-	I
18	1	I
19	.	O

1	Two	O
2	experiments	O
3	(	O
4	N	O
5	=	O
6	20	O
7	each	O
8	)	O
9	were	O
10	carried	O
11	out	O
12	to	O
13	explore	O
14	the	O
15	nature	O
16	of	O
17	ERP	O
18	negativities	O
19	in	O
20	a	O
21	visuospatial	O
22	memory	O
23	task	O
24	and	O
25	in	O
26	an	O
27	auditory	O
28	spatial	O
29	memory	O
30	task	O
31	,	O
32	respectively	O
33	.	O

1	The	O
2	two	O
3	IL6	B
4	mRNA	I
5	species	O
6	are	O
7	generated	O
8	by	O
9	alternative	O
10	polyadenylation	O
11	at	O
12	sites	O
13	separated	O
14	by	O
15	a	O
16	distance	O
17	of	O
18	1	O
19	.	O
20	2	O
21	kilobases	O
22	.	O

1	The	O
2	character	O
3	of	O
4	specific	O
5	immune	O
6	response	O
7	in	O
8	101	O
9	immunized	O
10	children	O
11	and	O
12	in	O
13	12	O
14	adults	O
15	belonging	O
16	to	O
17	a	O
18	high	O
19	risk	O
20	group	O
21	with	O
22	respect	O
23	to	O
24	VHB	O
25	.	O

1	I	O
2	.	O

1	Poliomyelitis	O
2	from	O
3	a	O
4	vaccine	O
5	.	O

1	CES4	B
2	on	O
3	a	O
4	multicopy	O
5	plasmid	O
6	was	O
7	unable	O
8	to	O
9	suppress	O
10	tif1	B
11	-	I
12	A79V	I
13	.	O

1	All	O
2	33	O
3	subjects	O
4	were	O
5	given	O
6	psychometric	O
7	instruments	O
8	for	O
9	measuring	O
10	various	O
11	components	O
12	of	O
13	anger	O
14	and	O
15	anxiety	O
16	:	O
17	Spielberger	O
18	'	O
19	s	O
20	State	O
21	-	O
22	Trait	O
23	Personality	O
24	Inventory	O
25	,	O
26	the	O
27	Anger	O
28	Expression	O
29	Scale	O
30	,	O
31	and	O
32	the	O
33	State	O
34	Anger	O
35	Reaction	O
36	Scale	O
37	.	O

1	WA	O
2	constructs	O
3	afforded	O
4	relaxed	O
5	and	O
6	positive	O
7	topoisomers	O
8	,	O
9	and	O
10	cyclization	O
11	kinetics	O
12	indicated	O
13	slow	O
14	interconversion	O
15	of	O
16	precursors	O
17	to	O
18	the	O
19	two	O
20	topoisomers	O
21	.	O

1	In	O
2	rats	O
3	,	O
4	we	O
5	examined	O
6	the	O
7	effect	O
8	of	O
9	an	O
10	omentum	O
11	wrapping	O
12	on	O
13	the	O
14	vascularization	O
15	of	O
16	the	O
17	trachea	O
18	and	O
19	on	O
20	regeneration	O
21	of	O
22	the	O
23	mucosal	O
24	epithelium	O
25	in	O
26	the	O
27	very	O
28	early	O
29	stage	O
30	after	O
31	free	O
32	tracheal	O
33	grafting	O
34	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	spv	B
7	virulence	I
8	genes	I
9	belong	O
10	simultaneously	O
11	to	O
12	several	O
13	regulons	O
14	in	O
15	the	O
16	cell	O
17	,	O
18	raising	O
19	the	O
20	possibility	O
21	that	O
22	spv	B
23	expression	O
24	can	O
25	be	O
26	fine	O
27	-	O
28	tuned	O
29	in	O
30	response	O
31	to	O
32	multiple	O
33	environmental	O
34	inputs	O
35	.	O

1	In	O
2	vitro	O
3	translation	O
4	and	O
5	in	O
6	vivo	O
7	polysome	O
8	profile	O
9	analysis	O
10	indicated	O
11	that	O
12	transcripts	B
13	C	I
14	and	I
15	E	I
16	were	O
17	translated	O
18	with	O
19	similar	O
20	translational	O
21	efficiencies	O
22	that	O
23	are	O
24	substantially	O
25	greater	O
26	than	O
27	that	O
28	of	O
29	transcript	B
30	D	I
31	,	O
32	suggesting	O
33	that	O
34	5	O
35	'-	O
36	untranslated	O
37	regions	O
38	play	O
39	a	O
40	role	O
41	in	O
42	translational	O
43	control	O
44	.	O

1	Similar	O
2	results	O
3	were	O
4	obtained	O
5	with	O
6	xylitol	O
7	,	O
8	an	O
9	activator	O
10	of	O
11	the	O
12	pentose	O
13	phosphate	O
14	pathway	O
15	.	O

1	Three	O
2	-	O
3	dimensional	O
4	structural	O
5	studies	O
6	using	O
7	electron	O
8	cryomicroscopy	O
9	showed	O
10	that	O
11	the	O
12	binding	O
13	of	O
14	one	O
15	Fab	B
16	(	O
17	8H2	O
18	/	O
19	G5	O
20	)	O
21	does	O
22	not	O
23	affect	O
24	the	O
25	conformation	O
26	of	O
27	the	O
28	capsid	O
29	,	O
30	and	O
31	the	O
32	efficiency	O
33	of	O
34	mRNA	O
35	production	O
36	is	O
37	similar	O
38	to	O
39	that	O
40	of	O
41	the	O
42	native	O
43	subviral	O
44	particle	O
45	.	O

1	1	O
2	.	O

1	BACKGROUND	O
2	:	O
3	Chemicals	O
4	vary	O
5	considerably	O
6	in	O
7	their	O
8	intrinsic	O
9	ability	O
10	to	O
11	cause	O
12	allergic	O
13	contact	O
14	dermatitis	O
15	.	O

1	The	O
2	responses	O
3	of	O
4	the	O
5	"	O
6	stress	O
7	hormones	O
8	"	O
9	cortisol	O
10	,	O
11	11	O
12	-	O
13	deoxycortisol	O
14	,	O
15	ACTH	B
16	,	O
17	vasopressin	B
18	(	O
19	AVP	B
20	),	O
21	and	O
22	corticotropin	B
23	releasing	I
24	factor	I
25	(	O
26	CRF	B
27	)	O
28	were	O
29	studied	O
30	in	O
31	6	O
32	normal	O
33	males	O
34	in	O
35	response	O
36	to	O
37	acute	O
38	cortisol	O
39	deficiency	O
40	induced	O
41	by	O
42	the	O
43	11	B
44	-	I
45	beta	I
46	-	I
47	hydroxylase	I
48	inhibitor	O
49	,	O
50	metyrapone	O
51	.	O

1	To	O
2	study	O
3	the	O
4	origin	O
5	of	O
6	different	O
7	fMLF	B
8	-	I
9	R	I
10	transcripts	I
11	,	O
12	the	O
13	genetic	O
14	linkage	O
15	of	O
16	chemotactic	O
17	receptor	O
18	genes	O
19	,	O
20	and	O
21	the	O
22	regulation	O
23	of	O
24	fMLF	B
25	-	I
26	R	I
27	gene	I
28	expression	O
29	,	O
30	we	O
31	determined	O
32	the	O
33	copy	O
34	number	O
35	,	O
36	chromosomal	O
37	location	O
38	,	O
39	structural	O
40	organization	O
41	,	O
42	and	O
43	5	O
44	'-	O
45	flanking	O
46	sequence	O
47	of	O
48	the	O
49	human	B
50	fMLF	I
51	-	I
52	R	I
53	gene	I
54	.	O

1	Because	O
2	of	O
3	its	O
4	great	O
5	reliability	O
6	,	O
7	conventional	O
8	arteriography	O
9	occupies	O
10	a	O
11	place	O
12	of	O
13	choice	O
14	among	O
15	the	O
16	medical	O
17	imaging	O
18	techniques	O
19	.	O

1	Relationships	O
2	with	O
3	the	O
4	acquired	O
5	immune	O
6	deficiency	O
7	syndrome	O
8	.	O

1	Most	O
2	of	O
3	the	O
4	phenomena	O
5	of	O
6	azotaemic	O
7	osteodystrophy	O
8	are	O
9	encountered	O
10	in	O
11	simple	O
12	vitamin	O
13	D	O
14	deficiency	O
15	;	O
16	as	O
17	in	O
18	that	O
19	condition	O
20	,	O
21	deficiency	O
22	of	O
23	1	O
24	,	O
25	25	O
26	-	O
27	dihydroxycholecalciferol	O
28	may	O
29	be	O
30	of	O
31	primary	O
32	significance	O
33	in	O
34	causing	O
35	secondary	O
36	hyperparathyroidism	O
37	in	O
38	renal	O
39	failure	O
40	.	O

1	Preliminary	O
2	report	O
3	.	O

1	Analysis	O
2	with	O
3	additional	O
4	anti	O
5	-	O
6	peptide	O
7	antibodies	O
8	specific	O
9	for	O
10	alpha	B
11	,	I
12	beta	I
13	,	I
14	or	I
15	gamma	I
16	PKC	I
17	indicated	O
18	that	O
19	all	O
20	three	O
21	types	O
22	of	O
23	PKC	B
24	are	O
25	expressed	O
26	in	O
27	JK	O
28	cells	O
29	;	O
30	however	O
31	,	O
32	JKPE	O
33	cells	O
34	lost	O
35	a	O
36	major	O
37	approximately	O
38	82	O
39	kDa	O
40	immunoreactive	O
41	cytosolic	O
42	protein	O
43	detectable	O
44	with	O
45	anti	B
46	-	I
47	PKC	I
48	alpha	I
49	antibody	I
50	.	O

1	CM	B
2	-	I
3	ACO3	I
4	is	O
5	expressed	O
6	in	O
7	flowers	O
8	and	O
9	is	O
10	not	O
11	induced	O
12	by	O
13	any	O
14	of	O
15	the	O
16	stimuli	O
17	tested	O
18	.	O

1	Panlobular	O
2	emphysema	O

1	The	O
2	elevated	O
3	Viso	O
4	V	O
5	in	O
6	the	O
7	RDS	O
8	group	O
9	suggests	O
10	an	O
11	increase	O
12	in	O
13	small	O
14	airway	O
15	resistance	O
16	secondary	O
17	to	O
18	the	O
19	disease	O
20	or	O
21	to	O
22	its	O
23	therapy	O
24	.	O

1	The	O
2	roxithromycin	O
3	doses	O
4	that	O
5	were	O
6	chosen	O
7	for	O
8	these	O
9	studies	O
10	were	O
11	less	O
12	than	O
13	achievable	O
14	blood	O
15	levels	O
16	.	O

1	To	O
2	determine	O
3	the	O
4	true	O
5	molecular	O
6	identity	O
7	of	O
8	SFD	B
9	,	O
10	both	O
11	the	O
12	50	O
13	-	O
14	and	O
15	57	O
16	-	O
17	kDa	O
18	polypeptides	O
19	were	O
20	directly	O
21	sequenced	O
22	.	O

1	Muscular	O
2	pathology	O

1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	O
6	5	B
7	-	I
8	nucleotidase	I
9	.	O

1	The	O
2	partial	O
3	categories	O
4	of	O
5	the	O
6	SIP	O
7	that	O
8	were	O
9	more	O
10	affected	O
11	were	O
12	work	O
13	,	O
14	recreation	O
15	and	O
16	pastimes	O
17	,	O
18	home	O
19	management	O
20	,	O
21	and	O
22	sleep	O
23	and	O
24	rest	O
25	.	O

1	IST	B
2	is	O
3	not	O
4	the	O
5	RNA	O
6	target	O
7	(	O
8	TAR	O
9	)	O
10	for	O
11	Tat	B
12	trans	O
13	-	O
14	activation	O
15	;	O
16	however	O
17	,	O
18	because	O
19	it	O
20	relies	O
21	entirely	O
22	on	O
23	cellular	O
24	factors	O
25	for	O
26	activity	O
27	,	O
28	IST	B
29	may	O
30	serve	O
31	to	O
32	provide	O
33	abundant	O
34	RNA	O
35	targets	O
36	for	O
37	Tat	B
38	trans	O
39	-	O
40	activation	O
41	without	O
42	a	O
43	requirement	O
44	for	O
45	full	O
46	-	O
47	length	O
48	viral	O
49	mRNA	O
50	expression	O
51	.	O

1	In	O
2	Rat	O
3	-	O
4	1a	O
5	cells	O
6	the	O
7	expression	O
8	of	O
9	human	B
10	c	I
11	-	I
12	jun	I
13	mRNA	I
14	was	O
15	associated	O
16	with	O
17	the	O
18	ability	O
19	to	O
20	clone	O
21	in	O
22	soft	O
23	agarose	O
24	and	O
25	form	O
26	tumors	O
27	in	O
28	nude	O
29	mice	O
30	.	O

1	Therapeutic	O
2	action	O
3	of	O
4	a	O
5	new	O
6	antibiotic	O
7	-	O
8	corticoid	O
9	association	O
10	used	O
11	for	O
12	instillations	O
13	in	O
14	otology	O

1	Haplotype	O
2	mapping	O
3	and	O
4	sequence	O
5	analysis	O
6	of	O
7	the	O
8	mouse	O
9	Nramp	B
10	gene	I
11	predict	O
12	susceptibility	O
13	to	O
14	infection	O
15	with	O
16	intracellular	O
17	parasites	O
18	.	O

1	T	O
2	-	O
3	cell	O
4	hybridomas	O
5	,	O
6	thymocytes	O
7	,	O
8	and	O
9	T	O
10	cells	O
11	can	O
12	be	O
13	induced	O
14	to	O
15	undergo	O
16	apoptotic	O
17	cell	O
18	death	O
19	by	O
20	activation	O
21	through	O
22	the	O
23	T	B
24	-	I
25	cell	I
26	receptor	I
27	.	O

1	Rss1p	B
2	encodes	O
3	a	O
4	novel	O
5	essential	O
6	protein	O
7	of	O
8	538	O
9	amino	O
10	acids	O
11	,	O
12	which	O
13	contains	O
14	an	O
15	extended	O
16	predicted	O
17	coiled	O
18	-	O
19	coil	O
20	domain	O
21	and	O
22	is	O
23	located	O
24	both	O
25	at	O
26	nuclear	O
27	pore	O
28	complexes	O
29	(	O
30	NPCs	O
31	)	O
32	and	O
33	in	O
34	the	O
35	cytoplasm	O
36	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	serum	B
6	alpha1AT	I
7	quantitation	O
8	,	O
9	newborn	O
10	infants	O
11	may	O
12	be	O
13	separated	O
14	into	O
15	two	O
16	groups	O
17	,	O
18	characterized	O
19	respectively	O
20	by	O
21	concentrations	O
22	above	O
23	or	O
24	below	O
25	150	O
26	mg	O
27	%.	O

1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	CAS	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	estrone	O
17	(	O
18	CAS	O
19	53	O
20	-	O
21	16	O
22	-	O
23	7	O
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	menopause	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	transdermal	O
43	patch	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	enhancers	O
51	designed	O
52	for	O
53	epicutaneous	O
54	applications	O
55	of	O
56	7	O
57	days	O
58	(	O
59	hereinafter	O
60	called	O
61	"	O
62	patch	O
63	7D	O
64	").	O

1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	crossover	O
7	AM	O
8	between	O
9	dissimilar	O
10	textures	O
11	was	O
12	investigated	O
13	,	O
14	and	O
15	it	O
16	was	O
17	found	O
18	that	O
19	the	O
20	more	O
21	salient	O
22	textures	O
23	carried	O
24	the	O
25	AM	O
26	.	O

1	Differential	O
2	expression	O
3	and	O
4	regulation	O
5	by	O
6	20	O
7	-	O
8	hydroxyecdysone	O
9	of	O
10	mosquito	O
11	ultraspiracle	O
12	isoforms	O
13	.	O

1	The	O
2	patients	O
3	in	O
4	one	O
5	group	O
6	had	O
7	intrauterine	O
8	catheters	O
9	inserted	O
10	and	O
11	oxytocin	B
12	was	O
13	titrated	O
14	to	O
15	achieve	O
16	the	O
17	75th	O
18	percentile	O
19	of	O
20	uterine	O
21	activity	O
22	observed	O
23	in	O
24	spontaneous	O
25	normal	O
26	labour	O
27	according	O
28	to	O
29	parity	O
30	.	O

1	Exchange	O
2	of	O
3	the	O
4	LPL	B
5	and	O
6	HL	B
7	lids	O
8	resulted	O
9	in	O
10	a	O
11	reversal	O
12	of	O
13	the	O
14	phospholipase	B
15	/	O
16	neutral	O
17	lipase	B
18	ratio	O
19	,	O
20	establishing	O
21	the	O
22	important	O
23	role	O
24	of	O
25	this	O
26	region	O
27	in	O
28	mediating	O
29	substrate	O
30	specificity	O
31	.	O

1	This	O
2	sequence	O
3	is	O
4	almost	O
5	identical	O
6	with	O
7	that	O
8	of	O
9	human	B
10	luteinizing	I
11	hormone	I
12	(	O
13	Sairam	O
14	,	O
15	M	O
16	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	elongation	O
6	activity	O
7	,	O
8	ELL	B
9	contains	O
10	a	O
11	novel	O
12	type	O
13	of	O
14	RNA	B
15	polymerase	I
16	II	I
17	interaction	I
18	domain	I
19	that	O
20	is	O
21	capable	O
22	of	O
23	repressing	O
24	polymerase	O
25	activity	O
26	in	O
27	promoter	O
28	-	O
29	specific	O
30	transcription	O
31	.	O

1	Most	O
2	of	O
3	the	O
4	expressed	O
5	human	B
6	E3	I
7	polypeptides	I
8	(	O
9	five	O
10	bands	O
11	)	O
12	were	O
13	found	O
14	in	O
15	the	O
16	insoluble	O
17	pellet	O
18	while	O
19	primarily	O
20	full	B
21	-	I
22	length	I
23	mature	I
24	E3	I
25	was	O
26	found	O
27	in	O
28	the	O
29	soluble	O
30	fraction	O
31	.	O

1	The	O
2	gene	O
3	amplification	O
4	model	O
5	of	O
6	Coquelle	O
7	et	O
8	al	O
9	.	O

1	Finally	O
2	,	O
3	using	O
4	in	O
5	vitro	O
6	binding	O
7	studies	O
8	,	O
9	we	O
10	showed	O
11	that	O
12	SREBP2	B
13	was	O
14	able	O
15	to	O
16	displace	O
17	ADD1	B
18	/	O
19	SREBP1	B
20	binding	O
21	from	O
22	the	O
23	sterol	O
24	regulatory	O
25	element	O
26	(	O
27	SRE	O
28	)	O
29	site	O
30	.	O

1	Magnetic	O
2	resonance	O
3	spectroscopy	O
4	(	O
5	MRS	O
6	)	O
7	and	O
8	imaging	O
9	(	O
10	MRI	O
11	)	O
12	are	O
13	now	O
14	well	O
15	established	O
16	techniques	O
17	for	O
18	the	O
19	study	O
20	of	O
21	cellular	O
22	metabolism	O
23	and	O
24	gross	O
25	structure	O
26	of	O
27	muscle	O
28	.	O

1	Progression	O
2	after	O
3	first	O
4	-	O
5	line	O
6	chemotherapy	O
7	was	O
8	associated	O
9	with	O
10	significantly	O
11	worse	O
12	survival	O
13	for	O
14	patients	O
15	with	O
16	metastasis	O
17	.	O

1	The	O
2	structural	O
3	gene	O
4	encoding	O
5	the	O
6	novel	O
7	lantibiotic	O
8	epilancin	B
9	K7	I
10	from	O
11	Staphylococcus	O
12	epidermidis	O
13	K7	O
14	was	O
15	cloned	O
16	and	O
17	its	O
18	nucleotide	O
19	sequence	O
20	was	O
21	determined	O
22	.	O

1	UbiA	B
2	is	O
3	also	O
4	unique	O
5	among	O
6	known	O
7	polyubiquitin	B
8	genes	I
9	in	O
10	containing	O
11	four	O
12	cis	O
13	-	O
14	spliced	O
15	introns	O
16	within	O
17	its	O
18	coding	O
19	sequence	O
20	.	O

1	Latexin	B
2	,	O
3	a	O
4	carboxypeptidase	B
5	A	I
6	inhibitor	O
7	,	O
8	is	O
9	expressed	O
10	in	O
11	a	O
12	cell	O
13	type	O
14	-	O
15	specific	O
16	manner	O
17	in	O
18	both	O
19	central	O
20	and	O
21	peripheral	O
22	nervous	O
23	systems	O
24	in	O
25	the	O
26	rat	O
27	.	O

1	DAF16	B
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	O
25	IGF	B
26	-	I
27	1	I
28	receptor	I
29	,	O
30	PtdIns	B
31	3	I
32	-	I
33	kinase	I
34	and	O
35	PKB	B
36	.	O

1	Seventeen	O
2	of	O
3	them	O
4	were	O
5	on	O
6	treatment	O
7	with	O
8	systemic	O
9	steroids	O
10	.	O

1	However	O
2	,	O
3	D8	B
4	binding	O
5	was	O
6	observed	O
7	by	O
8	nuclease	O
9	protection	O
10	with	O
11	lactotroph	B
12	-	I
13	as	I
14	well	I
15	as	I
16	somatotroph	I
17	-	I
18	like	I
19	cell	I
20	nuclear	I
21	protein	I
22	.	O

1	A	O
2	new	O
3	,	O
4	flexible	O
5	fiberoptic	O
6	ventriculoscope	O
7	for	O
8	observation	O
9	of	O
10	the	O
11	ventricles	O
12	and	O
13	major	O
14	cisterns	O
15	is	O
16	reported	O
17	.	O

1	Acid	O
2	instilled	O
3	on	O
4	the	O
5	larynx	O
6	of	O
7	maturing	O
8	rabbits	O
9	resulted	O
10	in	O
11	significant	O
12	obstructive	O
13	,	O
14	central	O
15	,	O
16	and	O
17	mixed	O
18	apnea	O
19	.	O

1	In	O
2	ICU	O
3	patients	O
4	,	O
5	the	O
6	LIS	O
7	related	O
8	to	O
9	the	O
10	postoperative	O
11	rise	O
12	in	O
13	IL	B
14	-	I
15	6	I
16	level	O
17	only	O
18	,	O
19	even	O
20	though	O
21	the	O
22	rise	O
23	in	O
24	plasma	O
25	concentrations	O
26	of	O
27	cytokines	O
28	interrelated	O
29	.	O

1	Examples	O
2	of	O
3	its	O
4	use	O
5	in	O
6	the	O
7	intensive	O
8	therapy	O
9	unit	O
10	are	O
11	described	O
12	.	O

1	SPA	O
2	from	O
3	PAG	O
4	sites	O
5	was	O
6	associated	O
7	with	O
8	aversion	O
9	.	O

1	In	O
2	whole	O
3	sardine	O
4	,	O
5	domoic	O
6	acid	O
7	was	O
8	detected	O
9	in	O
10	levels	O
11	exceeding	O
12	sometimes	O
13	the	O
14	regulatory	O
15	limit	O
16	.	O

1	Cocaine	O
2	-	O
3	treated	O
4	rats	O
5	acquired	O
6	a	O
7	preference	O
8	for	O
9	cocaine	O
10	-	O
11	associated	O
12	contextual	O
13	stimuli	O
14	(	O
15	CS	O
16	)	O
17	relative	O
18	to	O
19	saline	O
20	-	O
21	injected	O
22	control	O
23	rats	O
24	.	O

1	Serum	O
2	leptin	B
3	concentrations	O
4	in	O
5	women	O
6	during	O
7	gonadotropin	B
8	stimulation	O
9	cycles	O
10	.	O

1	The	O
2	cytogenetic	O
3	expression	O
4	of	O
5	the	O
6	folate	O
7	sensitive	O
8	fragile	O
9	site	O
10	,	O
11	FRAXE	B
12	,	O
13	is	O
14	due	O
15	to	O
16	the	O
17	expansion	O
18	of	O
19	a	O
20	GCC	O
21	repeat	O
22	in	O
23	proximal	O
24	Xq28	O
25	of	O
26	the	O
27	human	O
28	X	O
29	chromosome	O
30	and	O
31	is	O
32	associated	O
33	with	O
34	a	O
35	mild	O
36	form	O
37	of	O
38	mental	O
39	handicap	O
40	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	-	I
5	alpha	I
6	(	O
7	TNF	B
8	alpha	I
9	)	O
10	is	O
11	one	O
12	of	O
13	several	O
14	autocrine	O
15	/	O
16	paracrine	O
17	factors	O
18	known	O
19	to	O
20	exert	O
21	potent	O
22	inhibitory	O
23	effects	O
24	on	O
25	bone	O
26	.	O

1	Since	O
2	one	O
3	group	O
4	of	O
5	adolescents	O
6	more	O
7	difficult	O
8	to	O
9	influence	O
10	are	O
11	those	O
12	whose	O
13	parents	O
14	smoke	O
15	,	O
16	parental	O
17	involvement	O
18	in	O
19	smoking	O
20	prevention	O
21	may	O
22	be	O
23	a	O
24	powerful	O
25	enhancer	O
26	.	O

1	Genetic	O
2	studies	O
3	in	O
4	Drosophila	O
5	have	O
6	led	O
7	to	O
8	the	O
9	identification	O
10	of	O
11	several	O
12	components	O
13	of	O
14	the	O
15	Notch	B
16	pathway	O
17	.	O

1	This	O
2	result	O
3	indicates	O
4	that	O
5	separate	O
6	complexes	O
7	exist	O
8	containing	O
9	ankyrin	B
10	and	O
11	fodrin	B
12	with	O
13	either	O
14	uvomorulin	B
15	or	O
16	Na	B
17	+,	I
18	K	I
19	+-	I
20	ATPase	I
21	.	O

1	Here	O
2	the	O
3	cloning	O
4	and	O
5	molecular	O
6	analysis	O
7	of	O
8	the	O
9	Zm	B
10	-	I
11	ERabp1	I
12	,	O
13	Zm	B
14	-	I
15	ERabp4	I
16	,	O
17	and	O
18	Zm	B
19	-	I
20	ERabp5	I
21	genes	I
22	is	O
23	presented	O
24	.	O

1	Partial	O
2	correction	O
3	of	O
4	anemia	O
5	with	O
6	recombinant	B
7	human	I
8	erythropoietin	I
9	likely	O
10	reduces	O
11	left	O
12	ventricular	O
13	mass	O
14	and	O
15	volume	O
16	.	O

1	Estrogen	O
2	replacement	O
3	therapy	O
4	and	O
5	risk	O
6	of	O
7	breast	O
8	cancer	O
9	:	O
10	results	O
11	of	O
12	two	O
13	meta	O
14	-	O
15	analyses	O
16	.	O

1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	O
8	-	O
9	threonine	O
10	-	O
11	rich	O
12	peptides	O
13	.	O

1	Fructokinase	B
2	activity	O
3	is	O
4	elevated	O
5	up	O
6	to	O
7	twofold	O
8	when	O
9	Z	O
10	.	O
11	mobilis	O
12	was	O
13	grown	O
14	on	O
15	fructose	O
16	instead	O
17	of	O
18	glucose	O
19	,	O
20	and	O
21	there	O
22	was	O
23	a	O
24	parallel	O
25	increase	O
26	in	O
27	frk	B
28	mRNA	I
29	levels	O
30	.	O

1	Three	O
2	different	O
3	site	O
4	-	O
5	directed	O
6	mutations	O
7	of	O
8	the	O
9	cyclic	O
10	AMP	O
11	response	O
12	element	O
13	each	O
14	reduced	O
15	the	O
16	nerve	B
17	growth	I
18	factor	I
19	effect	O
20	by	O
21	>	O
22	90	O
23	%.	O

1	Comparison	O
2	of	O
3	1	O
4	.	O
5	5	O
6	Tesla	O
7	and	O
8	0	O
9	.	O
10	35	O
11	Tesla	O
12	field	O
13	strength	O
14	magnetic	O
15	resonance	O
16	imaging	O
17	scans	O
18	in	O
19	the	O
20	morphometric	O
21	evaluation	O
22	of	O
23	the	O
24	lumbar	O
25	intervertebral	O
26	foramina	O
27	.	O

1	The	O
2	Psc2	B
3	cDNA	I
4	contained	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	homologous	O
10	to	O
11	CP2	B
12	family	I
13	proteins	I
14	.	O

1	Studies	O
2	on	O
3	the	O
4	life	O
5	cycle	O
6	of	O
7	Haplorchis	O
8	pumilio	O
9	(	O
10	Looss	O
11	,	O
12	1896	O
13	)	O
14	Looss	O
15	,	O
16	1899	O
17	with	O
18	morphological	O
19	redescription	O
20	of	O
21	larval	O
22	and	O
23	adult	O
24	stages	O
25	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	domain	O
6	of	O
7	approximately	O
8	70	O
9	kDa	O
10	exhibits	O
11	11	O
12	imperfect	O
13	amino	O
14	acid	O
15	repeats	O
16	that	O
17	show	O
18	some	O
19	homology	O
20	to	O
21	promastigote	O
22	surface	O
23	glycoproteins	O
24	of	O
25	the	O
26	psa2	B
27	/	O
28	gp46	B
29	complex	O
30	.	O

1	None	O
2	of	O
3	the	O
4	patients	O
5	was	O
6	obese	O
7	.	O

1	Strikingly	O
2	,	O
3	this	O
4	subdomain	O
5	is	O
6	also	O
7	present	O
8	in	O
9	the	O
10	otherwise	O
11	unrelated	O
12	N	O
13	-	O
14	terminal	O
15	activating	O
16	region	O
17	of	O
18	p58c	B
19	-	I
20	ets	I
21	-	I
22	2	I
23	and	O
24	was	O
25	thus	O
26	named	O
27	BEC	B
28	for	O
29	Ets	B
30	-	I
31	1	I
32	-	I
33	beta	I
34	/	O
35	Ets	B
36	-	I
37	2	I
38	-	I
39	Conserved	I
40	sequence	I
41	.	O

1	Plasma	O
2	thromboxane	O
3	B2	O
4	levels	O
5	in	O
6	the	O
7	older	O
8	group	O
9	were	O
10	about	O
11	double	O
12	those	O
13	in	O
14	younger	O
15	piglets	O
16	.	O

1	Under	O
2	these	O
3	schedules	O
4	,	O
5	a	O
6	reinforced	O
7	response	O
8	run	O
9	consisted	O
10	of	O
11	responding	O
12	between	O
13	eight	O
14	and	O
15	12	O
16	times	O
17	on	O
18	one	O
19	response	O
20	key	O
21	(	O
22	work	O
23	key	O
24	)	O
25	and	O
26	then	O
27	responding	O
28	once	O
29	on	O
30	a	O
31	second	O
32	response	O
33	key	O
34	(	O
35	reinforced	O
36	key	O
37	).	O

1	The	O
2	high	O
3	level	O
4	of	O
5	transformation	O
6	-	O
7	associated	O
8	deletions	O
9	in	O
10	the	O
11	human	O
12	YACs	O
13	was	O
14	reduced	O
15	over	O
16	10	O
17	-	O
18	fold	O
19	when	O
20	the	O
21	host	O
22	was	O
23	a	O
24	recombination	O
25	-	O
26	deficient	O
27	strain	O
28	deleted	O
29	for	O
30	the	O
31	RAD52	B
32	gene	I
33	.	O

1	The	O
2	response	O
3	chain	O
4	in	O
5	each	O
6	component	O
7	was	O
8	maintained	O
9	by	O
10	food	O
11	presentation	O
12	under	O
13	a	O
14	fixed	O
15	-	O
16	ratio	O
17	schedule	O
18	.	O

1	Phylogenetic	O
2	position	O
3	of	O
4	the	O
5	Phacotaceae	O
6	within	O
7	the	O
8	Chlamydophyceaeas	O
9	revealed	O
10	by	O
11	analysis	O
12	of	O
13	18S	B
14	rDNA	I
15	and	O
16	rbcL	B
17	sequences	I
18	.	O

1	The	O
2	interferon	B
3	-	O
4	inducible	O
5	protein	B
6	kinase	I
7	PKR	I
8	modulates	O
9	the	O
10	transcriptional	O
11	activation	O
12	of	O
13	immunoglobulin	B
14	kappa	I
15	gene	I
16	.	O

1	When	O
2	examined	O
3	as	O
4	adults	O
5	(	O
6	8	O
7	weeks	O
8	old	O
9	),	O
10	the	O
11	external	O
12	genitalia	O
13	of	O
14	TA	O
15	-	O
16	exposed	O
17	offspring	O
18	were	O
19	normal	O
20	.	O

1	Dietary	O
2	supplement	O
3	with	O
4	fish	O
5	oil	O
6	and	O
7	related	O
8	n	O
9	-	O
10	3	O
11	EFAs	O
12	has	O
13	been	O
14	used	O
15	to	O
16	study	O
17	their	O
18	antihypertensive	O
19	property	O
20	in	O
21	animals	O
22	and	O
23	humans	O
24	with	O
25	borderline	O
26	and	O
27	essential	O
28	hypertension	O
29	.	O

1	The	O
2	TUP1	B
3	gene	I
4	was	O
5	isolated	O
6	in	O
7	a	O
8	screen	O
9	for	O
10	genes	O
11	that	O
12	regulate	O
13	mating	O
14	type	O
15	(	O
16	V	O
17	.	O
18	L	O
19	.	O

1	Serum	O
2	and	O
3	peritoneal	O
4	dialysis	O
5	fluid	O
6	(	O
7	PDF	O
8	)	O
9	were	O
10	collected	O
11	for	O
12	assay	O
13	throughout	O
14	the	O
15	course	O
16	of	O
17	the	O
18	study	O
19	and	O
20	for	O
21	5	O
22	days	O
23	thereafter	O
24	.	O

1	Human	O
2	isoforms	O
3	,	O
4	designated	O
5	1	O
6	to	O
7	4	O
8	,	O
9	differ	O
10	from	O
11	each	O
12	other	O
13	by	O
14	the	O
15	start	O
16	codon	O
17	used	O
18	.	O

1	Moreover	O
2	,	O
3	the	O
4	reconstitution	O
5	of	O
6	eUSF	B
7	and	O
8	TFIID	B
9	-	O
10	depleted	O
11	transcription	O
12	complexes	O
13	with	O
14	purified	O
15	protein	O
16	fractions	O
17	demonstrate	O
18	that	O
19	not	O
20	only	O
21	TFIID	B
22	but	O
23	also	O
24	eUSF	B
25	essentially	O
26	participates	O
27	in	O
28	complex	O
29	formation	O
30	even	O
31	on	O
32	H5	B
33	promoter	I
34	mutations	O
35	lacking	O
36	the	O
37	TATA	O
38	-	O
39	box	O
40	.	O

1	All	O
2	patients	O
3	in	O
4	the	O
5	control	O
6	group	O
7	showed	O
8	a	O
9	significant	O
10	improvement	O
11	in	O
12	their	O
13	PEFR	O
14	while	O
15	only	O
16	3	O
17	patients	O
18	in	O
19	the	O
20	treated	O
21	group	O
22	showed	O
23	an	O
24	improvement	O
25	.	O

1	All	O
2	six	O
3	genes	O
4	were	O
5	cloned	O
6	and	O
7	characterised	O
8	.	O

1	Comparison	O
2	with	O
3	a	O
4	recently	O
5	described	O
6	c	B
7	-	I
8	sis	I
9	cDNA	I
10	clone	I
11	(	O
12	Collins	O
13	et	O
14	al	O
15	.,	O
16	Nature	O
17	316	O
18	,	O
19	748	O
20	-	O
21	750	O
22	(	O
23	1985	O
24	))	O
25	revealed	O
26	that	O
27	the	O
28	1	O
29	.	O
30	9	O
31	kbp	O
32	DNA	O
33	region	O
34	contained	O
35	a	O
36	large	O
37	5	B
38	'	I
39	c	I
40	-	I
41	sis	I
42	exon	I
43	of	O
44	at	O
45	least	O
46	1050	O
47	bp	O
48	.	O

1	Cooperative	O
2	dimerization	O
3	of	O
4	paired	B
5	class	O
6	homeo	O
7	domains	O
8	on	O
9	DNA	O
10	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	showed	O
5	that	O
6	site	O
7	A	O
8	is	O
9	necessary	O
10	and	O
11	sufficient	O
12	for	O
13	RXR	B
14	alpha	I
15	-	O
16	mediated	O
17	transactivation	O
18	of	O
19	the	O
20	apoAI	B
21	gene	I
22	basal	I
23	promoter	I
24	in	O
25	human	O
26	hepatoma	O
27	HepG2	O
28	cells	O
29	in	O
30	the	O
31	presence	O
32	of	O
33	RA	O
34	and	O
35	that	O
36	this	O
37	transactivation	O
38	is	O
39	abolished	O
40	by	O
41	increasing	O
42	amounts	O
43	of	O
44	cotransfected	O
45	ARP	B
46	-	I
47	1	I
48	.	O

1	Calcification	O
2	of	O
3	a	O
4	cariogenic	O
5	Streptococcus	O
6	and	O
7	of	O
8	Corynebacterium	O
9	(	O
10	Bacterionema	O
11	)	O
12	matruchotii	O
13	.	O

1	Synchronous	O
2	extracts	O
3	showed	O
4	no	O
5	significant	O
6	migration	O
7	inhibition	O
8	in	O
9	allogeneic	O
10	assays	O
11	.	O

1	Furthermore	O
2	,	O
3	the	O
4	use	O
5	of	O
6	zero	O
7	-	O
8	loss	O
9	filtering	O
10	in	O
11	combination	O
12	with	O
13	exit	O
14	wavefront	O
15	reconstruction	O
16	is	O
17	considerably	O
18	more	O
19	effective	O
20	at	O
21	removing	O
22	the	O
23	effects	O
24	of	O
25	multiple	O
26	elastic	O
27	and	O
28	inelastic	O
29	scattering	O
30	and	O
31	microscope	O
32	objective	O
33	lens	O
34	aberrations	O
35	than	O
36	either	O
37	technique	O
38	by	O
39	itself	O
40	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	both	O
6	in	O
7	the	O
8	early	O
9	stages	O
10	(	O
11	0T	O
12	,	O
13	0N	O
14	)	O
15	and	O
16	in	O
17	more	O
18	severe	O
19	stages	O
20	of	O
21	VWF	O
22	(	O
23	stages	O
24	1	O
25	-	O
26	2	O
27	)	O
28	cold	O
29	induced	O
30	hyperreactivity	O
31	in	O
32	the	O
33	digital	O
34	vessels	O
35	and	O
36	Raynaud	O
37	'	O
38	s	O
39	syndrome	O
40	are	O
41	vascular	O
42	disorders	O
43	of	O
44	functional	O
45	origin	O
46	occurring	O
47	without	O
48	any	O
49	prethrombotic	O
50	alterations	O
51	.	O

1	E1A	B
2	autoactivation	O
3	mediated	O
4	by	O
5	these	O
6	sites	O
7	was	O
8	about	O
9	twofold	O
10	compared	O
11	with	O
12	a	O
13	ninefold	O
14	activation	O
15	described	O
16	for	O
17	the	O
18	complete	O
19	E1A	B
20	promoter	I
21	.	O

1	This	O
2	result	O
3	suggests	O
4	that	O
5	phosphorylation	O
6	of	O
7	Thr	O
8	14	O
9	and	O
10	/	O
11	or	O
12	Tyr	O
13	15	O
14	inhibits	O
15	p34cdc2	B
16	kinase	I
17	activity	O
18	,	O
19	in	O
20	line	O
21	with	O
22	the	O
23	location	O
24	of	O
25	these	O
26	residues	O
27	within	O
28	the	O
29	putative	O
30	ATP	O
31	binding	O
32	site	O
33	of	O
34	the	O
35	kinase	O
36	.	O

1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	O
7	greatly	O
8	reduced	O
9	the	O
10	association	O
11	of	O
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	B
20	.	O

1	A	O
2	platelet	B
3	-	I
4	derived	I
5	growth	I
6	factor	I
7	receptor	I
8	(	O
9	PDGF	B
10	-	I
11	R	I
12	)	O
13	phosphopeptide	O
14	containing	O
15	Tyr	O
16	-	O
17	857	O
18	does	O
19	not	O
20	bind	O
21	appreciably	O
22	to	O
23	the	O
24	Src	B
25	SH2	I
26	domain	I
27	,	O
28	suggesting	O
29	it	O
30	is	O
31	not	O
32	the	O
33	PDGF	B
34	-	I
35	R	I
36	binding	O
37	site	O
38	for	O
39	Src	B
40	as	O
41	previously	O
42	reported	O
43	.	O

1	A	O
2	polymorphic	O
3	bipartite	O
4	motif	O
5	signals	O
6	nuclear	O
7	targeting	O
8	of	O
9	early	O
10	auxin	O
11	-	O
12	inducible	O
13	proteins	O
14	related	O
15	to	O
16	PS	O
17	-	O
18	IAA4	O
19	from	O
20	pea	O
21	(	O
22	Pisum	O
23	sativum	O
24	).	O

1	A	O
2	p21	B
3	peptide	I
4	spanning	O
5	amino	O
6	acids	O
7	139	O
8	-	O
9	164	O
10	was	O
11	found	O
12	to	O
13	bind	O
14	PCNA	B
15	in	O
16	a	O
17	filter	O
18	binding	O
19	assay	O
20	and	O
21	this	O
22	peptide	O
23	suppressed	O
24	recombinant	O
25	p21	B
26	-	O
27	PCNA	B
28	interaction	O
29	.	O

1	Copyright	O
2	1998	O
3	Academic	O
4	Press	O
5	.	O

1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	[	O
6	Hisanaga	O
7	,	O
8	S	O
9	.,	O
10	Kusubata	O
11	,	O
12	M	O
13	.,	O
14	Okumura	O
15	,	O
16	E	O
17	.	O
18	&	O
19	Kishimoto	O
20	,	O
21	T	O
22	.	O

1	Three	O
2	FGF	B
3	-	I
4	AS	I
5	cDNAs	I
6	were	O
7	isolated	O
8	;	O
9	the	O
10	full	B
11	-	I
12	length	I
13	FGF	I
14	-	I
15	AS	I
16	mRNA	I
17	and	O
18	two	O
19	alternative	O
20	splice	O
21	variants	O
22	lacking	O
23	exon	O
24	2	O
25	or	O
26	exons	O
27	2	O
28	and	O
29	3	O
30	of	O
31	the	O
32	FGF	B
33	-	I
34	AS	I
35	sequence	I
36	.	O

1	Diacylglycerol	B
2	kinase	I
3	(	O
4	DGK	B
5	)	O
6	attenuates	O
7	levels	O
8	of	O
9	second	O
10	messenger	O
11	diacylglycerol	O
12	in	O
13	cells	O
14	and	O
15	produces	O
16	another	O
17	(	O
18	putative	O
19	)	O
20	messenger	O
21	,	O
22	phosphatidic	O
23	acid	O
24	.	O

1	Thomas	O
2	'	O
3	Hospital	O
4	solution	O
5	(	O
6	with	O
7	95	O
8	%	O
9	O2	O
10	:	O
11	5	O
12	%	O
13	CO2	O
14	)	O
15	can	O
16	meet	O
17	the	O
18	metabolic	O
19	demand	O
20	of	O
21	the	O
22	ischaemic	O
23	myocardium	O
24	and	O
25	thus	O
26	increase	O
27	the	O
28	safe	O
29	duration	O
30	of	O
31	cardiac	O
32	arrest	O
33	.	O

1	Furthermore	O
2	,	O
3	the	O
4	potency	O
5	of	O
6	Dacarbacine	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	carcinoid	O
12	tumors	O
13	seems	O
14	to	O
15	be	O
16	underestimated	O
17	up	O
18	to	O
19	now	O
20	.	O

1	The	O
2	identification	O
3	of	O
4	viable	O
5	myocardium	O
6	with	O
7	both	O
8	99mTc	O
9	-	O
10	tetrofosmin	O
11	and	O
12	201Tl	O
13	can	O
14	be	O
15	greatly	O
16	enhanced	O
17	to	O
18	a	O
19	similar	O
20	degree	O
21	if	O
22	the	O
23	severity	O
24	of	O
25	reduction	O
26	in	O
27	activity	O
28	within	O
29	nonreversible	O
30	defects	O
31	is	O
32	considered	O
33	.	O

1	We	O
2	found	O
3	that	O
4	TCR	B
5	signaling	O
6	induces	O
7	AP	B
8	-	I
9	1	I
10	binding	O
11	to	O
12	this	O
13	site	O
14	and	O
15	regulates	O
16	the	O
17	fasl	B
18	promoter	I
19	function	O
20	in	O
21	a	O
22	fashion	O
23	dependent	O
24	on	O
25	NF	B
26	-	I
27	kappaB	I
28	binding	O
29	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	combined	O
6	lesions	O
7	of	O
8	cholinergic	O
9	and	O
10	serotonergic	O
11	neurons	O
12	in	O
13	the	O
14	rat	O
15	brain	O
16	do	O
17	not	O
18	alter	O
19	olfactory	O
20	perception	O
21	or	O
22	olfactory	O
23	short	O
24	-	O
25	term	O
26	memory	O
27	.	O

1	Control	O
2	intact	O
3	rats	O
4	were	O
5	age	O
6	-	O
7	matched	O
8	to	O
9	the	O
10	different	O
11	treated	O
12	groups	O
13	.	O

1	The	O
2	IgG	B
3	subclass	O
4	profile	O
5	of	O
6	untreated	O
7	coeliac	O
8	disease	O
9	was	O
10	found	O
11	to	O
12	be	O
13	the	O
14	same	O
15	as	O
16	in	O
17	healthy	O
18	controls	O
19	(	O
20	IgG1	B
21	approximately	O
22	IgG2	B
23	>	O
24	IgG3	B
25	>	O
26	IgG4	B
27	),	O
28	with	O
29	only	O
30	the	O
31	magnitude	O
32	of	O
33	the	O
34	individual	O
35	subclass	O
36	responses	O
37	being	O
38	increased	O
39	in	O
40	coeliac	O
41	patients	O
42	.	O

1	A	O
2	protocol	O
3	is	O
4	elaborated	O
5	for	O
6	the	O
7	preparation	O
8	and	O
9	characterization	O
10	of	O
11	a	O
12	quality	O
13	control	O
14	material	O
15	(	O
16	QCM	O
17	)	O
18	containing	O
19	intrinsic	O
20	concentration	O
21	of	O
22	cadmium	O
23	(	O
24	Cd	O
25	)	O
26	(	O
27	0	O
28	.	O
29	8	O
30	microgram	O
31	/	O
32	L	O
33	)	O
34	and	O
35	lead	O
36	(	O
37	Pb	O
38	)	O
39	(	O
40	13	O
41	.	O
42	4	O
43	micrograms	O
44	/	O
45	dL	O
46	)	O
47	from	O
48	bovine	O
49	blood	O
50	and	O
51	an	O
52	elevated	O
53	QCM	O
54	containing	O
55	Cd	O
56	(	O
57	5	O
58	.	O
59	0	O
60	micrograms	O
61	/	O
62	L	O
63	),	O
64	mercury	O
65	(	O
66	Hg	O
67	)	O
68	(	O
69	11	O
70	.	O
71	2	O
72	micrograms	O
73	/	O
74	L	O
75	),	O
76	and	O
77	Pb	O
78	(	O
79	34	O
80	.	O
81	5	O
82	micrograms	O
83	/	O
84	dL	O
85	)	O
86	from	O
87	bovine	O
88	blood	O
89	spiked	O
90	with	O
91	aqueous	O
92	spiking	O
93	-	O
94	solutions	O
95	prepared	O
96	with	O
97	salts	O
98	of	O
99	Cd	O
100	,	O
101	Hg	O
102	,	O
103	and	O
104	Pb	O
105	.	O

1	GCD10	B
2	was	O
3	first	O
4	identified	O
5	genetically	O
6	as	O
7	a	O
8	translational	O
9	repressor	O
10	of	O
11	GCN4	B
12	.	O

1	2	O
2	-	O
3	Chemical	O
4	occlusion	O
5	of	O
6	vas	O
7	is	O
8	quite	O
9	effective	O
10	in	O
11	producing	O
12	a	O
13	block	O
14	in	O
15	the	O
16	vas	O
17	deferens	O
18	of	O
19	dogs	O
20	.	O

1	ALT	B
2	levels	O
3	in	O
4	responders	O
5	were	O
6	lowered	O
7	by	O
8	46	O
9	%	O
10	and	O
11	AST	B
12	levels	O
13	were	O
14	lowered	O
15	by	O
16	35	O
17	%	O
18	after	O
19	12	O
20	weeks	O
21	of	O
22	vitamin	O
23	E	O
24	treatment	O
25	.	O

1	The	O
2	effects	O
3	of	O
4	two	O
5	levels	O
6	of	O
7	caffeine	O
8	ingestion	O
9	on	O
10	excess	O
11	postexercise	O
12	oxygen	O
13	consumption	O
14	in	O
15	untrained	O
16	women	O
17	.	O

1	To	O
2	do	O
3	this	O
4	,	O
5	segments	O
6	of	O
7	DNA	O
8	from	O
9	the	O
10	5	O
11	'	O
12	flank	O
13	of	O
14	the	O
15	initiation	O
16	sites	O
17	for	O
18	germline	O
19	epsilon	O
20	RNA	O
21	were	O
22	ligated	O
23	to	O
24	a	O
25	luciferase	B
26	reporter	I
27	gene	I
28	and	O
29	transfected	O
30	into	O
31	two	O
32	mouse	O
33	B	O
34	cell	O
35	lines	O
36	,	O
37	one	O
38	of	O
39	which	O
40	can	O
41	be	O
42	induced	O
43	to	O
44	switch	O
45	to	O
46	IgE	B
47	.	O

1	The	O
2	enzyme	O
3	displays	O
4	optimal	O
5	activity	O
6	at	O
7	about	O
8	0	O
9	.	O
10	5	O
11	mM	O
12	pantoate	O
13	(	O
14	k	O
15	(	O
16	cat	O
17	)	O
18	0	O
19	.	O
20	63	O
21	s	O
22	(-	O
23	1	O
24	))	O
25	and	O
26	at	O
27	pH	O
28	7	O
29	.	O
30	8	O
31	.	O

1	The	O
2	concentrations	O
3	of	O
4	plasma	O
5	ACTH	B
6	and	O
7	cortisol	O
8	increased	O
9	by	O
10	40	O
11	%	O
12	and	O
13	60	O
14	%	O
15	after	O
16	MPTP	O
17	treatment	O
18	,	O
19	respectively	O
20	.	O

1	Daily	O
2	and	O
3	seasonal	O
4	rhythmicity	O
5	in	O
6	the	O
7	methylation	O
8	of	O
9	pineal	O
10	indolic	O
11	compounds	O
12	in	O
13	adult	O
14	male	O
15	golden	O
16	hamsters	O
17	,	O
18	kept	O
19	under	O
20	natural	O
21	conditions	O
22	.	O

1	The	O
2	hypertension	O
3	with	O
4	elevated	O
5	PRA	O
6	,	O
7	however	O
8	,	O
9	was	O
10	resistant	O
11	to	O
12	the	O
13	angiotensin	B
14	II	I
15	(	O
16	AII	B
17	)	O
18	analog	O
19	[	O
20	Sar1	O
21	,	O
22	Ile8	O
23	]	O
24	ALL	O
25	.	O

1	The	O
2	mRNAs	O
3	of	O
4	the	O
5	GRF	B
6	genes	I
7	are	O
8	encoded	O
9	by	O
10	six	O
11	exons	O
12	interrupted	O
13	by	O
14	five	O
15	introns	O
16	.	O

1	Hydroxypropyl	O
2	methacrylate	O
3	,	O
4	a	O
5	new	O
6	water	O
7	-	O
8	miscible	O
9	embedding	O
10	medium	O
11	for	O
12	electron	O
13	microscopy	O
14	.	O

1	Transcription	O
2	factor	O
3	binding	O
4	sites	O
5	downstream	O
6	of	O
7	the	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	type	O
12	1	O
13	transcription	O
14	start	O
15	site	O
16	are	O
17	important	O
18	for	O
19	virus	O
20	infectivity	O
21	.	O

1	We	O
2	determined	O
3	whether	O
4	the	O
5	human	B
6	StAR	I
7	promoter	I
8	is	O
9	responsive	O
10	to	O
11	sterol	B
12	regulatory	I
13	element	I
14	-	I
15	binding	I
16	proteins	I
17	(	O
18	SREBPs	B
19	).	O

1	Peripheral	O
2	vitreochorioretinal	O
3	dystrophies	O
4	in	O
5	myopia	O
6	patients	O

1	During	O
2	the	O
3	1980	O
4	'	O
5	s	O
6	,	O
7	quantifications	O
8	of	O
9	immunoserological	O
10	testings	O
11	,	O
12	especially	O
13	C	B
14	reactive	I
15	protein	I
16	,	O
17	rheumatoid	B
18	factor	I
19	and	O
20	antistreptolysin	B
21	O	I
22	,	O
23	progressed	O
24	rapidly	O
25	.	O

1	Ivermectin	O
2	uptake	O
3	and	O
4	distribution	O
5	in	O
6	the	O
7	plasma	O
8	and	O
9	tissue	O
10	of	O
11	Sudanese	O
12	and	O
13	Mexican	O
14	patients	O
15	infected	O
16	with	O
17	Onchocerca	O
18	volvulus	O
19	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	CDC2	B
9	-	I
10	related	I
11	kinase	I
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	B
17	yeast	I
18	cdc28	I
19	mutation	O
20	.	O

1	The	O
2	prevalence	O
3	and	O
4	incidence	O
5	of	O
6	human	O
7	immunodeficiency	O
8	virus	O
9	types	O
10	1	O
11	and	O
12	2	O
13	(	O
14	HIV	O
15	-	O
16	1	O
17	,	O
18	HIV	O
19	-	O
20	2	O
21	),	O
22	human	O
23	T	O
24	-	O
25	lymphotropic	O
26	virus	O
27	types	O
28	I	O
29	and	O
30	II	O
31	(	O
32	HTLV	O
33	-	O
34	I	O
35	/	O
36	II	O
37	),	O
38	and	O
39	syphilitic	O
40	infections	O
41	and	O
42	the	O
43	association	O
44	between	O
45	these	O
46	infections	O
47	were	O
48	determined	O
49	in	O
50	a	O
51	cohort	O
52	of	O
53	police	O
54	officers	O
55	in	O
56	Guinea	O
57	-	O
58	Bissau	O
59	.	O

1	Gel	O
2	-	O
3	mobility	O
4	shift	O
5	analysis	O
6	was	O
7	also	O
8	performed	O
9	for	O
10	the	O
11	CCAAT	O
12	motif	O
13	at	O
14	-	O
15	67	O
16	.	O

1	TNF	B
2	-	I
3	alpha	I
4	exposure	O
5	markedly	O
6	increased	O
7	activity	O
8	of	O
9	several	O
10	RNA	O
11	-	O
12	binding	O
13	proteins	O
14	,	O
15	especially	O
16	a	O
17	novel	O
18	Mr	O
19	50	O
20	,	O
21	000	O
22	-	O
23	55	O
24	,	O
25	000	O
26	RNA	O
27	-	O
28	binding	O
29	protein	O
30	.	O

1	This	O
2	finding	O
3	is	O
4	the	O
5	first	O
6	example	O
7	of	O
8	utilization	O
9	of	O
10	noncomplementary	O
11	dinucleotide	O
12	primer	O
13	by	O
14	an	O
15	RNA	B
16	polymerase	I
17	.	O

1	Epithelial	O
2	damage	O
3	was	O
4	not	O
5	observed	O
6	in	O
7	any	O
8	controls	O
9	but	O
10	was	O
11	in	O
12	all	O
13	tissues	O
14	exposed	O
15	to	O
16	SO2	O
17	.	O

1	Three	O
2	of	O
3	these	O
4	subunits	O
5	are	O
6	also	O
7	homologous	O
8	to	O
9	the	O
10	dimeric	O
11	POR	B
12	from	O
13	a	O
14	mesophilic	O
15	archaeon	O
16	,	O
17	Halobacterium	O
18	halobium	O
19	(	O
20	21	O
21	%	O
22	identity	O
23	).	O

1	To	O
2	address	O
3	these	O
4	questions	O
5	,	O
6	a	O
7	recombinant	O
8	FRAP	B
9	/	O
10	mTOR	B
11	protein	O
12	and	O
13	a	O
14	FRAP	B
15	/	O
16	mTOR	B
17	immunoprecipitate	O
18	were	O
19	utilized	O
20	in	O
21	in	O
22	vitro	O
23	kinase	O
24	assays	O
25	to	O
26	phosphorylate	O
27	4E	B
28	-	I
29	BP1	I
30	.	O

1	Glucocorticoid	O
2	induced	O
3	hypertension	O
4	has	O
5	been	O
6	regarded	O
7	as	O
8	independent	O
9	of	O
10	sodium	O
11	(	O
12	Na	O
13	),	O
14	in	O
15	contrast	O
16	to	O
17	mineralocorticoid	O
18	induced	O
19	hypertension	O
20	,	O
21	which	O
22	is	O
23	Na	O
24	+-	O
25	dependent	O
26	.	O

1	In	O
2	30	O
3	dogs	O
4	the	O
5	left	O
6	limb	O
7	(	O
8	tail	O
9	)	O
10	of	O
11	the	O
12	pancreas	O
13	was	O
14	removed	O
15	but	O
16	left	O
17	in	O
18	the	O
19	abdominal	O
20	cavity	O
21	after	O
22	cessation	O
23	of	O
24	blood	O
25	flow	O
26	to	O
27	produce	O
28	warm	O
29	ischemia	O
30	for	O
31	30	O
32	,	O
33	60	O
34	,	O
35	and	O
36	120	O
37	min	O
38	(	O
39	10	O
40	dogs	O
41	at	O
42	each	O
43	time	O
44	point	O
45	),	O
46	and	O
47	then	O
48	was	O
49	flushed	O
50	with	O
51	cold	O
52	Ringers	O
53	'	O
54	lactate	O
55	and	O
56	transplanted	O
57	to	O
58	the	O
59	iliac	O
60	vessels	O
61	.	O

1	Cross	O
2	-	O
3	reaction	O
4	between	O
5	a	O
6	monoclonal	O
7	antibody	O
8	and	O
9	two	O
10	alpha	B
11	beta	I
12	T	I
13	cell	I
14	receptors	I
15	.	O

1	Remarkably	O
2	,	O
3	a	O
4	construct	O
5	corresponding	O
6	to	O
7	residues	O
8	631	O
9	to	O
10	970	O
11	,	O
12	which	O
13	contains	O
14	only	O
15	the	O
16	LXXLL	O
17	motifs	O
18	and	O
19	the	O
20	AD1	O
21	region	O
22	of	O
23	SRC1	B
24	,	O
25	retained	O
26	strong	O
27	coactivator	O
28	activity	O
29	in	O
30	our	O
31	assays	O
32	.	O

1	However	O
2	,	O
3	after	O
4	PRK	O
5	at	O
6	5	O
7	weeks	O
8	of	O
9	age	O
10	,	O
11	partial	O
12	retreatment	O
13	may	O
14	be	O
15	necessary	O
16	due	O
17	to	O
18	regression	O
19	of	O
20	the	O
21	PRK	O
22	effect	O
23	.	O

1	The	O
2	coordinate	O
3	increase	O
4	in	O
5	cyclin	B
6	D1	I
7	and	O
8	p21	B
9	had	O
10	the	O
11	effect	O
12	of	O
13	decreasing	O
14	the	O
15	specific	O
16	but	O
17	not	O
18	absolute	O
19	activity	O
20	of	O
21	cyclin	B
22	D1	I
23	/	O
24	cdk4	B
25	.	O
26	p53	B
27	was	O
28	not	O
29	involved	O
30	since	O
31	CSF	B
32	-	I
33	1	I
34	induction	O
35	of	O
36	p21	B
37	was	O
38	unaffected	O
39	by	O
40	dominant	B
41	-	I
42	negative	I
43	p53	I
44	expression	O
45	.	O

1	Splice	O
2	-	O
3	junction	O
4	elements	O
5	and	O
6	intronic	O
7	sequences	O
8	regulate	O
9	alternative	O
10	splicing	O
11	of	O
12	the	O
13	Drosophila	O
14	myosin	B
15	heavy	I
16	chain	I
17	gene	I
18	transcript	O
19	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	significance	O
6	of	O
7	these	O
8	subdomains	O
9	in	O
10	PRL	B
11	binding	O
12	and	O
13	signal	O
14	transduction	O
15	,	O
16	deletion	O
17	mutants	O
18	of	O
19	S1	O
20	or	O
21	/	O
22	and	O
23	S2	O
24	subdomains	O
25	were	O
26	constructed	O
27	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	or	O
5	mouse	O
6	skin	O
7	with	O
8	antisense	O
9	oligonucleotides	O
10	of	O
11	PKCzeta	B
12	impaired	O
13	UV	O
14	-	O
15	induced	O
16	activation	O
17	of	O
18	AP	B
19	-	I
20	1	I
21	in	O
22	JB6	O
23	cells	O
24	as	O
25	well	O
26	as	O
27	in	O
28	AP	B
29	-	I
30	1	I
31	-	O
32	luciferase	B
33	transgenic	O
34	mice	O
35	.	O

1	A	O
2	patient	O
3	matches	O
4	a	O
5	PIC	O
6	patient	O
7	if	O
8	both	O
9	have	O
10	the	O
11	same	O
12	mechanism	O
13	of	O
14	injury	O
15	,	O
16	the	O
17	same	O
18	coding	O
19	of	O
20	Revised	O
21	Trauma	O
22	Score	O
23	variables	O
24	(	O
25	Glascow	O
26	Coma	O
27	Scale	O
28	score	O
29	,	O
30	systolic	O
31	blood	O
32	pressure	O
33	,	O
34	respiratory	O
35	rate	O
36	),	O
37	the	O
38	same	O
39	coded	O
40	age	O
41	per	O
42	A	O
43	Severity	O
44	Characterization	O
45	of	O
46	Trauma	O
47	)	O
48	(	O
49	ASCOT	O
50	),	O
51	and	O
52	if	O
53	they	O
54	differ	O
55	by	O
56	no	O
57	more	O
58	than	O
59	0	O
60	.	O
61	5	O
62	for	O
63	A	O
64	,	O
65	B	O
66	,	O
67	and	O
68	C	O
69	(	O
70	the	O
71	ASCOT	O
72	components	O
73	for	O
74	serious	O
75	injuries	O
76	).	O

1	We	O
2	also	O
3	examined	O
4	the	O
5	relationship	O
6	between	O
7	the	O
8	side	O
9	of	O
10	sinusitis	O
11	and	O
12	the	O
13	cleft	O
14	side	O
15	in	O
16	patients	O
17	with	O
18	unilateral	O
19	cleft	O
20	palate	O
21	.	O

1	Scalp	O
2	flaps	O
3	can	O
4	be	O
5	expanded	O
6	just	O
7	to	O
8	the	O
9	point	O
10	of	O
11	becoming	O
12	noticeable	O
13	over	O
14	4	O
15	to	O
16	6	O
17	weeks	O
18	followed	O
19	by	O
20	scalp	O
21	flap	O
22	transposition	O
23	and	O
24	easy	O
25	closure	O
26	of	O
27	the	O
28	donor	O
29	site	O
30	.	O

1	25	O
2	-	O
3	OH	O
4	-	O
5	D3	O
6	did	O
7	not	O
8	adversely	O
9	affect	O
10	animal	O
11	health	O
12	at	O
13	the	O
14	proposed	O
15	use	O
16	level	O
17	of	O
18	99	O
19	micrograms	O
20	/	O
21	kg	O
22	feed	O
23	when	O
24	replacing	O
25	vitamin	O
26	D3	O
27	in	O
28	turkey	O
29	rations	O
30	.	O

1	Malaria	O
2	,	O
3	anaemia	O
4	,	O
5	and	O
6	HIV	O
7	-	O
8	1	O
9	transmission	O
10	in	O
11	central	O
12	Africa	O
13	.	O

1	The	O
2	frequency	O
3	of	O
4	SPs	O
5	for	O
6	both	O
7	the	O
8	moderate	O
9	and	O
10	severe	O
11	groups	O
12	was	O
13	significantly	O
14	higher	O
15	than	O
16	that	O
17	in	O
18	patients	O
19	with	O
20	a	O
21	normal	O
22	MMFCV	O
23	(	O
24	p	O
25	<	O
26	.	O
27	01	O
28	);	O
29	of	O
30	154	O
31	arms	O
32	with	O
33	a	O
34	normal	O
35	MMFCV	O
36	,	O
37	only	O
38	9	O
39	(	O
40	6	O
41	%)	O
42	had	O
43	an	O
44	SP	O
45	.	O

1	Electronic	O
2	data	O
3	processing	O
4	(	O
5	EDP	O
6	)	O
7	latex	O
8	immunoassay	O
9	using	O
10	anti	B
11	-	I
12	human	I
13	seminal	I
14	acid	I
15	phosphatase	I
16	(	O
17	anti	B
18	-	I
19	HSAP	I
20	)	O
21	immune	O
22	serum	O
23	was	O
24	applied	O
25	for	O
26	the	O
27	species	O
28	and	O
29	organ	O
30	identification	O
31	of	O
32	human	O
33	seminal	O
34	stains	O
35	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	identified	O
8	as	O
9	CACGTGACCCG	O
10	,	O
11	is	O
12	located	O
13	34	O
14	bp	O
15	upstream	O
16	from	O
17	the	O
18	transcription	O
19	initiation	O
20	site	O
21	,	O
22	and	O
23	contains	O
24	the	O
25	core	O
26	sequence	O
27	of	O
28	the	O
29	upstream	O
30	promoter	O
31	sequence	O
32	of	O
33	Ad2MLP	B
34	.	O

1	Therefore	O
2	,	O
3	analogs	O
4	of	O
5	vitamin	O
6	D3	O
7	have	O
8	been	O
9	investigated	O
10	in	O
11	a	O
12	number	O
13	of	O
14	trials	O
15	showing	O
16	improvement	O
17	of	O
18	psoriasis	O
19	.	O

1	Cardiac	B
2	endothelin	I
3	release	O
4	and	O
5	infarct	O
6	size	O
7	,	O
8	myocardial	O
9	blood	O
10	flow	O
11	,	O
12	and	O
13	ventricular	O
14	function	O
15	in	O
16	canine	O
17	infarction	O
18	and	O
19	reperfusion	O
20	.	O

1	Foreign	O
2	profiles	O
3	in	O
4	air	O
5	pollution	O
6	control	O
7	activities	O
8	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	CT	O
6	should	O
7	be	O
8	routinely	O
9	employed	O
10	in	O
11	patients	O
12	with	O
13	N1	O
14	-	O
15	N3	O
16	neck	O
17	disease	O
18	to	O
19	determine	O
20	the	O
21	proper	O
22	electron	O
23	-	O
24	energy	O
25	prescription	O
26	.	O

1	Calcinosis	O
2	cutis	O
3	following	O
4	intravenous	O
5	infusion	O
6	of	O
7	calcium	O
8	gluconate	O
9	.	O

1	Moreover	O
2	,	O
3	promoters	O
4	containing	O
5	a	O
6	TATA	O
7	box	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	Sp1	B
13	sites	I
14	or	O
15	Sp1	B
16	sites	I
17	in	O
18	the	O
19	absence	O
20	of	O
21	a	O
22	TATA	O
23	box	O
24	were	O
25	equally	O
26	inducible	O
27	in	O
28	vitro	O
29	,	O
30	as	O
31	was	O
32	an	O
33	RNA	B
34	polymerase	I
35	III	I
36	promoter	I
37	.	O

1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	SNF2	B
7	,	O
8	SNF5	B
9	,	O
10	and	O
11	SNF6	B
12	function	O
13	interdependently	O
14	in	O
15	transcriptional	O
16	activation	O
17	,	O
18	possibly	O
19	forming	O
20	a	O
21	heteromeric	O
22	complex	O
23	.	O

1	It	O
2	is	O
3	present	O
4	in	O
5	the	O
6	nucleus	O
7	of	O
8	the	O
9	cells	O
10	in	O
11	which	O
12	it	O
13	is	O
14	expressed	O
15	and	O
16	can	O
17	phosphorylate	O
18	and	O
19	activate	O
20	the	O
21	cyclic	B
22	AMP	I
23	response	I
24	element	I
25	binding	I
26	proteins	I
27	CREB	I
28	and	O
29	CREM	B
30	tau	I
31	in	O
32	a	O
33	manner	O
34	analogous	O
35	to	O
36	protein	B
37	kinase	I
38	A	I
39	.	O

1	CONCLUSION	O
2	:	O
3	Sonographic	O
4	angiography	O
5	has	O
6	a	O
7	possible	O
8	role	O
9	in	O
10	the	O
11	detection	O
12	of	O
13	small	O
14	nodules	O
15	in	O
16	patients	O
17	with	O
18	CRF	O
19	.	O

1	195mPt	O
2	-	O
3	labeled	O
4	cisplatin	O
5	was	O
6	administered	O
7	iv	O
8	and	O
9	ip	O
10	to	O
11	control	O
12	mice	O
13	and	O
14	to	O
15	mice	O
16	bearing	O
17	Sarcoma	O
18	180	O
19	.	O

1	With	O
2	a	O
3	cutoff	O
4	level	O
5	for	O
6	TSST	B
7	-	I
8	1	I
9	of	O
10	less	O
11	than	O
12	100	O
13	pg	O
14	/	O
15	ml	O
16	,	O
17	28	O
18	samples	O
19	obtained	O
20	from	O
21	12	O
22	patients	O
23	were	O
24	positive	O
25	for	O
26	TSST	B
27	-	I
28	1	I
29	.	O

1	In	O
2	Wnt	B
3	signaling	O
4	,	O
5	beta	B
6	-	I
7	catenin	I
8	and	O
9	plakoglobin	B
10	transduce	O
11	signals	O
12	to	O
13	the	O
14	nucleus	O
15	through	O
16	interactions	O
17	with	O
18	TCF	B
19	-	I
20	type	I
21	transcription	I
22	factors	I
23	.	O

1	From	O
2	August	O
3	1989	O
4	to	O
5	October	O
6	1990	O
7	,	O
8	83	O
9	pregnant	O
10	Chinese	O
11	women	O
12	were	O
13	the	O
14	subjects	O
15	for	O
16	measuring	O
17	the	O
18	levels	O
19	of	O
20	plasma	O
21	functional	O
22	antithrombin	B
23	III	I
24	(	O
25	AT	B
26	III	I
27	)	O
28	activity	O
29	.	O

1	The	O
2	controversy	O
3	of	O
4	significance	O
5	testing	O
6	:	O
7	misconceptions	O
8	and	O
9	alternatives	O
10	.	O

1	Amplification	O
2	and	O
3	overexpression	O
4	of	O
5	the	O
6	c	B
7	-	I
8	erbB	I
9	-	I
10	2	I
11	gene	I
12	in	O
13	21MT	O
14	-	O
15	2	O
16	and	O
17	21MT	O
18	-	O
19	1	O
20	human	O
21	breast	O
22	carcinoma	O
23	cells	O
24	results	O
25	in	O
26	progressively	O
27	elevated	O
28	levels	O
29	of	O
30	constitutively	O
31	tyrosine	B
32	-	I
33	phosphorylated	I
34	p185erbB	I
35	-	I
36	2	I
37	and	O
38	is	O
39	associated	O
40	with	O
41	progressive	O
42	insulin	B
43	-	I
44	like	I
45	growth	I
46	factor	I
47	(	O
48	IGF	B
49	)	O
50	and	O
51	combined	O
52	IGF	B
53	/	O
54	epidermal	B
55	growth	I
56	factor	I
57	(	O
58	EGF	B
59	)	O
60	independence	O
61	in	O
62	culture	O
63	.	O

1	The	O
2	ratio	O
3	of	O
4	P	O
5	-	O
6	31	O
7	NMR	O
8	-	O
9	S	O
10	derived	O
11	inorganic	O
12	phosphates	O
13	[	O
14	Pi	O
15	]	O
16	to	O
17	phosphocreatine	O
18	[	O
19	PCr	O
20	]	O
21	was	O
22	significantly	O
23	greater	O
24	at	O
25	rest	O
26	in	O
27	LVH	O
28	baboons	O
29	[	O
30	0	O
31	.	O
32	53	O
33	+/-	O
34	0	O
35	.	O
36	06	O
37	versus	O
38	controls	O
39	=	O
40	0	O
41	.	O
42	41	O
43	+/-	O
44	0	O
45	.	O
46	17	O
47	;	O
48	P	O
49	less	O
50	than	O
51	0	O
52	.	O
53	05	O
54	].	O

1	RESULTS	O
2	:	O
3	Fournier	O
4	'	O
5	s	O
6	gangrene	O
7	occurs	O
8	worldwide	O
9	.	O

1	This	O
2	effect	O
3	required	O
4	(	O
5	i	O
6	)	O
7	IR	B
8	activation	O
9	since	O
10	it	O
11	was	O
12	abrogated	O
13	by	O
14	IR	B
15	mutation	O
16	at	O
17	tyrosines	O
18	1162	O
19	and	O
20	1163	O
21	and	O
22	(	O
23	ii	O
24	)	O
25	NF	B
26	-	I
27	kappaB	I
28	activation	O
29	since	O
30	it	O
31	was	O
32	abolished	O
33	by	O
34	overexpression	O
35	of	O
36	dominant	B
37	-	I
38	negative	I
39	IkappaB	I
40	-	I
41	alpha	I
42	(	I
43	A32	I
44	/	I
45	36	I
46	)	I
47	and	O
48	mimicked	O
49	by	O
50	overexpression	O
51	of	O
52	the	O
53	NF	B
54	-	I
55	kappaB	I
56	c	I
57	-	I
58	Rel	I
59	subunit	I
60	.	O

1	Increasing	O
2	the	O
3	extracellular	O
4	calcium	O
5	concentration	O
6	enhanced	O
7	detrusor	O
8	contractility	O
9	in	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	both	O
17	control	O
18	and	O
19	obstructed	O
20	bladders	O
21	.	O

1	Finding	O
2	of	O
3	Rhodnius	O
4	prolixus	O
5	Stal	O
6	,	O
7	1859	O
8	,	O
9	in	O
10	babassu	O
11	palm	O
12	trees	O

1	T	O
2	cells	O
3	express	O
4	two	O
5	isoforms	O
6	of	O
7	S6k1	B
8	:	O
9	a	O
10	70	O
11	kDa	O
12	cytoplasmic	O
13	kinase	O
14	and	O
15	an	O
16	85	O
17	kDa	O
18	isoform	O
19	that	O
20	has	O
21	a	O
22	classic	O
23	nuclear	O
24	localisation	O
25	.	O

1	Neuronal	O
2	signaling	O
3	properties	O
4	are	O
5	largely	O
6	determined	O
7	by	O
8	the	O
9	quantity	O
10	and	O
11	combination	O
12	of	O
13	ion	O
14	channels	O
15	expressed	O
16	.	O

1	The	O
2	mean	O
3	extracted	O
4	concentration	O
5	of	O
6	flucloxacillin	O
7	obtained	O
8	at	O
9	operation	O
10	was	O
11	12	O
12	.	O
13	9	O
14	micrograms	O
15	/	O
16	ml	O
17	(	O
18	SD	O
19	5	O
20	.	O
21	25	O
22	)	O
23	in	O
24	synovial	O
25	fluid	O
26	;	O
27	2	O
28	.	O
29	9	O
30	micrograms	O
31	/	O
32	g	O
33	(	O
34	SD	O
35	3	O
36	.	O
37	59	O
38	)	O
39	in	O
40	synovium	O
41	;	O
42	2	O
43	.	O
44	0	O
45	micrograms	O
46	/	O
47	g	O
48	(	O
49	SD	O
50	1	O
51	.	O
52	48	O
53	)	O
54	in	O
55	cancellous	O
56	bone	O
57	and	O
58	1	O
59	.	O
60	3	O
61	micrograms	O
62	/	O
63	g	O
64	(	O
65	SD	O
66	1	O
67	.	O
68	25	O
69	)	O
70	in	O
71	cortical	O
72	bone	O
73	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	In	O
6	807	O
7	consecutive	O
8	patients	O
9	from	O
10	the	O
11	Chilean	O
12	National	O
13	Registry	O
14	of	O
15	Acute	O
16	Myocardial	O
17	Infarction	O
18	we	O
19	analyzed	O
20	the	O
21	resolution	O
22	of	O
23	chest	O
24	pain	O
25	and	O
26	ST	O
27	segment	O
28	elevation	O
29	over	O
30	50	O
31	%	O
32	within	O
33	the	O
34	first	O
35	90	O
36	min	O
37	,	O
38	abrupt	O
39	CK	B
40	rise	O
41	within	O
42	8	O
43	h	O
44	and	O
45	T	O
46	wave	O
47	inversion	O
48	in	O
49	infarct	O
50	related	O
51	EKG	O
52	leads	O
53	within	O
54	the	O
55	first	O
56	24	O
57	h	O
58	after	O
59	thrombolysis	O
60	.	O

1	So	O
2	far	O
3	15	O
4	children	O
5	have	O
6	been	O
7	studied	O
8	.	O

1	The	O
2	N1	O
3	and	O
4	P2	O
5	were	O
6	comparable	O
7	in	O
8	amplitude	O
9	and	O
10	both	O
11	had	O
12	prolonged	O
13	refractory	O
14	periods	O
15	.	O

1	Although	O
2	noninhibitory	O
3	fluid	O
4	had	O
5	higher	O
6	mean	O
7	concentrations	O
8	of	O
9	phosphorus	O
10	and	O
11	zinc	O
12	,	O
13	these	O
14	differences	O
15	did	O
16	not	O
17	hold	O
18	after	O
19	meconium	O
20	-	O
21	stained	O
22	samples	O
23	were	O
24	excluded	O
25	.	O

1	LH	B
2	/	I
3	CG	I
4	receptor	I
5	activation	O
6	of	O
7	ARNO	B
8	is	O
9	not	O
10	mediated	O
11	by	O
12	activation	O
13	of	O
14	phosphatidylinositol	B
15	3	I
16	-	I
17	kinase	I
18	(	O
19	PI	B
20	3	I
21	-	I
22	kinase	I
23	)	O
24	or	O
25	by	O
26	G	B
27	protein	I
28	beta	I
29	gamma	I
30	subunits	I
31	.	O

1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O

1	We	O
2	found	O
3	that	O
4	PML	B
5	was	O
6	expressed	O
7	at	O
8	a	O
9	lower	O
10	level	O
11	in	O
12	S	O
13	,	O
14	G2	O
15	,	O
16	and	O
17	M	O
18	phases	O
19	and	O
20	at	O
21	a	O
22	significantly	O
23	higher	O
24	level	O
25	in	O
26	G1	O
27	phase	O
28	.	O

1	Ovaries	O
2	of	O
3	10	O
4	animals	O
5	per	O
6	group	O
7	from	O
8	16	O
9	studies	O
10	in	O
11	CD	O
12	-	O
13	1	O
14	mice	O
15	and	O
16	1	O
17	study	O
18	each	O
19	in	O
20	C3H	O
21	and	O
22	C57BL	O
23	/	O
24	6	O
25	mice	O
26	were	O
27	sectioned	O
28	serially	O
29	at	O
30	6	O
31	microm	O
32	.	O

1	The	O
2	CCAAT	O
3	core	O
4	sequence	O
5	mutants	O
6	in	O
7	which	O
8	both	O
9	CIII	O
10	and	O
11	CI	O
12	/	O
13	CII	O
14	were	O
15	abolished	O
16	,	O
17	also	O
18	increased	O
19	the	O
20	promoter	O
21	activity	O
22	.	O

1	Forty	O
2	-	O
3	five	O
4	patients	O
5	with	O
6	pleural	O
7	lesions	O
8	identified	O
9	on	O
10	CT	O
11	scans	O
12	were	O
13	subsequently	O
14	examined	O
15	by	O
16	MR	O
17	imaging	O
18	at	O
19	0	O
20	.	O
21	5	O
22	T	O
23	.	O

1	In	O
2	the	O
3	second	O
4	case	O
5	,	O
6	an	O
7	epidermal	O
8	cyst	O
9	was	O
10	diagnosed	O
11	.	O

1	The	O
2	17	O
3	-	O
4	kDa	O
5	protein	O
6	is	O
7	required	O
8	for	O
9	the	O
10	systemic	O
11	infection	O
12	of	O
13	plants	O
14	.	O

1	In	O
2	a	O
3	gntR	B
4	deletion	I
5	mutant	I
6	,	O
7	the	O
8	expression	O
9	of	O
10	a	O
11	chromosomal	O
12	gntT	B
13	::	O
14	lacZ	B
15	fusion	O
16	is	O
17	both	O
18	high	O
19	and	O
20	constitutive	O
21	,	O
22	confirming	O
23	that	O
24	GntR	B
25	is	O
26	the	O
27	negative	O
28	regulator	O
29	of	O
30	gntT	B
31	.	O

1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	B
14	type	I
15	IV	I
16	than	O
17	similarly	O
18	sized	O
19	vessels	O
20	in	O
21	the	O
22	submucosa	O
23	,	O
24	and	O
25	perforating	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	O
40	mucosae	O
41	.	O

1	Anti	B
2	-	I
3	hepatitis	I
4	A	I
5	virus	O
6	(	O
7	HAV	O
8	)	O
9	titer	O
10	after	O
11	vaccination	O
12	was	O
13	measured	O
14	in	O
15	83	O
16	HIV	O
17	-	O
18	positive	O
19	and	O
20	39	O
21	HIV	O
22	-	O
23	negative	O
24	men	O
25	.	O

1	The	O
2	impact	O
3	of	O
4	social	O
5	support	O
6	on	O
7	the	O
8	relationships	O
9	of	O
10	gay	O
11	male	O
12	couples	O
13	is	O
14	examined	O
15	.	O

1	The	O
2	"	O
3	cracked	O
4	-	O
5	tooth	O
6	"	O
7	syndrome	O
8	.	O

1	Purified	O
2	PLB	B
3	showed	O
4	optimal	O
5	lyase	B
6	activity	O
7	at	O
8	pH	O
9	10	O
10	.	O
11	0	O
12	.	O

1	Beg2	B
2	and	O
3	Beg1	B
4	are	O
5	regulated	O
6	differently	O
7	which	O
8	may	O
9	indicate	O
10	variation	O
11	in	O
12	storage	O
13	or	O
14	utilization	O
15	properties	O
16	among	O
17	the	O
18	barley	B
19	globulins	I
20	.	O

1	However	O
2	,	O
3	the	O
4	range	O
5	of	O
6	values	O
7	observed	O
8	is	O
9	suggestive	O
10	of	O
11	the	O
12	need	O
13	to	O
14	investigate	O
15	districts	O
16	with	O
17	contrasting	O
18	values	O
19	of	O
20	SYPLR	O
21	with	O
22	respect	O
23	to	O
24	the	O
25	inter	O
26	-	O
27	relationships	O
28	between	O
29	sociodemographic	O
30	characteristics	O
31	,	O
32	duration	O
33	of	O
34	symptoms	O
35	,	O
36	clinical	O
37	presentation	O
38	and	O
39	treatment	O
40	efficacy	O
41	.	O

1	Petko	O
2	,	O
3	and	O
4	S	O
5	.	O

1	To	O
2	assess	O
3	the	O
4	function	O
5	(	O
6	s	O
7	)	O
8	of	O
9	E74	B
10	during	O
11	metamorphosis	O
12	,	O
13	we	O
14	have	O
15	isolated	O
16	and	O
17	characterized	O
18	recessive	O
19	loss	O
20	-	O
21	of	O
22	-	O
23	function	O
24	mutations	O
25	specific	O
26	to	O
27	each	O
28	transcription	O
29	unit	O
30	.	O

1	Ion	O
2	injection	O
3	.	O

1	C	O
2	.,	O
3	Sun	O
4	,	O
5	J	O
6	.,	O
7	Hsu	O
8	,	O
9	M	O
10	.-	O
11	Y	O
12	.,	O
13	Vallejo	O
14	-	O
15	Ramirez	O
16	,	O
17	J	O
18	.,	O
19	Inouye	O
20	,	O
21	S	O
22	.,	O
23	and	O
24	Inouye	O
25	,	O
26	M	O
27	.	O

1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	diazepam	B
8	-	I
9	binding	I
10	inhibitor	I
11	in	O
12	Drosophila	O
13	melanogaster	O
14	:	O
15	cloning	O
16	,	O
17	structure	O
18	,	O
19	and	O
20	localization	O
21	of	O
22	the	O
23	gene	O
24	.	O

1	Ovulation	O
2	was	O
3	induced	O
4	in	O
5	8	O
6	(	O
7	56	O
8	.	O
9	7	O
10	%)	O
11	patients	O
12	who	O
13	conceived	O
14	.	O

1	Although	O
2	large	O
3	epidemiologic	O
4	studies	O
5	are	O
6	best	O
7	able	O
8	to	O
9	identify	O
10	the	O
11	relative	O
12	contributions	O
13	of	O
14	specific	O
15	risk	O
16	factors	O
17	while	O
18	controlling	O
19	for	O
20	other	O
21	risk	O
22	factors	O
23	,	O
24	new	O
25	studies	O
26	need	O
27	to	O
28	focus	O
29	on	O
30	important	O
31	unresolved	O
32	questions	O
33	.	O

1	Neither	O
2	mutant	O
3	exhibited	O
4	derepression	O
5	of	O
6	the	O
7	silent	B
8	mating	I
9	type	I
10	loci	I
11	.	O

1	The	O
2	predicted	O
3	receptor	O
4	structure	O
5	includes	O
6	a	O
7	cysteine	O
8	-	O
9	rich	O
10	extracellular	O
11	domain	O
12	,	O
13	a	O
14	single	O
15	hydrophobic	O
16	transmembrane	O
17	domain	O
18	,	O
19	and	O
20	a	O
21	predicted	O
22	cytoplasmic	B
23	serine	I
24	/	I
25	threonine	I
26	kinase	I
27	domain	I
28	.	O

1	To	O
2	gain	O
3	further	O
4	insight	O
5	into	O
6	the	O
7	pathogenesis	O
8	of	O
9	the	O
10	adult	O
11	respiratory	O
12	distress	O
13	syndrome	O
14	(	O
15	ARDS	O
16	),	O
17	the	O
18	authors	O
19	studied	O
20	possible	O
21	relationships	O
22	among	O
23	the	O
24	activation	O
25	status	O
26	of	O
27	circulating	O
28	polymorphonuclear	O
29	neutrophils	O
30	(	O
31	PMN	O
32	),	O
33	cytokine	O
34	levels	O
35	,	O
36	and	O
37	the	O
38	severity	O
39	of	O
40	lung	O
41	injury	O
42	in	O
43	31	O
44	patients	O
45	:	O
46	15	O
47	with	O
48	ARDS	O
49	,	O
50	9	O
51	with	O
52	severe	O
53	pneumonia	O
54	uncomplicated	O
55	by	O
56	ARDS	O
57	,	O
58	and	O
59	7	O
60	mechanically	O
61	ventilated	O
62	patients	O
63	with	O
64	neither	O
65	ARDS	O
66	nor	O
67	pneumonia	O
68	.	O

1	66	O
2	:	O
3	469	O
4	-	O
5	479	O
6	,	O
7	1992	O
8	).	O

1	Though	O
2	the	O
3	BACTEC	O
4	9000	O
5	MB	O
6	system	O
7	is	O
8	recommended	O
9	for	O
10	respiratory	O
11	specimens	O
12	,	O
13	we	O
14	demonstrated	O
15	that	O
16	it	O
17	can	O
18	be	O
19	successfully	O
20	used	O
21	also	O
22	for	O
23	recovery	O
24	of	O
25	mycobacteria	O
26	from	O
27	clinical	O
28	specimens	O
29	from	O
30	various	O
31	extrapulmonary	O
32	sites	O
33	.	O

1	We	O
2	have	O
3	tested	O
4	this	O
5	possibility	O
6	by	O
7	constructing	O
8	a	O
9	consecutive	O
10	series	O
11	of	O
12	cysteine	O
13	substitutions	O
14	in	O
15	the	O
16	Neu	B
17	juxtamembrane	I
18	domain	I
19	in	O
20	order	O
21	to	O
22	force	O
23	dimerization	O
24	along	O
25	a	O
26	series	O
27	of	O
28	interreceptor	O
29	faces	O
30	.	O

1	Sodium	O
2	restriction	O
3	in	O
4	cardiac	O
5	failure	O
6	.	O

1	In	O
2	the	O
3	formalin	O
4	test	O
5	,	O
6	however	O
7	,	O
8	naloxone	O
9	attenuated	O
10	morphine	O
11	analgesia	O
12	at	O
13	the	O
14	lower	O
15	doses	O
16	(	O
17	0	O
18	.	O
19	1	O
20	and	O
21	0	O
22	.	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	)	O
28	and	O
29	potentiated	O
30	morphine	O
31	analgesia	O
32	at	O
33	the	O
34	highest	O
35	dose	O
36	(	O
37	10	O
38	mg	O
39	/	O
40	kg	O
41	).	O

1	Measurement	O
2	of	O
3	gastric	O
4	acid	O
5	secretion	O
6	by	O
7	conductivity	O
8	.	O

1	Reverse	B
2	transcriptase	I
3	-	O
4	polymerase	O
5	chain	O
6	reaction	O
7	(	O
8	RT	B
9	-	O
10	PCR	O
11	)	O
12	was	O
13	performed	O
14	using	O
15	eyestalk	O
16	complementary	O
17	DNA	O
18	of	O
19	the	O
20	sand	O
21	shrimp	O
22	Metapenaeus	O
23	ensis	O
24	.	O

1	In	O
2	order	O
3	to	O
4	better	O
5	characterize	O
6	the	O
7	distribution	O
8	of	O
9	ML	O
10	and	O
11	MAP	O
12	estimates	O
13	under	O
14	these	O
15	conditions	O
16	,	O
17	we	O
18	derive	O
19	a	O
20	point	O
21	approximation	O
22	to	O
23	density	O
24	values	O
25	of	O
26	the	O
27	conditional	O
28	distribution	O
29	of	O
30	such	O
31	estimates	O
32	.	O

1	The	O
2	nifJ	B
3	and	O
4	nifH	B
5	promoters	I
6	of	I
7	Klebsiella	I
8	pneumoniae	I
9	are	O
10	divergently	O
11	transcribed	O
12	sigma	B
13	54	I
14	-	I
15	dependent	I
16	promoters	I
17	that	O
18	are	O
19	positively	O
20	activated	O
21	by	O
22	the	O
23	NifA	B
24	protein	I
25	.	O

1	3	O
2	'-	O
3	Methyl	O
4	,	O
5	8	O
6	-	O
7	methyl	O
8	,	O
9	and	O
10	8	O
11	-	O
12	phenyl	O
13	derivatives	O
14	of	O
15	5	O
16	,	O
17	9	O
18	-	O
19	dimethyl	O
20	-	O
21	6	O
22	,	O
23	7	O
24	-	O
25	benzomorphans	O
26	.	O

1	Acute	O
2	pancreatitis	O
3	as	O
4	a	O
5	complication	O
6	of	O
7	polyarteritis	O
8	nodosa	O
9	.	O

1	One	O
2	antibody	O
3	,	O
4	mAb1C2	B
5	,	O
6	and	O
7	a	O
8	synthetic	O
9	peptide	O
10	comprising	O
11	its	O
12	epitope	O
13	selectively	O
14	inhibited	O
15	in	O
16	vitro	O
17	transcription	O
18	from	O
19	TATA	O
20	-	O
21	containing	O
22	,	O
23	but	O
24	not	O
25	from	O
26	TATA	O
27	-	O
28	less	O
29	promoters	O
30	,	O
31	irrespective	O
32	of	O
33	whether	O
34	they	O
35	were	O
36	transcribed	O
37	by	O
38	Pol	B
39	II	I
40	or	O
41	Pol	B
42	III	I
43	.	O

1	To	O
2	analyze	O
3	the	O
4	regulatory	O
5	activity	O
6	of	O
7	Gtx	B
8	,	O
9	we	O
10	first	O
11	identified	O
12	the	O
13	optimal	O
14	Gtx	B
15	-	I
16	binding	I
17	sequence	I
18	using	O
19	an	O
20	in	O
21	vitro	O
22	DNA	O
23	-	O
24	binding	O
25	assay	O
26	.	O

1	The	O
2	13	O
3	,	O
4	14	O
5	-	O
6	dihydro	O
7	-	O
8	15	O
9	-	O
10	keto	O
11	-	O
12	metabolites	O
13	of	O
14	PGE2	O
15	and	O
16	PGF2	O
17	alpha	O
18	had	O
19	no	O
20	statistically	O
21	significant	O
22	antiarrhythmic	O
23	effect	O
24	.	O

1	IL	B
2	-	I
3	12	I
4	production	O
5	was	O
6	correlated	O
7	with	O
8	C3a	O
9	concentration	O
10	measured	O
11	at	O
12	the	O
13	outlet	O
14	of	O
15	hemodialyzer	O
16	after	O
17	15	O
18	min	O
19	of	O
20	dialysis	O
21	(	O
22	r	O
23	=	O
24	0	O
25	.	O
26	69	O
27	,	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	).	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	zebrafish	B
6	egr1	I
7	coding	I
8	region	I
9	revealed	O
10	a	O
11	high	O
12	level	O
13	of	O
14	homology	O
15	to	O
16	the	O
17	mouse	O
18	,	O
19	rat	O
20	,	O
21	and	O
22	human	B
23	Egr1	I
24	genes	I
25	with	O
26	the	O
27	notable	O
28	exception	O
29	of	O
30	a	O
31	polymorphic	O
32	,	O
33	triplet	O
34	nucleotide	O
35	repeat	O
36	sequence	O
37	in	O
38	the	O
39	region	O
40	coding	O
41	for	O
42	the	O
43	amino	O
44	terminus	O
45	of	O
46	the	O
47	Egr1	B
48	protein	I
49	.	O

1	The	O
2	mRNA	O
3	from	O
4	this	O
5	gene	O
6	,	O
7	termed	O
8	HES1	B
9	,	O
10	is	O
11	ubiquitously	O
12	expressed	O
13	,	O
14	but	O
15	strongly	O
16	so	O
17	in	O
18	heart	O
19	and	O
20	skeletal	O
21	muscle	O
22	.	O

1	Joys	O
2	and	O
3	F	O
4	.	O

1	Intriguingly	O
2	,	O
3	three	O
4	hypomorphic	O
5	Scm	B
6	mutations	O
7	,	O
8	which	O
9	map	O
10	within	O
11	an	O
12	mbt	B
13	repeat	I
14	,	O
15	interact	O
16	with	O
17	PcG	B
18	mutations	I
19	more	O
20	strongly	O
21	than	O
22	do	O
23	Scm	B
24	null	O
25	alleles	O
26	.	O

1	LysR	B
2	proteins	I
3	have	O
4	been	O
5	shown	O
6	to	O
7	regulate	O
8	urease	B
9	in	I
10	Klebsiella	I
11	aerogenes	I
12	(	O
13	NAC	B
14	),	O
15	and	O
16	catalase	B
17	in	I
18	Escherichia	I
19	coli	I
20	(	O
21	OxyR	B
22	),	O
23	which	O
24	offers	O
25	the	O
26	intracellular	O
27	bacterium	O
28	protection	O
29	from	O
30	phagolysosome	O
31	damage	O
32	.	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	yeast	O
8	and	O
9	mammalian	O
10	mitochondrial	O
11	targeting	O
12	sequences	O
13	are	O
14	similar	O
15	but	O
16	less	O
17	related	O
18	than	O
19	the	O
20	mature	O
21	polypeptides	O
22	.	O

1	Interferon	B
2	beta	I
3	therapy	O
4	was	O
5	discontinued	O
6	for	O
7	4	O
8	weeks	O
9	.	O

1	The	O
2	GRE	O
3	at	O
4	nucleotide	O
5	7640	O
6	is	O
7	a	O
8	composite	O
9	GRE	O
10	(	O
11	cGRE	O
12	)	O
13	containing	O
14	an	O
15	overlapping	O
16	activator	B
17	protein	I
18	-	I
19	1	I
20	(	O
21	AP	B
22	-	I
23	1	I
24	)	O
25	motif	O
26	for	O
27	the	O
28	c	B
29	-	I
30	jun	I
31	homodimer	I
32	and	O
33	c	B
34	-	I
35	jun	I
36	/	O
37	c	B
38	-	I
39	fos	I
40	heterodimer	O
41	.	O

1	Endothelial	O
2	cells	O
3	stored	O
4	with	O
5	University	O
6	of	O
7	Wisconsin	O
8	solution	O
9	excluded	O
10	trypan	O
11	blue	O
12	better	O
13	(	O
14	1	O
15	.	O
16	0	O
17	%	O
18	+/-	O
19	0	O
20	.	O
21	5	O
22	%	O
23	cells	O
24	stained	O
25	,	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	.	O

1	The	O
2	EPO	B
3	levels	O
4	were	O
5	distinctly	O
6	increased	O
7	before	O
8	transfusion	O
9	;	O
10	they	O
11	did	O
12	not	O
13	significantly	O
14	change	O
15	just	O
16	after	O
17	transfusion	O
18	,	O
19	but	O
20	subsequently	O
21	decreased	O
22	.	O

1	Infection	O
2	with	O
3	Neisseria	O
4	meningitidis	O
5	group	O
6	B	O
7	has	O
8	been	O
9	difficult	O
10	to	O
11	detect	O
12	,	O
13	partly	O
14	because	O
15	this	O
16	bacterial	O
17	group	O
18	'	O
19	s	O
20	polysaccharide	O
21	is	O
22	a	O
23	weak	O
24	immunogen	O
25	.	O

1	The	O
2	influence	O
3	of	O
4	a	O
5	mobile	O
6	pupil	O
7	on	O
8	the	O
9	response	O
10	in	O
11	the	O
12	DC	O
13	-	O
14	ERG	O
15	is	O
16	demonstrated	O
17	.	O

1	These	O
2	different	O
3	observations	O
4	exclude	O
5	a	O
6	heterozygosity	O
7	of	O
8	the	O
9	A	O
10	-->	O
11	G	O
12	mutation	O
13	at	O
14	codon	O
15	beta	O
16	77	O
17	,	O
18	as	O
19	well	O
20	as	O
21	a	O
22	deletion	O
23	comparable	O
24	to	O
25	that	O
26	of	O
27	Hbs	B
28	Lepore	I
29	or	I
30	Kenya	I
31	,	O
32	or	O
33	a	O
34	beta	B
35	-	I
36	globin	I
37	gene	I
38	duplication	O
39	,	O
40	and	O
41	point	O
42	to	O
43	a	O
44	nontraditional	O
45	inheritance	O
46	of	O
47	Hb	B
48	Costa	I
49	Rica	I
50	.	O

1	Electrocardiograms	O
2	of	O
3	the	O
4	month	O
5	.	O

1	Fission	B
2	yeast	I
3	mal2	I
4	+	I
5	is	O
6	required	O
7	for	O
8	chromosome	O
9	segregation	O
10	.	O

1	Initial	O
2	experience	O
3	with	O
4	a	O
5	serotonin	O
6	agonist	O
7	.	O

1	Marrow	O
2	dysplasia	O
3	is	O
4	a	O
5	major	O
6	characteristic	O
7	of	O
8	patients	O
9	with	O
10	myelodysplastic	O
11	syndrome	O
12	(	O
13	MDS	O
14	),	O
15	along	O
16	with	O
17	marrow	O
18	blastosis	O
19	,	O
20	cytopenia	O
21	and	O
22	cytogenetic	O
23	anomalies	O
24	.	O

1	This	O
2	review	O
3	summarizes	O
4	the	O
5	clinical	O
6	evidence	O
7	to	O
8	support	O
9	current	O
10	therapies	O
11	in	O
12	irritable	O
13	bowel	O
14	syndrome	O
15	(	O
16	IBS	O
17	).	O

1	Mitogen	B
2	-	I
3	activated	I
4	protein	I
5	(	I
6	MAP	I
7	)	I
8	kinase	I
9	phosphatase	I
10	-	I
11	3	I
12	(	O
13	MKP	B
14	-	I
15	3	I
16	)	O
17	is	O
18	a	O
19	dual	O
20	specificity	O
21	phosphatase	O
22	that	O
23	inactivates	O
24	extracellular	B
25	signal	I
26	-	I
27	regulated	I
28	kinase	I
29	(	O
30	ERK	B
31	)	O
32	MAP	B
33	kinases	I
34	.	O

1	The	O
2	FBF	O
3	questionnaire	O
4	did	O
5	not	O
6	highlight	O
7	a	O
8	characteristic	O
9	basic	O
10	symptoms	O
11	profile	O
12	of	O
13	schizoaffective	O
14	disorder	O
15	,	O
16	when	O
17	compared	O
18	with	O
19	bipolar	O
20	affective	O
21	disorder	O
22	and	O
23	schizophrenia	O
24	.	O

1	One	O
2	is	O
3	to	O
4	act	O
5	within	O
6	the	O
7	visceral	O
8	endoderm	O
9	to	O
10	promote	O
11	proper	O
12	streak	O
13	morphogenesis	O
14	.	O

1	The	O
2	C	B
3	-	I
4	terminal	I
5	Cdk2	I
6	truncations	O
7	,	O
8	however	O
9	,	O
10	were	O
11	non	O
12	-	O
13	functional	O
14	in	O
15	these	O
16	strains	O
17	and	O
18	thus	O
19	dependent	O
20	for	O
21	activity	O
22	on	O
23	the	O
24	pho85	B
25	coding	I
26	region	I
27	which	O
28	remained	O
29	in	O
30	the	O
31	mutant	B
32	pho85	I
33	::	O
34	HIS3	B
35	chromosomal	I
36	locus	I
37	.	O

1	Similarly	O
2	,	O
3	comparison	O
4	of	O
5	percentage	O
6	reductions	O
7	of	O
8	heart	O
9	rate	O
10	at	O
11	supine	O
12	,	O
13	sitting	O
14	and	O
15	exercise	O
16	by	O
17	repeated	O
18	measure	O
19	analysis	O
20	showed	O
21	the	O
22	Malays	O
23	to	O
24	have	O
25	significantly	O
26	higher	O
27	change	O
28	compared	O
29	to	O
30	the	O
31	Chinese	O
32	(	O
33	p	O
34	=	O
35	0	O
36	.	O
37	040	O
38	).	O

1	The	O
2	major	O
3	myosin	B
4	-	I
5	binding	I
6	domain	I
7	of	O
8	skeletal	B
9	muscle	I
10	MyBP	I
11	-	I
12	C	I
13	(	O
14	C	B
15	protein	I
16	)	O
17	resides	O
18	in	O
19	the	O
20	COOH	O
21	-	O
22	terminal	O
23	,	O
24	immunoglobulin	B
25	C2	I
26	motif	I
27	.	O

1	The	O
2	Italian	O
3	Lung	O
4	Cancer	O
5	Task	O
6	Force	O
7	(	O
8	FONICAP	O
9	).	O

1	E3	B
2	/	I
3	19K	I
4	resides	O
5	in	O
6	the	O
7	endoplasmic	O
8	reticulum	O
9	where	O
10	it	O
11	binds	O
12	to	O
13	MHC	B
14	class	I
15	I	I
16	molecules	I
17	,	O
18	thereby	O
19	preventing	O
20	their	O
21	transport	O
22	to	O
23	the	O
24	cell	O
25	surface	O
26	.	O

1	Full	O
2	thyroid	O
3	function	O
4	testing	O
5	was	O
6	performed	O
7	on	O
8	600	O
9	randomly	O
10	selected	O
11	samples	O
12	with	O
13	normal	O
14	TSH	B
15	values	O
16	and	O
17	also	O
18	on	O
19	subjects	O
20	with	O
21	abnormal	O
22	TSH	B
23	levels	O
24	.	O

1	Alternatively	O
2	processed	O
3	isoforms	O
4	of	O
5	cellular	B
6	nucleic	I
7	acid	I
8	-	I
9	binding	I
10	protein	I
11	interact	O
12	with	O
13	a	O
14	suppressor	O
15	region	O
16	of	O
17	the	O
18	human	B
19	beta	I
20	-	I
21	myosin	I
22	heavy	I
23	chain	I
24	gene	I
25	.	O

1	Another	O
2	stem	O
3	-	O
4	loop	O
5	called	O
6	structure	O
7	III	O
8	near	O
9	the	O
10	3	O
11	'-	O
12	end	O
13	of	O
14	repY	B
15	sequesters	O
16	both	O
17	the	O
18	5	O
19	'-	O
20	rCGCC	O
21	-	O
22	3	O
23	'	O
24	sequence	O
25	and	O
26	the	O
27	repZ	B
28	ribosome	I
29	-	I
30	binding	I
31	site	I
32	.	O

1	Gene	O
2	silencing	O
3	associated	O
4	with	O
5	repeated	O
6	DNA	O
7	sequences	O
8	has	O
9	been	O
10	reported	O
11	for	O
12	many	O
13	eukaryotes	O
14	,	O
15	including	O
16	plants	O
17	.	O

1	In	O
2	a	O
3	similar	O
4	experiment	O
5	,	O
6	simultaneous	O
7	nitrofurazone	O
8	administration	O
9	and	O
10	S	O
11	.	O
12	enteritidis	O
13	challenge	O
14	resulted	O
15	in	O
16	no	O
17	significant	O
18	differences	O
19	in	O
20	S	O
21	.	O
22	enteritidis	O
23	isolation	O
24	frequency	O
25	.	O

1	Consistent	O
2	with	O
3	previous	O
4	reports	O
5	,	O
6	addition	O
7	of	O
8	a	O
9	myristoylation	O
10	signal	O
11	to	O
12	mSos1	B
13	(	O
14	MyrSos1	B
15	)	O
16	rendered	O
17	it	O
18	transforming	O
19	for	O
20	NIH	O
21	3T3	O
22	cells	O
23	and	O
24	deletion	O
25	of	O
26	the	O
27	mSos	B
28	C	I
29	terminus	I
30	(	O
31	MyrSos1	B
32	-	I
33	deltaC	I
34	)	O
35	did	O
36	not	O
37	interfere	O
38	with	O
39	this	O
40	activity	O
41	.	O

1	The	O
2	ERH	B
3	expression	O
4	profile	O
5	is	O
6	similar	O
7	,	O
8	to	O
9	that	O
10	of	O
11	An3	B
12	,	O
13	which	O
14	localizes	O
15	to	O
16	the	O
17	animal	O
18	hemisphere	O
19	of	O
20	oocytes	O
21	and	O
22	is	O
23	abundantly	O
24	expressed	O
25	in	O
26	the	O
27	embryo	O
28	.	O

1	Intracellular	O
2	activity	O
3	studies	O
4	indicated	O
5	that	O
6	,	O
7	at	O
8	ten	O
9	times	O
10	MBC	O
11	,	O
12	only	O
13	penicillin	O
14	had	O
15	any	O
16	significant	O
17	activity	O
18	against	O
19	intracellular	O
20	staphylococci	O
21	,	O
22	reducing	O
23	survival	O
24	by	O
25	28	O
26	%.	O

1	This	O
2	work	O
3	unravels	O
4	a	O
5	new	O
6	model	O
7	for	O
8	the	O
9	ets	B
10	-	I
11	1	I
12	/	O
13	ets	B
14	-	I
15	2	I
16	gene	I
17	'	O
18	s	O
19	evolution	O
20	,	O
21	based	O
22	for	O
23	the	O
24	first	O
25	time	O
26	on	O
27	both	O
28	structural	O
29	and	O
30	functional	O
31	evidences	O
32	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	R206S	B
6	HSF	I
7	substitution	O
8	exhibits	O
9	constitutive	O
10	transcriptional	O
11	activation	O
12	from	O
13	a	O
14	consensus	O
15	HSE	O
16	(	O
17	HSE2	O
18	).	O

1	Recombination	O
2	,	O
3	replication	O
4	,	O
5	repair	O
6	:	O
7	from	O
8	complexity	O
9	to	O
10	harmony	O
11	.	O

1	Formation	O
2	of	O
3	hyphae	O
4	and	O
5	chlamydospores	O
6	by	O
7	Cryptococcus	O
8	laurentii	O
9	.	O

1	Among	O
2	the	O
3	remaining	O
4	22	O
5	sites	O
6	,	O
7	six	O
8	are	O
9	in	O
10	the	O
11	promoters	O
12	of	O
13	known	O
14	alpha	O
15	-	O
16	specific	O
17	genes	O
18	and	O
19	two	O
20	other	O
21	sites	O
22	have	O
23	an	O
24	alpha2	B
25	-	O
26	Mcm1	B
27	-	O
28	dependent	O
29	role	O
30	in	O
31	determining	O
32	the	O
33	direction	O
34	of	O
35	mating	O
36	type	O
37	switching	O
38	.	O

1	The	O
2	gene	O
3	includes	O
4	three	O
5	exons	O
6	and	O
7	two	O
8	introns	O
9	within	O
10	1	O
11	.	O
12	6	O
13	kilobases	O
14	of	O
15	DNA	O
16	,	O
17	and	O
18	the	O
19	entire	O
20	open	O
21	reading	O
22	frame	O
23	for	O
24	glycoprotein	B
25	IX	I
26	is	O
27	included	O
28	within	O
29	the	O
30	third	O
31	exon	O
32	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	residue	O
6	266	O
7	serves	O
8	as	O
9	a	O
10	"	O
11	protein	O
12	sensor	O
13	"	O
14	of	O
15	altered	O
16	minor	O
17	groove	O
18	interactions	O
19	and	O
20	identifies	O
21	which	O
22	base	O
23	pair	O
24	interactions	O
25	are	O
26	altered	O
27	by	O
28	these	O
29	lesions	O
30	.	O

1	The	O
2	lowest	O
3	detectable	O
4	concentration	O
5	was	O
6	1	O
7	.	O
8	0	O
9	ng	O
10	/	O
11	ml	O
12	in	O
13	the	O
14	serum	O
15	.	O

1	Furthermore	O
2	,	O
3	the	O
4	deletion	O
5	of	O
6	bcp	B
7	from	O
8	the	O
9	chromosome	O
10	had	O
11	no	O
12	effect	O
13	on	O
14	gcv	B
15	-	O
16	lacZ	B
17	expression	O
18	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	observations	O
6	indicate	O
7	that	O
8	the	O
9	C	O
10	-	O
11	terminal	O
12	24	O
13	amino	O
14	acids	O
15	are	O
16	sufficient	O
17	for	O
18	NodO	B
19	secretion	O
20	although	O
21	the	O
22	region	O
23	adjacent	O
24	to	O
25	this	O
26	domain	O
27	appears	O
28	to	O
29	affect	O
30	secretion	O
31	efficiency	O
32	.	O

1	A	O
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	O
14	fluid	O
15	gamma	B
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	Combined	O
2	intravenous	O
3	and	O
4	intra	O
5	-	O
6	arterial	O
7	recombinant	O
8	tissue	B
9	plasminogen	I
10	activator	I
11	in	O
12	acute	O
13	ischemic	O
14	stroke	O
15	.	O

1	Seventy	O
2	-	O
3	five	O
4	percent	O
5	of	O
6	children	O
7	who	O
8	received	O
9	a	O
10	second	O
11	transplant	O
12	for	O
13	HCV	O
14	hepatitis	O
15	had	O
16	early	O
17	histologic	O
18	recurrence	O
19	that	O
20	led	O
21	to	O
22	liver	O
23	failure	O
24	and	O
25	death	O
26	.	O

1	Anti	B
2	-	I
3	NPROSP	I
4	-	I
5	C	I
6	also	O
7	exclusively	O
8	detected	O
9	time	O
10	-	O
11	dependent	O
12	appearances	O
13	of	O
14	5	B
15	-	I
16	10	I
17	-	I
18	kDa	I
19	proSP	I
20	-	I
21	C	I
22	forms	O
23	in	O
24	lamellar	O
25	bodies	O
26	and	O
27	homogenates	O
28	.	O

1	Mucolipidosis	O
2	type	O
3	IV	O
4	:	O
5	clinical	O
6	spectrum	O
7	and	O
8	natural	O
9	history	O
10	.	O

1	We	O
2	have	O
3	used	O
4	the	O
5	hydrophobic	O
6	repeats	O
7	of	O
8	the	O
9	HSF1	B
10	trimerization	I
11	domain	I
12	in	O
13	the	O
14	yeast	O
15	two	O
16	-	O
17	hybrid	O
18	protein	O
19	interaction	O
20	assay	O
21	to	O
22	identify	O
23	heat	B
24	shock	I
25	factor	I
26	binding	I
27	protein	I
28	1	I
29	(	O
30	HSBP1	B
31	),	O
32	a	O
33	novel	O
34	,	O
35	conserved	O
36	,	O
37	76	O
38	-	O
39	amino	O
40	-	O
41	acid	O
42	protein	O
43	that	O
44	contains	O
45	two	O
46	extended	O
47	arrays	O
48	of	O
49	hydrophobic	O
50	repeats	O
51	that	O
52	interact	O
53	with	O
54	the	O
55	HSF1	B
56	heptad	I
57	repeats	I
58	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	purposes	O
5	of	O
6	the	O
7	present	O
8	study	O
9	were	O
10	to	O
11	assess	O
12	the	O
13	effects	O
14	of	O
15	a	O
16	12	O
17	-	O
18	wk	O
19	laboratory	O
20	based	O
21	aerobic	O
22	exercise	O
23	program	O
24	on	O
25	cardiopulmonary	O
26	function	O
27	,	O
28	CD4	B
29	cell	O
30	count	O
31	,	O
32	and	O
33	physician	O
34	-	O
35	assessed	O
36	health	O
37	status	O
38	among	O
39	symptomatic	O
40	pre	O
41	-	O
42	AIDS	O
43	HIV	O
44	-	O
45	infected	O
46	individuals	O
47	(	O
48	N	O
49	=	O
50	28	O
51	)	O
52	and	O
53	to	O
54	assess	O
55	the	O
56	degree	O
57	to	O
58	which	O
59	ill	O
60	health	O
61	was	O
62	associated	O
63	with	O
64	exercise	O
65	relapse	O
66	.	O

1	A	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	compare	O
7	the	O
8	ONLINE	O
9	and	O
10	EMIT	O
11	II	O
12	immunoassays	O
13	with	O
14	gas	O
15	chromatographic	O
16	/	O
17	mass	O
18	spectrometric	O
19	(	O
20	GC	O
21	/	O
22	MS	O
23	)	O
24	analysis	O
25	of	O
26	methaqualone	O
27	metabolites	O
28	on	O
29	urine	O
30	using	O
31	samples	O
32	obtained	O
33	from	O
34	a	O
35	clinical	O
36	study	O
37	.	O

1	Recombinant	B
2	soluble	I
3	pMCP	I
4	that	O
5	lacked	O
6	transmembrane	O
7	and	O
8	cytoplasmic	O
9	domains	O
10	had	O
11	factor	B
12	I	I
13	cofactor	I
14	activity	O
15	in	O
16	C3b	B
17	cleavage	O
18	,	O
19	indicating	O
20	that	O
21	it	O
22	is	O
23	functionally	O
24	,	O
25	as	O
26	well	O
27	as	O
28	structurally	O
29	homologous	O
30	to	O
31	MCP	B
32	.	O

1	High	B
2	-	I
3	mobility	I
4	-	I
5	group	I
6	protein	I
7	I	I
8	can	O
9	modulate	O
10	binding	O
11	of	O
12	transcription	O
13	factors	O
14	to	O
15	the	O
16	U5	B
17	region	I
18	of	O
19	the	O
20	human	B
21	immunodeficiency	I
22	virus	I
23	type	I
24	1	I
25	proviral	I
26	promoter	I
27	.	O

1	The	O
2	Saccharomyces	O
3	cerevisiae	O
4	spindle	O
5	pole	O
6	body	O
7	duplication	O
8	gene	B
9	MPS1	I
10	is	O
11	part	O
12	of	O
13	a	O
14	mitotic	O
15	checkpoint	O
16	.	O

1	Moreover	O
2	,	O
3	the	O
4	hypoxia	O
5	-	O
6	induced	O
7	expression	O
8	of	O
9	the	O
10	endogenous	O
11	Epo	B
12	gene	I
13	was	O
14	significantly	O
15	inhibited	O
16	in	O
17	Hep3B	O
18	cells	O
19	stably	O
20	transfected	O
21	with	O
22	HNF	B
23	-	I
24	4	I
25	delta	I
26	C	I
27	.	O

1	Molecular	O
2	characterization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	Erwinia	B
8	carotovora	I
9	hrpNEcc	I
10	gene	I
11	,	O
12	which	O
13	encodes	O
14	an	O
15	elicitor	O
16	of	O
17	the	O
18	hypersensitive	O
19	reaction	O
20	.	O

1	Familial	O
2	autoimmune	O
3	hepatitis	O
4	and	O
5	C4	B
6	deficiency	O

1	CONCLUSION	O
2	:	O
3	In	O
4	Cdks	B
5	functioning	O
6	throughout	O
7	the	O
8	cell	O
9	cycle	O
10	,	O
11	tyrosine	O
12	phosphorylation	O
13	is	O
14	inhibitory	O
15	to	O
16	the	O
17	activation	O
18	of	O
19	kinase	O
20	,	O
21	whereas	O
22	the	O
23	phosphorylation	O
24	of	O
25	threonine	O
26	in	O
27	the	O
28	T	O
29	-	O
30	loop	O
31	is	O
32	essential	O
33	for	O
34	activation	O
35	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	human	B
16	nidogen	I
17	gene	I
18	.	O

1	The	O
2	matrix	O
3	surrounding	O
4	the	O
5	clusters	O
6	either	O
7	showed	O
8	a	O
9	normal	O
10	morphology	O
11	or	O
12	a	O
13	homogeneous	O
14	appearance	O
15	,	O
16	within	O
17	which	O
18	faint	O
19	cross	O
20	striations	O
21	but	O
22	no	O
23	distinctly	O
24	fibrillar	O
25	outlines	O
26	could	O
27	be	O
28	identified	O
29	.	O

1	In	O
2	the	O
3	controls	O
4	,	O
5	it	O
6	was	O
7	found	O
8	that	O
9	all	O
10	right	O
11	-	O
12	handed	O
13	and	O
14	10	O
15	out	O
16	of	O
17	14	O
18	left	O
19	-	O
20	handed	O
21	control	O
22	subjects	O
23	showed	O
24	a	O
25	right	O
26	VHF	O
27	(	O
28	i	O
29	.	O
30	e	O
31	.,	O
32	left	O
33	hemisphere	O
34	)	O
35	advantage	O
36	.	O

1	The	O
2	imprinted	O
3	expression	O
4	of	O
5	the	O
6	endogenous	O
7	gene	O
8	can	O
9	be	O
10	recapitulated	O
11	in	O
12	mice	O
13	by	O
14	using	O
15	a	O
16	14	O
17	-	O
18	kb	O
19	transgene	O
20	encompassing	O
21	4	O
22	kb	O
23	of	O
24	5	O
25	'-	O
26	flanking	O
27	sequence	O
28	,	O
29	8	O
30	kb	O
31	of	O
32	3	O
33	'-	O
34	flanking	O
35	sequence	O
36	,	O
37	which	O
38	includes	O
39	the	O
40	two	O
41	endoderm	O
42	-	O
43	specific	O
44	enhancers	O
45	,	O
46	and	O
47	an	O
48	internally	O
49	deleted	O
50	structural	O
51	gene	O
52	.	O

1	The	O
2	operation	O
3	recommended	O
4	is	O
5	excision	O
6	of	O
7	3	O
8	mm	O
9	of	O
10	central	O
11	slip	O
12	followed	O
13	by	O
14	end	O
15	-	O
16	to	O
17	-	O
18	end	O
19	repair	O
20	of	O
21	the	O
22	tendon	O
23	.	O

1	HPLC	O
2	phosphopeptide	O
3	mapping	O
4	,	O
5	amino	O
6	acid	O
7	sequencing	O
8	,	O
9	and	O
10	site	O
11	-	O
12	directed	O
13	mutagenesis	O
14	determined	O
15	that	O
16	NCLK	B
17	phosphorylates	O
18	Ser	O
19	(	O
20	67	O
21	)	O
22	of	O
23	I	B
24	-	I
25	1	I
26	.	O

1	While	O
2	blood	O
3	pressure	O
4	and	O
5	noradrenergic	O
6	activity	O
7	,	O
8	assessed	O
9	as	O
10	changes	O
11	in	O
12	the	O
13	plasma	O
14	levels	O
15	and	O
16	urinary	O
17	excretion	O
18	of	O
19	norepinephrine	O
20	,	O
21	remained	O
22	unaffected	O
23	in	O
24	the	O
25	Pl	O
26	group	O
27	,	O
28	a	O
29	significant	O
30	drop	O
31	in	O
32	the	O
33	supine	O
34	systolic	O
35	and	O
36	diastolic	O
37	blood	O
38	pressures	O
39	,	O
40	as	O
41	well	O
42	as	O
43	in	O
44	the	O
45	resting	O
46	venous	O
47	norepinephrine	O
48	level	O
49	and	O
50	in	O
51	urinary	O
52	norepinephrine	O
53	excretion	O
54	was	O
55	found	O
56	after	O
57	the	O
58	first	O
59	month	O
60	of	O
61	dF	O
62	administration	O
63	.	O

1	The	O
2	sequence	O
3	similarity	O
4	has	O
5	suggested	O
6	that	O
7	SCG10	B
8	and	O
9	stathmin	B
10	have	O
11	been	O
12	derived	O
13	from	O
14	structurally	O
15	and	O
16	evolutionarily	O
17	related	O
18	genes	O
19	.	O

1	The	O
2	studied	O
3	protein	O
4	fragments	O
5	consist	O
6	of	O
7	residues	O
8	Arg183	O
9	-	O
10	His267	O
11	of	O
12	the	O
13	human	B
14	ER	I
15	and	O
16	residues	O
17	Lys438	O
18	-	O
19	Gln520	O
20	of	O
21	the	O
22	rat	O
23	GR	B
24	.	O

1	The	O
2	human	B
3	eps15	I
4	gene	I
5	,	O
6	encoding	O
7	a	O
8	tyrosine	B
9	kinase	I
10	substrate	O
11	,	O
12	is	O
13	conserved	O
14	in	O
15	evolution	O
16	and	O
17	maps	O
18	to	O
19	1p31	O
20	-	O
21	p32	O
22	.	O

1	Evaluating	O
2	dietary	O
3	department	O
4	management	O
5	.	O

1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	survive	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	secondaries	O
29	,	O
30	survive	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O

1	The	O
2	subjects	O
3	from	O
4	the	O
5	two	O
6	regions	O
7	with	O
8	a	O
9	higher	O
10	pollution	O
11	level	O
12	had	O
13	lower	O
14	FVC	O
15	and	O
16	FEV1	O
17	values	O
18	than	O
19	those	O
20	from	O
21	the	O
22	Viskovo	O
23	region	O
24	.	O

1	Mutations	O
2	at	O
3	the	O
4	extreme	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	EIAV	B
10	Tat	I
11	impaired	O
12	both	O
13	RNA	O
14	binding	O
15	and	O
16	activation	O
17	domain	O
18	functions	O
19	,	O
20	suggesting	O
21	effects	O
22	on	O
23	secondary	O
24	or	O
25	tertiary	O
26	structure	O
27	.	O

1	Transient	O
2	transfections	O
3	of	O
4	a	O
5	construct	O
6	expressing	O
7	the	O
8	RNA	O
9	transcript	O
10	defined	O
11	by	O
12	clone	O
13	B1	O
14	.	O
15	1	O
16	into	O
17	D17	O
18	cells	O
19	led	O
20	to	O
21	the	O
22	expression	O
23	of	O
24	an	O
25	Env	B
26	/	O
27	Mlvi	B
28	-	I
29	4	I
30	fusion	O
31	protein	O
32	with	O
33	an	O
34	apparent	O
35	molecular	O
36	mass	O
37	of	O
38	33	O
39	kDa	O
40	.	O

1	Enhancer	O
2	activity	O
3	requires	O
4	both	O
5	the	O
6	AP	B
7	-	I
8	1	I
9	site	I
10	and	O
11	these	O
12	adjacent	O
13	sequences	O
14	.	O

1	The	O
2	two	O
3	mouse	O
4	lines	O
5	carrying	O
6	the	O
7	unfragmented	O
8	Hnf3g	B
9	-	O
10	lacZ	B
11	YAC	O
12	showed	O
13	tissue	O
14	-	O
15	specific	O
16	,	O
17	copy	O
18	number	O
19	-	O
20	dependent	O
21	and	O
22	position	O
23	-	O
24	independent	O
25	expression	O
26	,	O
27	proving	O
28	that	O
29	170	O
30	kb	O
31	of	O
32	the	O
33	Hnf3g	B
34	locus	O
35	contain	O
36	all	O
37	elements	O
38	important	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	Hnf3g	B
44	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	routinely	O
5	collected	O
6	data	O
7	provided	O
8	quantitative	O
9	estimates	O
10	of	O
11	changes	O
12	in	O
13	CBZ	O
14	Cl	O
15	/	O
16	F	O
17	due	O
18	to	O
19	comedication	O
20	and	O
21	an	O
22	age	O
23	-	O
24	related	O
25	decrease	O
26	in	O
27	Cl	O
28	/	O
29	F	O
30	The	O
31	derived	O
32	regression	O
33	equations	O
34	reasonably	O
35	predicted	O
36	concentrations	O
37	in	O
38	a	O
39	separate	O
40	validation	O
41	set	O
42	.	O

1	The	O
2	pp90rsk	B
3	-	I
4	protein	I
5	kinase	I
6	activity	O
7	(	O
8	referred	O
9	to	O
10	as	O
11	rsk	B
12	-	I
13	kinase	I
14	)	O
15	is	O
16	also	O
17	not	O
18	related	O
19	to	O
20	cofactor	O
21	-	O
22	dependent	O
23	signal	O
24	transducing	O
25	protein	O
26	kinases	O
27	such	O
28	as	O
29	the	O
30	cyclic	B
31	AMP	I
32	-	I
33	dependent	I
34	protein	I
35	kinases	I
36	,	O
37	members	O
38	of	O
39	the	O
40	protein	B
41	kinase	I
42	C	I
43	family	I
44	,	O
45	or	O
46	other	O
47	Ca2	B
48	(+)-	I
49	dependent	I
50	protein	I
51	kinases	I
52	.	O

1	The	O
2	TAF	O
3	factor	O
4	appears	O
5	to	O
6	be	O
7	particularly	O
8	significant	O
9	in	O
10	OCD	O
11	.	O

1	Cleavage	O
2	and	O
3	DNA	O
4	joining	O
5	reactions	O
6	,	O
7	carried	O
8	out	O
9	by	O
10	human	B
11	immunodeficiency	I
12	virus	I
13	type	I
14	1	I
15	(	I
16	HIV	I
17	-	I
18	1	I
19	)	I
20	integrase	I
21	,	O
22	are	O
23	necessary	O
24	to	O
25	effect	O
26	the	O
27	covalent	O
28	insertion	O
29	of	O
30	HIV	O
31	-	O
32	1	O
33	DNA	O
34	into	O
35	the	O
36	host	O
37	genome	O
38	.	O

1	The	O
2	progression	O
3	of	O
4	acute	O
5	bronchitis	O
6	is	O
7	associated	O
8	with	O
9	elevated	O
10	blood	O
11	concentrations	O
12	of	O
13	acute	O
14	-	O
15	phase	O
16	proteins	O
17	,	O
18	KKS	B
19	activation	O
20	in	O
21	the	O
22	blood	O
23	and	O
24	high	O
25	serotonin	O
26	and	O
27	lactic	O
28	acid	O
29	content	O
30	in	O
31	the	O
32	humor	O
33	condensated	O
34	from	O
35	the	O
36	exhaled	O
37	air	O
38	.	O

1	Such	O
2	a	O
3	mechanism	O
4	may	O
5	allow	O
6	acceleration	O
7	of	O
8	degenerative	O
9	joint	O
10	conditions	O
11	,	O
12	and	O
13	may	O
14	account	O
15	for	O
16	the	O
17	increased	O
18	prevalence	O
19	of	O
20	such	O
21	conditions	O
22	seen	O
23	with	O
24	HMS	O
25	subjects	O
26	.	O

1	Serological	O
2	studies	O
3	of	O
4	antibodies	O
5	to	O
6	Epstein	O
7	-	O
8	Barr	O
9	virus	O
10	in	O
11	infectious	O
12	mononucleosis	O

1	Synthesis	O
2	of	O
3	(+)-	O
4	lysergic	O
5	acid	O
6	diethylamide	O
7	tartrate	O

1	Serum	O
2	prostatic	B
3	acid	I
4	phosphatase	I
5	levels	O
6	showed	O
7	a	O
8	significantly	O
9	weaker	O
10	correlation	O
11	with	O
12	cancer	O
13	volume	O
14	(	O
15	r	O
16	equals	O
17	0	O
18	.	O
19	51	O
20	)	O
21	and	O
22	every	O
23	other	O
24	pathological	O
25	parameter	O
26	.	O

1	By	O
2	using	O
3	a	O
4	DNA	O
5	sequence	O
6	selected	O
7	for	O
8	its	O
9	ability	O
10	to	O
11	bind	O
12	recombinant	B
13	BCL	I
14	-	I
15	6	I
16	in	O
17	vitro	O
18	,	O
19	we	O
20	show	O
21	here	O
22	that	O
23	BCL	B
24	-	I
25	6	I
26	is	O
27	present	O
28	in	O
29	DNA	O
30	-	O
31	binding	O
32	complexes	O
33	in	O
34	nuclear	O
35	extracts	O
36	from	O
37	various	O
38	B	O
39	-	O
40	cell	O
41	lines	O
42	.	O

1	The	O
2	Bacillus	B
3	subtilis	I
4	phage	I
5	phi	I
6	105	I
7	repressor	I
8	,	O
9	a	O
10	lambda	B
11	repressor	I
12	-	O
13	like	O
14	transcriptional	O
15	regulatory	O
16	protein	O
17	,	O
18	was	O
19	overproduced	O
20	in	O
21	Escherichia	O
22	coli	O
23	and	O
24	purified	O
25	to	O
26	near	O
27	homogeneity	O
28	in	O
29	order	O
30	to	O
31	examine	O
32	its	O
33	in	O
34	vitro	O
35	DNA	O
36	-	O
37	binding	O
38	properties	O
39	.	O

1	Sp1	B
2	and	O
3	two	O
4	Sp3	B
5	isoforms	I
6	were	O
7	detected	O
8	as	O
9	the	O
10	primary	O
11	cellular	O
12	constituents	O
13	of	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	formed	O
19	with	O
20	the	O
21	NF	B
22	-	I
23	kappaB	I
24	-	I
25	proximal	I
26	site	I
27	.	O

1	In	O
2	contrast	O
3	,	O
4	resensitization	O
5	of	O
6	a	O
7	sequestration	O
8	-	O
9	impaired	O
10	beta2AR	B
11	mutant	O
12	(	O
13	Y326A	O
14	)	O
15	was	O
16	reestablished	O
17	following	O
18	the	O
19	overexpression	O
20	of	O
21	either	O
22	GRK2	B
23	or	O
24	beta	B
25	-	I
26	arrestin	I
27	1	I
28	.	O

1	The	O
2	pre	O
3	-	O
4	and	O
5	postoperative	O
6	haemoglobin	B
7	concentrations	O
8	in	O
9	the	O
10	autologous	O
11	group	O
12	were	O
13	lower	O
14	by	O
15	15	O
16	and	O
17	10	O
18	g	O
19	/	O
20	L	O
21	,	O
22	respectively	O
23	,	O
24	after	O
25	primary	O
26	THR	O
27	and	O
28	by	O
29	10	O
30	g	O
31	/	O
32	L	O
33	in	O
34	both	O
35	instances	O
36	after	O
37	revision	O
38	THR	O
39	.	O

1	Proteinuria	O
2	--	O
3	selected	O
4	physiopathological	O
5	and	O
6	clinical	O
7	problems	O

1	Proximal	O
2	CBD	O
3	was	O
4	inversely	O
5	correlated	O
6	with	O
7	bone	B
8	alkaline	I
9	phosphatase	I
10	(	O
11	r	O
12	=	O
13	-	O
14	0	O
15	.	O
16	71	O
17	,	O
18	p	O
19	<	O
20	0	O
21	.	O
22	01	O
23	)	O
24	and	O
25	intact	O
26	PTH	B
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	59	O
34	,	O
35	p	O
36	<	O
37	0	O
38	.	O
39	05	O
40	).	O

1	The	O
2	intron	O
3	RNA	O
4	consists	O
5	of	O
6	2492	O
7	nucleotides	O
8	which	O
9	can	O
10	be	O
11	folded	O
12	into	O
13	a	O
14	secondary	O
15	structure	O
16	with	O
17	all	O
18	the	O
19	expected	O
20	sequence	O
21	motifs	O
22	of	O
23	subgroup	O
24	-	O
25	IIA1	O
26	introns	O
27	(	O
28	Michel	O
29	et	O
30	al	O
31	.	O

1	An	O
2	examination	O
3	of	O
4	the	O
5	properties	O
6	of	O
7	sequences	O
8	surrounding	O
9	ARS1	O
10	left	O
11	open	O
12	the	O
13	possibility	O
14	that	O
15	ABFI	B
16	enhances	O
17	the	O
18	initiation	O
19	of	O
20	DNA	O
21	replication	O
22	at	O
23	ARS1	O
24	by	O
25	transcriptional	O
26	activation	O
27	.	O

1	Thus	O
2	,	O
3	unlike	O
4	other	O
5	proteins	O
6	reported	O
7	to	O
8	inhibit	O
9	SRF	B
10	activity	O
11	,	O
12	the	O
13	repressor	O
14	activity	O
15	associated	O
16	with	O
17	the	O
18	GC	O
19	-	O
20	rich	O
21	element	O
22	does	O
23	not	O
24	appear	O
25	to	O
26	function	O
27	through	O
28	direct	O
29	inhibition	O
30	of	O
31	SRF	B
32	binding	O
33	.	O

1	A	O
2	one	O
3	-	O
4	way	O
5	analysis	O
6	of	O
7	variance	O
8	,	O
9	performed	O
10	separately	O
11	for	O
12	men	O
13	and	O
14	women	O
15	for	O
16	differences	O
17	among	O
18	the	O
19	three	O
20	phobic	O
21	groups	O
22	on	O
23	field	O
24	dependence	O
25	,	O
26	showed	O
27	significance	O
28	(	O
29	rho	O
30	less	O
31	than	O
32	.	O
33	05	O
34	)	O
35	for	O
36	the	O
37	females	O
38	,	O
39	with	O
40	the	O
41	famale	O
42	agoraphobic	O
43	being	O
44	more	O
45	field	O
46	dependent	O
47	than	O
48	the	O
49	female	O
50	simple	O
51	phobic	O
52	groups	O
53	,	O
54	but	O
55	not	O
56	for	O
57	the	O
58	males	O
59	.	O

1	BACKGROUND	O
2	:	O
3	Chronic	O
4	alcohol	O
5	consumption	O
6	has	O
7	been	O
8	demonstrated	O
9	to	O
10	be	O
11	deleterious	O
12	to	O
13	bone	O
14	health	O
15	.	O

1	Individual	O
2	alcohol	O
3	reaction	O
4	profiles	O
5	.	O

1	Although	O
2	there	O
3	is	O
4	little	O
5	evidence	O
6	that	O
7	diet	O
8	composition	O
9	plays	O
10	a	O
11	clinically	O
12	important	O
13	role	O
14	in	O
15	the	O
16	absorption	O
17	or	O
18	expenditure	O
19	of	O
20	energy	O
21	,	O
22	it	O
23	does	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	food	O
31	intake	O
32	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	ULK2	B
6	is	O
7	involved	O
8	in	O
9	a	O
10	previously	O
11	uncharacterized	O
12	signaling	O
13	pathway	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O

1	After	O
2	phosphorylation	O
3	,	O
4	STAT	B
5	proteins	I
6	are	O
7	transported	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O

1	Based	O
2	on	O
3	these	O
4	data	O
5	,	O
6	we	O
7	conclude	O
8	that	O
9	transcription	O
10	of	O
11	prgX	B
12	is	O
13	initiated	O
14	from	O
15	the	O
16	Qa	B
17	promoter	I
18	in	O
19	prgQ	B
20	,	O
21	and	O
22	PrgX	B
23	autoregulates	O
24	its	O
25	transcription	O
26	either	O
27	by	O
28	mediating	O
29	transcriptional	O
30	readthrough	O
31	or	O
32	increasing	O
33	mRNA	O
34	stability	O
35	.	O

1	Concomitantly	O
2	,	O
3	the	O
4	total	O
5	cellular	O
6	level	O
7	of	O
8	p21	B
9	increased	O
10	severalfold	O
11	via	O
12	a	O
13	posttranscriptional	O
14	mechanism	O
15	.	O

1	Cyclin	B
2	-	I
3	dependent	I
4	kinase	I
5	-	I
6	2	I
7	(	O
8	Cdk2	B
9	)	O
10	forms	O
11	an	O
12	inactive	O
13	complex	O
14	with	O
15	cyclin	B
16	D1	I
17	since	O
18	Cdk2	B
19	associated	O
20	with	O
21	cyclin	B
22	D1	I
23	is	O
24	not	O
25	phosphorylated	O
26	by	O
27	Cdk7	B
28	-	O
29	cyclin	B
30	-	I
31	H	I
32	.	O

1	As	O
2	a	O
3	result	O
4	,	O
5	the	O
6	subendocardial	O
7	/	O
8	subepicardial	O
9	blood	O
10	flow	O
11	ratio	O
12	(	O
13	ENDO	O
14	/	O
15	EPI	O
16	)	O
17	increased	O
18	from	O
19	0	O
20	.	O
21	44	O
22	+/-	O
23	0	O
24	.	O
25	09	O
26	during	O
27	control	O
28	stenosis	O
29	to	O
30	0	O
31	.	O
32	85	O
33	+/-	O
34	0	O
35	.	O
36	13	O
37	after	O
38	ITF	O
39	1129	O
40	(	O
41	10	O
42	micrograms	O
43	/	O
44	kg	O
45	/	O
46	min	O
47	i	O
48	.	O
49	v	O
50	.)	O
51	and	O
52	to	O
53	0	O
54	.	O
55	81	O
56	+/-	O
57	0	O
58	.	O
59	12	O
60	after	O
61	NTG	O
62	.	O

1	The	O
2	study	O
3	suggests	O
4	the	O
5	presence	O
6	of	O
7	an	O
8	anatomical	O
9	sphincter	O
10	at	O
11	the	O
12	RSJ	O
13	which	O
14	seems	O
15	to	O
16	regulate	O
17	the	O
18	passage	O
19	of	O
20	stools	O
21	from	O
22	the	O
23	sigmoid	O
24	colon	O
25	to	O
26	the	O
27	rectum	O
28	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	dopaminergic	O
6	regulation	O
7	of	O
8	adrenal	O
9	zona	O
10	glomerulosa	O
11	corticosteroid	O
12	and	O
13	renal	B
14	renin	I
15	secretion	O
16	is	O
17	absent	O
18	in	O
19	patients	O
20	with	O
21	high	O
22	spinal	O
23	cord	O
24	transections	O
25	,	O
26	suggesting	O
27	that	O
28	intact	O
29	neural	O
30	pathways	O
31	from	O
32	the	O
33	central	O
34	nervous	O
35	system	O
36	are	O
37	necessary	O
38	for	O
39	metoclopramide	O
40	stimulation	O
41	of	O
42	aldosterone	O
43	and	O
44	renin	B
45	secretion	O
46	in	O
47	men	O
48	.	O

1	(	O
2	iv	O
3	)	O
4	The	O
5	accumulation	O
6	of	O
7	cyclin	B
8	D3	I
9	protein	I
10	in	O
11	Vero	O
12	cells	O
13	infected	O
14	with	O
15	an	O
16	alpha0	B
17	deletion	I
18	mutant	I
19	was	O
20	reduced	O
21	relative	O
22	to	O
23	that	O
24	of	O
25	cells	O
26	infected	O
27	with	O
28	wild	O
29	-	O
30	type	O
31	virus	O
32	or	O
33	a	O
34	recombinant	O
35	virus	O
36	in	O
37	which	O
38	the	O
39	deleted	O
40	alpha0	B
41	sequences	I
42	were	O
43	restored	O
44	.	O

1	One	O
2	extract	O
3	with	O
4	the	O
5	lowest	O
6	PCA	O
7	content	O
8	was	O
9	non	O
10	-	O
11	carcinogenic	O
12	.	O

1	Different	O
2	cortical	O
3	malformations	O
4	were	O
5	produced	O
6	in	O
7	rats	O
8	by	O
9	a	O
10	single	O
11	dose	O
12	of	O
13	X	O
14	-	O
15	rays	O
16	(	O
17	200	O
18	cGy	O
19	)	O
20	given	O
21	on	O
22	different	O
23	days	O
24	during	O
25	gestation	O
26	.	O

1	As	O
2	hypothesized	O
3	,	O
4	believers	O
5	showed	O
6	relatively	O
7	higher	O
8	right	O
9	hemispheric	O
10	activation	O
11	and	O
12	reduced	O
13	hemispheric	O
14	asymmetry	O
15	of	O
16	functional	O
17	complexity	O
18	.	O

1	Applications	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	analysis	O
7	to	O
8	the	O
9	auditory	O
10	P300	O
11	.	O

1	In	O
2	contrast	O
3	,	O
4	capsid	B
5	proteins	I
6	derived	O
7	from	O
8	the	O
9	P1	B
10	precursor	I
11	with	O
12	a	O
13	valine	O
14	substitution	O
15	at	O
16	the	O
17	amino	O
18	terminus	O
19	of	O
20	VP1	B
21	(	O
22	VP1	B
23	-	I
24	G001V	I
25	)	O
26	assembled	O
27	empty	O
28	capsid	O
29	particles	O
30	but	O
31	were	O
32	deficient	O
33	in	O
34	assembling	O
35	RNA	O
36	-	O
37	containing	O
38	virions	O
39	.	O

1	Controlled	O
2	versus	O
3	uncontrolled	O
4	reperfusion	O
5	of	O
6	ischemic	O
7	myocardium	O
8	after	O
9	experimental	O
10	coronary	O
11	artery	O
12	occlusion	O
13	was	O
14	studied	O
15	to	O
16	determine	O
17	the	O
18	effect	O
19	on	O
20	regional	O
21	ventricular	O
22	wall	O
23	motion	O
24	and	O
25	associated	O
26	biochemical	O
27	alterations	O
28	.	O

1	The	O
2	rational	O
3	for	O
4	the	O
5	prophylactic	O
6	treatment	O
7	,	O
8	the	O
9	therapy	O
10	of	O
11	the	O
12	meningopathy	O
13	and	O
14	AIL	O
15	-	O
16	AIEOP	O
17	protocols	O
18	are	O
19	exposed	O
20	.	O

1	The	O
2	RNase	B
3	MRP	I
4	RNA	I
5	gene	I
6	was	O
7	deleted	O
8	by	O
9	insertional	O
10	replacement	O
11	and	O
12	found	O
13	to	O
14	be	O
15	essential	O
16	for	O
17	cellular	O
18	viability	O
19	,	O
20	indicating	O
21	a	O
22	critical	O
23	nuclear	O
24	role	O
25	for	O
26	RNase	B
27	MRP	I
28	.	O

1	CCAAT	B
2	displacement	I
3	protein	I
4	binds	O
5	to	O
6	and	O
7	negatively	O
8	regulates	O
9	human	O
10	papillomavirus	O
11	type	O
12	6	O
13	E6	B
14	,	O
15	E7	B
16	,	O
17	and	O
18	E1	B
19	promoters	O
20	.	O

1	The	O
2	sample	O
3	includes	O
4	all	O
5	the	O
6	HIV	O
7	-	O
8	infected	O
9	-	O
10	patients	O
11	continuously	O
12	referred	O
13	to	O
14	the	O
15	Outpatient	O
16	Service	O
17	of	O
18	the	O
19	Infectious	O
20	Diseases	O
21	dept	O
22	.	O
23	of	O
24	Bologna	O
25	'	O
26	s	O
27	"	O
28	Ospedale	O
29	Maggiore	O
30	"	O
31	General	O
32	Hospital	O
33	during	O
34	some	O
35	five	O
36	days	O
37	(	O
38	19	O
39	-	O
40	23rd	O
41	,	O
42	July	O
43	1993	O
44	).	O

1	Phenotypic	O
2	changes	O
3	induced	O
4	by	O
5	wild	B
6	type	I
7	and	I
8	variant	I
9	c	I
10	-	I
11	src	I
12	genes	I
13	carrying	O
14	C	O
15	-	O
16	terminal	O
17	sequence	O
18	alterations	O
19	.	O

1	After	O
2	PTCA	O
3	,	O
4	ejection	O
5	fraction	O
6	increased	O
7	from	O
8	54	O
9	+/-	O
10	8	O
11	%	O
12	to	O
13	59	O
14	+/-	O
15	8	O
16	%	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	05	O
24	)	O
25	and	O
26	regional	O
27	function	O
28	improved	O
29	significantly	O
30	(	O
31	maximal	O
32	standard	O
33	deviation	O
34	before	O
35	PTCA	O
36	:	O
37	2	O
38	.	O
39	8	O
40	+/-	O
41	0	O
42	.	O
43	8	O
44	;	O
45	after	O
46	PTCA	O
47	:	O
48	1	O
49	.	O
50	9	O
51	+/-	O
52	0	O
53	.	O
54	9	O
55	-	O
56	segments	O
57	below	O
58	the	O
59	first	O
60	standard	O
61	deviation	O
62	before	O
63	PTCA	O
64	:	O
65	31	O
66	+/-	O
67	16	O
68	;	O
69	after	O
70	PTCA	O
71	:	O
72	19	O
73	+/-	O
74	17	O
75	).	O

1	The	O
2	median	O
3	durations	O
4	for	O
5	response	O
6	and	O
7	survival	O
8	time	O
9	in	O
10	the	O
11	late	O
12	phase	O
13	II	O
14	trial	O
15	were	O
16	2	O
17	.	O
18	3	O
19	months	O
20	and	O
21	5	O
22	.	O
23	8	O
24	months	O
25	,	O
26	respectively	O
27	.	O

1	Seventy	O
2	-	O
3	one	O
4	supplementary	O
5	doses	O
6	of	O
7	vecuronium	O
8	were	O
9	used	O
10	for	O
11	muscle	O
12	relaxation	O
13	during	O
14	a	O
15	22	O
16	-	O
17	h	O
18	-	O
19	long	O
20	NLA	O
21	II	O
22	anaesthesia	O
23	.	O

1	We	O
2	used	O
3	expression	O
4	cloning	O
5	to	O
6	identify	O
7	interleukin	B
8	-	I
9	6	I
10	(	O
11	IL	B
12	-	I
13	6	I
14	)	O
15	as	O
16	one	O
17	factor	O
18	that	O
19	suppressed	O
20	growth	O
21	of	O
22	a	O
23	pre	O
24	-	O
25	B	O
26	-	O
27	cell	O
28	variant	O
29	line	O
30	,	O
31	1A9	O
32	-	O
33	M	O
34	.	O

1	Such	O
2	an	O
3	increase	O
4	in	O
5	the	O
6	steady	O
7	-	O
8	state	O
9	testicular	B
10	TIMP	I
11	-	I
12	2	I
13	mRNA	I
14	level	O
15	apparently	O
16	is	O
17	not	O
18	the	O
19	result	O
20	of	O
21	an	O
22	up	O
23	-	O
24	regulation	O
25	by	O
26	germ	O
27	cells	O
28	because	O
29	germ	O
30	cells	O
31	cocultured	O
32	with	O
33	Sertoli	O
34	cells	O
35	failed	O
36	to	O
37	elicit	O
38	an	O
39	increase	O
40	in	O
41	the	O
42	Sertoli	O
43	cell	O
44	steady	O
45	-	O
46	state	O
47	TIMP	B
48	-	I
49	2	I
50	mRNA	I
51	level	O
52	.	O

1	A	O
2	data	O
3	base	O
4	homology	O
5	search	O
6	revealed	O
7	that	O
8	the	O
9	predicted	O
10	ER1	B
11	amino	O
12	acid	O
13	sequence	O
14	contains	O
15	three	O
16	regions	O
17	of	O
18	similarity	O
19	to	O
20	the	O
21	rat	O
22	and	O
23	human	O
24	proteins	O
25	encoded	O
26	by	O
27	the	O
28	metastasis	O
29	-	O
30	associated	O
31	gene	O
32	,	O
33	mta1	B
34	,	O
35	and	O
36	two	O
37	regions	O
38	of	O
39	similarity	O
40	to	O
41	the	O
42	Caenorhabditis	O
43	elegans	O
44	sequence	O
45	that	O
46	is	O
47	similar	O
48	to	O
49	mta1	B
50	.	O

1	Neither	O
2	the	O
3	reaction	O
4	of	O
5	monosaccharides	O
6	nor	O
7	the	O
8	disaccharides	O
9	with	O
10	beta	O
11	-	O
12	alanine	O
13	resulted	O
14	in	O
15	the	O
16	formation	O
17	of	O
18	maltol	O
19	.	O

1	Host	O
2	lipids	O
3	in	O
4	tuberculous	O
5	infection	O
6	.	O

1	The	O
2	pea	B
3	rps10	I
4	intron	I
5	is	O
6	homologous	O
7	to	O
8	introns	O
9	in	O
10	rrn26	B
11	and	O
12	cox3	B
13	in	O
14	the	O
15	Marchantia	O
16	mitochondrial	O
17	genome	O
18	,	O
19	while	O
20	the	O
21	Marchantia	B
22	rps10	I
23	gene	I
24	lacks	O
25	an	O
26	intron	O
27	.	O

1	Selenium	O
2	status	O
3	of	O
4	thoroughbreds	O
5	in	O
6	the	O
7	United	O
8	Kingdom	O
9	.	O

1	Elevated	O
2	expression	O
3	of	O
4	a	O
5	previously	O
6	uncharacterized	O
7	gene	O
8	,	O
9	SPP381	B
10	,	O
11	efficiently	O
12	suppresses	O
13	the	O
14	growth	O
15	and	O
16	splicing	O
17	defects	O
18	of	O
19	a	O
20	temperature	O
21	-	O
22	sensitive	O
23	(	O
24	Ts	O
25	)	O
26	mutant	B
27	prp38	I
28	-	I
29	1	I
30	.	O

1	Epidemiologic	O
2	evidence	O
3	indicates	O
4	that	O
5	estrogen	O
6	replacement	O
7	therapy	O
8	after	O
9	menopause	O
10	increases	O
11	breast	O
12	cancer	O
13	risk	O
14	.	O

1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	transrepression	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	activity	O
23	.	O

1	RNase	B
2	protection	O
3	assays	O
4	revealed	O
5	a	O
6	correlation	O
7	between	O
8	the	O
9	levels	O
10	of	O
11	dorsal	O
12	and	O
13	ventral	O
14	skin	O
15	expression	O
16	with	O
17	pigmentation	O
18	/	O
19	phaeomelanin	O
20	phenotypes	O
21	.	O

1	The	O
2	cpc	B
3	-	I
4	1	I
5	-	I
6	encoded	I
7	transcript	I
8	contains	O
9	three	O
10	open	O
11	reading	O
12	frames	O
13	,	O
14	two	O
15	of	O
16	which	O
17	are	O
18	located	O
19	in	O
20	the	O
21	720	O
22	-	O
23	nucleotide	O
24	leader	O
25	segment	O
26	preceding	O
27	the	O
28	cpc	B
29	-	I
30	1	I
31	coding	I
32	region	I
33	.	O

1	The	O
2	ipsilateral	O
3	breast	O
4	tumor	O
5	relapse	O
6	rate	O
7	was	O
8	similar	O
9	between	O
10	the	O
11	PALP	O
12	and	O
13	MGDET	O
14	groups	O
15	.	O

1	The	O
2	mean	O
3	times	O
4	to	O
5	detection	O
6	of	O
7	all	O
8	mycobacteria	O
9	with	O
10	BACTEC	O
11	9000	O
12	MB	O
13	and	O
14	BACTEC	O
15	460	O
16	TB	O
17	were	O
18	similar	O
19	(	O
20	10	O
21	.	O
22	3	O
23	and	O
24	10	O
25	.	O
26	0	O
27	days	O
28	,	O
29	respectively	O
30	).	O

1	The	O
2	results	O
3	obtained	O
4	tend	O
5	to	O
6	prove	O
7	that	O
8	the	O
9	reticuloendothelial	O
10	system	O
11	mainly	O
12	participated	O
13	in	O
14	beryllium	O
15	retention	O
16	.	O

1	(	O
2	1980	O
3	):	O
4	Science	O
5	210	O
6	,	O
7	77	O
8	-	O
9	72	O
10	)	O
11	that	O
12	stimulating	O
13	the	O
14	crossed	O
15	olivocochlear	O
16	bundle	O
17	(	O
18	COCB	O
19	)	O
20	can	O
21	change	O
22	the	O
23	magnitude	O
24	of	O
25	the	O
26	distortion	O
27	product	O
28	(	O
29	f2	O
30	-	O
31	f1	O
32	)	O
33	in	O
34	the	O
35	ear	O
36	-	O
37	canal	O
38	sound	O
39	pressure	O
40	.	O

1	Gastrointestinal	O
2	manifestations	O
3	of	O
4	systemic	O
5	sclerosis	O

1	Laser	O
2	ablation	O
3	has	O
4	been	O
5	employed	O
6	as	O
7	a	O
8	therapeutic	O
9	measure	O
10	for	O
11	chronic	O
12	pulmonary	O
13	emphysema	O
14	.	O

1	Because	O
2	the	O
3	biosynthetic	O
4	pathway	O
5	to	O
6	the	O
7	vacuole	O
8	intersects	O
9	with	O
10	the	O
11	endocytic	O
12	pathway	O
13	,	O
14	internalization	O
15	of	O
16	a	O
17	bulk	O
18	membrane	O
19	endocytic	O
20	marker	O
21	FM	O
22	4	O
23	-	O
24	64	O
25	was	O
26	assayed	O
27	in	O
28	the	O
29	sop	B
30	mutants	I
31	.	O

1	RESULTS	O
2	:	O
3	The	O
4	overall	O
5	FNF	O
6	for	O
7	1992	O
8	was	O
9	12	O
10	.	O
11	3	O
12	%	O
13	and	O
14	was	O
15	19	O
16	.	O
17	1	O
18	%,	O
19	22	O
20	.	O
21	2	O
22	%,	O
23	3	O
24	.	O
25	8	O
26	%	O
27	and	O
28	6	O
29	.	O
30	1	O
31	%	O
32	per	O
33	successive	O
34	quarters	O
35	in	O
36	1992	O
37	.	O

1	Imaging	O
2	features	O
3	of	O
4	splenic	O
5	epidermoid	O
6	cyst	O
7	with	O
8	pathologic	O
9	correlation	O
10	.	O

1	Despite	O
2	supraphysiologic	O
3	E2	O
4	concentrations	O
5	,	O
6	however	O
7	,	O
8	cervical	O
9	mucus	O
10	scores	O
11	were	O
12	significantly	O
13	reduced	O
14	in	O
15	the	O
16	CC	O
17	-	O
18	treated	O
19	group	O
20	(	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	01	O
27	).	O

1	Here	O
2	we	O
3	report	O
4	on	O
5	the	O
6	isolation	O
7	of	O
8	ICK2	B
9	,	O
10	and	O
11	show	O
12	that	O
13	it	O
14	interacts	O
15	with	O
16	Cdc2aAt	B
17	,	O
18	but	O
19	not	O
20	with	O
21	a	O
22	second	O
23	CDK	B
24	from	I
25	Arabidopsis	I
26	,	O
27	Cdc2bAt	B
28	.	O

1	3	O
2	.	O

1	Immunofluoresence	O
2	data	O
3	indicated	O
4	that	O
5	once	O
6	bound	O
7	to	O
8	the	O
9	mutant	O
10	receptor	O
11	,	O
12	fluorescent	O
13	-	O
14	labeled	O
15	RAP	B
16	co	O
17	-	O
18	localized	O
19	with	O
20	markers	O
21	of	O
22	the	O
23	endosomal	O
24	pathway	O
25	,	O
26	whereas	O
27	,	O
28	in	O
29	cells	O
30	expressing	O
31	the	O
32	wild	O
33	-	O
34	type	O
35	receptor	O
36	,	O
37	RAP	B
38	fluorescence	O
39	co	O
40	-	O
41	localized	O
42	with	O
43	lysosomal	O
44	markers	O
45	.	O

1	In	O
2	previous	O
3	work	O
4	(	O
5	E	O
6	.	O

1	Furthermore	O
2	,	O
3	heparin	B
4	lyase	I
5	treatment	O
6	of	O
7	extracts	O
8	of	O
9	cells	O
10	expressing	O
11	recombinant	B
12	YD	I
13	-	I
14	repeat	I
15	protein	I
16	releases	O
17	this	O
18	protein	O
19	from	O
20	high	O
21	molecular	O
22	mass	O
23	aggregates	O
24	.	O

1	We	O
2	analysed	O
3	two	O
4	regions	O
5	involved	O
6	in	O
7	preS2	B
8	/	O
9	S	B
10	gene	I
11	transcription	O
12	of	O
13	the	O
14	HBV	O
15	adw	O
16	subtype	O
17	:	O
18	the	O
19	diverged	O
20	TATA	O
21	box	O
22	and	O
23	a	O
24	putative	O
25	initiator	O
26	element	O
27	.	O

1	Isolation	O
2	of	O
3	a	O
4	novel	O
5	TP53	B
6	target	I
7	gene	I
8	from	O
9	a	O
10	colon	O
11	cancer	O
12	cell	O
13	line	O
14	carrying	O
15	a	O
16	highly	O
17	regulated	O
18	wild	B
19	-	I
20	type	I
21	TP53	I
22	expression	O
23	system	O
24	.	O

1	In	O
2	this	O
3	animal	O
4	,	O
5	infected	O
6	with	O
7	what	O
8	was	O
9	judged	O
10	previously	O
11	to	O
12	be	O
13	the	O
14	less	O
15	virulent	O
16	of	O
17	the	O
18	two	O
19	T	O
20	.	O
21	cruzi	O
22	stocks	O
23	used	O
24	('	O
25	strain	O
26	7	O
27	'),	O
28	there	O
29	was	O
30	severe	O
31	myocarditis	O
32	,	O
33	with	O
34	myofibre	O
35	degeneration	O
36	,	O
37	and	O
38	lesions	O
39	of	O
40	the	O
41	oesophagus	O
42	.	O

1	Concurrent	O
2	with	O
3	ligand	O
4	-	O
5	dependent	O
6	uptake	O
7	,	O
8	we	O
9	now	O
10	show	O
11	that	O
12	the	O
13	receptor	O
14	undergoes	O
15	ligand	O
16	-	O
17	induced	O
18	ubiquitination	O
19	,	O
20	suggesting	O
21	that	O
22	receptor	O
23	ubiquitination	O
24	may	O
25	function	O
26	in	O
27	the	O
28	ligand	O
29	-	O
30	dependent	O
31	endocytosis	O
32	of	O
33	the	O
34	a	B
35	-	I
36	factor	I
37	receptor	I
38	as	O
39	well	O
40	as	O
41	in	O
42	its	O
43	constitutive	O
44	endocytosis	O
45	.	O

1	A	O
2	centromere	O
3	in	O
4	S	O
5	.	O
6	cerevisiae	O
7	consists	O
8	of	O
9	a	O
10	region	O
11	of	O
12	DNA	O
13	,	O
14	approximately	O
15	150	O
16	bp	O
17	in	O
18	length	O
19	,	O
20	containing	O
21	three	O
22	important	O
23	sequence	O
24	elements	O
25	,	O
26	which	O
27	are	O
28	folded	O
29	with	O
30	proteins	O
31	into	O
32	a	O
33	specific	O
34	conformation	O
35	in	O
36	the	O
37	chromatin	O
38	(	O
39	the	O
40	yeast	O
41	kinetochore	O
42	).	O

1	The	O
2	protein	O
3	product	O
4	of	O
5	orfD	B
6	,	O
7	which	O
8	is	O
9	probably	O
10	a	O
11	new	O
12	tra	B
13	gene	I
14	(	O
15	named	O
16	traX	B
17	),	O
18	contains	O
19	65	O
20	%	O
21	hydrophobic	O
22	amino	O
23	acids	O
24	,	O
25	especially	O
26	rich	O
27	in	O
28	alanine	O
29	and	O
30	leucine	O
31	.	O

1	Examination	O
2	of	O
3	nuclear	O
4	magnetic	O
5	resonance	O
6	(	O
7	NMR	O
8	)	O
9	spectra	O
10	of	O
11	a	O
12	series	O
13	of	O
14	N	B
15	-	I
16	terminally	I
17	truncated	I
18	MIP	I
19	-	I
20	1	I
21	beta	I
22	variants	I
23	reveals	O
24	that	O
25	these	O
26	proteins	O
27	possess	O
28	a	O
29	range	O
30	of	O
31	ability	O
32	to	O
33	dimerize	O
34	.	O

1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	a	O
7	model	O
8	in	O
9	which	O
10	GATA	B
11	-	I
12	5	I
13	performs	O
14	a	O
15	unique	O
16	temporally	O
17	and	O
18	spatially	O
19	restricted	O
20	function	O
21	in	O
22	the	O
23	embryonic	O
24	heart	O
25	and	O
26	lung	O
27	.	O

1	These	O
2	results	O
3	establish	O
4	that	O
5	hydroquinones	O
6	lead	O
7	to	O
8	mutagenicity	O
9	and	O
10	carcinogenicity	O
11	.	O

1	Among	O
2	the	O
3	few	O
4	proteins	O
5	of	O
6	the	O
7	eukaryotic	O
8	nucleolus	O
9	that	O
10	have	O
11	been	O
12	characterized	O
13	,	O
14	four	O
15	proteins	O
16	,	O
17	nucleolin	B
18	,	O
19	fibrillarin	B
20	,	O
21	SSB1	B
22	and	O
23	NSR1	B
24	,	O
25	possess	O
26	a	O
27	common	O
28	structural	O
29	motif	O
30	,	O
31	the	O
32	GAR	O
33	domain	O
34	,	O
35	which	O
36	is	O
37	rich	O
38	in	O
39	glycine	O
40	and	O
41	arginine	O
42	residues	O
43	.	O

1	Finally	O
2	,	O
3	the	O
4	recovery	O
5	indexes	O
6	represented	O
7	by	O
8	the	O
9	times	O
10	required	O
11	for	O
12	T1	O
13	/	O
14	T0	O
15	and	O
16	T4	O
17	/	O
18	T1	O
19	to	O
20	rise	O
21	from	O
22	25	O
23	%	O
24	to	O
25	75	O
26	%	O
27	respectively	O
28	were	O
29	studied	O
30	.	O

1	Transactivation	O
2	of	O
3	the	O
4	HIV	B
5	-	I
6	1	I
7	LTR	I
8	by	O
9	T3R	B
10	alpha	I
11	and	O
12	several	O
13	receptor	O
14	mutants	O
15	revealed	O
16	that	O
17	the	O
18	50	O
19	-	O
20	amino	O
21	-	O
22	acid	O
23	N	O
24	-	O
25	terminal	O
26	A	O
27	/	O
28	B	O
29	region	O
30	of	O
31	T3R	B
32	alpha	I
33	,	O
34	known	O
35	to	O
36	interact	O
37	with	O
38	the	O
39	basal	B
40	transcription	I
41	factor	I
42	TFIIB	I
43	,	O
44	is	O
45	critical	O
46	for	O
47	activation	O
48	of	O
49	both	O
50	Tat	B
51	-	O
52	dependent	O
53	and	O
54	Tat	B
55	-	O
56	independent	O
57	responsive	O
58	sequences	O
59	of	O
60	the	O
61	LTR	O
62	.	O

1	To	O
2	confirm	O
3	the	O
4	binding	O
5	of	O
6	protein	O
7	to	O
8	these	O
9	sites	O
10	in	O
11	cells	O
12	,	O
13	we	O
14	carried	O
15	out	O
16	an	O
17	in	O
18	vivo	O
19	genomic	O
20	footprinting	O
21	analysis	O
22	of	O
23	this	O
24	portion	O
25	of	O
26	the	O
27	TGF	B
28	alpha	I
29	promoter	I
30	in	O
31	normal	O
32	and	O
33	transformed	O
34	rat	O
35	liver	O
36	epithelial	O
37	cell	O
38	lines	O
39	that	O
40	express	O
41	the	O
42	endogenous	O
43	gene	O
44	at	O
45	varying	O
46	levels	O
47	.	O

1	Transfection	O
2	analyses	O
3	indicated	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	Tbxas1	B
9	is	O
10	controlled	O
11	by	O
12	a	O
13	short	O
14	(	O
15	70	O
16	-	O
17	bp	O
18	)	O
19	positive	O
20	regulatory	O
21	sequence	O
22	and	O
23	several	O
24	upstream	O
25	repressive	O
26	elements	O
27	.	O

1	RESULTS	O
2	:	O
3	The	O
4	diagnostic	O
5	quality	O
6	of	O
7	FDG	O
8	images	O
9	was	O
10	at	O
11	least	O
12	as	O
13	good	O
14	as	O
15	that	O
16	of	O
17	their	O
18	Tl	O
19	-	O
20	201	O
21	counterparts	O
22	,	O
23	with	O
24	less	O
25	liver	O
26	background	O
27	in	O
28	all	O
29	but	O
30	one	O
31	FDG	O
32	study	O
33	.	O

1	Lithium	O
2	-	O
3	carbonate	O
4	action	O
5	during	O
6	radiation	O
7	therapy	O
8	has	O
9	been	O
10	studied	O
11	,	O
12	valuing	O
13	the	O
14	positive	O
15	effect	O
16	on	O
17	leukopoiesis	O
18	and	O
19	the	O
20	consequent	O
21	better	O
22	clinical	O
23	conditions	O
24	of	O
25	the	O
26	patients	O
27	in	O
28	course	O
29	of	O
30	treatment	O
31	.	O

1	The	O
2	nuclear	O
3	proteins	O
4	encoded	O
5	by	O
6	the	O
7	c	B
8	-	I
9	fos	I
10	and	O
11	c	B
12	-	I
13	jun	I
14	protooncogenes	I
15	are	O
16	expressed	O
17	during	O
18	the	O
19	proliferation	O
20	period	O
21	of	O
22	osteoblast	O
23	phenotype	O
24	development	O
25	.	O

1	Continued	O
2	development	O
3	of	O
4	the	O
5	rat	O
6	conditioning	O
7	paradigm	O
8	is	O
9	especially	O
10	warranted	O
11	because	O
12	of	O
13	the	O
14	ability	O
15	to	O
16	record	O
17	sympathetic	O
18	nerve	O
19	activity	O
20	in	O
21	intact	O
22	,	O
23	awake	O
24	subjects	O
25	and	O
26	the	O
27	large	O
28	number	O
29	of	O
30	readily	O
31	available	O
32	genetic	O
33	strains	O
34	,	O
35	which	O
36	model	O
37	human	O
38	pathological	O
39	states	O
40	.	O

1	In	O
2	contrast	O
3	,	O
4	peak	O
5	filling	O
6	rate	O
7	(	O
8	PFR	O
9	),	O
10	normalized	O
11	to	O
12	end	O
13	diastolic	O
14	volume	O
15	(	O
16	EDV	O
17	),	O
18	or	O
19	stroke	O
20	volume	O
21	(	O
22	SV	O
23	),	O
24	or	O
25	expressed	O
26	as	O
27	the	O
28	ratio	O
29	of	O
30	PFR	O
31	-	O
32	to	O
33	-	O
34	PER	O
35	was	O
36	reduced	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	01	O
43	),	O
44	time	O
45	to	O
46	PFR	O
47	(	O
48	TPFR	O
49	)	O
50	was	O
51	prolonged	O
52	(	O
53	p	O
54	<	O
55	0	O
56	.	O
57	01	O
58	),	O
59	and	O
60	echocardiographic	O
61	left	O
62	ventricular	O
63	mass	O
64	index	O
65	was	O
66	higher	O
67	(	O
68	p	O
69	<	O
70	0	O
71	.	O
72	001	O
73	)	O
74	in	O
75	patients	O
76	with	O
77	acromegaly	O
78	compared	O
79	to	O
80	normals	O
81	.	O

1	The	O
2	role	O
3	of	O
4	ascorbic	O
5	acid	O
6	in	O
7	the	O
8	prevention	O
9	of	O
10	bladder	O
11	tumor	O
12	formation	O
13	.	O

1	Urinary	B
2	N	I
3	-	I
4	acetylglucosaminidase	I
5	activity	O
6	per	O
7	mg	O
8	creatinine	O
9	did	O
10	not	O
11	differ	O
12	significantly	O
13	between	O
14	groups	O
15	.	O

1	At	O
2	4	O
3	wk	O
4	however	O
5	,	O
6	tumor	O
7	relapse	O
8	was	O
9	noted	O
10	in	O
11	6	O
12	of	O
13	7	O
14	group	O
15	4	O
16	responders	O
17	,	O
18	10	O
19	of	O
20	12	O
21	in	O
22	group	O
23	5	O
24	,	O
25	13	O
26	of	O
27	16	O
28	in	O
29	group	O
30	7	O
31	,	O
32	but	O
33	only	O
34	4	O
35	of	O
36	19	O
37	group	O
38	8	O
39	responders	O
40	(	O
41	p	O
42	less	O
43	than	O
44	.	O
45	001	O
46	group	O
47	8	O
48	versus	O
49	4	O
50	,	O
51	5	O
52	,	O
53	7	O
54	).	O

1	The	O
2	regulatory	O
3	region	O
4	also	O
5	has	O
6	a	O
7	sequence	O
8	similar	O
9	to	O
10	the	O
11	binding	O
12	site	O
13	for	O
14	a	O
15	liver	O
16	-	O
17	specific	O
18	transcription	O
19	factor	O
20	,	O
21	hepatocyte	B
22	nuclear	I
23	factor	I
24	1	I
25	(	O
26	HNF	B
27	-	I
28	1	I
29	),	O
30	at	O
31	positions	O
32	-	O
33	120	O
34	to	O
35	-	O
36	132	O
37	.	O

1	Using	O
2	transgenic	O
3	Xenopus	O
4	embryos	O
5	,	O
6	we	O
7	demonstrate	O
8	that	O
9	the	O
10	integrity	O
11	of	O
12	these	O
13	two	O
14	sequences	O
15	is	O
16	necessary	O
17	for	O
18	correct	O
19	spatial	O
20	expression	O
21	of	O
22	a	O
23	Xbra2	B
24	promoter	I
25	-	I
26	driven	I
27	reporter	I
28	gene	I
29	.	O

1	The	O
2	rate	O
3	of	O
4	enzymic	O
5	stimulation	O
6	induced	O
7	by	O
8	a	O
9	given	O
10	nitrate	O
11	correlates	O
12	closely	O
13	with	O
14	the	O
15	rate	O
16	of	O
17	measured	O
18	NO	O
19	production	O
20	from	O
21	the	O
22	nitrate	O
23	molecule	O
24	.	O

1	Patients	O
2	with	O
3	psychotropic	O
4	drugs	O
5	showed	O
6	significantly	O
7	higher	O
8	PRL	B
9	levels	O
10	.	O

1	Compound	O
2	1	O
3	is	O
4	either	O
5	21	O
6	-	O
7	O	O
8	-	O
9	angeloyl	O
10	,	O
11	22	O
12	-	O
13	O	O
14	-	O
15	tigloyl	O
16	R1	O
17	-	O
18	barrigenol	O
19	,	O
20	or	O
21	21	O
22	-	O
23	O	O
24	-	O
25	tigloyl	O
26	,	O
27	22	O
28	-	O
29	O	O
30	-	O
31	angeloyl	O
32	R1	O
33	-	O
34	barrigenol	O
35	.	O

1	From	O
2	life	O
3	-	O
4	table	O
5	analyses	O
6	of	O
7	these	O
8	patients	O
9	,	O
10	we	O
11	estimated	O
12	that	O
13	the	O
14	incidence	O
15	of	O
16	secondary	O
17	chondrosarcoma	O
18	in	O
19	patients	O
20	who	O
21	have	O
22	Ollier	O
23	disease	O
24	is	O
25	about	O
26	25	O
27	per	O
28	cent	O
29	at	O
30	the	O
31	age	O
32	of	O
33	forty	O
34	years	O
35	,	O
36	and	O
37	that	O
38	malignant	O
39	degeneration	O
40	is	O
41	almost	O
42	a	O
43	certainty	O
44	in	O
45	patients	O
46	who	O
47	have	O
48	Maffucci	O
49	syndrome	O
50	.	O

1	The	O
2	computer	O
3	-	O
4	programmed	O
5	cytocentrifuge	O
6	is	O
7	currently	O
8	most	O
9	popular	O
10	.	O

1	Pneumothorax	O
2	during	O
3	laparoscopic	O
4	dissection	O
5	of	O
6	the	O
7	diaphragmatic	O
8	hiatus	O
9	.	O

1	The	O
2	effects	O
3	of	O
4	glutaraldehyde	O
5	on	O
6	dimensions	O
7	and	O
8	ultrastructure	O
9	of	O
10	microvascular	O
11	beds	O
12	in	O
13	rat	O
14	mesentery	O
15	were	O
16	studied	O
17	in	O
18	two	O
19	kinds	O
20	of	O
21	experiment	O
22	,	O
23	administering	O
24	the	O
25	fixative	O
26	by	O
27	intra	O
28	-	O
29	arterial	O
30	perfusion	O
31	at	O
32	a	O
33	pressure	O
34	of	O
35	80	O
36	mm	O
37	Hg	O
38	and	O
39	by	O
40	superfusion	O
41	of	O
42	the	O
43	exteriorized	O
44	mesenteric	O
45	membrane	O
46	.	O

1	The	O
2	cost	O
3	per	O
4	test	O
5	is	O
6	less	O
7	than	O
8	those	O
9	for	O
10	CC	O
11	,	O
12	kEIA	O
13	and	O
14	PACE2	O
15	.	O

1	In	O
2	metabolic	O
3	acidosis	O
4	there	O
5	was	O
6	a	O
7	marked	O
8	stimulation	O
9	when	O
10	clamped	O
11	at	O
12	-	O
13	10	O
14	to	O
15	-	O
16	100	O
17	mV	O
18	.	O

1	Three	O
2	patients	O
3	had	O
4	well	O
5	-,	O
6	6	O
7	patients	O
8	had	O
9	moderately	O
10	-,	O
11	and	O
12	5	O
13	patients	O
14	had	O
15	poorly	O
16	-	O
17	differentiated	O
18	adenocarcinoma	O
19	of	O
20	the	O
21	prostate	O
22	.	O

1	Moreover	O
2	,	O
3	we	O
4	observed	O
5	that	O
6	the	O
7	function	O
8	of	O
9	T3R	B
10	-	O
11	RXR	B
12	heterodimers	O
13	on	O
14	response	O
15	elements	O
16	composed	O
17	of	O
18	two	O
19	half	O
20	-	O
21	sites	O
22	in	O
23	a	O
24	directly	O
25	repeated	O
26	orientation	O
27	spaced	O
28	by	O
29	4	O
30	nucleotides	O
31	is	O
32	determined	O
33	in	O
34	major	O
35	parts	O
36	by	O
37	the	O
38	5	O
39	'-	O
40	flanking	O
41	sequence	O
42	of	O
43	the	O
44	upstream	O
45	half	O
46	-	O
47	site	O
48	.	O

1	The	O
2	other	O
3	element	O
4	bound	O
5	RBP	B
6	-	I
7	J	I
8	kappa	I
9	with	O
10	low	O
11	affinity	O
12	.	O

1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	O
9	p53	B
10	-	O
11	induced	O
12	Waf1	B
13	/	O
14	Cip1	B
15	-	O
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	O
26	myb	B
27	oncogene	I
28	family	I
29	.	O

1	The	O
2	problem	O
3	of	O
4	disablement	O
5	due	O
6	to	O
7	pulmonary	O
8	tuberculosis	O
9	,	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	an	O
15	analysis	O
16	of	O
17	the	O
18	history	O
19	of	O
20	395	O
21	cases	O
22	as	O
23	observed	O
24	in	O
25	Gdansk	O
26	in	O
27	the	O
28	years	O
29	1946	O
30	-	O
31	1965	O

1	Ume6p	B
2	,	O
3	which	O
4	also	O
5	controls	O
6	the	O
7	expression	O
8	of	O
9	early	O
10	meiotic	O
11	genes	O
12	,	O
13	represses	O
14	CAR1	B
15	expression	O
16	through	O
17	a	O
18	sequence	O
19	called	O
20	URS	O
21	,	O
22	as	O
23	a	O
24	function	O
25	of	O
26	nitrogen	O
27	availability	O
28	.	O

1	Lithium	O
2	phthalocyanine	O
3	(	O
4	LiPc	O
5	)	O
6	is	O
7	a	O
8	prototype	O
9	of	O
10	another	O
11	generation	O
12	of	O
13	synthetic	O
14	,	O
15	metallic	O
16	-	O
17	organic	O
18	,	O
19	paramagnetic	O
20	crystallites	O
21	that	O
22	appear	O
23	very	O
24	useful	O
25	for	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	electron	O
32	paramagnetic	O
33	resonance	O
34	oximetry	O
35	.	O

1	Among	O
2	38	O
3	patients	O
4	with	O
5	inducible	O
6	reentrant	O
7	VTs	O
8	who	O
9	underwent	O
10	electrophysiologic	O
11	study	O
12	(	O
13	EPS	O
14	),	O
15	10	O
16	VTs	O
17	of	O
18	six	O
19	patients	O
20	were	O
21	selected	O
22	.	O

1	A	O
2	large	O
3	increase	O
4	of	O
5	serum	O
6	ketones	O
7	occurred	O
8	under	O
9	all	O
10	conditions	O
11	,	O
12	and	O
13	the	O
14	exercise	O
15	respiratory	O
16	quotient	O
17	suggested	O
18	some	O
19	increase	O
20	of	O
21	fat	O
22	utilization	O
23	,	O
24	WW	O
25	(	O
26	0	O
27	.	O
28	85	O
29	)	O
30	through	O
31	CW	O
32	(	O
33	0	O
34	.	O
35	84	O
36	)	O
37	to	O
38	CC	O
39	(	O
40	0	O
41	.	O
42	83	O
43	).	O

1	Activation	O
2	was	O
3	biphasic	O
4	;	O
5	peaking	O
6	at	O
7	5	O
8	-	O
9	10	O
10	min	O
11	and	O
12	24	O
13	h	O
14	after	O
15	treatment	O
16	.	O

1	Of	O
2	the	O
3	53	O
4	units	O
5	tested	O
6	during	O
7	sinusoidal	O
8	motion	O
9	at	O
10	0	O
11	.	O
12	05	O
13	Hz	O
14	(	O
15	9	O
16	.	O
17	1	O
18	cm	O
19	/	O
20	s	O
21	),	O
22	1	O
23	(	O
24	1	O
25	.	O
26	9	O
27	%)	O
28	was	O
29	responsive	O
30	to	O
31	the	O
32	otolith	O
33	input	O
34	only	O
35	,	O
36	13	O
37	(	O
38	24	O
39	.	O
40	5	O
41	%)	O
42	were	O
43	influenced	O
44	by	O
45	the	O
46	visual	O
47	input	O
48	only	O
49	and	O
50	23	O
51	(	O
52	43	O
53	.	O
54	4	O
55	%)	O
56	responded	O
57	to	O
58	both	O
59	modalities	O
60	.	O

1	In	O
2	the	O
3	Arithmetic	O
4	subtest	O
5	one	O
6	of	O
7	the	O
8	items	O
9	would	O
10	not	O
11	meet	O
12	the	O
13	difficulty	O
14	grading	O
15	shown	O
16	while	O
17	the	O
18	last	O
19	two	O
20	items	O
21	offer	O
22	very	O
23	little	O
24	possibility	O
25	of	O
26	success	O
27	for	O
28	all	O
29	subjects	O
30	.(	O
31	ABSTRACT	O
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O

1	They	O
2	also	O
3	interact	O
4	with	O
5	GTPase	B
6	activating	I
7	proteins	I
8	encoded	O
9	by	O
10	IRA1	B
11	and	O
12	IRA2	B
13	.	O

1	The	O
2	application	O
3	of	O
4	ultrafiltration	O
5	to	O
6	sample	O
7	preparation	O
8	in	O
9	the	O
10	detection	O
11	and	O
12	quantification	O
13	of	O
14	ethylene	O
15	glycol	O
16	in	O
17	plasma	O
18	by	O
19	gas	O
20	chromatography	O
21	is	O
22	described	O
23	.	O

1	The	O
2	vaccine	O
3	used	O
4	was	O
5	known	O
6	to	O
7	be	O
8	immunogenic	O
9	for	O
10	older	O
11	children	O
12	and	O
13	adults	O
14	.	O

1	Drosophila	B
2	UbcD1	I
3	encodes	O
4	a	O
5	highly	O
6	conserved	O
7	ubiquitin	B
8	-	O
9	conjugating	O
10	enzyme	O
11	involved	O
12	in	O
13	selective	O
14	protein	O
15	degradation	O
16	.	O

1	Maternal	O
2	seizures	O
3	had	O
4	occurred	O
5	during	O
6	pregnancy	O
7	in	O
8	52	O
9	per	O
10	cent	O
11	.	O

1	Two	O
2	promoters	O
3	were	O
4	identified	O
5	by	O
6	S1	B
7	nuclease	I
8	mapping	O
9	:	O
10	P1	O
11	,	O
12	which	O
13	lies	O
14	about	O
15	72	O
16	bp	O
17	upstream	O
18	from	O
19	the	O
20	structural	O
21	gene	O
22	;	O
23	and	O
24	P2	O
25	,	O
26	which	O
27	lies	O
28	about	O
29	35	O
30	bp	O
31	upstream	O
32	.	O

1	Currents	O
2	aspects	O
3	of	O
4	H2	B
5	receptor	I
6	antagonists	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	ulcers	O

1	After	O
2	peripheral	O
3	administration	O
4	of	O
5	both	O
6	CRF	B
7	and	O
8	TRH	B
9	,	O
10	ACTH	B
11	levels	O
12	were	O
13	significantly	O
14	higher	O
15	on	O
16	the	O
17	tumor	O
18	side	O
19	in	O
20	all	O
21	patients	O
22	.	O

1	Alternatively	O
2	,	O
3	the	O
4	similarity	O
5	in	O
6	apparent	O
7	regulatory	O
8	action	O
9	of	O
10	the	O
11	genes	O
12	may	O
13	indicate	O
14	allelic	O
15	differences	O
16	wherein	O
17	the	O
18	IS1112C	B
19	Rf3	I
20	allele	I
21	may	O
22	differ	O
23	from	O
24	alleles	O
25	of	O
26	maintainer	O
27	lines	O
28	by	O
29	the	O
30	capability	O
31	to	O
32	regulate	O
33	both	O
34	orf107	B
35	and	O
36	urf209	B
37	processing	O
38	activities	O
39	.	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	the	O
6	fruA	B
7	transcript	I
8	is	O
9	well	O
10	conserved	O
11	with	O
12	the	O
13	D	B
14	.	I
15	melanogaster	I
16	type	I
17	A	I
18	protein	I
19	,	O
20	particularly	O
21	the	O
22	BTB	B
23	protein	I
24	-	O
25	protein	O
26	-	O
27	binding	O
28	domain	O
29	,	O
30	which	O
31	is	O
32	encoded	O
33	by	O
34	exons	O
35	I	O
36	and	O
37	II	O
38	and	O
39	is	O
40	100	O
41	%	O
42	conserved	O
43	.	O

1	The	O
2	present	O
3	paper	O
4	elucidates	O
5	the	O
6	existing	O
7	discrepancies	O
8	,	O
9	and	O
10	offers	O
11	a	O
12	consistent	O
13	terminology	O
14	incorporating	O
15	also	O
16	such	O
17	terms	O
18	as	O
19	"	O
20	additivity	O
21	",	O
22	"	O
23	potentiation	O
24	",	O
25	and	O
26	"	O
27	simple	O
28	similarity	O
29	".	O

1	Studies	O
2	of	O
3	MPO	B
4	gene	I
5	regulation	O
6	can	O
7	help	O
8	to	O
9	elucidate	O
10	the	O
11	mechanism	O
12	of	O
13	normal	O
14	and	O
15	abnormal	O
16	myeloid	O
17	differentiation	O
18	.	O

1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	by	O
8	S1	B
9	nuclease	I
10	mapping	O
11	.	O

1	The	O
2	remaining	O
3	six	O
4	patients	O
5	had	O
6	slightly	O
7	decreased	O
8	(	O
9	n	O
10	=	O
11	3	O
12	)	O
13	or	O
14	normal	O
15	(	O
16	n	O
17	=	O
18	3	O
19	)	O
20	seminal	O
21	parameters	O
22	.	O

1	Comparison	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequence	O
7	of	O
8	the	O
9	M	B
10	RNA	I
11	product	I
12	of	I
13	Uukuniemi	I
14	virus	I
15	with	O
16	that	O
17	of	O
18	Punta	O
19	Toro	O
20	and	O
21	Rift	O
22	Valley	O
23	fever	O
24	viruses	O
25	showed	O
26	in	O
27	both	O
28	cases	O
29	a	O
30	weak	O
31	homology	O
32	that	O
33	was	O
34	more	O
35	pronounced	O
36	for	O
37	the	O
38	proteins	O
39	located	O
40	at	O
41	the	O
42	COOH	O
43	-	O
44	terminal	O
45	end	O
46	of	O
47	the	O
48	precursor	O
49	.	O

1	Acquired	O
2	bile	O
3	duct	O
4	blockage	O
5	:	O
6	entry	O
7	of	O
8	hepatobiliary	O
9	agent	O
10	into	O
11	an	O
12	intrahepatic	O
13	abscess	O
14	.	O

1	Expression	O
2	and	O
3	characterization	O
4	of	O
5	recombinant	B
6	single	I
7	-	I
8	chain	I
9	Fv	I
10	and	O
11	Fv	B
12	fragments	I
13	derived	O
14	from	O
15	a	O
16	set	O
17	of	O
18	catalytic	O
19	antibodies	O
20	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	microinjection	O
6	of	O
7	an	O
8	anti	B
9	-	I
10	CBP	I
11	antiserum	I
12	into	O
13	fibroblasts	O
14	can	O
15	inhibit	O
16	transcription	O
17	from	O
18	a	O
19	cAMP	O
20	responsive	O
21	promoter	O
22	.	O

1	Because	O
2	the	O
3	adrenergic	O
4	nervous	O
5	system	O
6	influences	O
7	cardiac	O
8	arrhythmias	O
9	and	O
10	myocardial	O
11	infarction	O
12	can	O
13	directly	O
14	affect	O
15	sympathetic	O
16	innervation	O
17	in	O
18	the	O
19	heart	O
20	,	O
21	we	O
22	investigated	O
23	the	O
24	role	O
25	of	O
26	the	O
27	sympathetic	O
28	nervous	O
29	system	O
30	on	O
31	reentry	O
32	in	O
33	the	O
34	canine	O
35	heart	O
36	4	O
37	days	O
38	after	O
39	infarction	O
40	.	O

1	S2F	B
2	,	O
3	a	O
4	leaf	O
5	-	O
6	specific	O
7	trans	O
8	-	O
9	acting	O
10	factor	O
11	,	O
12	binds	O
13	to	O
14	a	O
15	novel	O
16	cis	O
17	-	O
18	acting	O
19	element	O
20	and	O
21	differentially	O
22	activates	O
23	the	O
24	RPL21	B
25	gene	I
26	.	O

1	Mutations	O
2	truncating	O
3	as	O
4	many	O
5	as	O
6	143	O
7	C	O
8	-	O
9	terminal	O
10	residues	O
11	from	O
12	the	O
13	transcriptional	O
14	activator	O
15	encoded	O
16	by	O
17	the	O
18	areA	B
19	gene	I
20	,	O
21	mediating	O
22	nitrogen	O
23	metabolite	O
24	repression	O
25	in	O
26	Aspergillus	O
27	nidulans	O
28	,	O
29	do	O
30	not	O
31	significantly	O
32	reduce	O
33	the	O
34	ability	O
35	of	O
36	the	O
37	areA	B
38	product	I
39	to	O
40	activate	O
41	expression	O
42	of	O
43	most	O
44	genes	O
45	under	O
46	areA	B
47	control	O
48	.	O

1	In	O
2	the	O
3	ePTFE	O
4	specimens	O
5	,	O
6	tissue	O
7	coverage	O
8	had	O
9	increased	O
10	.	O

1	Specific	O
2	class	B
3	I	I
4	and	I
5	II	I
6	histone	I
7	deacetylases	I
8	(	O
9	HDACs	B
10	)	O
11	interact	O
12	in	O
13	vivo	O
14	with	O
15	BCoR	B
16	,	O
17	suggesting	O
18	that	O
19	BCoR	B
20	may	O
21	functionally	O
22	link	O
23	these	O
24	two	O
25	classes	O
26	of	O
27	HDACs	B
28	.	O

1	Once	O
2	more	O
3	Hong	O
4	Kong	O
5	influenza	O
6	in	O
7	the	O
8	Netherlands	O

1	The	O
2	muskox	O
3	is	O
4	a	O
5	new	O
6	host	O
7	record	O
8	for	O
9	T	O
10	.	O
11	gondii	O
12	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	established	O
6	that	O
7	progression	O
8	through	O
9	the	O
10	eukaryotic	O
11	cell	O
12	cycle	O
13	is	O
14	controlled	O
15	by	O
16	oscillations	O
17	in	O
18	the	O
19	activity	O
20	of	O
21	cyclin	B
22	-	I
23	dependent	I
24	kinases	I
25	(	O
26	CDKs	B
27	).	O

1	The	O
2	manifestations	O
3	often	O
4	include	O
5	a	O
6	moderate	O
7	thrombocytopenia	O
8	and	O
9	,	O
10	less	O
11	commonly	O
12	,	O
13	hemolysis	O
14	.	O

1	Six	O
2	patients	O
3	with	O
4	the	O
5	diagnosis	O
6	of	O
7	acute	O
8	mania	O
9	were	O
10	treated	O
11	with	O
12	high	O
13	doses	O
14	of	O
15	the	O
16	beta	O
17	-	O
18	adrenergic	O
19	blocking	O
20	agent	O
21	propranolol	O
22	.	O

1	C	O
2	.	O
3	elegans	O
4	KLP	B
5	-	I
6	11	I
7	/	O
8	OSM	B
9	-	I
10	3	I
11	/	O
12	KAP	B
13	-	I
14	1	I
15	:	O
16	orthologs	O
17	of	O
18	the	O
19	sea	B
20	urchin	I
21	kinesin	I
22	-	I
23	II	I
24	,	O
25	and	O
26	mouse	O
27	KIF3A	B
28	/	O
29	KIFB	B
30	/	O
31	KAP3	B
32	kinesin	I
33	complexes	O
34	.	O

1	Analysis	O
2	of	O
3	the	O
4	upstream	O
5	untranslated	O
6	region	O
7	of	O
8	CHL15	B
9	revealed	O
10	the	O
11	presence	O
12	of	O
13	the	O
14	hexamer	O
15	element	O
16	,	O
17	ACGCGT	O
18	(	O
19	an	O
20	MluI	B
21	restriction	I
22	site	I
23	)	O
24	controlling	O
25	both	O
26	the	O
27	periodic	O
28	expression	O
29	and	O
30	coordinate	O
31	regulation	O
32	of	O
33	the	O
34	DNA	O
35	synthesis	O
36	genes	O
37	in	O
38	budding	O
39	yeast	O
40	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	endometriosis	O
8	increases	O
9	soluble	O
10	CD23	B
11	levels	O
12	,	O
13	which	O
14	can	O
15	be	O
16	suppressed	O
17	with	O
18	either	O
19	danazol	O
20	or	O
21	leuprolide	O
22	acetate	O
23	injection	O
24	.	O

1	A	O
2	yeast	O
3	DNA	O
4	fragment	O
5	carrying	O
6	the	O
7	gene	B
8	CP	I
9	A1	I
10	encoding	O
11	the	O
12	small	O
13	subunit	O
14	of	O
15	the	O
16	arginine	O
17	pathway	O
18	carbamoyl	B
19	-	I
20	phosphate	I
21	synthetase	I
22	has	O
23	been	O
24	sequenced	O
25	.	O

1	Respiratory	O
2	chain	O
3	enzyme	O
4	activity	O
5	was	O
6	normal	O
7	.	O

1	The	O
2	men	O
3	self	O
4	-	O
5	selected	O
6	a	O
7	prescribed	O
8	diet	O
9	at	O
10	home	O
11	emphasizing	O
12	saturated	O
13	fat	O
14	as	O
15	the	O
16	visible	O
17	fat	O
18	for	O
19	1	O
20	week	O
21	.	O

1	Thus	O
2	,	O
3	the	O
4	P	O
5	.	O
6	aeruginosa	O
7	orfX	O
8	and	O
9	vfr	B
10	promoters	I
11	are	O
12	arranged	O
13	in	O
14	a	O
15	back	O
16	-	O
17	to	O
18	-	O
19	back	O
20	orientation	O
21	rather	O
22	than	O
23	the	O
24	face	O
25	-	O
26	to	O
27	-	O
28	face	O
29	orientation	O
30	of	O
31	the	O
32	dorf	O
33	and	O
34	crp	B
35	promoters	I
36	.	O

1	The	O
2	mMIWC1	B
3	promoter	I
4	was	O
5	identified	O
6	and	O
7	contained	O
8	TATA	O
9	,	O
10	CAAT	O
11	,	O
12	GATA	O
13	,	O
14	and	O
15	AP	B
16	-	I
17	2	I
18	elements	I
19	;	O
20	primer	O
21	extension	O
22	revealed	O
23	mMIWC	B
24	transcription	O
25	initiation	O
26	at	O
27	621	O
28	bp	O
29	upstream	O
30	from	O
31	the	O
32	mMIWC1	B
33	translational	O
34	initiation	O
35	site	O
36	.	O

1	Disruption	O
2	of	O
3	re	O
4	-	O
5	replication	O
6	control	O
7	by	O
8	overexpression	O
9	of	O
10	human	B
11	ORC1	I
12	in	O
13	fission	O
14	yeast	O
15	.	O

1	OBJECTIVES	O
2	:	O
3	To	O
4	assess	O
5	the	O
6	ability	O
7	of	O
8	pretreatment	O
9	and	O
10	post	O
11	-	O
12	treatment	O
13	prostate	B
14	-	I
15	specific	I
16	antigen	I
17	(	O
18	PSA	B
19	)	O
20	measurements	O
21	,	O
22	clinical	O
23	tumor	O
24	stage	O
25	,	O
26	tumor	O
27	grade	O
28	,	O
29	Gleason	O
30	sum	O
31	,	O
32	race	O
33	,	O
34	age	O
35	,	O
36	and	O
37	radiation	O
38	dose	O
39	to	O
40	predict	O
41	the	O
42	recurrence	O
43	of	O
44	prostate	O
45	cancer	O
46	following	O
47	external	O
48	beam	O
49	radiation	O
50	therapy	O
51	(	O
52	XRT	O
53	)	O
54	since	O
55	the	O
56	introduction	O
57	of	O
58	PSA	B
59	as	O
60	a	O
61	tumor	O
62	marker	O
63	at	O
64	one	O
65	tertiary	O
66	care	O
67	center	O
68	.	O

1	The	O
2	authors	O
3	evaluate	O
4	the	O
5	clinical	O
6	efficacy	O
7	of	O
8	EMB	O
9	AZS	O
10	in	O
11	recurrent	O
12	ulcer	O
13	after	O
14	operation	O
15	on	O
16	the	O
17	stomach	O
18	caused	O
19	by	O
20	a	O
21	high	O
22	level	O
23	of	O
24	acid	O
25	production	O
26	and	O
27	ulcerative	O
28	gastroduodenal	O
29	bleeding	O
30	.	O

1	In	O
2	64	O
3	%	O
4	a	O
5	small	O
6	cardiac	O
7	vein	O
8	does	O
9	not	O
10	exist	O
11	,	O
12	but	O
13	its	O
14	origin	O
15	,	O
16	the	O
17	right	O
18	marginal	O
19	vein	O
20	,	O
21	joins	O
22	the	O
23	system	O
24	of	O
25	anterior	O
26	cardiac	O
27	veins	O
28	.	O

1	Postoperative	O
2	serum	O
3	ACTH	B
4	levels	O
5	were	O
6	normal	O
7	.	O

1	Vascular	O
2	endothelial	O
3	cells	O
4	undergo	O
5	profound	O
6	changes	O
7	upon	O
8	cellular	O
9	activation	O
10	including	O
11	expression	O
12	of	O
13	a	O
14	spectrum	O
15	of	O
16	cell	O
17	activation	O
18	-	O
19	associated	O
20	genes	O
21	.	O

1	(	O
2	1994	O
3	,	O
4	Hum	O
5	.	O

1	To	O
2	determine	O
3	if	O
4	CYC2	B
5	is	O
6	found	O
7	in	O
8	a	O
9	complex	O
10	with	O
11	previously	O
12	identified	O
13	trypanosome	B
14	cdc2	I
15	-	I
16	related	I
17	kinases	I
18	(	O
19	CRKs	B
20	),	O
21	the	O
22	CYC2	B
23	gene	I
24	was	O
25	fused	O
26	to	O
27	the	O
28	TY	B
29	epitope	I
30	tag	O
31	,	O
32	integrated	O
33	into	O
34	the	O
35	trypanosome	O
36	genome	O
37	,	O
38	and	O
39	expressed	O
40	under	O
41	inducible	O
42	control	O
43	.	O

1	Interestingly	O
2	,	O
3	one	O
4	IRF	B
5	binding	I
6	site	I
7	was	O
8	found	O
9	within	O
10	the	O
11	IRF	B
12	-	I
13	2	I
14	promoter	I
15	,	O
16	and	O
17	expression	O
18	of	O
19	the	O
20	IRF	B
21	-	I
22	2	I
23	gene	I
24	was	O
25	affected	O
26	by	O
27	both	O
28	transient	O
29	and	O
30	stable	O
31	IRF	B
32	-	I
33	1	I
34	expression	O
35	.	O

1	The	O
2	human	B
3	MSH	I
4	-	I
5	2	I
6	gene	I
7	product	I
8	is	O
9	a	O
10	member	O
11	of	O
12	a	O
13	highly	O
14	conserved	O
15	family	O
16	of	O
17	proteins	O
18	which	O
19	are	O
20	involved	O
21	in	O
22	post	O
23	-	O
24	replication	O
25	mismatch	O
26	repair	O
27	.	O
28	hMSH	B
29	-	I
30	2	I
31	is	O
32	homologous	O
33	to	O
34	Escherichia	O
35	coli	O
36	(	O
37	E	O
38	.	O
39	coli	O
40	)	O
41	MutS	B
42	and	O
43	Sacchromyces	B
44	cerevisiae	I
45	MSH	I
46	-	I
47	1	I
48	and	O
49	MSH	B
50	-	I
51	2	I
52	proteins	I
53	,	O
54	which	O
55	recognise	O
56	heteroduplex	O
57	DNA	O
58	at	O
59	the	O
60	sites	O
61	of	O
62	all	O
63	single	O
64	base	O
65	mismatches	O
66	and	O
67	deletions	O
68	or	O
69	insertions	O
70	up	O
71	to	O
72	4	O
73	base	O
74	pairs	O
75	.	O
76	hMSH	B
77	-	I
78	2	I
79	is	O
80	one	O
81	of	O
82	the	O
83	hereditary	B
84	non	I
85	-	I
86	polyposis	I
87	colorectal	I
88	cancer	I
89	(	I
90	HNPCC	I
91	)	I
92	tumor	I
93	suppressor	I
94	genes	I
95	,	O
96	and	O
97	maps	O
98	to	O
99	human	O
100	chromosome	O
101	2p16	O
102	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	putative	O
6	RNA	B
7	and	I
8	/	I
9	or	I
10	DNA	I
11	helicase	I
12	has	O
13	been	O
14	isolated	O
15	from	O
16	Arabidopsis	O
17	thaliana	O
18	cDNA	O
19	libraries	O
20	.	O

1	Although	O
2	the	O
3	N13	O
4	-	O
5	N20	O
6	interpeak	O
7	interval	O
8	remained	O
9	stable	O
10	because	O
11	of	O
12	the	O
13	parallel	O
14	shift	O
15	of	O
16	the	O
17	2	O
18	peaks	O
19	,	O
20	the	O
21	central	O
22	conduction	O
23	time	O
24	measured	O
25	from	O
26	onset	O
27	latencies	O
28	of	O
29	N11	O
30	and	O
31	N20	O
32	significantly	O
33	increased	O
34	.	O

1	Effects	O
2	of	O
3	single	O
4	and	O
5	combined	O
6	maltose	O
7	tetrapalmitate	O
8	immunotherapy	O
9	,	O
10	cyclophosphamide	O
11	chemotherapy	O
12	and	O
13	radiotherapy	O
14	on	O
15	ethyl	O
16	carbamate	O
17	accelerated	O
18	primary	O
19	lung	O
20	cancer	O
21	in	O
22	A	O
23	/	O
24	J	O
25	mice	O
26	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	binding	O
9	of	O
10	the	O
11	GA	B
12	-	I
13	binding	I
14	protein	I
15	(	O
16	GABP	B
17	)	O
18	to	O
19	ets	B
20	sequence	I
21	motifs	I
22	within	O
23	each	O
24	repeated	O
25	unit	O
26	is	O
27	required	O
28	for	O
29	transcriptional	O
30	activation	O
31	of	O
32	the	O
33	COXIV	B
34	promoter	I
35	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	calbindin	B
6	-	I
7	D28K	I
8	promoter	I
9	is	O
10	composed	O
11	of	O
12	a	O
13	variety	O
14	of	O
15	simple	O
16	repeated	O
17	sequences	O
18	,	O
19	some	O
20	of	O
21	which	O
22	are	O
23	components	O
24	of	O
25	putative	O
26	regulatory	O
27	signals	O
28	.	O

1	In	O
2	only	O
3	two	O
4	patients	O
5	were	O
6	we	O
7	able	O
8	to	O
9	demonstrate	O
10	changes	O
11	suggestive	O
12	of	O
13	pulmonary	O
14	metastases	O
15	any	O
16	earlier	O
17	with	O
18	a	O
19	99mTc	O
20	-	O
21	EHDP	O
22	scan	O
23	than	O
24	with	O
25	chest	O
26	radiographs	O
27	and	O
28	one	O
29	of	O
30	these	O
31	resolved	O
32	spontaneously	O
33	.	O

1	Position	O
2	-	O
3	independent	O
4	expression	O
5	of	O
6	a	O
7	human	O
8	nerve	B
9	growth	I
10	factor	I
11	-	O
12	luciferase	B
13	reporter	O
14	gene	O
15	cloned	O
16	on	O
17	a	O
18	yeast	O
19	artificial	O
20	chromosome	O
21	vector	O
22	.	O

1	Despite	O
2	the	O
3	absence	O
4	of	O
5	exercise	O
6	-	O
7	induced	O
8	asthma	O
9	(	O
10	EIA	O
11	)	O
12	while	O
13	breathing	O
14	WH	O
15	air	O
16	,	O
17	asthmatic	O
18	patients	O
19	still	O
20	had	O
21	significantly	O
22	higher	O
23	mean	O
24	GH	O
25	increments	O
26	than	O
27	normal	O
28	subjects	O
29	(	O
30	9	O
31	.	O
32	2	O
33	vs	O
34	2	O
35	.	O
36	3	O
37	ng	O
38	/	O
39	ml	O
40	,	O
41	P	O
42	less	O
43	than	O
44	0	O
45	.	O
46	05	O
47	).	O

